

P2 1191937

REC'D 03 AUG 2004

WIPO

PCT

# THE UNITED STATES OF AMERICA

**TO ALL TO WHOM THESE PRESENTS SHALL COME:**

**UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office**

**July 31, 2004**


**THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM  
THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK  
OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT  
APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A  
FILING DATE.**

**APPLICATION NUMBER: *PCT/US03/41642***

**FILING DATE: *December 29, 2003***

**RELATED PCT APPLICATION NUMBER: *PCT/US04/09947***

**By Authority of the  
COMMISSIONER OF PATENTS AND TRADEMARKS**



**T. LAWRENCE  
Certifying Officer**

**PRIORITY  
DOCUMENT**

**SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH RULE 17.1(a) OR (b)**

PCT/US03/41642

PCT

HOME COPY

REQUEST

The undersigned requests that the present international application be processed according to the Patent Cooperation Treaty.

For receiving Office use only

International Application No.

PCT/US 03/41642

International Filing Date

29 DEC 2003 (29.12.03)

PCT INTERNATIONAL

Name of receiving Office and "PCT International Application"

APPLICATION ROWS

Applicant's or agent's file reference  
(if desired) (12 characters maximum)

TPI-2900C3XC234

**Box No. I TITLE OF INVENTION**

Pharmaceutical Propylene Glycol Solvate Compositions

**Box No. II APPLICANT**☐ This person is also inventor

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

TRANSFORM PHARMACEUTICALS, INC.

29 Hartwell Avenue  
Lexington, MA 02421

US

Telephone No.

Facsimile No.

Teleprinter No.

Applicant's registration No. with the Office

State (that is, country) of nationality:

US

State (that is, country) of residence:

US

This person is applicant  
for the purposes of:all designated  
Statesall designated States except  
the United States of Americathe United States  
of America onlythe States indicated in  
the Supplemental Box**Box No. III FURTHER APPLICANT(S) AND/OR (FURTHER) INVENTOR(S)**

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

TAWA, MARK

111 Kenrick Street  
Brighton, MA 02135  
US

This person is:



applicant only



applicant and inventor

inventor only (If this check-box  
is marked, do not fill in below.)

Applicant's registration No. with the Office

State (that is, country) of nationality:

US

State (that is, country) of residence:

US

This person is applicant  
for the purposes of:all designated  
Statesall designated States except  
the United States of Americathe United States  
of America onlythe States indicated in  
the Supplemental Box

Further applicants and/or (further) inventors are indicated on a continuation sheet.

**Box No. IV AGENT OR COMMON REPRESENTATIVE; OR ADDRESS FOR CORRESPONDENCE**

The person identified below is hereby/has been appointed to act on behalf of the applicant(s) before the competent International Authorities as:



agent

common  
representative

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.)

EISENSCHENK, FRANK C., Ph.D.

Saliwanchik, Lloyd & Saliwanchik  
2421 N.W. 41st Street, Suite A-1  
Gainesville, Florida 32606  
US

Telephone No.

(352) 375-8100

Facsimile No.

(352) 372-5800

Teleprinter No.

Agent's registration No. with the Office

45,332



Address for correspondence: Mark this check-box where no agent or common representative is/has been appointed and the space above is used instead to indicate a special address to which correspondence should be sent.

## Continuation of Box No. III FURTHER APPLICANT(S) AND/OR (FURTHER) INVENTOR(S)

If none of the following sub-boxes is used, this sheet should not be included in the request.

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

ALMARSSON, ÖRN  
22 Farmington Drive  
Shrewsbury, MA 01545  
US

This person is:

- ☐ applicant only  
☒ applicant and inventor  
☐ inventor only (If this check-box is marked, do not fill in below.)

Applicant's registration No. with the Office

State (that is, country) of nationality:  
IS

State (that is, country) of residence:  
US

This person is applicant for the purposes of:

- ☐ all designated States ☐ all designated States except the United States of America ☒ the United States of America only ☐ the States indicated in the Supplemental Box

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

REMENAR, JULIUS  
9 Eaton Road  
Framingham, MA 01701  
US

This person is:

- ☐ applicant only  
☒ applicant and inventor  
☐ inventor only (If this check-box is marked, do not fill in below.)

Applicant's registration No. with the Office

State (that is, country) of nationality:  
US

State (that is, country) of residence:  
US

This person is applicant for the purposes of:

- ☐ all designated States ☐ all designated States except the United States of America ☒ the United States of America only ☐ the States indicated in the Supplemental Box

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

This person is:

- ☐ applicant only  
☐ applicant and inventor  
☐ inventor only (If this check-box is marked, do not fill in below.)

Applicant's registration No. with the Office

State (that is, country) of nationality:

State (that is, country) of residence:

This person is applicant for the purposes of:

- ☐ all designated States ☐ all designated States except the United States of America ☐ the United States of America only ☐ the States indicated in the Supplemental Box

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

This person is:

- ☐ applicant only  
☐ applicant and inventor  
☐ inventor only (If this check-box is marked, do not fill in below.)

Applicant's registration No. with the Office

State (that is, country) of nationality:

State (that is, country) of residence:

This person is applicant for the purposes of:

- ☐ all designated States ☐ all designated States except the United States of America ☐ the United States of America only ☐ the States indicated in the Supplemental Box

☐ Further applicants and/or (further) inventors are indicated on another continuation sheet.



## Box No. V DESIGNATION OF STATES

Mark the applicable check-boxes below; at least one must be marked.

The following designations are hereby made under Rule 4.9(a):

## Regional Patent

- ☒ **AP ARIPO Patent:** GH Ghana, GM Gambia, KE Kenya, LS Lesotho, MW Malawi, MZ Mozambique, SD Sudan, SL Sierra Leone, SZ Swaziland, TZ United Republic of Tanzania, UG Uganda, ZM Zambia, ZW Zimbabwe, and any other State which is a Contracting State of the Harare Protocol and of the PCT (if other kind of protection or treatment desired, specify on dotted line) .....
- ☒ **EA Eurasian Patent:** AM Armenia, AZ Azerbaijan, BY Belarus, KG Kyrgyzstan, KZ Kazakhstan, MD Republic of Moldova, RU Russian Federation, TJ Tajikistan, TM Turkmenistan, and any other State which is a Contracting State of the Eurasian Patent Convention and of the PCT
- ☒ **EP European Patent:** AT Austria, BE Belgium, BG Bulgaria, CH & LI Switzerland and Liechtenstein, CY Cyprus, CZ Czech Republic, DE Germany, DK Denmark, EE Estonia, ES Spain, FI Finland, FR France, GB United Kingdom, GR Greece, HU Hungary, IE Ireland, IT Italy, LU Luxembourg, MC Monaco, NL Netherlands, PT Portugal, RO Romania, SE Sweden, SI Slovenia, SK Slovakia, TR Turkey, and any other State which is a Contracting State of the European Patent Convention and of the PCT
- ☒ **OA OAPI Patent:** BF Burkina Faso, BJ Benin, CF Central African Republic, CG Congo, CI Côte d'Ivoire, CM Cameroon, GA Gabon, GN Guinea, GQ Equatorial Guinea, GW Guinea-Bissau, ML Mali, MR Mauritania, NE Niger, SN Senegal, TD Chad, TG Togo, and any other State which is a member State of OAPI and a Contracting State of the PCT (if other kind of protection or treatment desired, specify on dotted line) .....

## National Patent (if other kind of protection or treatment desired, specify on dotted line):

- |   |  |   |
|---|--|---|
| <input checked="" type="checkbox"/> AE United Arab Emirates               | <input checked="" type="checkbox"/> HR Croatia                                   | <input checked="" type="checkbox"/> OM Oman                             |
| <input checked="" type="checkbox"/> AG Antigua and Barbuda                | <input checked="" type="checkbox"/> HU Hungary                                   | <input checked="" type="checkbox"/> PG Papua New Guinea                 |
| <input checked="" type="checkbox"/> AL Albania                            | <input checked="" type="checkbox"/> ID Indonesia                                 | <input checked="" type="checkbox"/> PH Philippines                      |
| <input checked="" type="checkbox"/> AM Armenia                            | <input checked="" type="checkbox"/> IL Israel                                    | <input checked="" type="checkbox"/> PL Poland                           |
| <input checked="" type="checkbox"/> AT Austria                            | <input checked="" type="checkbox"/> IN India                                     | <input checked="" type="checkbox"/> PT Portugal                         |
| <input checked="" type="checkbox"/> AU Australia                          | <input checked="" type="checkbox"/> IS Iceland                                   | <input checked="" type="checkbox"/> RO Romania                          |
| <input checked="" type="checkbox"/> AZ Azerbaijan                         | <input checked="" type="checkbox"/> JP Japan                                     | <input checked="" type="checkbox"/> RU Russian Federation               |
| <input checked="" type="checkbox"/> BA Bosnia and Herzegovina             | <input checked="" type="checkbox"/> KE Kenya                                     | <input checked="" type="checkbox"/> SC Seychelles                       |
| <input checked="" type="checkbox"/> BB Barbados                           | <input checked="" type="checkbox"/> KG Kyrgyzstan                                | <input checked="" type="checkbox"/> SD Sudan                            |
| <input checked="" type="checkbox"/> BG Bulgaria                           | <input checked="" type="checkbox"/> KP Democratic People's Republic of Korea     | <input checked="" type="checkbox"/> SE Sweden                           |
| <input checked="" type="checkbox"/> BR Brazil                             | <input checked="" type="checkbox"/> KR Republic of Korea                         | <input checked="" type="checkbox"/> SG Singapore                        |
| <input checked="" type="checkbox"/> BY Belarus                            | <input checked="" type="checkbox"/> KZ Kazakhstan                                | <input checked="" type="checkbox"/> SK Slovakia                         |
| <input checked="" type="checkbox"/> BZ Belize                             | <input checked="" type="checkbox"/> LC Saint Lucia                               | <input checked="" type="checkbox"/> SL Sierra Leone                     |
| <input checked="" type="checkbox"/> CA Canada                             | <input checked="" type="checkbox"/> LK Sri Lanka                                 | <input checked="" type="checkbox"/> SY Syrian Arab Republic             |
| <input checked="" type="checkbox"/> CH & LI Switzerland and Liechtenstein | <input checked="" type="checkbox"/> LR Liberia                                   | <input checked="" type="checkbox"/> TJ Tajikistan                       |
| <input checked="" type="checkbox"/> CN China                              | <input checked="" type="checkbox"/> LS Lesotho                                   | <input checked="" type="checkbox"/> TM Turkmenistan                     |
| <input checked="" type="checkbox"/> CO Colombia                           | <input checked="" type="checkbox"/> LT Lithuania                                 | <input checked="" type="checkbox"/> TN Tunisia                          |
| <input checked="" type="checkbox"/> CR Costa Rica                         | <input checked="" type="checkbox"/> LU Luxembourg                                | <input checked="" type="checkbox"/> TR Turkey                           |
| <input checked="" type="checkbox"/> CU Cuba                               | <input checked="" type="checkbox"/> LV Latvia                                    | <input checked="" type="checkbox"/> TT Trinidad and Tobago              |
| <input checked="" type="checkbox"/> CZ Czech Republic                     | <input checked="" type="checkbox"/> MA Morocco                                   | <input checked="" type="checkbox"/> TZ United Republic of Tanzania      |
| <input checked="" type="checkbox"/> DE Germany                            | <input checked="" type="checkbox"/> MD Republic of Moldova                       | <input checked="" type="checkbox"/> UA Ukraine                          |
| <input checked="" type="checkbox"/> DK Denmark                            | <input checked="" type="checkbox"/> MG Madagascar                                | <input checked="" type="checkbox"/> UG Uganda                           |
| <input checked="" type="checkbox"/> DM Dominica                           | <input checked="" type="checkbox"/> MK The former Yugoslav Republic of Macedonia | <input checked="" type="checkbox"/> US United States of America         |
| <input checked="" type="checkbox"/> DZ Algeria                            | <input checked="" type="checkbox"/> MN Mongolia                                  | <input checked="" type="checkbox"/> Continuation-in-part                |
| <input checked="" type="checkbox"/> EC Ecuador                            | <input checked="" type="checkbox"/> MWMalawi                                     | <input checked="" type="checkbox"/> UZ Uzbekistan                       |
| <input checked="" type="checkbox"/> EE Estonia                            | <input checked="" type="checkbox"/> MX Mexico                                    | <input checked="" type="checkbox"/> VC Saint Vincent and the Grenadines |
| <input checked="" type="checkbox"/> ES Spain                              | <input checked="" type="checkbox"/> MZ Mozambique                                | <input checked="" type="checkbox"/> VN Viet Nam                         |
| <input checked="" type="checkbox"/> FI Finland                            | <input checked="" type="checkbox"/> NI Nicaragua                                 | <input checked="" type="checkbox"/> YU Serbia and Montenegro (CS)       |
| <input checked="" type="checkbox"/> GB United Kingdom                     | <input checked="" type="checkbox"/> NO Norway                                    | <input checked="" type="checkbox"/> ZA South Africa                     |
| <input checked="" type="checkbox"/> GD Grenada                            | <input checked="" type="checkbox"/> NZ New Zealand                               | <input checked="" type="checkbox"/> ZM Zambia                           |
| <input checked="" type="checkbox"/> GE Georgia                            |  | <input checked="" type="checkbox"/> ZW Zimbabwe                         |
| <input checked="" type="checkbox"/> GH Ghana                              |  |   |
| <input checked="" type="checkbox"/> GM Gambia                             |  |   |

Check-boxes below reserved for designating States which have become party to the PCT after issuance of this sheet:

☒ Botswana (BW)

**Precautionary Designation Statement:** In addition to the designations made above, the applicant also makes under Rule 4.9(b) all other designations which would be permitted under the PCT except any designation(s) indicated in the Supplemental Box as being excluded from the scope of this statement. The applicant declares that those additional designations are subject to confirmation and that any designation which is not confirmed before the expiration of 15 months from the priority date is to be regarded as withdrawn by the applicant at the expiration of that time limit. (Confirmation (including fees) must reach the receiving Office within the 15-month time limit.)



**TRANSMITTAL LETTER TO THE  
UNITED STATES RECEIVING OFFICE**

Date	02 March 2004
International Application No.	PCT/US03/41642
Attorney Docket No.	TPI-2900C3XC2

**I. Certification under 37 CFR 1.10 (if applicable)**

ER716411586US

02 March 2004

Date of Deposit

I hereby certify that the application/correspondence attached hereto is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Assistant Commissioner for Patents, Washington, D.C. 20231.

  
Signature of person mailing correspondence

Betty Audette

Typed or printed name of person mailing correspondence

**II. ☐ New International Application**

TITLE

Earliest priority date  
(Day/Month/Year)

**SCREENING DISCLOSURE INFORMATION:** In order to assist in screening the accompanying international application for purposes of determining whether a license for foreign transmittal should and could be granted and for other purposes, the following information is supplied. (Note: check as many boxes as apply):

- A. ☐ The invention disclosed was not made in the United States.  
 B. ☐ There is no prior U.S. application relating to this invention.  
 C. ☐ The following prior U.S. application(s) contain subject matter which is related to the invention disclosed in the attached international application. (NOTE: priority to these applications may or may not be claimed on form PCT/RO/101 (Request) and this listing does not constitute a claim for priority.)

application no.		filed on	
application no.		filed on	

- D. ☐ The present international application contains additional subject matter not found in the prior U.S. application(s) identified in paragraph C. above. The additional subject matter is found on pages  and ☐ DOES NOT ALTER ☐ MIGHT BE CONSIDERED TO ALTER the general nature of the invention in a manner which would require the U.S. application to have been made available for inspection by the appropriate defense agencies under 35 U.S.C. 181 and 37 CFR 5.1. See 37 CFR 5.15

**III. ☒ A Response to an Invitation from the RO/US. The following document(s) is(are) enclosed:**

- A. ☐ A Request for An Extension of Time to File a Response  
 B. ☒ A Power of Attorney (General or Regular) Transform Pharmaceuticals, Inc.; Mark Tawa;  
 C. ☒ Replacement pages: Orn Almarsson; Julius Remenar

pages	4	of the request (PCT/RO/101)	pages		of the figures
pages		of the description	pages		of the abstract
pages		of the claims			

- D. ☐ Submission of Priority Documents

Priority document		Priority document	
-------------------	--	-------------------	--

- E. ☐ Fees as specified on attached Fee Calculation sheet form PCT/RO/101 annex

**IV. ☐ A Request for Rectification under PCT 91 ☐ A Petition ☐ A Sequence Listing Diskette**

**V. ☐ Other (please specify):**

The person signing this form is the:

☐ Applicant

Frank C. Eisenschenk, Ph.D.

☒ Attorney/Agent (Reg. No.)  
45,332

Typed name of signer

☐ Common Representative

Signature

## Supplemental Box

If the Supplemental Box is not used, this sheet should not be included in the request.

1. If, in any of the Boxes, except Boxes Nos. VIII(i) to (v) for which a special continuation box is provided, the space is insufficient to furnish all the information: in such case, write "Continuation of Box No. ...." (indicate the number of the Box) and furnish the information in the same manner as required according to the captions of the Box in which the space was insufficient, in particular:
  - (i) if more than two persons are to be indicated as applicants and/or inventors and no "continuation sheet" is available: in such case, write "Continuation of Box No. III" and indicate for each additional person the same type of information as required in Box No. III. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below;
  - (ii) if, in Box No. II or in any of the sub-boxes of Box No. III, the indication "the States indicated in the Supplemental Box" is checked: in such case, write "Continuation of Box No. II" or "Continuation of Box No. III" or "Continuation of Boxes No. II and No. III" (as the case may be), indicate the name of the applicant(s) involved and, next to (each) such name, the State(s) (and/or, where applicable, ARIPO, Eurasian, European or OAPI patent) for the purposes of which the named person is applicant;
  - (iii) if, in Box No. II or in any of the sub-boxes of Box No. III, the inventor or the inventor/applicant is not inventor for the purposes of all designated States or for the purposes of the United States of America: in such case, write "Continuation of Box No. II" or "Continuation of Box No. III" or "Continuation of Boxes No. II and No. III" (as the case may be), indicate the name of the inventor(s) and, next to (each) such name, the State(s) (and/or, where applicable, ARIPO, Eurasian, European or OAPI patent) for the purposes of which the named person is inventor;
  - (iv) if, in addition to the agent(s) indicated in Box No. IV, there are further agents: in such case, write "Continuation of Box No. IV" and indicate for each further agent the same type of information as required in Box No. IV;
  - (v) if, in Box No. V, the name of any State (or OAPI) is accompanied by the indication "patent of addition," or "certificate of addition," or if, in Box No. V, the name of the United States of America is accompanied by an indication "continuation" or "continuation-in-part": in such case, write "Continuation of Box No. V" and the name of each State involved (or OAPI), and after the name of each such State (or OAPI), the number of the parent title or parent application and the date of grant of the parent title or filing of the parent application;
  - (vi) if, in Box No. VI, there are more than five earlier applications whose priority is claimed: in such case, write "Continuation of Box No. VI" and indicate for each additional earlier application the same type of information as required in Box No. VI.
2. If, with regard to the precautionary designation statement contained in Box No. V, the applicant wishes to exclude any State(s) from the scope of that statement: in such case, write "Designation(s) excluded from precautionary designation statement" and indicate the name or two-letter code of each State so excluded.

## Continuation of Box IV:

SALIWANCHIK, David R.; LLOYD, Jeff; PACE, Doran R.; SANDERS, Jay M.; KYLE, Jean; PARKER, James S.; LADWIG, Glenn P.; EISENSCHENK, Frank C.; EFRON, Margaret H.; and DANIELS, Gwendolyn L.

THE ABOVE ARE MEMBERS OF THE FIRM OF SALIWANCHIK, LLOYD & SALIWANCHIK, AND HAVE THE SAME ADDRESS AS THE INDIVIDUAL LISTED IN BOX IV.

## Continuation of Box V:

This application is a continuation-in-part of PCT/US03/XXXXX, filed on December 24, 2003, entitled "Pharmaceutical Compositions With Improved Dissolution" (Attorney Docket No. TPI-1700CXC2 PCT) by Tawa et al., which claims the benefit of U.S. Provisional Applications 60/437,516 (filed December 30, 2002); and 60/456,027 (filed March 18, 2003). Said PCT/US03/XXXXX is a continuation-in-part of PCT/US03/19574, filed June 21, 2003, which claims the benefit of U.S. Provisional Applications 60/456,027, filed March 18, 2003, and 60/437,516, filed December 30, 2002; said PCT/US03/XXXXX is also a continuation-in-part of U.S. Application 10/601,092, filed June 20, 2003, which claims the benefit of U.S. Provisional Applications 60/456,027, filed March 18, 2003, and 60/437,516, filed December 30, 2002.

This application also claims the benefit of U.S. Provisional Application Serial Nos. 60/437,516 (filed December 30, 2002); 60/441,335 (filed January 21, 2003); 60/456,608 (filed March 21, 2003); 60/459,501 (filed April 1, 2003); and 60/486,713 (filed July 11, 2003).

The content of each of these applications is hereby incorporated by reference in its entirety.

## Continuation of Box VI:

21/06/2003 (21 June 2003): PCT/US03/19574 (PCT)

11/07/2003 (11 July 2003): US 60/486,713 (US)

24/12/2003 (24 December 2003):  
PCT/US03/XXXXX (PCT)

**Box No. VI PRIORITY CLAIM**

The priority of the following earlier application(s) is hereby claimed:

Filing date of earlier application (day/month/year)	Number of earlier application	Where earlier application is:		
		national application: country or Member of WTO	regional application:* regional Office	international application: receiving Office
item (1) 30/12/2002 30 December 2002	US 60/437,516	US		
item (2) 21/01/2003 21 January 2003	US 60/441,335	US		
item (3) 21/03/2003 21 March 2003	US 60/456,608	US		
item (4) 01/04/2003 1 April 2003	US 60/459,501	US		
item (5) 20/06/2003 20 June 2003	US 10/601,092	US		

☒ Further priority claims are indicated in the Supplemental Box.

The receiving Office is requested to prepare and transmit to the International Bureau a certified copy of the earlier application(s) (only if the earlier application was filed with the Office which for the purposes of this international application is the receiving Office) identified above as:

☒ all items ☐ item (1) ☐ item (2) ☐ item (3) ☐ item (4) ☐ item (5) ☐ other, see Supplemental Box

\* Where the earlier application is an ARIPO application, indicate at least one country party to the Paris Convention for the Protection of Industrial Property or one Member of the World Trade Organization for which that earlier application was filed (Rule 4.10(b)(ii)): . . . .

**Box No. VII INTERNATIONAL SEARCHING AUTHORITY**

Choice of International Searching Authority (ISA) (if two or more International Searching Authorities are competent to carry out the international search, indicate the Authority chosen; the two-letter code may be used):

ISA / EP

Request to use results of earlier search; reference to that search (if an earlier search has been carried out by or requested from the International Searching Authority):

Date (day/month/year) Number Country (or regional Office)

**Box No. VIII DECLARATIONS**

The following declarations are contained in Boxes Nos. VIII (i) to (v) (mark the applicable check-boxes below and indicate in the right column the number of each type of declaration):

		Number of declarations
<input type="checkbox"/> Box No. VIII (i)	Declaration as to the identity of the inventor	:
<input type="checkbox"/> Box No. VIII (ii)	Declaration as to the applicant's entitlement, as at the international filing date, to apply for and be granted a patent	:
<input type="checkbox"/> Box No. VIII (iii)	Declaration as to the applicant's entitlement, as at the international filing date, to claim the priority of the earlier application	:
<input type="checkbox"/> Box No. VIII (iv)	Declaration of inventorship (only for the purposes of the designation of the United States of America)	:
<input type="checkbox"/> Box No. VIII (v)	Declaration as to non-prejudicial disclosures or exceptions to lack of novelty	:



## Box No. IX CHECK LIST; LANGUAGE OF FILING

This international application contains:

(a) in paper form, the following number of sheets:

request (including declaration sheets) : 6  
description (excluding sequence listings and/or tables related thereto) : 296  
claims : 5  
abstract : 1  
drawings : 15

Sub-total number of sheets : 323

sequence listings :  
tables related thereto :

(for both, actual number of sheets if filed in paper form, whether or not also filed in computer readable form; see (c) below)

Total number of sheets : 323

(b) ☐ only in computer readable form (Section 801(a)(i))(i) ☐ sequence listings(ii) ☐ tables related thereto(c) ☐ also in computer readable form (Section 801(a)(ii))(i) ☐ sequence listings(ii) ☐ tables related thereto

Type and number of carriers (diskette, CD-ROM, CD-R or other) on which are contained the

☐ sequence listings: .....☐ tables related thereto: .....

(additional copies to be indicated under items 9(ii) and/or 10(ii), in right column)

This international application is accompanied by the following item(s) (mark the applicable check-boxes below and indicate in right column the number of each item):

1. ☒ fee calculation sheet : 1  
2. ☐ original separate power of attorney :  
3. ☐ original general power of attorney :  
4. ☐ copy of general power of attorney; reference number, if any: ..... :  
5. ☐ statement explaining lack of signature :  
6. ☐ priority document(s) identified in Box No. VI as item(s): ..... :  
7. ☐ translation of international application into (language): ..... :  
8. ☐ separate indications concerning deposited microorganism or other biological material :  
9. ☐ sequence listings in computer readable form (indicate type and number of carriers)  
(i) ☐ copy submitted for the purposes of international search under Rule 13ter only (and not as part of the international application) :  
(ii) ☐ (only where check-box (b)(i) or (c)(i) is marked in left column) additional copies including, where applicable, the copy for the purposes of international search under Rule 13ter :  
(iii) ☐ together with relevant statement as to the identity of the copy or copies with the sequence listings mentioned in left column :  
10. ☐ tables in computer readable form related to sequence listings (indicate type and number of carriers)  
(i) ☐ copy submitted for the purposes of international search under Section 802(b-quater) only (and not as part of the international application) :  
(ii) ☐ (only where check-box (b)(ii) or (c)(ii) is marked in left column) additional copies including, where applicable, the copy for the purposes of international search under Section 802(b-quater) :  
(iii) ☐ together with relevant statement as to the identity of the copy or copies with the tables mentioned in left column :  
11. ☒ other (specify): Transmittal Letter to US/RO ..... : 2

Figure of the drawings which should accompany the abstract:


None

Language of filing of the international application:

English

## Box No. X SIGNATURE OF APPLICANT, AGENT OR COMMON REPRESENTATIVE

Next to each signature, indicate the name of the person signing and the capacity in which the person signs (if such capacity is not obvious from reading the request).



Frank C. Eisenschenk, Ph.D.

For receiving Office use only

1. Date of actual receipt of the purported international application:

DT04 Rec'd PCT/PTO 29 DEC 2003  
29.12.03

3. Corrected date of actual receipt due to later but timely received papers or drawings completing the purported international application:

4. Date of timely receipt of the required corrections under PCT Article 11(2):

5. International Searching Authority (if two or more are competent): ISA /

EP

6. ☐ Transmittal of search copy delayed until search fee is paid

2. Drawings:

☒ received:☐ not received:

For International Bureau use only

Date of receipt of the record copy by the International Bureau:

**PCT****FEE CALCULATION SHEET**

Annex to the Request

For receiving Office use only

International Application No.

**PCT/US 03/41642**Applicant's or agent's  
file reference**TPI-2900C3XC2**

Date stamp of the receiving Office

Applicant

**TRANSFORM PHARMACEUTICALS, INC.****CALCULATION OF PRESCRIBED FEES**1. TRANSMITTAL FEE . . . . . **240.00** **T**2. SEARCH FEE . . . . . **1,119.00** **S**International search to be carried out by **EP**  
(If two or more International Searching Authorities are competent to carry out the international search, indicate the name of the Authority which is chosen to carry out the international search.)

3. INTERNATIONAL FEE

**Basic Fee**Where items (b) and/or (c) of Box No. IX apply, enter Sub-total number of sheets } **323**  
Where items (b) and (c) of Box No. IX do not apply, enter Total number of sheets }**b1** first 30 sheets . . . . . **476.00** **b1****b2** **293** x **12.00** = **3,516.00** **b2**  
number of sheets in excess of 30 fee per sheet**b3** additional component (only if sequence listings and/or tables related thereto are filed in computer readable form under Section 801(a)(i), or both in that form and on paper, under Section 801(a)(ii)):**400** x **12.00** = **0.00** **b3**  
fee per sheetAdd amounts entered at b1, b2 and b3 and enter total at B . . . . . **3,992.00** **B****Designation Fees**The international application contains **98** designations.**5** x **104.00** = **520.00** **D**  
number of designation fees payable (maximum 5) amount of designation feeAdd amounts entered at B and D and enter total at I . . . . . **5,871.00** **I**

(Applicants from certain States are entitled to a reduction of 75% of the international fee. Where the applicant is (or all applicants are) so entitled, the total to be entered at I is 25% of the sum of the amounts entered at B and D.)

4. FEE FOR PRIORITY DOCUMENT (if applicable) . . . . . **160.00** **P**5. TOTAL FEES PAYABLE . . . . . **6,031.00**

Add amounts entered at T, S, I and P, and enter total in the TOTAL box

**TOTAL**☐ The designation fees are not paid at this time.**MODE OF PAYMENT**☒ authorization to charge  
deposit account (see below)☐ postal money order☐ cash☐ coupons☐ cheque☐ bank draft☐ revenue stamps☐ other (specify):**AUTHORIZATION TO CHARGE (OR CREDIT) DEPOSIT ACCOUNT**

(This mode of payment may not be available at all receiving Offices)

☐ Authorization to charge the total fees indicated above.☐ (This check-box may be marked only if the conditions for deposit accounts of the receiving Office so permit) Authorization to charge any deficiency or credit any overpayment in the total fees indicated above.☐ Authorization to charge the fee for priority document.Receiving Office: RO/ **US**Deposit Account No.: **19-0065**Date: **December 29, 2003**Name: **Frank C. Eisenschenk**Signature: 

## **Pharmaceutical Propylene Glycol Solvate Compositions**

### **INCORPORATION BY REFERENCE**

The content of PCT/US03/XXXXX, filed on December 24, 2003, entitled "Pharmaceutical Compositions With Improved Dissolution" (Attorney Docket No. TPI-1700CXC2 PCT) by Tawa et al.; U.S. Provisional Application Serial Nos. 60/437,516 (filed December 30, 2002); 60/441,335 (filed January 21, 2003); 60/456,608 (filed March 21, 2003); 60/459,501 (filed April 1, 2003); 60/486,713 (filed July 11, 2003); 60/437,516, filed December 30, 2002; and 60/441,335, filed January 21, 2003, are incorporated herein by reference in its entirety.

### **FIELD OF THE INVENTION**

The present invention relates to drug-containing compositions, pharmaceutical compositions comprising such drugs, and methods for preparing same.

### **BACKGROUND OF THE INVENTION**

Drugs in pharmaceutical compositions can be prepared in a variety of different forms. Such drugs can be prepared so as to have a variety of different chemical forms including chemical derivatives or salts. Such drugs can also be prepared to have different physical forms. For example, the drugs may be amorphous or may have different crystalline polymorphs, perhaps existing in different solvation or hydration states. By varying the form of a drug, it is possible to vary the physical properties thereof. For example, crystalline polymorphs typically have different solubilities from one another, such that a more thermodynamically stable polymorph is less soluble than a less thermodynamically stable polymorph. Pharmaceutical polymorphs can also differ in properties such as shelf-life, bioavailability, morphology, vapor pressure, density, color, and compressibility. Accordingly, variation of the solvation state of a drug is one of many ways in which to modulate the physical properties thereof.

A solvate may be defined as a compound formed by solvation, for example as a combination of solvent molecules with molecules or ions of a solute. Well known solvent molecules include water, alcohols and other polar organic solvents. Alcohols



include methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutanol, and t-butanol. Alcohols also include polymerized alcohols such as polyalkylene glycols (e.g., polyethylene glycol, polypropylene glycol). The best-known and preferred solvent is typically water, and solvate compounds formed by solvation with water are termed hydrates.

Propylene glycol (1,2-propanediol) is a known substance which is a liquid at ambient temperature. As far as the applicants are aware, propylene glycol is not generally well-known for use in the formation of solvates. US Pat. No. 3,970,651 does disclose the use of propylene glycol in the formation of a crystalline cephalosporin derivative. According to this disclosure a propylene glycolate derivative of a specific cephalosporin zwitterion may be formed in the presence of propylene glycol at acidic pH. This disclosure indicates that the propylene glycol derivative is more stable in solid form than the corresponding ethanolate, especially having excellent colour stability and thermal stability. No other solvates are disclosed in this US patent other than the specific solvate of cephalosporin.

In pharmaceutical formulations certain chemical classes of drugs pose particular problems in preparing pharmaceutical formulations for medical use. One such problem arises in the case of hygroscopic drugs, which tend to absorb water from the air. This is disadvantageous because it makes storage of the drug difficult and can cause degradation of the drug in some cases. Such compounds must be handled in controlled humidity environments during manufacture in order to prevent potency errors due to the changing weight of the drug. The final product must be packaged in individual moisture resistant blisters in order to prevent changes in or degradation of the product. Another problem arises from variable hydration states: molecules may change to a more or less stable form as water, a volatile liquid, is lost. Such changes have been known to cause some hydrates to become amorphous. Likewise, absorption of water by a hygroscopic molecule can plasticise the system and lead to recrystallization as a less stable polymorph.

#### SUMMARY OF THE INVENTION

Solvates are rarely used in pharmaceuticals because the solvents are usually volatile thus making it difficult to maintain the solvent in the crystal. If one were to desolvate

a pharmaceutical solvate or if it desolvated due to storage conditions or otherwise, it could lead to the formation of multiple polymorphs or complete collapse of the crystal structure, forming an amorphous compound with different physical properties. Obviously, this batch-to-batch variability and questionable shelf life is undesired. Typically people find solvates of common solvents, such as propanol and ethanol. Propylene glycol is similar in structure to propanol, but is not thought of as a solvent. Propylene glycol solvates of the present invention desolvate only at considerably higher temperatures and harsher conditions than traditional solvates. Propylene glycol solvates are also pharmaceutically acceptable in much larger amounts than one would expose people to with a traditional solvate. Thus, the propylene glycol solvates of the present invention have characteristics that are vastly superior to traditional solvates.

It has now been found that amorphous, crystalline, hygroscopic, or poorly soluble drugs can be made more soluble, more stable, and less hygroscopic and can be prepared simply, reliably and inexpensively.

In a first aspect, the present invention provides a pharmaceutical composition comprising a propylene glycol solvate of a drug which is hygroscopic or has low aqueous solubility.

It has surprisingly been found that by using propylene glycol to form a solvate of a hygroscopic drug, the hygroscopicity of the drug is decreased and/or the stability and aqueous solubility is increased. The drug is therefore much easier to formulate and store than its counterpart untreated or hydrated form.

A number of advantages have been found from the use of propylene glycol in this way. First of all, a higher temperature is required to remove propylene glycol as compared with water or ethanol. This therefore results in an increased thermal stability. Thus the invention further relates to methods of making a pharmaceutical solvate more stable at high temperatures by making a PG solvate of the drug. Secondly, propylene glycol solvates are generally more pharmaceutically acceptable than other common solvates, including those formed from alcohols other than ethanol. It has further been found that the PG solvates of the present invention have fewer

solvation states than hydration states. This is beneficial because production and quality of a drug can be more predictable and consistent. Thus an aspect of the present invention relates to methods of reducing the number of hydration states by making a PG solvate of a drug. PG solvates are also beneficial in addressing the problem of polymorphism. Thus an aspect of the present invention relates to methods of reducing the rate and extent a drug changes form and methods of reducing the chance of making an unwanted form because the PG solvates drive production of a single form. Another aspect of the present invention relates to changing the crystal habit of the drug crystal and preventing a drug crystalline habit from changing to a different habit.

The invention relates to making a pharmaceutical that can be made as a hydrate, more soluble or stable by forming a PG solvate of the drug.

The invention further relates to making a pharmaceutical more stable in a humid environment by making a PG solvate of the drug.

The invention further relates to making a crystalline compound from a pharmaceutical that does not readily crystallize by making a crystalline PG solvate of the drug.

The invention further relates to increasing the solubility of a crystalline pharmaceutical by making a PG solvate of the drug.

The invention further relates to methods of lowering the amount of drug solvation during wet granulation by making a PG solvate of the drug.

A particularly important aspect of the present invention is the realization that formation of propylene glycol solvates is applicable in a general way to drugs whereby the above advantages may be conferred. For example, the invention further relates to reducing the level of hygroscopicity of a pharmaceutical metal salt (crystalline, amorphous, solvate (e.g., hydrate)) by forming a PG solvate of the salt. Surprisingly, it has been found that the invention is particularly applicable to those drugs that are in the form of metal salts, such as alkali metal or alkaline earth metal



salts. This is especially the case where the metal is selected from sodium, potassium, lithium, calcium and magnesium. Such salts can be hygroscopic and it has hitherto been difficult to find a suitable general means of formulation for these drugs.

Generally, the molar ratio of propylene glycol to drug in the solvate is in the range 0.5 to 2, (e.g., 0.5, 1.0, 1.5, 2.0). Depending on the nature of the drug, the ratio of propylene glycol to drug in the solvate may be approximately 0.25, 0.33, 0.5, 0.67, 0.75, 1.0, 1.5, 2.0 or 3.0.

The composition may further comprise a pharmaceutically-acceptable diluent, excipient or carrier and details of pharmaceutical compositions are also set out in further detail below. The solvate of the pharmaceutical composition according to the present invention is preferably in a crystalline form.

Advantageously, the powder X-ray diffraction spectrum of the composition according to the invention differs from the corresponding powder X-ray diffraction spectrum of unsolvated drug by at least one property selected from:

- (i) a loss of at least one peak;
- (ii) shifting of more than half the peaks at the 2-theta angle by at least 0.2, 0.3, 0.4, or 0.5 degrees; or
- (iii) formation of at least one new peak.

It is preferred that the solvate is stable to temperatures of up to 50 degrees C under a stream of nitrogen gas in a thermogravimetric analysis apparatus.

The PXRD could be the same if there were a host-guest relationship and the PG was not completely frozen out. This would be an inclusion compound rather than a true solvate, but it may still be less hygroscopic than a hydrate, less prone to solvent loss than an inclusion with ethanol, less prone to being filled by some toxic co-solvent if PG fits well, and less prone to polymorphism to a less soluble form due to instability caused by a vacated void in the structure. The DSC transitions are likely to occur at different temperatures and have different intensities than for the parent molecule and its other hydrates/solvates.

In one aspect of the invention, the drug is a hygroscopic drug, including hygroscopic metal salts. A non-exhaustive list of hygroscopic drugs is set out in Table 1, along with their suppliers and routes of administration.

Table 1- Hygroscopic Drugs

Product (company)	Active ingredient	Hygroscopic	Route(s) of Administration
Solu-Medrol (P&U)	Methyl prednisolone succinate ester	X	Intravenous
Primaxin IV and IM (Merck)	Imipenem/cilastatin	X (cilastatin)	Intravenous/ Intramuscular
Vitravene Injection (CIBA)	Fomivirsen sodium	X	Intravenous
Baycol (Bayer)	Cerivastatin sodium	X	Oral
Synercid IV (Aventis)	Dalfopristin/Quinopristin	X	Intravenous
Factrel (Wyeth)	Gonadorelin HCl (decapeptide)	X	Intravenous/ Subcutaneous
Clindets Pledgets (Stiefel)	Clindamycin phosphate (ester prodrug)	X	Topical
Famvir (SKB)	Famciclovir	X	Oral
Nascobal Gel (Schwarz)	Cyanocobalamin	X	Intranasal
Tasmar (Roche)	Tolcapone	X	Oral
Ellence Injection (P&U)	Epirubicin HCl	X	Intravenous
Colestid (P&U)	Colestipol HCl (anion excluded)	X	Oral
Pfizerpen Injection (Pfizer)	Penicillin G potassium	X	Intravenous
Bacitracin Injection (Paddock)	Bacitracin (peptide)	X	Intravenous
Lescol (Novartis)	Fluvastatin sodium	X	Oral
Voltaren XR (Novartis)	Diclofenac sodium	X	Oral
Salagen (MGI)	Pilocarpine HCl	X	Oral
Urecholine injection (Merck)	Bethanechol chloride	X	Intravenous
Syprine (Merck)	Trientine 2(HCl)	X	Oral
Singulair chewable (Merck)	Montelukast sodium	X	Oral
Mustargen injection (Merck)	Mechlorethamine HCl	X	Intravenous
Hydrocortone phosphate injection (Merck)	Hydrocortisone phosphate ester	X	Intravenous
Decadron phosphate injection (Merck)	Dexamethasone phosphate ester	X	Intravenous
Gastrocrom (Medeva)	Chromolyn sodium	X	Oral
Mestinon (ICN)	Pyridostigmine bromide	X	Oral
Adipex-P (Gate)	Phentermine HCl	X	Oral
Micardis (Boehringer-	Telmisartan	X	Oral

Ingelh.)			
Cerubidine injection (Bedford)	Daunorubicin HCl	X	Intravenous
Biltricide (Bayer)	Praziquantel	X	Oral
Elmiron (Alza)	Pentosan polysulfate sodium	X	Oral

In one embodiment, the formulation comprises celecoxib. Although the invention is not limited to this particular drug, celecoxib provides a suitable example of the efficacy of the invention. Further details of celecoxib are set out below. In a further embodiment, the drug comprises naproxen, further details of which are also set out below.

In another aspect of the invention, the drug has low aqueous solubility. Typically, low aqueous solubility in the present application refers to a compound having a solubility in water which is less than or equal to 10mg/ml, when measured at 37 degrees C, and preferably less than or equal to 5mg/ml or 1mg/ml. "Low aqueous solubility" can further be defined as less than or equal to 900, 800, 700, 600, 500, 400, 300, 200 150 100, 90, 80, 70, 60, 50, 40, 30, 20 micrograms/ml, or further 10, 5 or 1 micrograms/ml, or further 900, 800, 700, 600, 500, 400, 300, 200 150, 100 90, 80, 70, 60, 50, 40, 30, 20, or 10 ng/ml, or less than 10 ng/ml when measured at 37 degrees C. Aqueous solubility can also be specified as less than 500, 400, 300, 200, 150, 100, 75, 50 or 25 mg/ml. As embodiments of the present invention, solubility can be increased 2, 3, 4, 5, 7, 10, 15, 20, 25, 50, 75, 100, 200, 300, 500, 750, 1000, 5000, or 10,000 times by making a PG solvate of the neutral (crystalline or amorphous), salt, or solvate form(e.g., hydrate, ethanolate, methanolate, isopropanolate, etc.). Further aqueous solubility can be measured in simulated gastric fluid (SGF) rather than water. SGF (non-diluted) of the present invention is made by combining 1 g/L Triton X-100 and 2 g/L NaCl in water and adjusting the pH with 200mM HCl to obtain a solution with a final pH=1.7.

PG solvates of steroids are also included as embodiments of the present invention. Steroids are an important class of drugs which have low aqueous solubility. Particularly important steroids include acetoxypregnenolone, alclometasone



dipropionate, aldosterone, anagestone , norethynodrel., androsterone, betamethasone, budesonide, chlormadinone , chloroprednisone , corticosterone, cortisone, cyclosporine, desogestrel , desoximethasone, desoxycorticosterone, dexamethasone, dichlorisone , dimethisterone, equilenin, equilin, estradiol, estriol, estrogens, estrone, ethisterone, ethynodiol di, ethynyl estradiol, fludrocortisone, fludrocortisone , flunolide, fluocinolone acetonide, fluorohydrocortisone, fluorometholone, fluoxymesterone, fluprednisolone, flurandrenolide, flurandrenolone, fluogestone , fluticasone propionate, hydrocortisone, hydroxydion, hydroxymethylprogesterone, hydroxyprogesterone, leuprolide , levonorgestrel, loteprednol etabonate, medroxyprogesterone , melengestrol , mesalamine, mestranol, methandrostenolone, methazolamide, methyl testosterone, methylandrostenediol, methylprednisolone, mometasone furoate, norelgestromin , norethandrolone, norethindrone, norethindrone, norethisterone, norgestimate, norgestrel, normethisterone, ondansetron hydrochloride, oxandrolone, oxymetholone, paramethasone, paramethasone , prednisolone, prednisolone , prednisone, pregnenolone, progesterone, prometholone, spironolactone, testosterone, testosterone enanthate, triamcinolone, triamcinolone acetonide, triamcinolone acetonide, betamethasone disodium phosphate (for some steroids alternative names are included). Formulating steroid drugs presents a problem because of their low aqueous solubility. Embodiments of the present invention are methods of increasing the solubility of steroids by making a PG solvate. Solubility can be specified as discussed above. It is difficult to make crystals of steroids because of their planar structure. Crystallization can be facilitated by making PG solvates. Thus, crystalline PG solvates of steroids and methods of making the same are included in embodiments of the present invention. Steroids generally tend to form non-stoichiometric channel hydrates in which water molecules are trapped in channels between planar steroid regions. Thus, embodiments of the present invention include inhibiting channel formation in steroids by making a PG solvate. Metal salts of steroid drugs can be made and are another example of hygroscopic drugs. Thus, steroid PG solvates are in accordance with one aspect of the present invention. Steroid drugs, whether hygroscopic or not, surprisingly and advantageously form stoichiometric solvates with propylene glycol. Further, the dissolution rate and solubility can be increased with propylene glycol solvates. Thus, the steroid solvates

have surprisingly new properties that make them more favourable for pharmaceutical use and are easier to handle than other forms such as hydrates.

In a further aspect, the present invention provides a method for preparing a propylene glycol solvate of a drug, which method comprises:

- (a) contacting propylene glycol with a drug in solution;
- (b) crystallizing a propylene glycol solvate of the drug from the solution;  
and
- (c) isolating the solvate. (the drug may be, for example, a hygroscopic drug or a drug of low aqueous solubility).

In a further aspect, the present invention provides a method for decreasing the hygroscopicity of a drug, which method comprises

- (a) contacting the drug with propylene glycol in solution;
- (b) crystallizing a propylene glycol solvate of the drug from the solution;  
and
- (c) isolating the solvate, wherein the solvate has decreased hygroscopicity as compared to the drug.

In a further aspect, the present invention provides a method for increasing the aqueous solubility of a drug, which method comprises

- (a) contacting the drug with propylene glycol in solution;
- (b) crystallizing a propylene glycol solvate of the drug from the solution;  
and
- (c) isolating the solvate, wherein the solvate has increased aqueous solubility as compared to the drug.

Typically, conditions for making a solvate are the same as for preparing the corresponding non-solvated form of the drug: the solvate of neutral compound would not be pH controlled; the solvate of an acid addition salt would be prepared by including PG with the drug and the acid; and the solvate of a base addition salt would involve adding the drug, the desired base, and the PG. Different co-solvent systems, anti-solvents, or temperature conditions may be used to encourage PG solvate

formation. Seed crystals may be added if they have previously been prepared and isolated.

The step of isolating the solvate may include separating the solution phase from the solvate. Any common method of separation may be employed, including filtration and decanting. The crystalline solvate may be rinsed one or more times with an appropriate solvent following filtration or decanting. The crystalline solvate is preferably dried to remove excess solution phase. Drying may be carried out by thermal processing, vacuum, blowing a stream of gas such as air, nitrogen, argon or another inert gas, or a combination of any or all of these methods. The intention of the rinsing and drying steps is to remove impurities including residual co-solvents and excess PG, acid, or base if used.

The invention will now be described in further detail, by way of example only, with reference to the accompanying drawings.

#### BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 shows a thermogravimetric analysis of a propylene glycol solvate of a celecoxib sodium salt.

Fig. 2A-D shows the PXRD pattern of a propylene glycol solvate of a celecoxib sodium salt.

Fig. 3 shows a thermogravimetric analysis of a propylene glycol solvate of a celecoxib potassium salt.

Fig. 4 shows the PXRD pattern of a propylene glycol solvate of a celecoxib potassium salt.

Fig. 5 shows a thermogravimetric analysis of a propylene glycol solvate of a celecoxib lithium salt.

Fig. 6 shows the PXRD pattern of a propylene glycol solvate of a celecoxib lithium salt.

Fig. 7 shows the thermogravimetric analysis of a propylene glycol solvate of naproxen sodium salt.

Fig. 8 shows a PXRD pattern of a propylene glycol solvate of naproxen sodium salt.

Fig. 9 shows the thermogravimetric analysis of a propylene glycol solvate of olanzapine form I.

Fig. 10 shows the differential scanning calorimetry thermogram of a propylene glycol solvate of olanzapine form I.

Fig. 11A-B shows PXRD patterns of a propylene glycol solvate of olanzapine form I.

Fig. 12 shows a packing diagram of olanzapine form I PG solvate.

Fig. 13 shows the thermogravimetric analysis of a propylene glycol solvate of cortisone acetate.

Fig. 14 shows the differential scanning calorimetry thermogram of a propylene glycol solvate of cortisone acetate.

Fig. 15A-B shows PXRD patterns of a propylene glycol solvate of cortisone acetate.

Fig. 16 shows a PXRD pattern of cortisone acetate.

Fig. 17 shows a packing diagram of cortisone acetate PG solvate.

Fig. 18 shows the thermogravimetric analysis of a trihydrate of celecoxib sodium PG solvate.

Fig. 19 shows the PXRD pattern of a trihydrate of celecoxib sodium PG solvate.

Fig. 20 shows the thermogravimetric analysis of a trihydrate of celecoxib sodium PG solvate.

Fig. 21 shows the PXRD pattern of a trihydrate of celecoxib sodium PG solvate.

Fig. 22 shows the PXRD pattern of celecoxib sodium salt.

Fig. 23 shows the PXRD pattern of celecoxib lithium salt.

Fig. 24 shows the PXRD pattern of celecoxib potassium salt.

## DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to propylene glycol solvate forms, preferably stoichiometric, of certain drugs, including those which are hygroscopic or have low aqueous solubility. Whilst the invention is applicable to any such drugs in general, metal salts of the non-steroidal anti-inflammatory drug celecoxib serve to illustrate



the present invention by way of example. Unlike traditional non-steroidal anti-inflammatory drugs (NSAIDs), celecoxib is a selective inhibitor of cyclooxygenase II (COX-2) which causes fewer side effects when administered to a subject. The present applicants have identified new forms of celecoxib that have improved properties, particularly as oral formulations. The applicants have found that a stable, crystalline sodium salt of celecoxib can be synthesised which is significantly more soluble in water than the neutral celecoxib on the market. This sodium salt, or other metal salts can subsequently be improved according to the present invention by the production of a propylene glycol solvate thereof.

Salts of celecoxib are formed by reaction of celecoxib with an acceptable base. Acceptable bases include, but are not limited to, metal hydroxides and alkoxides with sufficiently high  $pK_a$ 's (e.g.,  $pK_a$ 's greater than about 11 to about 12).

Naproxen is a further API which may be used to illustrate the present invention. Naproxen is a member of the ibufenac group of NSAIDs. This API is practically insoluble in water. Other examples of illustrations of the present invention include olanzapine and cortisone acetate.

An aspect of the present invention provides a pharmaceutical composition comprising a propylene glycol solvate of a drug that is less hygroscopic than the amorphorous, neutral crystalline, or salt crystalline form, and/or has greater aqueous solubility. Hygroscopicity should be assessed by dynamic vapor sorption analysis, in which 5-50 mg of the compound is suspended from a Cahn microbalance. The compound being analyzed should be placed in a non-hygroscopic pan and its weight should be measured relative to an empty pan composed of identical material and having nearly identical size, shape, and weight. Ideally, platinum pans should be used. The pans should be suspended in a chamber through which a gas, such as air or nitrogen, having a controlled and known percent relative humidity (%RH) is flowed until equilibrium criteria are met. Typical equilibrium criteria include weight changes of less than 0.01 % change over 3 minutes at constant humidity and temperature. The relative humidity should be measured for samples dried under dry nitrogen to constant weight (<0.01 % change in 3 minutes) at 40 degrees C unless doing so would de-

solvate or otherwise convert the material to an amorphous compound. In one aspect, the hygroscopicity of a dried compound can be assessed by increasing the RH from 5 to 95 % in increments of 5 % RH and then decreasing the RH from 95 to 5 % in 5 % increments to generate a moisture sorption isotherm. The sample weight should be allowed to equilibrate between each change in % RH. If the compound deliquesces or becomes amorphous between above 75 % RH, but below 95 % RH, the experiment should be repeated with a fresh sample and the relative humidity range for the cycling should be narrowed to 5-75 % RH or 10-75 % RH instead of 5-95 %RH. If the sample cannot be dried prior to testing due to lack of form stability, than the sample should be studied using two complete humidity cycles of either 10-75 % RH or 5-95 % RH, and the results of the second cycle should be used if there is significant weight loss at the end of the first cycle.

Hygroscopicity can be defined using various parameters. For purposes of the present invention, a non-hygroscopic molecule should not gain or lose more than 1.0%, or more preferably, 0.5 % weight at 25 degrees C when cycled between 10 and 75 % RH (relative humidity at 25 degrees C). The non-hygroscopic molecule more preferably should not gain or lose more than 1.0%, or more preferably, 0.5 % weight when cycled between 5 and 95 %RH at 25 degrees C, or more than 0.25 % of its weight between 10 and 75 % RH. Most preferably, a non-hygroscopic molecule will not gain or lose more than 0.25 % of its weight when cycled between 5 and 95 % RH.

Alternatively, for purposes of the present invention, hygroscopicity can be defined using the parameters of Callaghan et al., *Equilibrium moisture content of pharmaceutical excipients*, in Drug Dev. Ind. Pharm., Vol. 8, pp. 335-369 (1982). Callaghan et al. classified the degree of hygroscopicity into four classes.

Class 1: Non-hygroscopic  
at

Essentially no moisture increases occur  
relative humidities below 90%.

Class 2: Slightly hygroscopic

Essentially no moisture increases occur  
at relative humidities below 80%.

Class 3: Moderately hygroscopic

Moisture content does not increase more than 5% after storage for 1 week at relative humidities below 60%.

Class 4: Very hygroscopic    Moisture content increase may occur at relative humidities as low as 40 to 50%.

Alternatively, for purposes of the present invention, hygroscopicity can be defined using the parameters of the European Pharmacopoeia Technical Guide (1999, p. 86) which has defined hygroscopicity, based on the static method, after storage at 25 degrees C for 24 h at 80 % RH:

Slightly hygroscopic: Increase in mass is less than 2 percent m/m and equal to or greater than 0.2 percent m/m.

Hygroscopic: Increase in mass is less than 15 percent m/m and equal to or greater than 0.2 percent m/m.

Very hygroscopic: Increase in mass is equal to or greater than 15 percent m/m.

Deliquescent: Sufficient water is absorbed to form a liquid.

PG solvates of the present invention can be set forth as being in Class 1, Class 2, or Class 3, or as being Slightly hygroscopic, Hygroscopic, or Very hygroscopic. PG solvates of the present invention can also be set forth based on their ability to reduce hygroscopicity. Thus, preferred PG solvates of the present invention are less hygroscopic than the non-PG solvated reference compound, e.g., the reference compound of a celecoxib sodium salt PG solvate is celecoxib sodium salt. Further included in the present invention are PG solvates that do not gain or lose more than 1.0% weight at 25 degrees C when cycled between 10 and 75 % RH, wherein the reference compound gains or loses more than 1.0% weight under the same conditions. Further included in the present invention are PG solvates that do not gain or lose more

than 0.5% weight at 25 degrees C when cycled between 10 and 75 % RH, wherein the reference compound gains or loses more than 0.5% or more than 1.0% weight under the same conditions. Further included in the present invention are PG solvates that do not gain or lose more than 1.0% weight at 25 degrees C when cycled between 5 and 95 % RH, wherein the reference compound gains or loses more than 1.0% weight under the same conditions. Further included in the present invention are PG solvates that do not gain or lose more than 0.5% weight at 25 degrees C when cycled between 5 and 95 % RH, wherein the reference compound gains or loses more than 0.5% or more than 1.0% weight under the same conditions. Further included in the present invention are PG solvates that do not gain or lose more than 0.25% weight at 25 degrees C when cycled between 5 and 95 % RH, wherein the reference compound gains or loses more than 0.5% or more than 1.0% weight under the same conditions.

Further included in the present invention are PG solvates that have a hygroscopicity (according to Callaghan et al.) that is at least one class lower than the reference compound or at least two classes lower than the reference compound. Non-limiting examples include; a Class 1 PG solvate of a Class 2 reference compound, a Class 2 PG solvate of a Class 3 reference compound, a Class 3 PG solvate of a Class 4 reference compound, a Class 1 PG solvate of a Class 3 reference compound, a Class 1 PG solvate of a Class 4 reference compound, or a Class 2 PG solvate of a Class 4 reference compound.

Further included in the present invention are PG solvates that have a hygroscopicity (according to the European Pharmacopoeia Technical Guide) that is at least one class lower than the reference compound or at least two classes lower than the reference compound. Non-limiting examples include; a Slightly hygroscopic PG solvate of a Hygroscopic reference compound, a Hygroscopic PG solvate of a Very Hygroscopic reference compound, a Very Hygroscopic PG solvate of a Deliquescent reference compound, a Slightly hygroscopic PG solvate of a Very Hygroscopic reference compound, a Slightly hygroscopic PG solvate of a Deliquescent reference compound, a Hygroscopic PG solvate of a Deliquescent reference compound.



In another aspect of the present invention, the dissolution profile of the API (active pharmaceutical ingredient) (e.g. celecoxib) is modulated whereby the aqueous dissolution rate or the dissolution rate in simulated gastric fluid (SGF) or in simulated intestinal fluid (SIF), or in a solvent or plurality of solvents is increased. Dissolution rate is the rate at which API solids dissolve in a dissolution medium. For APIs whose absorption rates are faster than the dissolution rates (e.g., steroids), the rate-limiting step in the absorption process is often the dissolution rate. Because of a limited residence time at the absorption site, APIs that are not dissolved before they are removed from the intestinal absorption site are considered useless. Therefore, the rate of dissolution has a major impact on the performance of APIs that are poorly soluble. Because of this factor, the dissolution rate of APIs in solid dosage forms is an important, routine, quality control parameter used in the API manufacturing process.

$$\text{Dissolution rate} = K S (C_s - C) \quad (1)$$

where K is dissolution rate constant, S is the surface area,  $C_s$  is the apparent solubility, and C is the concentration of API in the dissolution media. For rapid API absorption,  $C_s - C$  is approximately equal to  $C_s$ . The dissolution rate of APIs may be measured by conventional means known in the art.

The increase in the dissolution rate of a composition of the present invention, as compared to the unsolvated form, may be specified, such as by 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100 %, or by 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 40, 50, 75, 100, 125, 150, 175, 200, 250, 300, 350, 400, 500, 1000, 10,000, or 100,000 fold greater than the unsolvated form in the same solution. Conditions under which the dissolution rate is measured are discussed above. The increase in dissolution may be further specified by the time the composition remains supersaturated. Examples of above embodiments include: compositions with a dissolution rate, at 37 degrees C and a pH of 7.0, that is increased at least 5 fold over the unsolvated form, compositions with a dissolution rate in SGF that is increased at least 5 fold over the unsolvated form, compositions with a dissolution rate in SIF that is increased at least 5 fold over the unsolvated form.

The present invention demonstrates that the length of time in which celecoxib or other APIs remains in solution can be increased to a surprising high degree by using a PG

solvate form as discussed herein. The presence of propylene glycol allows the formation of a supersaturated solution of the API and a high concentration of API will remain in solution for an extended period of time. Celecoxib, for example, has a solubility in water of less than 1 microgram/mL and cannot be maintained as a supersaturated solution for any appreciable time. The present invention has drawn compositions that can be maintained for a period of time (e.g., 15, 30, 45, 60, minutes and longer) as supersaturated solutions at concentrations 2, 3, 5, 7, 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100%, or by 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 40, 50, 75, 100, 125, 150, 175, 200, 250, 300, 350, 400, 500, 1000, 10,000, or 100,000 fold greater than the solubility of the unsolvated form in the same solution (e.g., water or SGF).

The methods of the present invention can be used to make a pharmaceutical API formulation with greater solubility, dissolution, bioavailability, AUC, reduced time to  $T_{max}$ , the average time from administration to reach peak blood serum levels, higher  $C_{max}$ , the average maximum blood serum concentration of API following administration, and longer  $T_{1/2}$ , the average terminal half-life of API blood serum concentration following  $T_{max}$ , when compared to the unsolvated form.

AUC is the area under the plot of plasma concentration of API (not logarithm of the concentration) against time after API administration. The area is conveniently determined by the "trapezoidal rule": the data points are connected by straight line segments, perpendiculars are erected from the abscissa to each data point, and the sum of the areas of the triangles and trapezoids so constructed is computed. When the last measured concentration ( $C_n$ , at time  $t_n$ ) is not zero, the AUC from  $t_n$  to infinite time is estimated by  $C_n/k_{el}$ .

The AUC is of particular use in estimating bioavailability of drugs, and in estimating total clearance of drugs ( $Cl_T$ ). Following single intravenous doses,  $AUC = D/Cl_T$ , where  $D$  is the dose, for single compartment systems obeying first-order elimination kinetics; alternatively,  $AUC = C_0/k_{el}$ , where  $k_{el}$  is the drug elimination rate constant. With routes other than the intravenous  $AUC = F \cdot D/Cl_T$ , where  $F$  is the bioavailability of the drug.

Thus, in a further aspect, the present invention provides a process for modulating the bioavailability of an API when administered in its normal and effective dose range, whereby the AUC is increased, the time to  $T_{max}$  is reduced, or  $C_{max}$  is increased, which process comprises the preparation of a PG solvate.

Examples of the above embodiments include: compositions with a time to  $T_{max}$  that is reduced by at least 10% as compared to the neutral free form, compositions with a time to  $T_{max}$  that is reduced by at least 20% over the free form, compositions with a time to  $T_{max}$  that is reduced by at least 40% over the free form, compositions with a time to  $T_{max}$  that is reduced by at least 50% over the free form, compositions with a  $T_{max}$  that is reduced by at least 60% over the free form, compositions with a  $T_{max}$  that is reduced by at least 70% over the free form, compositions with a  $T_{max}$  that is reduced by at least 80% over the free form, compositions with a  $C_{max}$  that is increased by at least 20% over the free form, compositions with a  $C_{max}$  that is increased by at least 30% over the free form, compositions with a  $C_{max}$  that is increased by at least 40% over the free form, compositions with a  $C_{max}$  that is increased by at least 50% over the free form, compositions with a  $C_{max}$  that is increased by at least 60% over the free form, compositions with a  $C_{max}$  that is increased by at least 70% over the free form, compositions with a  $C_{max}$  that is increased by at least 80% over the free form, compositions with a  $C_{max}$  that is increased by at least 2 times the free form, compositions with a  $C_{max}$  that is increased by at least 3 times the free form, compositions with a  $C_{max}$  that is increased by at least 4 times the free form, compositions with a  $C_{max}$  that is increased by at least 5 times the free form, compositions with a  $C_{max}$  that is increased by at least 6 times the free form, compositions with a  $C_{max}$  that is increased by at least 7 times the free form, compositions with a  $C_{max}$  that is increased by at least 8 times the free form, compositions with a  $C_{max}$  that is increased by at least 9 times the free form, compositions with a  $C_{max}$  that is increased by at least 10 times the free form, compositions with an AUC that is increased by at least 10% over the free form, compositions with an AUC that is increased by at least 20% over the free form, compositions with an AUC that is increased by at least 30% over the free form, compositions with an AUC that is increased by at least 40% over the free form, compositions with an AUC that is increased by at least 50% over the free form,

compositions with an AUC that is increased by at least 60% over the free form,  
compositions with an AUC that is increased by at least 70% over the free form,  
compositions with an AUC that is increased by at least 80% over the free form,  
compositions with an AUC that is increased by at least 1 times the free form,  
compositions with an AUC that is increased by at least 2 times the free form,  
compositions with an AUC that is increased by at least 3 times the free form, or  
compositions with an AUC that is increased by at least 4 times the free form.

The uptake of a drug by a subject can also be assessed in terms of maximum blood serum concentration and time to reach maximum blood serum concentration. Pharmaceutical compositions with a more rapid onset to therapeutic effect typically reach a higher maximum blood serum concentration ( $C_{\max}$ ) a shorter time after oral administration ( $T_{\max}$ ). Preferably, compositions of the present invention have a higher  $C_{\max}$  and/or a shorter  $T_{\max}$  than in the unsolvated form. The  $T_{\max}$  for the compositions of the present invention occurs within about 60 minutes, 55 minutes, 50 minutes, 45 minutes, 40 minutes, 35 minutes, 30 minutes, 25 minutes, 20 minutes, 15 minutes, 10 minutes, or within about 5 minutes of administration (e.g., oral administration). Even more preferably, the therapeutic effects of compositions of the present invention begin to occur within about 60 minutes, 55 minutes, 50 minutes, 45 minutes, 40 minutes, 35 minutes, 30 minutes, within about 25 minutes, within about 20 minutes, within about 15 minutes, within about 10 minutes, or within about 5 minutes of administration (e.g., oral administration).

Compositions of the present invention have a bioavailability greater than their respective unsolvated forms. In other embodiments, the compositions of the present invention have a bioavailability of at least 50%, 60%, 65%, 70%, 75%, 80%, 85%, 87%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%.

In a particular embodiment of the present invention, administration of celecoxib PG solvate to a subject may result in effective pain relief. Pain relief can be attained by *inter alia* reaching an appropriate blood serum concentration of a suitable analgesic. In the case of the selective COX-2 inhibitor celecoxib, about 250 ng/mL is an appropriate concentration for the relief of pain of various causes. Any standard



pharmacokinetic protocol can be used to determine blood serum concentration profile in humans following oral administration of a celecoxib formulation, and thereby establish whether that formulation meets the pharmacokinetic criteria set out herein. The prior art includes many examples of pharmacokinetic studies and as such US Pat. No. 6,579,895 and WO 01/91750 are hereby included as references in their entirety.

In a further aspect the present invention provides a process for improving the dose response of an API by making a composition of the present invention. Dose response is the quantitative relationship between the magnitude of response and the dose inducing the response and may be measured by conventional means known in the art. The curve relating therapeutic effect (as the dependent variable) to dose (as the independent variable) for an API-cell system is the "dose-response curve". Typically, the dose-response curve is the measured response to an API plotted against the dose of the API (mg/kg) given. The dose response curve can also be a curve of AUC against the dose of the API given.

The dose-response curve for many APIs (e.g. presently-marketed celecoxib (CELEBREX<sup>TM</sup>)) is nonlinear. Preferably, the dose-response curves for the PG solvate compositions of the present invention are linear or contain a larger linear region than presently-marketed celecoxib. A preferred embodiment of the present invention may incorporate a dose-response curve with a linear slope that is steeper than that of celecoxib. This would allow a faster-onset of therapeutic relief from a smaller dosage of API. An initially steep dose-response curve which gradually levels out could be employed to generate a controlled-release formulation. Also, the absorption or uptake of many APIs (e.g. presently-marketed celecoxib) depends in part on food effects, such that uptake of the API increases when taken with food, especially fatty food. Preferably, uptake of the PG solvates of the present invention exhibit a decreased dependence on food, such that the difference in uptake of the PG solvates when taken with food and when not taken with food is less than the difference in uptake of the unsolvated form.

The compositions of the present invention, including the active pharmaceutical ingredient (API) and formulations comprising the API, are suitably stable for

pharmaceutical use. Preferably, the API or formulations thereof of the present invention are stable such that when stored at 30 degrees C for 2 years, less than 0.2% of any one degradant is formed. The term degradant refers herein to product(s) of a single type of chemical reaction. For example, if a hydrolysis event occurs that cleaves a molecule into two products, for the purpose of the present invention, it would be considered a single degradant. More preferably, when stored at 40 degrees C for 2 years, less than 0.2% of any one degradant is formed. Alternatively, when stored at 30 degrees C for 3 months, less than 0.2% or 0.15%, or 0.1% of any one degradant is formed, or when stored at 40 degrees C for 3 months, less than 0.2% or 0.15%, or 0.1% of any one degradant is formed. Further alternatively, when stored at 60 degrees C for 4 weeks, less than 0.2% or 0.15%, or 0.1% of any one degradant is formed. The relative humidity (RH) may be specified as ambient (RH), 75% (RH), or as any single integer between 1 to 99%.

APIs prepared in the form of propylene glycol solvates have several important advantages over other solvates and their free form counterparts. In general, solvates are more commonly formed with water, methanol, ethanol, or other alcohols than with propylene glycol. These more common solvates are more easily removed from the crystal matrix by elevated temperatures than propylene glycol. PG solvates have an increased thermal stability over those of more traditional solvates. Also, PG solvates are generally more pharmaceutically acceptable than other common solvates, including those formed from alcohols other than ethanol. Investigations of the PG solvates of the present invention have shown fewer solvation states than hydration states. Reference compounds for PG solvates can be unsolvated free acid, unsolvated free base, zwitter ions, hydrates, or other solvates (e.g. methanol, ethanol, etc.). This decrease in form diversity associated with PG solvates can lead to more predictability and more consistent results during production and quality control. Stabilization of a desired solvate or polymorph can be achieved by causing the less desirable forms (e.g. solvates, polymorphs, hydrates) to be energetically less favorable than the desired form. In this way, PG solvates can aid in the production of pharmaceutical formulations with increased form stability.

The present invention further relates to methods of making a pharmaceutical solvate more stable at elevated temperatures (e.g. 30, 40, 50 degrees C) by producing a PG solvate of the drug. The present invention further relates to methods of making a more pharmaceutically acceptable solvate of many APIs by employing propylene glycol rather than more biologically harmful solvents (e.g. methanol). The present invention further relates to methods of reducing the number of forms (e.g. hydration states, solvation states, polymorphs, etc.) possible for a pharmaceutical solvate.

Pharmaceutically acceptable PG solvates can be administered by controlled- or delayed-release means. Controlled-release pharmaceutical products have a common goal of improving drug therapy over that achieved by their non-controlled release counterparts. Ideally, the use of an optimally designed controlled-release preparation in medical treatment is characterized by a minimum of drug substance being employed to cure or control the condition in a minimum amount of time. Advantages of controlled-release formulations include: 1) extended activity of the drug; 2) reduced dosage frequency; 3) increased patient compliance; 4) usage of less total drug; 5) reduction in local or systemic side effects; 6) minimization of drug accumulation; 7) reduction in blood level fluctuations; 8) improvement in efficacy of treatment; 9) reduction of potentiation or loss of drug activity; and 10) improvement in speed of control of diseases or conditions. (Kim, Cherng-ju, Controlled Release Dosage Form Design, Technomic Publishing, Lancaster, Pa.: 2000).

Conventional dosage forms generally provide rapid or immediate drug release from the formulation. Depending on the pharmacology and pharmacokinetics of the drug, use of conventional dosage forms can lead to wide fluctuations in the concentrations of the drug in a patient's blood and other tissues. These fluctuations can impact a number of parameters, such as dose frequency, onset of action, duration of efficacy, maintenance of therapeutic blood levels, toxicity, side effects, and the like.

Advantageously, controlled-release formulations can be used to control a drug's onset of action, duration of action, plasma levels within the therapeutic window, and peak blood levels. In particular, controlled- or extended-release dosage forms or formulations can be used to ensure that the maximum effectiveness of a drug is

achieved while minimizing potential adverse effects and safety concerns, which can occur both from under dosing a drug (i.e., going below the minimum therapeutic levels) as well as exceeding the toxicity level for the drug.

Most controlled-release formulations are designed to initially release an amount of drug (active ingredient) that promptly produces the desired therapeutic effect, and gradually and continually release other amounts of drug to maintain this level of therapeutic or prophylactic effect over an extended period of time. In order to maintain this constant level of drug in the body, the drug must be released from the dosage form at a rate that will replace the amount of drug being metabolized and excreted from the body. Controlled-release of an active ingredient can be stimulated by various conditions including, but not limited to, pH, ionic strength, osmotic pressure, temperature, enzymes, water, and other physiological conditions or compounds.

A variety of known controlled- or extended-release dosage forms, formulations, and devices can be adapted for use with the PG solvates of the present invention. Examples include, but are not limited to, those described in U.S. Pat. Nos.: 3,845,770; 3,916,899; 3,536,809; 3,598,123; 4,008,719; 5,674,533; 5,059,595; 5,591,767; 5,120,548; 5,073,543; 5,639,476; 5,354,556; 5,733,566; and 6,365,185 B1; each of which is incorporated herein by reference. These dosage forms can be used to provide slow or controlled-release of one or more active ingredients using, for example, hydroxypropylmethyl cellulose, other polymer matrices, gels, permeable membranes, osmotic systems (such as OROS® (Alza Corporation, Mountain View, Calif. USA)), multilayer coatings, microparticles, liposomes, or microspheres or a combination thereof to provide the desired release profile in varying proportions. Additionally, ion exchange materials can be used to prepare immobilized, adsorbed salt forms and thus effect controlled delivery of the drug. Examples of specific anion exchangers include, but are not limited to, Duolite® A568 and Duolite® AP143 (Rohm & Haas, Spring House, PA. USA).

One embodiment of the invention encompasses a unit dosage form which comprises a pharmaceutically acceptable PG solvate, or a polymorph, solvate, hydrate, dehydrate,



co-crystal, anhydrous, or amorphous form thereof, and one or more pharmaceutically acceptable excipients or diluents, wherein the pharmaceutical composition or dosage form is formulated for controlled-release. Specific dosage forms utilize an osmotic drug delivery system.

A particular and well-known osmotic drug delivery system is referred to as OROS® (Alza Corporation, Mountain View, Calif. USA). This technology can readily be adapted for the delivery of compounds and compositions of the invention. Various aspects of the technology are disclosed in U.S. Pat. Nos. 6,375,978 B1; 6,368,626 B1; 6,342,249 B1; 6,333,050 B2; 6,287,295 B1; 6,283,953 B1; 6,270,787 B1; 6,245,357 B1; and 6,132,420; each of which is incorporated herein by reference. Specific adaptations of OROS® that can be used to administer compounds and compositions of the invention include, but are not limited to, the OROS® Push-Pull™, Delayed Push-Pull™, Multi-Layer Push-Pull™, and Push-Stick™ Systems, all of which are well known. See, e.g., <http://www.alza.com>. Additional OROS® systems that can be used for the controlled oral delivery of compounds and compositions of the invention include OROS®-CT and L-OROS®. Id.; see also, Delivery Times, vol. II, issue II (Alza Corporation).

Conventional OROS® oral dosage forms are made by compressing a drug powder (e.g., celecoxib sodium PG solvate) into a hard tablet, coating the tablet with cellulose derivatives to form a semi-permeable membrane, and then drilling an orifice in the coating (e.g., with a laser). (Kim, Cherng-ju, Controlled Release Dosage Form Design, Technomic Publishing, Lancaster, Pa.: 2000). The advantage of such dosage forms is that the delivery rate of the drug is not influenced by physiological or experimental conditions. Even a drug with a pH-dependent solubility can be delivered at a constant rate regardless of the pH of the delivery medium. But because these advantages are provided by a build-up of osmotic pressure within the dosage form after administration, conventional OROS® drug delivery systems cannot be used to effectively deliver drugs with low water solubility. Because PG solvates and complexes of this invention (e.g., celecoxib sodium PG solvate) are far more soluble in water than unsolvated forms, they are well suited for osmotic-based delivery to

patients.

A specific dosage form of the invention comprises: a wall defining a cavity, the wall having an exit orifice formed or formable therein and at least a portion of the wall being semipermeable; an expandable layer located within the cavity remote from the exit orifice and in fluid communication with the semipermeable portion of the wall; a dry or substantially dry state drug layer located within the cavity adjacent to the exit orifice and in direct or indirect contacting relationship with the expandable layer; and a flow-promoting layer interposed between the inner surface of the wall and at least the external surface of the drug layer located within the cavity, wherein the drug layer comprises a PG solvate, or a polymorph, solvate, hydrate, dehydrate, co-crystal, anhydrous, or amorphous form thereof. See U.S. Pat. No. 6,368,626, the entirety of which is incorporated herein by reference.

Another specific dosage form of the invention comprises: a wall defining a cavity, the wall having an exit orifice formed or formable therein and at least a portion of the wall being semipermeable; an expandable layer located within the cavity remote from the exit orifice and in fluid communication with the semipermeable portion of the wall; a drug layer located within the cavity adjacent the exit orifice and in direct or indirect contacting relationship with the expandable layer; the drug layer comprising a liquid, active agent formulation absorbed in porous particles, the porous particles being adapted to resist compaction forces sufficient to form a compacted drug layer without significant exudation of the liquid, active agent formulation, the dosage form optionally having a placebo layer between the exit orifice and the drug layer, wherein the active agent formulation comprises a PG solvate, or a polymorph, solvate, hydrate, dehydrate, co-crystal, anhydrous, or amorphous form thereof. See U.S. Pat. No. 6,342,249, the entirety of which is incorporated herein by reference.

Excipients employed in pharmaceutical compositions of the present invention can be solids, semi-solids, liquids or combinations thereof. Compositions of the invention containing excipients can be prepared by any known technique of pharmacy that comprises admixing an excipient with a drug or therapeutic agent. A pharmaceutical composition of the invention contains a desired amount of API per dose unit and, if

intended for oral administration, can be in the form, for example, of a tablet, a caplet, a pill, a hard or soft capsule, a lozenge, a cachet, a dispensable powder, granules, a suspension, an elixir, a dispersion, a liquid, or any other form reasonably adapted for such administration. Presently preferred are oral dosage forms that are discrete dose units each containing a predetermined amount of the drug, such as tablets or capsules.

Non-limiting examples follow of excipients that can be used to prepare pharmaceutical compositions of the invention.

Pharmaceutical compositions of the invention optionally comprise one or more pharmaceutically acceptable carriers or diluents as excipients. Suitable carriers or diluents illustratively include, but are not limited to, either individually or in combination, lactose, including anhydrous lactose and lactose monohydrate; starches, including directly compressible starch and hydrolyzed starches (e.g., Celutab<sup>TM</sup> and Emdex<sup>TM</sup>); mannitol; sorbitol; xylitol; dextrose (e.g., Cerelease<sup>TM</sup> 2000) and dextrose monohydrate; dibasic calcium phosphate dihydrate; sucrose-based diluents; confectioner's sugar; monobasic calcium sulfate monohydrate; calcium sulfate dihydrate; granular calcium lactate trihydrate; dextrates; inositol; hydrolyzed cereal solids; amylose; celluloses including microcrystalline cellulose, food grade sources of alpha- and amorphous cellulose (e.g., RexcelJ), powdered cellulose, hydroxypropylcellulose (HPC) and hydroxypropylmethylcellulose (HPMC); calcium carbonate; glycine; bentonite; block co-polymers; polyvinylpyrrolidone; and the like. Such carriers or diluents, if present, constitute in total about 5% to about 99%, preferably about 10% to about 85%, and more preferably about 20% to about 80%, of the total weight of the composition. The carrier, carriers, diluent, or diluents selected preferably exhibit suitable flow properties and, where tablets are desired, compressibility.

Lactose, mannitol, dibasic sodium phosphate, and microcrystalline cellulose (particularly Avicel PH microcrystalline cellulose such as Avicel PH 101), either individually or in combination, are preferred diluents. These diluents are chemically compatible with celecoxib. The use of extragranular microcrystalline cellulose (that is, microcrystalline cellulose added to a granulated composition) can be used to

improve hardness (for tablets) and/or disintegration time. Lactose, especially lactose monohydrate, is particularly preferred. Lactose typically provides compositions having suitable release rates of celecoxib, stability, pre-compression flowability, and/or drying properties at a relatively low diluent cost. It provides a high density substrate that aids densification during granulation (where wet granulation is employed) and therefore improves blend flow properties and tablet properties.

Pharmaceutical compositions of the invention optionally comprise one or more pharmaceutically acceptable disintegrants as excipients, particularly for tablet formulations. Suitable disintegrants include, but are not limited to, either individually or in combination, starches, including sodium starch glycolate (e.g., Explotab<sup>TM</sup> of PenWest) and pregelatinized corn starches (e.g., National<sup>TM</sup> 1551 of National Starch and Chemical Company, National<sup>TM</sup> 1550, and Colorcon<sup>TM</sup> 1500), clays (e.g., Veegum<sup>TM</sup> HV of R.T. Vanderbilt), celluloses such as purified cellulose, microcrystalline cellulose, methylcellulose, carboxymethylcellulose and sodium carboxymethylcellulose, croscarmellose sodium (e.g., Ac-Di-Sol<sup>TM</sup> of FMC), alginates, crospovidone, and gums such as agar, guar, locust bean, karaya, pectin and tragacanth gums.

Disintegrants may be added at any suitable step during the preparation of the composition, particularly prior to granulation or during a lubrication step prior to compression. Such disintegrants, if present, constitute in total about 0.2 % to about 30 %, preferably about 0.2 % to about 10 %, and more preferably about 0.2 % to about 5 %, of the total weight of the composition.

Croscarmellose sodium is a preferred disintegrant for tablet or capsule disintegration, and, if present, preferably constitutes about 0.2 % to about 10 %, more preferably about 0.2 % to about 7 %, and still more preferably about 0.2 % to about 5 %, of the total weight of the composition. Croscarmellose sodium confers superior intragranular disintegration capabilities to granulated pharmaceutical compositions of the present invention.



Pharmaceutical compositions of the invention optionally comprise one or more pharmaceutically acceptable binding agents or adhesives as excipients, particularly for tablet formulations. Such binding agents and adhesives preferably impart sufficient cohesion to the powder being tableted to allow for normal processing operations such as sizing, lubrication, compression and packaging, but still allow the tablet to disintegrate and the composition to be absorbed upon ingestion. Such binding agents may also prevent or inhibit crystallization or recrystallization of a celecoxib salt of the present invention once the salt has been dissolved in a solution. Suitable binding agents and adhesives include, but are not limited to, either individually or in combination, acacia; tragacanth; sucrose; gelatin; glucose; starches such as, but not limited to, pregelatinized starches (e.g., National<sup>TM</sup> 1511 and National<sup>TM</sup> 1500); celluloses such as, but not limited to, methylcellulose and carmellose sodium (e.g., Tylose<sup>TM</sup>); alginic acid and salts of alginic acid; magnesium aluminum silicate; PEG; guar gum; polysaccharide acids; bentonites; povidone, for example povidone K-15, K-30 and K-29/32; polymethacrylates; HPMC; hydroxypropylcellulose (e.g., Klucel<sup>TM</sup> of Aqualon); and ethylcellulose (e.g., Ethocel<sup>TM</sup> of the Dow Chemical Company). Such binding agents and/or adhesives, if present, constitute in total about 0.5 % to about 25 %, preferably about 0.75 % to about 15 %, and more preferably about 1 % to about 10 %, of the total weight of the pharmaceutical composition.

Many of the binding agents are polymers comprising amide, ester, ether, alcohol or ketone groups and, as such, are preferably included in pharmaceutical compositions of the present invention. Polyvinylpyrrolidones such as povidone K-30 are especially preferred. Polymeric binding agents can have varying molecular weight, degrees of crosslinking, and grades of polymer. Polymeric binding agents can also be copolymers, such as block co-polymers that contain mixtures of ethylene oxide and propylene oxide units. Variation in these units' ratios in a given polymer affects properties and performance. Examples of block co-polymers with varying compositions of block units are Poloxamer 188 and Poloxamer 237 (BASF Corporation).

Pharmaceutical compositions of the invention optionally comprise one or more pharmaceutically acceptable wetting agents as excipients. Non-limiting examples of

surfactants that can be used as wetting agents in pharmaceutical compositions of the invention include quaternary ammonium compounds, for example benzalkonium chloride, benzethonium chloride and cetylpyridinium chloride, dioctyl sodium sulfosuccinate, polyoxyethylene alkylphenyl ethers, for example nonoxynol 9, nonoxynol 10, and octoxynol 9, poloxamers (polyoxyethylene and polyoxypropylene block copolymers), polyoxyethylene fatty acid glycerides and oils, for example polyoxyethylene (8) caprylic/capric mono- and diglycerides (e.g., Labrasol<sup>TM</sup> of Gattefosse), polyoxyethylene (35) castor oil and polyoxyethylene (40) hydrogenated castor oil; polyoxyethylene alkyl ethers, for example polyoxyethylene (20) cetostearyl ether, polyoxyethylene fatty acid esters, for example polyoxyethylene (40) stearate, polyoxyethylene sorbitan esters, for example polysorbate 20 and polysorbate 80 (e.g., Tween<sup>TM</sup> 80 of ICI), propylene glycol fatty acid esters, for example propylene glycol laurate (e.g., Lauroglycol<sup>TM</sup> of Gattefosse), sodium lauryl sulfate, fatty acids and salts thereof, for example oleic acid, sodium oleate and triethanolamine oleate, glyceryl fatty acid esters, for example glyceryl monostearate, sorbitan esters, for example sorbitan monolaurate, sorbitan monooleate, sorbitan monopalmitate and sorbitan monostearate, tyloxapol, and mixtures thereof. Such wetting agents, if present, constitute in total about 0.25 % to about 15 %, preferably about 0.4 % to about 10 %, and more preferably about 0.5 % to about 5 %, of the total weight of the pharmaceutical composition.

Wetting agents that are anionic surfactants are preferred. Sodium lauryl sulfate is a particularly preferred wetting agent. Sodium lauryl sulfate, if present, constitutes about 0.25 % to about 7 %, more preferably about 0.4 % to about 4 %, and still more preferably about 0.5 % to about 2 %, of the total weight of the pharmaceutical composition.

Pharmaceutical compositions of the invention optionally comprise one or more pharmaceutically acceptable lubricants (including anti-adherents and/or glidants) as excipients. Suitable lubricants include, but are not limited to, either individually or in combination, glyceryl behapate (e.g., Compritol<sup>TM</sup> 888 of Gattefosse); stearic acid and salts thereof, including magnesium, calcium and sodium stearates; hydrogenated vegetable oils (e.g., Sterotex<sup>TM</sup> of Abitec); colloidal silica; talc; waxes; boric acid;

sodium benzoate; sodium acetate; sodium fumarate; sodium chloride; DL-leucine; PEG (e.g., Carbowax<sup>TM</sup> 4000 and Carbowax<sup>TM</sup> 6000 of the Dow Chemical Company); sodium oleate; sodium lauryl sulfate; and magnesium lauryl sulfate. Such lubricants, if present, constitute in total about 0.1 % to about 10 %, preferably about 0.2 % to about 8 %, and more preferably about 0.25 % to about 5 %, of the total weight of the pharmaceutical composition.

Magnesium stearate is a preferred lubricant used, for example, to reduce friction between the equipment and granulated mixture during compression of tablet formulations.

Suitable anti-adherents include, but are not limited to, talc, cornstarch, DL-leucine, sodium lauryl sulfate and metallic stearates. Talc is a preferred anti-adherent or glidant used, for example, to reduce formulation sticking to equipment surfaces and also to reduce static in the blend. Talc, if present, constitutes about 0.1 % to about 10 %, more preferably about 0.25 % to about 5 %, and still more preferably about 0.5 % to about 2 %, of the total weight of the pharmaceutical composition.

Glidants can be used to promote powder flow of a solid formulation. Suitable glidants include, but are not limited to, colloidal silicon dioxide, starch, talc, tribasic calcium phosphate, powdered cellulose and magnesium trisilicate. Colloidal silicon dioxide is particularly preferred.

Other excipients such as colorants, flavors and sweeteners are known in the pharmaceutical art and can be used in pharmaceutical compositions of the present invention. Tablets can be coated, for example with an enteric coating, or uncoated. Compositions of the invention can further comprise, for example, buffering agents.

Optionally, one or more effervescent agents can be used as disintegrants and/or to enhance organoleptic properties of pharmaceutical compositions of the invention. When present in pharmaceutical compositions of the invention to promote dosage form disintegration, one or more effervescent agents are preferably present in a total

amount of about 30 % to about 75 %, and preferably about 45 % to about 70 %, for example about 60 %, by weight of the pharmaceutical composition.

According to a particularly preferred embodiment of the invention, an effervescent agent, present in a solid dosage form in an amount less than that effective to promote disintegration of the dosage form, provides improved dispersion of the celecoxib in an aqueous medium. Without being bound by theory, it is believed that the effervescent agent is effective to accelerate dispersion of the drug, such as celecoxib, from the dosage form in the gastrointestinal tract, thereby further enhancing absorption and rapid onset of therapeutic effect. When present in a pharmaceutical composition of the invention to promote intragastric dispersion but not to enhance disintegration, an effervescent agent is preferably present in an amount of about 1 % to about 20 %, more preferably about 2.5 % to about 15 %, and still more preferably about 5 % to about 10 %, by weight of the pharmaceutical composition.

An "effervescent agent" herein is an agent comprising one or more compounds which, acting together or individually, evolve a gas on contact with water. The gas evolved is generally oxygen or, most commonly, carbon dioxide. Preferred effervescent agents comprise an acid and a base that react in the presence of water to generate carbon dioxide gas. Preferably, the base comprises an alkali metal or alkaline earth metal carbonate or bicarbonate and the acid comprises an aliphatic carboxylic acid.

Non-limiting examples of suitable bases as components of effervescent agents useful in the invention include carbonate salts (e.g., calcium carbonate), bicarbonate salts (e.g., sodium bicarbonate), sesquicarbonate salts, and mixtures thereof. Calcium carbonate is a preferred base.

Non-limiting examples of suitable acids as components of effervescent agents and/or solid organic acids useful in the invention include citric acid, tartaric acid (as D-, L-, or D/L-tartaric acid), malic acid, maleic acid, fumaric acid, adipic acid, succinic acid, acid anhydrides of such acids, acid salts of such acids, and mixtures thereof. Citric acid is a preferred acid.



In a preferred embodiment of the invention, where the effervescent agent comprises an acid and a base, the weight ratio of the acid to the base is about 1:100 to about 100:1, more preferably about 1:50 to about 50:1, and still more preferably about 1:10 to about 10:1. In a further preferred embodiment of the invention, where the effervescent agent comprises an acid and a base, the ratio of the acid to the base is approximately stoichiometric.

Excipients which solubilize metal salts of drugs like celecoxib typically have both hydrophilic and hydrophobic regions, or are preferably amphiphilic or have amphiphilic regions. One type of amphiphilic or partially-amphiphilic excipient comprises an amphiphilic polymer or is an amphiphilic polymer. A specific amphiphilic polymer is a polyalkylene glycol, which is commonly comprised of ethylene glycol and/or propylene glycol subunits. Such polyalkylene glycols can be esterified at their termini by a carboxylic acid, ester, acid anhydride or other suitable moiety. Examples of such excipients include poloxamers (symmetric block copolymers of ethylene glycol and propylene glycol; e.g., poloxamer 237), polyalkylene glycolated esters of tocopherol (including esters formed from a di- or multi-functional carboxylic acid; e.g., d-alpha-tocopherol polyethylene glycol-1000 succinate), and macroglycerides (formed by alcoholysis of an oil and esterification of a polyalkylene glycol to produce a mixture of mono-, di- and tri-glycerides and mono- and di-esters; e.g., stearyl macrogol-32 glycerides). Such pharmaceutical compositions are advantageously administered orally.

Solid dosage forms of the invention can be prepared by any suitable process, not limited to processes described herein.

An illustrative process comprises (a) a step of blending a celecoxib salt of the invention with one or more excipients to form a blend, and (b) a step of tableting or encapsulating the blend to form tablets or capsules, respectively.

In a preferred process, solid dosage forms are prepared by a process comprising (a) a step of blending a drug salt such as a celecoxib salt of the invention with one or more excipients to form a blend, (b) a step of granulating the blend to form a granulate, and

(c) a step of tableting or encapsulating the blend to form tablets or capsules respectively. Step (b) can be accomplished by any dry or wet granulation technique known in the art, but is preferably a dry granulation step. A salt of the present invention is advantageously granulated to form particles of about 1 micrometer to about 100 micrometer, about 5 micrometer to about 50 micrometer, or about 10 micrometer to about 25 micrometer. One or more diluents, one or more disintegrants and one or more binding agents are preferably added, for example in the blending step, a wetting agent can optionally be added, for example in the granulating step, and one or more disintegrants are preferably added after granulating but before tableting or encapsulating. A lubricant is preferably added before tableting. Blending and granulating can be performed independently under low or high shear. A process is preferably selected that forms a granulate that is uniform in drug content, that readily disintegrates, that flows with sufficient ease so that weight variation can be reliably controlled during capsule filling or tableting, and that is dense enough in bulk so that a batch can be processed in the selected equipment and individual doses fit into the specified capsules or tablet dies.

In an alternative embodiment, solid dosage forms are prepared by a process that includes a spray drying step, wherein a celecoxib salt is suspended with one or more excipients in one or more sprayable liquids, preferably a non-protic (e.g., non-aqueous or non-alcoholic) sprayable liquid, and then is rapidly spray dried over a current of warm air.

A granulate or spray dried powder resulting from any of the above illustrative processes can be compressed or molded to prepare tablets or encapsulated to prepare capsules. Conventional tableting and encapsulation techniques known in the art can be employed. Where coated tablets are desired, conventional coating techniques are suitable.

Excipients for tablet compositions of the invention are preferably selected to provide a disintegration time of less than about 30 minutes, preferably about 25 minutes or less, more preferably about 20 minutes or less, and still more preferably about 15 minutes or less, in a standard disintegration assay.

Celecoxib dosage forms of the invention preferably comprise celecoxib in a daily dosage amount of about 10 mg to about 1000 mg, more preferably about 25 mg to about 400 mg, and most preferably about 50 mg to about 200 mg.

In a further embodiment the PG solvate comprises an API from Table 3. For APIs in Table 3 listed as salts, solvates, hydrates, and the like, the PG solvate can either be of the form listed in Table 3 or a PG solvate of the free form, or a PG solvate of another form that is not listed. Table 3 includes the CAS number, chemical name or a PCT or patent reference (each incorporated herein in their entireties). In another embodiment, any one or more of the APIs of Table 3 may be specifically excluded from the present invention. Any APIs currently known in the art may also be specifically excluded from the present invention. For example, azithromycin and cephalosporin may be specifically excluded from the present invention.

## EXEMPLIFICATION

### *Procedure for Raman Acquisition*

#### *Acquisition*

The sample was either left in the glass vial in which it was processed or an aliquot of the sample was transferred to a glass slide. The glass vial or slide was positioned in the sample chamber. The measurement was made using an Almega™ Dispersive Raman (Almega™ Dispersive Raman, Thermo-Nicolet, 5225 Verona Road, Madison, WI 53711-4495) system fitted with a 785 nm laser source. The sample was manually brought into focus using the microscope portion of the apparatus with a 10x power objective (unless otherwise noted), thus directing the laser onto the surface of the sample. The spectrum was acquired using the parameters outlined in Table 1. (Exposure times and number of exposures may vary; changes to parameters will be indicated for each acquisition.)

Table 2. Raman Spectral acquisition parameters

<u>Parameter</u>	<u>Setting Used</u>
Exposure time (s)	2.0
Number of exposures	10
Laser source wavelength (nm)	785
Laser power (%)	100
Aperture shape	pin hole
Aperture size (um)	100
Spectral range	104-3428
Grating position	Single
Temperature at acquisition (degrees C)	24.0

#### Procedure for Powder X-Ray Diffraction (PXRD)

All powder x-ray diffraction patterns were obtained using the D/Max Rapid X-ray Diffractometer (D/Max Rapid, Contact Rigaku/MSO, 9009 New Trails Drive, The Woodlands, Texas, USA 77381-5209) equipped with a copper source ( $\text{Cu}/K_{\alpha}$  1.5406Å), manual x-y stage, and 0.3 mm collimator, unless otherwise indicated. The sample was loaded into a 0.3 mm boron rich glass capillary tube (e.g., Charles Supper Company, 15 Tech Circle, Natick Massachusetts 01760-1024) by sectioning off one end of the tube and tapping the open, sectioned end into a bed of the powdered sample or into the sediment of a slurried precipitate. Note, precipitate can be amorphous or crystalline. The loaded capillary was mounted in a holder that was secured into the x-y stage. A diffractogram was acquired (e.g., Control software: RINT Rapid Control Software, Rigaku Rapid/XRD, version 1.0.0, © 1999 Rigaku Co.) under ambient conditions at a power setting of 46 kV at 40 mA in reflection mode, while oscillating about the omega-axis from 0 - 5 degrees at 1 degree/s and spinning about the phi-axis at 2 degrees/s. The exposure time was 15 minutes unless otherwise specified. The diffractogram obtained was integrated over 2-theta from 2-60 degrees and chi (1 segment) from 0-360 degrees at a step size of 0.02 degrees using the *cyllnt* utility in the RINT Rapid display software (Analysis software: RINT Rapid display software,



version 1.18, Rigaku/MSO.) provided by Rigaku with the instrument. The dark counts value was set to 8 as per the system calibration (System set-up and calibration by Rigaku); normalization was set to average; the omega offset was set to 180°; and no chi or phi offsets were used for the integration. The analysis software JADE XRD Pattern Processing, versions 5.0 and 6.0 (©1995-2002, Materials Data, Inc. was also used.

The relative intensity of peaks in a diffractogram is not necessarily a limitation of the PXRD pattern because peak intensity can vary from sample to sample, e.g., due to crystalline impurities. Further, the angles of each peak can vary by about +/- 0.1 degrees, preferably +/-0.05. The entire pattern or most of the pattern peaks may also shift by about +/- 0.1 degree due to differences in calibration, settings, and other variations from instrument to instrument and from operator to operator. The above limitations result in a PXRD error of +/- 0.1 degrees 2-theta for each diffraction peak.

#### Procedure for Differential Scanning Calorimetry (DSC)

An aliquot of the sample was weighed into an aluminum sample pan. (e.g., Pan part # 900786.091; lid part # 900779.901; TA Instruments, 109 Lukens Drive, New Castle, Delaware 19720) The sample pan was sealed either by crimping for dry samples or press fitting for wet samples (e.g., hydrated or solvated samples). The sample pan was loaded in to the apparatus (DSC: Q1000 Differential Scanning Calorimeter, TA Instruments, 109 Lukens Drive, New Castle, Delaware 19720), which is equipped with an autosampler, and a thermogram was obtained by individually heating the sample (e.g., Control software: Advantage for QW- Series, version 1.0.0.78, Thermal Advantage Release 2.0, © 2001 TA instruments – Water LLC) at a rate of 10 degrees C /min from  $T_{\min}$  (typically 20 degrees C) to  $T_{\max}$  (typically 300 degrees C) (Heating rate and temperature range may vary, changes to these parameters will be indicated for each sample) using an empty aluminum pan as a reference. Dry nitrogen (e.g., Compressed nitrogen, grade 4.8, BOC Gases, 575 Mountain Avenue, Murray Hill, New Jersey 07974-2082) was used as a sample purge gas and was set at a flow rate of 50 mL/min. Thermal transitions were viewed and analyzed using the analysis software (Analysis Software: Universal Analysis 2000 for Windows

95/95/2000/NT, version 3.1E; Build 3.1.0.40, © 1991 - 2001TA instruments – Water LLC) provided with the instrument.

#### Procedure for Thermogravimetric Analysis (TGA)

An aliquot of the sample was transferred into a platinum sample pan. (Pan part # 952019.906; TA Instruments, 109 Lukens Drive, New Castle, Delaware 19720) The pan was placed on the loading platform and was then automatically loaded in to the apparatus (TGA: Q500 Thermogravimetric Analyzer, TA Instruments, 109 Lukens Drive, New Castle, Delaware 19720) using the control software (Control software: Advantage for QW- Series, version 1.0.0.78, Thermal Advantage Release 2.0, © 2001 TA instruments – Water LLC). Thermograms were obtained by individually heating the sample at 10 degrees C /min from 25 degrees C to 300 degrees C (Heating rate and temperature range may vary, changes in parameters will be indicated for each sample) under flowing dry nitrogen (e.g., Compressed nitrogen, grade 4.8, BOC Gases, 575 Mountain Avenue, Murray Hill, New Jersey 07974-2082), with a sample purge flow rate of 60 mL/min and a balance purge flow rate of 40 mL/min. Thermal transitions (e.g. weight changes) were viewed and analyzed using the analysis software (Analysis Software: Universal Analysis 2000 for Windows 95/95/2000/NT, version 3.1E; Build 3.1.0.40, © 1991 - 2001TA instruments – Water LLC) provided with the instrument.

#### Example 1

##### Celecoxib Sodium Salt PG solvate

A propylene glycol solvate of the sodium salt of celecoxib was prepared. To a solution of celecoxib (312 mg; 0.818 mmol) in diethyl ether (6 mL) was added propylene glycol (0.127 mL, 1.73 mmol). To the clear solution was added sodium ethoxide in ethanol (21%, 0.275 mL, 0.817 mmol). After 1 minute, crystals began to form. After 5 minutes, the solid had completely crystallized. The solid was collected by filtration and was washed with additional diethyl ether (10 mL). The off-white solid was then air-dried and collected. The crystalline salt form was identified as a

1:1 solvate of propylene glycol. The solid was characterized by TGA and PXRD. The results are depicted in Figs. 1 and 2A.

Fig. 1 shows the results of TGA. A weight loss of about 15.6 % was observed between about 65 and 200 degrees C which represents 1 molar equivalent of propylene glycol to celecoxib Na salt. Fig. 2A shows the results of PXRD. Peaks, in 2-theta angles, that can be used to characterize the solvate include any 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 of the following: 3.77, 7.57, 8.21, 11.33, 14.23, 16.13, 18.69, 20.65, 22.69 and 24.77 degrees or any one or any combination of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more peaks of Fig. 2A. The TGA thermogram or PXRD diffractogram data may be used alone or in any combination to characterize the solvate. A 0.8 mm collimator was used during acquisition of the diffractogram.

Several closely related, yet distinguishable, PXRD diffractograms have been obtained by performing the above synthesis several times. Figs. 2B, 2C, and 2D are additional diffractograms of the propylene glycol solvate of celecoxib sodium salt. A comparison of these diffractograms yields a number of noticeable differences. For example, the peak at 8.21 degrees 2-theta in Fig. 2A is not present in Figs. 2B or 2C. Another peak at 8.79 degrees 2-theta, present in Figs. 2B and 2D, is not found in Figs. 2A or 2C. Other distinctions can also be found between the four diffractograms. Such distinctions in otherwise similar diffractograms suggest the existence of polymorphism or perhaps a variable hydrate.

In another embodiment of the present invention, a PG solvate of an API can give rise to distinct PXRD diffractograms. This can be caused by polymorphism, a variable hydrate, a different environmental condition, etc. In one embodiment, the propylene glycol solvate of celecoxib sodium salt can yield a PXRD pattern with the absence or presence of a peak at 8.21 degrees 2-theta. In another embodiment, the propylene glycol solvate of celecoxib sodium salt can yield a PXRD pattern with the absence or presence of a peak at 8.79 degrees 2-theta.

## Example 2

### Celecoxib Potassium Salt PG Solvate

A propylene glycol solvate of the potassium salt of celecoxib was prepared. To a solution of celecoxib (253 mg, 0.664 mmol) in diethyl ether (6 mL) was added propylene glycol (0.075 mL, 1.02 mmol). To the clear solution was added potassium

t-butoxide in tetrahydrofuran (THF) (1 M, 0.66 mL, 0.66 mmol). Crystals immediately began to form. After 5 minutes, the solid had completely crystallized. The solid was collected by filtration and was washed with additional diethyl ether (10 mL). The white solid was then air-dried and collected. The crystalline salt form was found to be a 1:1 propylene glycol solvate of celecoxib K salt. The solid was characterized by TGA and PXRD. The results are depicted in Figs. 3 and 4.

Fig. 3 shows the results of TGA. A weight loss of about 14.94 % was observed between about 65 and about 250 degrees C which is consistent with 1 molar equivalent of propylene glycol to celecoxib K. Fig. 4 shows the results of PXRD. Peaks, in 2-theta angles, that can be used to characterize the solvate include any 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 of the following: 3.75, 7.47, 11.33, 14.89, 15.65, 18.31, 20.49, 21.73, 22.51, and 24.97 degrees or any one or any combination of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more peaks of Fig. 4.

### Example 3

#### Celecoxib Lithium Salt PG Solvate

A propylene glycol solvate of the lithium salt of celecoxib was prepared. To a solution of celecoxib (264 mg, 0.693 mmol) in diethyl ether (8 mL) was added propylene glycol (0.075 mL, 1.02 mmol). To the clear solution was added t-butyl lithium in pentane (1.7 M, 0.40 mL, 0.68 mmol). A brown solid formed immediately but dissolved within one minute which subsequently yielded a white fluffy solid. The white solid crystallized completely after 10 minutes. The solid was collected by filtration and was washed with additional diethyl ether (10 mL). The white solid was then air-dried and collected. The crystalline salt form was found to be a 1:1 propylene glycol solvate of celecoxib Li. The solid was characterized by TGA and PXRD. The results of TGA are depicted in Fig. 5 and show a weight loss of about 16.3 % between 50 degrees C and 210 degrees C which is consistent with 1 molar equivalent of propylene glycol to celecoxib Li. The results of PXRD are shown in Fig. 6. Characteristic peaks of 2-theta angles that can be used to characterize the salt include any one, or combination of any 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 of 3.79, 7.51, 8.19, 9.83, 11.41, 15.93, 18.29, 19.19, 19.87, 20.63, 22.01, or 25.09 degrees or any one or any combination of peaks of Fig. 6.



#### Example 4

##### Naproxen Sodium Salt PG Solvate

A propylene glycol solvate of a sodium salt of naproxen was prepared. To a solution of naproxen (348 mg, 1.51 mmol) in diethyl ether (10 mL) was added propylene glycol (0.200 ml, 2.72 mmol). To the clear solution was added sodium ethoxide in ethanol (21 %, 0.750 mL, 2.01 mmol). The solution became slightly yellow due to the sodium ethoxide. After 1 minute, crystals began to form. After 5 minutes, the solid had completely crystallized. The solid was collected by filtration and was washed with diethyl ether (10 mL). The product was then air-dried and collected. The solvate was 2:1 naproxen Na:propylene glycol. The solid was characterized by TGA and PXRD.

The TGA thermogram of naproxen sodium salt PG solvate is shown in Fig. 7, and indicates a 13.5 percent weight loss between about 75 and 150 degrees C. This weight loss is consistent with a 2:1 naproxen Na:propylene glycol solvate. The PXRD diffractogram of naproxen sodium salt PG solvate is shown in Fig. 8, and shows peaks at 2-theta angles, including but not limited to, 6.67, 9.65, 13.41, 15.77, 18.55, 20.83, 22.79, and 27.17 degrees. Any one, any two, any three, any four, any five, any six, any seven, or all eight of the above peaks or any one or any combination of peaks in Fig. 8 can be used to characterize naproxen sodium salt PG solvate.

#### Example 5

##### Preparation of Olanzapine PG solvate

Olanzapine PG solvate was prepared by dissolving 1.05 g of olanzapine form I in 8 mL of isopropylacetate and 2.0 mL of propylene glycol with heating. The hot liquid was filtered through a 0.2 micrometer nylon syringe filter. Crystallization occurred after cooling to room temperature. The addition of a small amount of seed crystals from a previous reaction followed by sonication for 10 seconds also facilitated crystallization. Olanzapine PG solvate was isolated by suction filtration, rinsed with isopropylacetate and allowed to air dry. The product was a fine yellow powder. The crystals grew in three dimensions, yielding chunks.

A second preparation of olanzapine form I PG solvate was completed by dissolving 16.2 mg of olanzapine form I in 0.05 ml of propylene glycol and 0.05 ml of isopropylacetate with heating. The sample was cooled to room temperature and a

single crystal from a previous preparation was added. The sample was allowed to sit undisturbed for 2 days during which an aggregate clump of several large crystals grew. The crystals were transferred to filter paper, rinsed with a single drop of isopropylacetate, and dried by dabbing with the filter paper. The rinse procedure was repeated a total of four times with fresh filter paper. Characterization of the product has been achieved via TGA, DSC, PXRD, and Raman spectroscopy.

Results from TGA analysis show an 18.05 % weight loss representing loss of about 1 equivalent of propylene glycol (Fig. 9). Results from DSC show a peak endothermic transition at 92.63 degrees C (Fig. 10).

The PXRD pattern has characteristic peaks as shown for two sample preparations in Fig. 11A and 11B. Peaks can be seen at 2-theta angles including but not limited to 8.33, 8.95, 11.75, 14.47, 15.61, 17.95, 19.21, 19.57, 20.65, 21.41, 22.03, and 23.29 in Fig. 11A. The crystal can be characterized by any one, any two, any three, any four, any 5, any 6, any 7, any 8, any 9, any 10, any 11, or all 12 of the peaks above or one or a combination of peaks in Fig. 11A. In the second representative sample, peaks can be seen at 2-theta angles including, but not limited to, 8.39, 8.89, 13.95, 14.45, 15.55, 17.91, 19.13, 19.55, 20.61, 21.47, 22.07, and 23.31 in Fig. 11B. The crystal can be characterized by any one, any two, any three, any four, any 5, any 6, any 7, any 8, any 9, any 10, any 11, or all 12 of the peaks above or one or a combination of peaks in Fig. 11B.

Single-crystal x-ray studies of olanzapine form I PG solvate were also completed. Fig. 12 shows a packing diagram of the single-crystal structure of olanzapine form I PG solvate. The unit cell data are as follows: space group P2(1)/c, A=10.4264(9), B=13.3916(11), C=14.4424(12), Alpha=90, Beta=95.503(2), Gamma=90, Volume=2007.2(3).

#### Example 6

##### Preparation of Cortisone Acetate PG Solvate

Cortisone acetate PG solvate was prepared by dissolving 9.7 mg cortisone acetate in 0.6 mL propylene glycol with heating. Needle-like crystals formed upon cooling, followed by the conversion to large, very thin, rectangular plates over a couple hours.

A second preparation of cortisone acetate PG solvate was completed by dissolving 11.9 mg cortisone acetate in 0.7 mL isopropylacetate with heating to reflux. Upon crystal formation, 0.05 mL propylene glycol was added, heated to reflux to dissolve, and crystals again formed. The resultant crystals were collected and analyzed by PXRD, TGA, and DSC.

A third preparation of cortisone acetate PG solvate was completed by dissolving 65.8 mg cortisone acetate in 7.0 mL isopropylacetate and 0.05 mL propylene glycol with heating. The mixture was cooled slightly and seed crystals from a previous reaction (second preparation above) were added. The resultant crystals form rods, or long rectangular plates that are birefringent when viewed by plane polarized microscopy. Crystals were harvested after 30 minutes and analyzed by single crystal x-ray. Prior to PXRD measurement, the sample was ground, transferred to a vial, and left open to the atmosphere for 4 days.

Results from TGA analysis show a 15.9 % weight loss at temperatures up to 150 degrees C (Fig. 13). 14.9 % weight loss occurred between 70 and 150 degrees C while up to 1.2 % weight loss occurred at lower temperatures. This weight loss is representative of a cortisone acetate PG solvate with 1.0 equivalents of propylene glycol. DSC was completed in a closed, not sealed aluminium pan from room temperature to 300 degrees C at 10 degrees/minute (Fig. 14). The compound was discovered to have two endothermic transitions, one at 148 degrees C with an intensity of 146 J/g, and the second at 237 degrees C with an intensity of 77 J/g.

The PXRD of cortisone acetate PG solvate crystallized from isopropylacetate/propylene glycol solution is shown in two diffractograms in Fig. 15A and Fig. 15B. Peaks can be seen at 2-theta angles including, but not limited to, 5.31, 10.71, 14.54, 15.66, 18.49, 21.33, and 23.49 degrees. The crystal can be characterized by any one, any two, any three, any four, any five, any six, or any seven, or any combination of the peaks listed above or one or a combination of peaks listed in Fig. 15A. In the second representative sample, peaks can be seen at 2-theta angles including, but not limited to, 5.29, 10.73, 14.57, 15.69, 18.51, 21.39, 23.51, and 27.49 in Fig. 15B. The crystal can be characterized by any one, any two, any three, any four, any 5, any 6, any 7, or all 8 of the peaks above or one or a combination of peaks in Fig. 15B. Fig. 16 shows a PXRD diffractogram of material

crystallized from isopropylacetate alone. This is provided only to differentiate the PG solvate from the unsolvated form of the API.

Single-crystal x-ray studies of cortisone acetate PG solvate were also completed. Fig. 17 shows a packing diagram of the single-crystal structure of cortisone acetate PG solvate. The unit cell data are as follows: space group P2(1), A=9.728(2), B=7.6306(15), C=16.454(3), Alpha=90, Beta=92.568(4), Gamma=90, Volume=1220.2(4).

#### Example 7

##### Celecoxib Sodium PG Solvate Trihydrate

##### Preparation:

Celecoxib Na propylene glycol trihydrate was formed by allowing the celecoxib sodium salt propylene glycol solvate to sit at 60 % RH and 20 degrees C for 3 days. (Note: Formation of the trihydrate at 75 % and 40 degrees C occurs as well). The trihydrate begins to form somewhere between 31 and 40 % RH at room temperature.

The solid was characterized by TGA and PXRD, which are shown in Fig. 18 and 19, respectively. Fig. 18 shows the results of the TGA where 9.64 % weight loss was observed between room temperature and 60 degrees C and 13.6 % weight loss was observed between 60 degrees C and 175 degrees C. The PXRD pattern has characteristic peaks at 2-theta angles shown in Fig. 19. Any 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more peaks can be used to characterize the trihydrate, including for example, peaks at 3.47, 6.97, 10.37, 13.97, 16.41, 19.45, 21.29, 22.69, 23.87, and 25.75 degrees. A 0.8 mm collimator was used during acquisition of the diffractogram.

The trihydrate can also be formed by crystallization of celecoxib Na propylene glycol solvate in the presence of H<sub>2</sub>O. To a solution of celecoxib (136.2 mg; 0.357 mmol) in diethyl ether (6.0 mL), water (0.025 mL; 1.39 mmol), and propylene glycol (0.030 mL; 0.408 mmol) was added sodium ethoxide in ethanol (21 wt. %; 0.135 mL; 0.362 mmol). A solid formed within one minute and was isolated via filtration. The solid was then washed with additional diethyl ether (2.0 mL) and allowed to air dry. This procedure gives essentially the same PXRD pattern but there is a slight excess of water, which is probably surface water.



The solid was characterized by TGA and PXRD, which are shown in Fig. 20 and 21, respectively. Fig. 20 shows the results of TGA where 10.92% weight loss was observed between room temperature and 50 degrees C and 12.95% weight loss was observed between 50 degrees C and 195 degrees C. The PXRD pattern has characteristic peaks at 2-theta angles shown in Fig. 21. Any 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or more peaks can be used to characterize the trihydrate, including for example, peaks at 3.43, 6.95, 10.25, 13.95, 16.39, 17.39, 17.75, 18.21, 19.43, 21.21, 22.61, and 25.71 degrees. A 0.8 mm collimator was used during acquisition of the diffractogram.

Figs. 22-24 have been included as reference PXRD diffractograms. Fig. 22 shows the PXRD diffractogram of celecoxib sodium salt. Fig. 23 shows the PXRD diffractogram of celecoxib lithium salt. Fig. 24 shows the PXRD diffractogram of celecoxib potassium salt. Dynamic moisture sorption studies of several embodiments of the present invention have been discussed in PCT/US03/XXXXXX filed on December 24, 2003, entitled "Pharmaceutical Compositions With Improved Dissolution" (Attorney Docket No. TPI-1700CXC2 PCT) by Tawa et al, which is hereby incorporated by reference, in its entirety. Dynamic moisture sorption studies can be used to illustrate important characteristics of the solvates of the present invention, such as decreased hygroscopicity or increased form stability.

While this invention has been particularly shown and described with references to preferred embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the scope of the invention encompassed by the appended claims.

Table 3						
API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication	
(-)-amlodipine	3,5-Pyridinedicarboxylic acid, 2-((2-aminoethoxy)methyl)-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-, 3-ethyl-5-methyl ester, (S)- [CAS]	103129-82-4	WO 9310779	Antihypertensive, other	Hypertension, general	
(-)-halofenate	(-)-Benzenecacetic acid, 4-chloro-Alpha-[3-(trifluoromethyl)-phenoxy]-, 2-(acetylamino)ethyl ester		US 6262118	Antidiabetic	Diabetes, Type II	
(R)-salbutamol	1,3-Benzenedimethanol, Alpha1-(((1,1-dimithylethyl)amino)methyl)-4-hydroxy-[CAS]			Formulation, modified-release, <=24hr	Asthma	
(R)-salbutamol	1,3-Benzenedimethanol, Alpha1-(((1,1-dimethyl)ethyl)amino)methyl)-4-hydroxy-[CAS]	34391-04-3	US 5547994	Antiasthma	Asthma	
(R,R)-formoterol	Formamide, N-(2-hydroxy-5-(1-hydroxy-2-((2-(4-methoxyphenyl)-1-methylethyl)amino)ethyl)phenyl)- (R- (R*,R*))- [CAS]	67346-49-0	US 5795564	Antiasthma	Asthma	
(S)-doxazosin	(S)-1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(1,4-benzodioxan-2-yl carbonyl)piperazine	70918-18-2	WO 9409785	Prostate disorders	Benign prostatic hyperplasia	
(S)-fluoxetine	Benzenepropanamide, N-methyl-Gamma-(4-(trifluoromethyl)phenoxy)- (S)			Antimigraine	Migraine	
(S)-oxybutynin	Benzenecacetic acid, Alpha-cyclohexyl-Alpha-hydroxy-, 4-(diethylamino)-2-butynyl ester, (S)- [CAS]	119618-22-3		Urological	Incontinence	
1,2-Naphthoquinone		524-42-5				
17a-Hydroxyprogesterone		68-96-2				
17-Methyltestosterone		58-18-4				
195mPt-cisplatin	Platinum-195m, diamminedichloro, (SP-4-2)		US 6074626	Anticancer, alkylating	Cancer, liver	
1a-Hydroxycholecalciferol		41294-56-8				
1-Naphthyl Salicylate		550-97-0				

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
1-Naphthylamine-4-sulfonic Acid		84-86-6			
1-Theobromineacetic Acid		5614-56-2			
2,4,6-Tribromo-m-cresol		4619-74-3			
2,6-Diamino-2 $\phi$ -butyloxy-3,5 $\phi$ -azopyridine		617-19-6			
21-Acetoxypregnenolone		566-78-9			
2-Amino-4-picoline		695-34-1			
2-Aminothiazole		96-50-4			
2-ethoxybenzoic acid	2-Ethoxybenzoic acid		DE 5134001	Analgesic, NSAID	Pain, general
2-Naphthol		135-19-3			
2-Naphthyl Benzoate		93-44-7			
2-Naphthyl Lactate		93-43-6			
2-Naphthyl Salicylate		613-78-5			
2-p-Sulfamylaniinoethanol		80-02-4			
2-Thiouracil		141-90-2			
3 $\phi$ ,3 $\phi$ ,5 $\phi$ ,5 $\phi$ -Tetrabromophenolphthalein		76-62-0			
3-Amino-4-hydroxybutyric Acid		589-44-6			
3-Bromo-d-camphor		76-29-9			
3-Hydroxycamphor		10373-81-6			
3-O-Lauroylpyridoxol Diacetate		1562-13-6			
3-Pentadecylcatechol		492-89-7			
3-Quinuclidinol		1619-34-7			
4,4 $\phi$ -Oxydi-2-butanol		821-33-0			
4,4 $\phi$ -Sulfinyldianiline		119-59-5			
4-Amino-3-hydroxybutyric Acid		352-21-6			
4-Amino-3-phenylbutyric Acid		1078-21-3			
4-aminosalicylic acid	Benzoic acid, 4-amino-2-hydroxy- [CAS]	65-49-6		GI inflammatory/bowel disorders	Inflammatory bowel disease
4-Chloro-m-cresol		59-50-7			
4-Hexylresorcinol		136-77-6			

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
4-Salicyloylmorpholine		3202-84-4			
5- $\beta$ -Nitro-2 $\beta$ -propoxyacetanilide		553-20-8			
5-aminolevulinic acid,	Pentanoic acid, 5-amino-4-oxo- [CAS]	106-60-5		Dermatological	Keratosis
5-azacitidine	1,3,5-Triazin-2(1H)-one, 4-amino-1- $\beta$ -D-ribofuranosyl- [CAS]	320-67-2		Anticancer, antimetabolite	Myelodysplastic syndrome
5-Bromosalicylhydroxamic Acid		5798-94-7			
5F-DF-203	2-(4-Amino-3-methylphenyl)-6-hydroxybenzothiazole			Anticancer, other	Cancer, breast
5-FU	2,4(1H,3H)-Pyrimidinedione, 5-fluoro [CAS]	51-21-8		Formulation, parenteral, targeted	Cancer, general
5-HT3 antagonists			US 6037360	Male sexual dysfunction	Premature ejaculation
6-Azauridine		54-25-1			
6-Mercaptopurine		50-44-2			
8-Hydroxyquinoline		148-24-3			
9-Aminocamptothecin		91421-43-1			
A-151892	N-[2-(2,2,2-Trifluoro-1-hydroxy-1-trifluoromethyl-ethyl)-naphthalen-1-yl] amide				
a1-Antitrypsin		9041-92-3		Urological	Overactive bladder
A-5021	6H-Purin-6-one, 2-amino-9-(((1S,2R)-1,2-bis(hydroxymethyl)cyclopropyl)methyl)-1,9-dihydro- [CAS]	145512-85-2		Antiviral, other	Infection, varicella zoster virus
abacavir	2-Cyclopentene-1-methanol, 4-(2-amino-6-(cyclopropylamino)-9H-purin-9-yl)-, (1S-cis)-[CAS]	136470-78-5 188062-50-2	EP 434450	Antiviral, anti-HIV	Infection, HIV/AIDS
abaperidone	7-[3-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidin-1-yl]propoxy]-3-(hydroxymethyl)chromen-4-one				
		183849-43-6	WO 9632389	Neuroleptic	Schizophrenia



API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
abarelix	D-Alaninamide, N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-N-methyl-L-tyrosyl-D-asparaginy-L-leucyl-N6-(1-methylethyl)-L-lysyl-L-prolyl- [CAS]	183552-38-7	US 5843902	Anticancer, hormonal	Cancer, prostate
Abciximab		143653-53-6			
Abecamil		111841-85-1			
abetimus		169147-32-4	US 5552391	Immunosuppressant	Lupus erythematosus, systemic
abiraterone	Androsta-5,16-dien-3-ol, 17-(3-pyridinyl)-, acetate (ester), (3S)- [CAS]	154229-18-2	GB 2265624	Anticancer, hormonal	Cancer, prostate
a-Bisabolol		515-69-5			
ABLC	Amphotericin B [CAS]	1397-89-3		Formulation, conjugate, carbohydrate	Infection, Candida, general
ABT-751	Benzenesulfonamide, N-[2-[(4-hydroxyphenyl)amino]-3-pyridinyl]-4-methoxy- [CAS]	141430-65-1	EP 472053	Anticancer, other	Cancer, general
AC-5216	N-benzyl-N-ethyl-2-(7,8-dihydro-7-methyl-8-oxo-2-phenyl-9H-purin-9-yl)acetamide			Anxiolytic	Anxiety, general
Acadesine		2627-69-2			
acamprosate	1-Propanesulfonic acid, 3-(acetylamino)- [CAS]	77337-76-9	GB 2051789	Dependence treatment	Addiction, alcohol
Acamprosate		77337-73-6			
Acarbose		56180-94-0			
acebrophylline	7H-Purine-7-acetic acid, 1,2,3,6-tetrahydro-1,3-dimethyl-2,6-dioxo-, compd. with trans-4-[[[(2-amino-3,5-dibromophenyl)methyl]amino]cyclohexanol (1:1) [CAS]	96989-76-3	DE 3425007	Antiasthma	Asthma
acebutolol	Butanamide, N-[3-acetyl-4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]phenyl]-, (+/-)- [CAS]	34381-68-5 37517-30-9	US 3726919	Antihypertensive, adrenergic	
Acetaminide		32795-44-1			
Acetabromal		77-66-7			

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
aceclofenac	Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]-, carboxymethyl ester [CAS]	89796-99-6	EP	119932	Anti-inflammatory	Pain, musculoskeletal
Acetapsone		77-46-3				
Acetiasulfone		80-03-5				
Acetyline		652-37-9				
Acetylutamide		2490-97-3				
acetylutamide	Aluminum, pentakis(N2-acetyl-L-glutaminato)tetrahydroxytri- [CAS]	12607-92-0	DE	2127176	Antiulcer	Ulcer, GI, general
acemetacin	1H-Indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-, carboxymethyl ester [CAS]	53164-05-9	US	3910952	Anti-inflammatory	
Acenocoumarol		152-72-7				
Acetal		105-57-7				
Acetamidoeugenol		305-13-5				
Acetaminophen		103-90-2				
Acetaminosalol		118-57-0				
Acetanilide		103-84-4				
Acetarsone		97-44-9				
Acetazolamide		59-66-5				
Acetamine		299-89-8				
Acetohexamide		968-81-0				
Acetohydroxamic Acid		546-88-3				
Acetophenazine		2751-68-0				
Acetophenone		98-86-2				
Acetosulfone		128-12-1				
acetoxolone	Olean-12-en-30-olic acid, 3β-hydroxy-11-oxo-acetate, aluminum salt [CAS]	29728-34-5 6277-14-1	US	3764618	Antiulcer	
Acetizoate		129-63-5				
Acetyl Sulfamethoxypyrazine		3590-05-4				
Acetylcarnitine		14992-62-2				
Acetylcholine		66-23-9				
Acetylcholine		60-31-1				
Acetylcysteine		616-91-1				

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Acetylleucine Monoethanolamine		149-90-6			
Acetylphenetidine		13402-08-9			
acetylsalicylic acid	Benzoic acid, 2-(acetyloxy)- [CAS]	50-78-2 75-6	530-	Formulation, optimized, microencapsulate	Pain, general
a-Chloralose		15879-93-3			
aciclovir	6H-Purin-6-one, 2-amino-1,9-dihydro-9-[(2-hydroxyethoxy)methyl]- [CAS]	59277-89-3		Formulation, dermal, topical	Infection, herpes simplex virus
Acifran		72420-38-3			
acipimox	Pyrazinecarboxylic acid, 5-methyl-, 4-oxide [CAS]	51037-30-0	GB	Hypolipaeimic/Antiatherosclerosis	Hyperlipidaemia, general
acitazanolast	Acetic acid, oxo[[3-(1H-tetrazol-5-yl)phenyl]amino]- [CAS]	114607-46-4	EP	Ophthalmological	Conjunctivitis
acitretin	2,4,6,8-Nonatetraenoic acid, 9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-, (all-E)- [CAS]	55079-83-9	GB	Antipsoriasis	Psoriasis
aclarubicin		57576-44-0			
Aclatonium Napadisilate		75443-99-1	US	Anticancer, antibiotic	
Aconitine		55077-30-0			
Acranil®		302-27-2			
Acriflavine		1684-42-0			
Acrisorcin		8048-52-0			
		7527-91-5			
acrivastine	2-Propenoic acid, 3-[6-[1-(4-methylphenyl)-3-(1-pyrrolidinyl)-1-propenyl]-2-pyridinyl]-, (E,E)- [CAS]	87848-99-5	EP	Antipruritic/inflamm, allergic	Rhinitis, allergic, general
acrivastine + pseudoephedrine	Benzenemethanol, Alpha-[1-(methylamino)ethyl]-, hydrochloride, [S-(R*,R*)]-, mixwith 2-Propenoic acid, 3-[6-[1-(4-methylphenyl)-3-(1-pyrrolidinyl)-1-propenyl]-2-pyridinyl]-, (E,E)-			Antiallergic, non-asthma	Rhinitis, allergic, seasonal
actagardine derivative	3,3-dimethyl-1-propylamide HCl monoxycarboxamide actagardine			Peptide antibiotic	Infection, general
Actarit		18699-02-0			
ACTH		9002-60-2			
Acyclovir		59277-89-3			

507/0503/42572

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
adapalene	2-Naphthalenecarboxylic acid, 6-(4-methoxy-3-tricyclo[3.3.1.1 <sup>3,7</sup> dec-1-ylphenyl)- [CAS]	106685-40-9	EP 199636	Antiacne	Acne
ADCON-L	GL 402 [CAS]	137802-74-5		Formulation, other	Fibrosis, epidural
Adefovir		106941-25-7			
adefovir dipivoxil	Propanoic acid, 2,2-dimethyl-, (((2-(6-amino-9H-purin-9-yl)ethoxy)methyl)phosphinylidene)bis(oxyethylene)ester- [CAS]	142340-99-6	EP 205826	Antiviral, other	Infection, hepatitis-B virus
Adenoscan	6-Amino-9-β-D-ribofuranosyl-9H-purine [CAS]	58-61-7		Imaging agent	Diagnosis, coronary
Adenosine Triphosphate		56-65-5			
ADEPT		156079-88-8		Immunconjugate, other	Cancer, colorectal
Adinazolam		37115-32-5			
Adiphenine		64-95-9			
ADL-10-0101			WO 9732857	Analgesic, other	Pain, general
Adrafinil		63547-13-7			
Adrenalone		99-45-6			
Adrenochrome		54-06-8			
adrogolide	Benzo(f)thieno(2,3-c)quinoline-9,10-diol, 4,5,6,7,11b-hexahydro-2-propyl-, diacetate (ester), hydrochloride (5aR-trans)- [CAS]	166591-11-3 171752-56-0	US 5597832	Dependence treatment	Addiction, cocaine
AEOL-10150			US 6103714	Neuroprotective	Unspecified
AET		56-10-0			
a-Ethylbenzyl Alcohol		93-54-9			
AF-2259	Benzeneacetic acid, Alpha-methyl-4-(2-methylpropyl)-, 2-methoxyphenyl ester [CAS]	66332-77-2	DE 2726435	Anti-inflammatory	Inflammation, general
Afloqualone		56287-74-2			
AG-041R	1H-Indole-3-acetamide, 1-(2,2-diethoxyethyl)-2,3-dihydro-N-(4-methylphenyl)-3-(((4-methylphenyl)amino)carbonyl)amino)-2-oxo-, (3R)- [CAS]	199800-49-2	WO 9419322	Alimentary/Metabolic, other	Unspecified



API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
AG-2037	N-(5-[2-(2-amino-4(3H)-oxo-5,6,7,8-tetrahydropyrido[2,3-d]pyrimidin-6-yl)ethyl]-4-methylthieno-2-yl)glutamic acid			Anticancer, antimetabolite	Cancer, general
a-Glucose-1-phosphate		59-56-3			
AGN-194310	Benzoic acid, 4-((4-(4-ethylphenyl)-2,2-dimethyl-2H-1-benzothiofuran-6-yl)ethynyl)- [CAS]	229961-45-9	WO 9709297	Dermatological	Psoriasis
agomelatine	Acetamide, N-(2-(7-methoxy-1-naphthalenyl)ethyl)- [CAS]	138112-76-2	EP 447285	Antidepressant	Sleep disorder, general
Ahistan		518-61-6			
AHL-157			US 5411972	Hypolipemic/Antiatherosclerosis	Atherosclerosis
AIT-034	9H-Purine-9-propanamide, 1,6-dihydro-6-oxo-N-(3-(2-oxo-1-pyrrolidinyl)propyl)- [CAS]	138117-48-3	US 5447939	Cognition enhancer	Dementia, senile, general
AIT-202	N-[2-(5-Hydroxy-1H-indol-3-yl)ethyl]-3-(6-oxo-6,9-dihydro-1H-purin-9-yl)propionamide		WO 9957120	Antidepressant	Unspecified
AJ-9677	Acetic acid, (3-((2R)-2-(((2R)-2-(3-chlorophenyl)-2-hydroxyethyl)amino)propyl)-1H-indol-7-yl)oxy)- [CAS]	244081-42-3		Antidiabetic	Diabetes, Type II
AJG-049			WO 9733885	Gastroprokinetic	Motility dysfunction, GI, general
Ajmaline		1210714360			
Alacepril		74258-86-9			
albaconazole	4(3H)-Quinazolinone, 7-chloro-3-[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]- [CAS]	187949-02-6	WO 9705131	Antifungal	Infection, Candida, general
albendazole	Carbamic acid, [5-(propylthio)-1H-benzimidazol-2-yl]-, methyl ester [CAS]	54029-12-8 54965-21-8	GB 1464326	Anthelmintic	Infection, helminth, general
Albuterol		18559-94-9			
Albutoin		830-89-7			

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
alclufenac	Benzenecetic acid, 3-chloro-4-(2-propenyloxy)- [CAS]	22131-79-9	GB 1174535	Anti-inflammatory	
alclometasone	Pregna-1,4-diene-3,20-dione, 7-chloro-11-hydroxy-16-methyl-17,21-bis(1-oxopropoxy)-, (7Alpha,11Beta,16Alpha)- [CAS]	66734-13-2 67452-97-5	US 4124707	Antipruritic/inflamm, allergic	Inflammation, dermal
Alcuronium		23214-96-2			
Aldioxa		5579-81-7			
Aldol		107-89-1			
Aldosterone		52-39-1			
alendronate	Phosphonic acid, (4-amino-1-hydroxybutylidene)bis- [CAS]	121268-17-5 129318-43-0	GB 2118042	Osteoporosis treatment	Osteoporosis
Alendronic Acid		66376-36-1			
Alexidine		22573-93-9			
alfacalcidol	9,10-Secostercholesta-5,7,10(19)-triene-1,3-diol, (1Alpha,3Beta,5Z,7E)- [CAS]	41294-56-8		Osteoporosis treatment	Osteodystrophy
Alfadolone		23930-37-2			
Alfaxalone		23930-19-0			
Alfentanil		71195-58-9			
alfimeprase		259074-76-5		Fibrinolytic	Peripheral vascular disease
alfuzosin	2-Furancarboxamide, N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro-[CAS]	81403-68-1 81403-80-7	GB 2013679	Prostate disorders	Benign prostatic hyperplasia
alfuzosin	2-Furancarboxamide, N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro-[CAS]	81403-68-1 81403-80-7		Formulation, modified-release, other	Benign prostatic hyperplasia
Algestone		595-77-7			
Algestone Acetophenide		24356-94-3			
Algin		9005-38-3			
Alglucerase		143003-46-7			
Alibendol		26750-81-2			

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
aliskiren	(2S,4S,5S,7S)-5-Amino-N-(2-carbamoyl-2-methylpropyl)-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-8-methylnonanamide	173334-57-1		Antihypertensive, renin system	Hypertension, general
alitretinoin	9-cis retinoic acid	03/08/5300		Antipruritic/Inflamm, allergic	Eczema, general
alizapride	1H-Benzotriazole-5-carboxamide, 6-methoxy-N-[[1-(2-propenyl)-2-pyrrolidinyl]methyl]- [CAS]	59338-93-1	GB 1475234	Antiemetic	Nausea and vomiting, general
Alkannin		517-88-4			
Alkofanone		7527-94-8			
Allantoin		97-59-6			
Allobarbitol		52-43-7			
Allopurinol		315-30-0			
Allyl Isothiocyanate		57-06-7			
Allylestrenol		432-60-0			
almagate	Magnesium, [carbonato(2-))heptahydroxy(aluminum)tri-, dihydrate [CAS]	66827-12-1 72526-11-5	US 4447417	Antacid/Antiflatulent	
alminoprofen	Benzeneacetic acid, Alpha-methyl-4-[(2-methyl-2-propenyl)amino]- [CAS]	39718-89-3	US 3957850	Analgesic, NSAID	
almitrine	1,3,5-Triazine-2,4-diamine, 6-[4-bis(4-fluorophenyl)methyl]-1-piperazinyl]-N,N'-di-2-propenyl-, dimethanesulfonate [CAS]	27469-53-0 29608-49-9	GB 1256513	Respiratory	Bronchitis, chronic
almotriptan	Pyrrolidine, 1-(((3-(2-(dimethylamino)ethyl)-1H-indol-5-yl)methyl)sulfonyl)- [CAS]	154323-57-6	WO 9402460	Antimigraine	Migraine
Aloe-Emodin		481-72-1			
Aloln		5133-19-7			
alosetron	2,3,4,5-Tetrahydro-5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-1H-pyrido[4,3-b]indol-1-one [CAS]	122852-42-0 122852-69-1 132414-02-9	EP 306323	GI inflammatory/bowel disorders	Irritable bowel syndrome
alovudine	Thymidine, 3'-deoxy-3'-fluoro- [CAS]	25526-93-6	EP 470355	Antiviral, anti-HIV	Infection, HIV/AIDS
Aloxiprin		9014-67-9			

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Alpha-1 protease inhibitor			US 5780014	Formulation, inhalable, topical	Emphysema, alpha-1 antitrypsin deficiency
Alpha-dihydroergocryptine	Ergocryptine, 9,10-dihydro-methanesulfonate (salt)- [CAS]	29261-93-6			
Alphaprodine		77-20-3		Formulation, other	Parkinson's disease
Alpidem		82626-01-5			
Alpiopride		81982-32-3			
alprazolam	4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-1-methyl-6-phenyl-[CAS]				
Alprenolol		28981-97-7	US 3987052	Anxiolytic	Anxiety, general
		13655-52-2			
alsacitide	Alpha1-17-Corticotropin, 1-β-alanine-17-[N-(4-aminobutyl)-L-lysineamide]- [CAS]	34765-96-3	US 3749704	ACTH	Arthritis, rheumatoid
ALT-711	Thiazolium, 4,5-dimethyl-3-(2-oxo-2-phenylethyl)-, bromide [CAS]	181069-80-7	WO 9622095	Symptomatic antidiabetic	Hypertension, general
Althiazide		5588-16-9			
altiniclincine	Pyridine, 3-ethynyl-5-((2S)-1-methyl-2-pyrrolidinyl)- [CAS]	179120-92-4	US 5594011	Antiparkinsonian	Parkinson's disease
altretamine	1,3,5-Triazine-2,4,6-triamine, N,N,N',N',N'',N''-hexamethyl- [CAS]	645-05-6	US 3424752	Anticancer, alkylating	Cancer, ovarian
aluminium chloride hexahydrate	Aluminium chloride, hexahydrate	7446-70-0		Dermatological	Hyperhidrosis
Aluminon		7784-13-6			
Aluminum Acetate Solution		569-58-4			
Aluminum Chlorate		8006-13-1			
Aluminum Hydroxychloride		15477-33-5			
Aluminum Potassium Sulfate		1327-41-9			
Aluminum Sodium Sulfate		10043-67-1			
		10102-71-3			
alusulf	Aluminum hydroxide sulfate (Al7(OH)17(SO4)2), dodecahydrate [CAS]	61115-28-4	DE 2510663	Urological	Hyperphosphataemia
Alverine		150-59-4			
alvimopan	Glycine, N-((2S)-2-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl)- [CAS]	156053-89-3	EP 657428	GI inflammatory/bowel disorders	Ileus



API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
alvocidib	4H-1-Benzopyran-4-one, 2-(2-chlorophenyl)-5,7-dihydroxy-8-(3-hydroxy-1-methyl-4-piperidinyl)-, cis-(-)- [CAS]	131740-09-5 146426-40-6		Anticancer, other	Cancer, renal
ALX-0646			WO 9506638	Antimigraine	Migraine
AM-24	2,4,6-Triiodophenol	609-23-4		GI inflammatory/bowel disorders	Crohn's disease
AM-36	1-Piperazineethanol, 4-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]methyl]-Alpha-(4-chlorophenyl)- [CAS]	199467-52-2		Neuroprotective	Unspecified
AM-477	2-Methoxyoestradiol			Antiasthma	Asthma
Amantadine		768-94-5			
amantanium	1-Decanaminium, N,N-dimethyl-N-[2-[[tricyclo[3.3.1.1 <sup>3,7</sup> ]dec-1-ylcarbonyl]oxy]ethyl]-, bromide [CAS]	58158-77-3	US 4288609	Antifungal	Infection, general
Ambazone		539-21-9			
Ambenonium		115-79-7			
ambrisentan	(+)-(2S)-2-[(4,6-dimethylpyrimidin-2-yl)oxy]-3-methoxy-3,3-diphenylpropanoic acid	177036-94-1		Vasodilator, peripheral	Heart failure
ambroxol	Cyclohexanol, 4-[[[2-amino-3,5-dibromophenyl]methyl]amino]-, trans- [CAS]	18683-91-5 23828-92-4	GB 1178034	COPD treatment	Bronchitis, chronic
Ambucaine		119-29-9			
Ambuphylline		5634-34-4			
Ambuside		3754-19-6			
Ambutonium Bromide		115-51-5			
amcinonide	Pregna-1,4-diene-3,20-dione, 21-(acetyloxy)-16,17-[cyclopentylidenebis(oxy)]-9-fluoro-11-hydroxy-, (11 $\beta$ ,16 $\alpha$ )- [CAS]	51022-69-6	DE 2437847	Antipsoriasis	
AMD-3100	1,4,8,11-Tetraazacyclotetradecane, 1,11-(1,4-phenylenebis(methylene))bis-, octahydrochloride [CAS]	155148-31-5	US 5612478	Haematological	Chemotherapy-induced injury, bone marrow, leucopenia
Aminocillin		32887-01-7			

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Amdinocillin Pivoxil		32886-97-8			
amdoxovir	1,3-Dioxolane-2-methanol, 4-(2,6-diamino-9H-purin-9-yl)- (2R-cl)- [CAS]	145514-04-1	EP 656778	Antiviral, anti-HIV	Infection, HIV/AIDS
amelubant	Carbamic acid, ((4-((3-((4-(1-(4-hydroxyphenyl)-1-methylethyl)phenoxy)methyl)phenyl)methoxy)phenyl)iminomethyl)- ethyl ester [CAS]	346735-24-8	DE 1000907	COPD treatment	Chronic obstructive pulmonary disease
Americaine	Benzenemethanaminium, N,N-dimethyl-N-[2-{2-[4-(1,1,3,3-tetramethylbutyl)phenoxy]ethoxy]ethyl]-, chloride, mixt. with ethyl 4-aminobenzoate [CAS]	129128-13-8		Formulation, inhalable, other	Pain, general
Amezinium		30578-37-1			
Amenac		51579-82-9			
Amidephrine		3354-67-4			
Amidinomycin		3572-60-9			
amifostine	Ethanthiol, 2-[(3-aminopropyl)amino]-, dihydrogen phosphate (ester)- [CAS]	20537-88-6 63717-27-1	EP 131500	Radio/chemoprotective	Chemotherapy-induced injury, renal
amiglumide	Pentanoic acid, 5-(dipentylamino)-4-((2-naphthalenylcarbonyl)amino)-5-oxo- (R)- [CAS]	119363-62-1	WO 8805774	GI inflammatory/bowel disorders	Pancreatitis
amikacin		37517-28-5 39831-55-5		Formulation, optimized, microencapsulate	Infection, general
Amiloride		2609-46-3			
Aminacrine		90-45-9			
amineptine	Heptanoic acid, 7-[(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)amino]-[CAS]	30272-08-3 57574-09-1	US 3758528	Antidepressant	
Aminlitroazole		140-40-9			
Amino Acid Preparations					
Aminocaproic Acid					
aminogluthetimide	2,6-Piperidinedione, 3-(4-aminophenyl)-3-ethyl- [CAS]	125-84-8	US 3944671	Anticancer, hormonal	Cancer, breast
Aminoguanidine		79-17-4			
Aminohippurate					
Aminometradine		642-44-4			

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Aminopentamide		60-46-8			
aminophylline	1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl-, compd. with 1,2-ethanediamine (2:1) [CAS]	317-34-0		Formulation, modified-release, other	Asthma
Aminopromazine		58-37-7			
Aminopyrine		58-15-1			
Aminoquinuride		3811-56-1			
Aminorex		2207-50-3			
amlodartone	Methanone, (2-butyl-3-benzofuranyl)[4-[2-(diethylamino)ethoxy]-3,5-diiodophenyl]-[CAS]	1951-25-3 19774-82-4	US 3248401	Antiarrhythmic	Arrhythmia, general
Amiphenazole		490-55-1			
Amiprilose		56824-20-5			
amisulpride	Benzamide, 4-amino-N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-(ethylsulfonyl)-2-methoxy- [CAS]	71675-85-9	US 4401822	Neuroleptic	Schizophrenia
Amitriptyline		50-48-6			
amitriptyline+ketamine	1-Propanamine,3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N,N-dimethyl + cyclohexanone,2-(2-chlorophenyl)-2-(methylamino)			Formulation, fixed-dose combinations	Pain, neuropathic
Amitriptylinoxide		4317-14-0			
amlexanox	5H-[1]Benzopyrano[2,3-b]pyridine-3-carboxylic acid, 2-amino-7-(1-methylethyl)-5-oxo- [CAS]	68302-57-8	US 4299963	Antiasthma	Asthma
amlodipine	3,5-Pyridinedicarboxylic acid, 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-, 3-ethyl 5-methyl ester [CAS]	111470-99-6 88150-42-9 88150-47-4	EP 89167	Antianginal	Hypertension, general
Ammoniacum		03/07/9000			
Ammonium Benzoate		1863-63-4			
Ammonium Mandelate		530-31-4			
Ammonium Salicylate		528-94-9			
Ammonium Valerate		42739-38-8			
Amobarbital		57-43-2			

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Amocazline		36590-19-9			
Amodiaquin		86-42-0			
amorolfine	Morpholine, 4-[3-[4-(1,1-dimethylpropyl)phenyl]-2-methylpropyl]-2,6-dimethyl-, dls- [CAS]	78613-35-1 78613-38-4	EP 24334	Antifungal	Infection, fungal, general
Amoscanate		26328-53-0			
amosulalol	Benzenesulfonamide, 5-[1-hydroxy-2-[[2-(2-methoxyphenoxy)ethyl]amino]ethyl]-2-methyl-, (+/-)- [CAS]	70958-86-0 85320-68-9	EP 136103	Antihypertensive, adrenergic	Hypertension, general
Amotriphene		5585-64-8			
amoxapine	Dibenz[b,f][1,4]oxazepine, 2-chloro-11-(1-piperazinyl)- [CAS]	14028-44-5	GB 1192812	Antidepressant	Depression, general
amoxicillin	4-Thia-1-azobicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[amino(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-, [2S-[2Alpha,5Alpha,6Beta(S*)]] [CAS]	26787-78-0 61336-70-7		Formulation, modified-release, other	Infection, general
amoxicillin+potassium clavulan		74469-00-4	GB 1508977	Formulation, fixed-dose combinations	Infection, respiratory tract, general
AMP Alex	Piperidine, 1-(6-quinoxalinyloxy)- [CAS]	154235-83-3	US 5650409	Psychostimulant	Attention deficit disorder
Amphetamine		300-62-9			
Amphetaminil		17590-01-1			
amphotericin B	Amphotericin B compd. with (3S)-cholest-5-en-3-yl hydrogen sulfate (1:1) [CAS]	120895-52-5 1397-89-3	US 4822777	Formulation, optimized, liposomes	Infection, general
ampicillin	4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[aminophenylacetyl]amino]-3,3-dimethyl-7-oxo-, [2S-[2Alpha,5Alpha,6Beta(S*)]]	69-53-4 7177-48-2		Formulation, fixed-dose combinations	Infection, general
Amproxicam		99464-64-9			
Ampligen		38640-92-5			

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
amprenavir	Carbamic acid, (3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)-, tetrahydro-3-furanyl ester, (3S-(3R*(1R*,2S*)))- [CAS]	161814-49-9	US 5783701	Antiviral, anti-HIV	Infection, HIV/AIDS
amrinone	[3,4'-Bipyridin]-6(1H)-one, 5-amino- [CAS]	60719-84-8 75898-90-7	US 4004012	Cardio stimulant	
amrubicin	5,12-Naphthacenedione, 9-acetyl-9-amino-7-[(2-deoxy-β-D-erythro-pentopyranosyl)oxy]-7,8,9,10-tetrahydro-6,11-dihydroxy-, hydrochloride, (7S-cis)- [CAS]	92395-36-3	EP 107486	Anticancer, antibiotic	Cancer, lung, non-small cell
amsacrine	Methanesulfonamide, N-[4-(9-acridinylamino)-3-methoxyphenyl]- [CAS]	51264-14-3		Anticancer, other	Cancer, leukaemia, acute lymphocytic
amtolmetin guacil	Glycine, N-[[1-methyl-5-(4-methylbenzoyl)-1H-pyrrol-2-yl]acetyl]-, 2-methoxyphenyl ester [CAS]	87344-06-7	GB 2115417	Analgesic, NSAID	Arthritis, rheumatoid
Amylocaine		532-59-2			
AN-152			WO 9719954	Anticancer, antibiotic	Cancer, prostate
anabolic steroids			WO 9848812	Cardiovascular	Heart failure
Anagesone		2740-52-5			
anagrelide	Imidazo[2,1-b]quinazolin-2(3H)-one, 6,7-dichloro-1,5-dihydro-, monohydrochloride [CAS]	58579-51-4 68475-42-3	GB 1418822	Haematological	Thrombocytosis
anastrozole	1,3-Benzenediacetonitrile, Alpha,Alpha,Alpha'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)- [CAS]	120511-73-1	EP 296749	Anticancer, hormonal	Cancer, breast
Anazolene		3861-73-2			
Anditabine		31698-14-3			
Ancrod		9046-56-4			
andolast	N-4'-[5-Tetrazolyl]-phenyl-4-(5-tetrazolyl)-benzamide	132640-22-3	EP 460083	Antiasthma	Asthma
Androisoxazole		360-66-7			
Androstenediol		521-17-5			



API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
anecortave	21-(Acetyloxy)-17-hydroxypregna-4,9(11)-diene-3,20-dione	7753-60-8		Ophthalmological	Macular degeneration
Anethole		4180-23-8; 104-46-1 (unspecified)			
Anethole Trithione		532-11-6			
Angiogenix			US 6417205	Cardiovascular	Cardiomyopathy, ischaemic
Angiotensin		1407-47-2			
anhydrovinblastine	Vincal leukoblastine, 3',4'-didehydro-4'-deoxy [CAS]	38390-45-3	US 6011041	Anticancer, other	Cancer, general
anidulafungin	Echinocandin B, 1-((4R,5R)-4,5-dihydroxy-N2-((4"- (pentyloxy)(1,1':4',1"-terphenyl)-4-yl)carbonyl)-L-ornithine)- [CAS]	166663-25-8	US 6384013	Antifungal	Infection, Candida, general
Anileridine		144-14-9			
Aniracetam		72432-10-1			
Anisindione		117-37-3			
Anisomycin		22862-76-6			
Anisotropine Methylbromide		80-50-2			
anistreplase	Anistreplase [CAS]	81669-57-0	EP 28489	Fibrinolytic	Infarction, myocardial
Antazoline		91-75-8			
Anthilolimine		305-97-5			
Anthralin		1143-38-0			
Anthramycin		4803-27-4			
Anthraxin		577-33-3			
anthrax inhibitor			US 6436933	Anti-infective, other	Infection, anthrax
antiangiogenic dendrimers			US 6426067	Anticancer, other	Cancer, general
Anticort	L-Ascorbic acid, mixt with 2-(diethylamino)ethyl 4-aminobenzoate monohydrochloride, disodium hydrogen phosphate, potassium benzoate and zinc sulfate (1:1) [CAS]	186646-39-9	WO 9640038	Anabolic	Cachexia
antidepressants			US 5898036	Antidepressant	Depression, general
anti-invasins			US 6303302	Antifungal	Infection, fungal, general
Antimony Potassium Tartrate		28300-74-5			

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Antimony Sodium Thioglycollate		539-54-8			
Antimony Thioglycollamide		6533-78-4			
Antiprogesterin	19-Norpregna-4,9-dien-3-one,(acetylphenyl) 20,20,21,21,21-pentafluoro-17-hydroxy- (11 $\beta$ ,17 $\alpha$ ) [CAS]	211254-73-8	DE 19706061	Anticancer, hormonal	Cancer, breast
Antipyrine		60-80-0			
Antipyrine Salicylate		520-07-0			
antithrombin III	Antithrombin, III [CAS]	9000-94-6 90170-80-2		Blood fraction	Antithrombin III deficiency
anxiolytics			US 5756538	Anxiolytic	Anxiety, general
AP-521	N-Piperonyl-2-amino-1,2,3,4- tetrahydrobenzo(b)thieno(2,3-c)pyridine-3- carbamide	151227-08-6	WO 9321189	Anxiolytic	Anxiety, general
AP-5280			US 5965118	Anticancer, alkylating	Cancer, general
Apalcillin		63469-19-2			
apaziquone	1H-Indole-4,7-dione, 5-(1-aziridinyl)-3- (hydroxymethyl)-2-(3-hydroxy-1-propenyl)-1- methyl-, (E)- [CAS]	114560-48-4	WO 8706227	Anticancer, alkylating	Cancer, breast
Apazone		13539-59-8			
a-Phenylbutyramide		90-26-6			
Apocodeline		641-36-1			
apomine	Phosphonic acid, (2-(3,5-bis(1,1- dimethylethyl)-4- hydroxyphenyl)ethylidene)bis- tetrakis(1- methylethyl) ester [CAS]	126411-13-0		Anticancer, other	Cancer, prostate
apomorphine	4H-Dibenzo[de,g]quinoline-10,11-diol, 5,6,6a,7-tetrahydro-6-methyl-, hydrochloride	314-19-2 00-4	58	Formulation, transmucosal, nasal	Impotence
apraclonidine	1,4-Benzenediamine, 2,6-dichloro-N1-(4,5- dihydro-1H-imidazol-2-yl)- [CAS]	66711-21-5 73218-79-8	US 4517199	Antiglaucoma	Glaucoma

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
aprepitant	3H-1,2,4-Triazol-3-one, 5-[[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro- [CAS]	170729-80-3	US 5719147	Antiemetic	Chemotherapy-induced nausea and vomiting
aprimidine	1,3-Propanediamine, N-(2,3-dihydro-1H-inden-2-yl)-N',N'-diethyl-N-phenyl-[CAS]	33237-74-0 37640-71-4	GB 1321424	Antiarrhythmic	
Aprobarbital		77-02-1			
Apronalide		528-92-7			
Aprotinin		9087-70-1			
Aptiganel		137159-92-3			
AQ4N	9,10-Anthracenedione, 1,4-bis[(2-(dimethyloxidoamino)ethyl)amino]-5,8-dihydroxy-[CAS]	136470-65-0	US 5132327	Anticancer, other	Cancer, general
Aquavan			US 6204257	Anaesthetic, injectable	Anaesthesia
AR-116081			US 6107324	Neuroleptic	Unspecified
AR-A2	(R)-N-[5-methyl-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydro-2-naphthyl]-4-morpholinobenzamide			Anxiolytic	Anxiety, general
Arachidonic Acid		506-32-1			
aranidipine	3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-, methyl 2-oxopropyl ester- [CAS]	86780-90-7	GB 2111978	Antihypertensive, other	Hypertension, general
arbekacin	D-Streptamine, O-3-amino-3-deoxy-Alpha-D-glucopyranosyl-(1-6)-O-[2,6-diamino-2,3,4,6-tetra-deoxy-Alpha-D-erythro-hexopyranosyl-(1-4)]-N1-(4-amino-2-hydroxy-1-oxobutyl)-2-deoxy-, (S)- [CAS]	51025-85-5 75282-65-4	US 4001208	Aminoglycoside antibiotic	Infection, general
Arbidol	1H-Indole-3-carboxylic acid, 6-bromo-4-((dimethylamino)methyl)-5-hydroxy-1-methyl-2-((phenylthio)methyl)-, ethylester, monohydrochloride [CAS]	131707-23-8	WO 9008135	Immunostimulant, other	Infection, influenza virus
arbutamine	1,2-Benzenediol, 4-[1-hydroxy-2-[4-(4-hydroxyphenyl)butyl]amino]ethyl]-, (R)-[CAS]	128470-16-6	WO 9220324	Diagnostic	Diagnosis, coronary

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Arcitumomab		154361-48-5			
ardeparin	Heparin [CAS]	9005-49-6		Anticoagulant	Thrombosis, venous
arecoline	1,2,5,6-Tetrahydro-1-methyl-3-pyridine carboxylic acid methyl ester			Formulation, transdermal, patch	Alzheimer's disease
argatroban	2-Piperidinecarboxylic acid, 1-[5-[(aminiminomethyl)amino]-1-oxo-2-[[[(1,2,3,4-tetrahydro-3-methyl-8-quinolinyl)sulfonyl]amino]pentyl]-4-methyl- [CAS]	74863-84-6	EP 8746	Anticoagulant	Thrombosis, arterial
Arginine		74-79-3			
Ariflo®		153259-65-5			
aripiprazole	2(1H)-Quinolinone, 7-[4-{4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy]-3,4-dihydro- [CAS]	129722-12-9	EP 367141	Neuroleptic	Schizophrenia
arofylline	1H-Purine-2,6-dione, 3-(4-chlorophenyl)-3,7-dihydro-1-propyl- [CAS]	136145-07-8	EP 435811	COPD treatment	Chronic obstructive pulmonary disease
arotinolol	2-Thiophenecarboxamide, 5-[2-[[3-[[1,1-dimethylethyl)amino]-2-hydroxypropyl]thio]-4-thiazolyl]-, (±)- [CAS]	104766-23-6 68377-92-4	US 3932400	Antihypertensive, adrenergic	Hypertension, general
Arsacetin		618-22-4			
arsenic trioxide	Arsenic oxide (As2O3) [CAS]	1327-53-3		Anticancer, other	Cancer, leukaemia, acute myelogenous
Arsphenamine		139-93-5			
Arsthinol		119-96-0			
Arteether		75887-54-6			
Arteflene		123407-36-3 (Z-form)			
Artemether		71963-77-4			
Artemisinin		63968-64-9			
artemotil	3,12-Epoxy-12H-pyrano[4,3-]-1,2-benzodioxepin, 10-ethoxydecahydro-3,6,9-trimethyl-, [3R-(3Alpha,5aBeta,6Beta,8aBeta,9aAlpha,10Alpha,12Beta,12aR*)]- [CAS]	75887-54-6		Antimalarial	Infection, malaria

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
artesunate	Butanedioic acid mono- [(3R,5aS,6R,8aS,9R,10R,12R,12aR)- decahydro-3,6,9-trimethyl-3,12-epoxy-12H- pyrano[4,3-j]-1,2-benzodioxepin-10-yl]ester	88495-63-0		Formulation, transmucosal, systemic	Infection, malaria
arzoxifene	Benzo(b)thiophene-6-ol, 2-(4- methoxyphenyl)-3-(4-(2-(1- piperidinyl)ethoxy)phenoxy)- [CAS]	182133-27-3	WO 9609041	Anticancer, hormonal	Cancer, breast
AS-3201	Spiro(pyrrolidine-3,4'-(1'H)-pyrrolo(1,2- a)pyrazine)-1',2,3',5(2'H)-tetrone, 2'-((4- bromo-2-fluorophenyl)methyl)-, (3'R)- [CAS]	147254-64-6	EP 520320	Symptomatic antidiabetic	Diabetic complication, general
ASA	Benzoic acid, 2-(acetyloxy)- [CAS]	50-78-2		Formulation, modified-release, other	Pain, general
a-Santonin		56449-07-1			
Ascaridole		481-06-1			
Ascorbic Acid		512-85-6			
		50-81-7			
asenaphine	1H-Dibenz[2,3:6,7]oxepino[4,5-c]pyrrole, 5- chloro-2,3,3a,12b-tetrahydro-2-methyl-, trans-, (Z)-2-butenedioate (1:1) [CAS]	85650-56-2	WO 9523600	Neuroleptic	Psychosis, general
asimadoline	Benzeneacetamide, N-[2-(3-hydroxy-1- pyrrolidinyl)-1-phenylethyl]-N-methyl-Alpha- phenyl-, [S-(R*,R*)]- [CAS]	153205-46-0	DE 4215213	GI inflammatory/bowel disorders	Irritable bowel syndrome
asoprisnil	11β-[4-(Hydroxyiminomethyl)phenyl]-17β- methoxy-17Alpha-(methoxymethyl)estra-4,9- dien-3-one	199396-76-4	EP 0648778	Menstruation disorders	Endometriosis
Asoxime		34433-31-3			
Aspartic Acid		56-84-8			
Aspidin		584-28-1			
Aspidinol		519-40-4			
Aspirin		50-78-2			
Aspirin, Dipyrindamole					



API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
aspoxicillin	Glycinamide, N-methyl-D-asparaginy-N-(2-carboxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-6-yl)-D-2-(4-hydroxyphenyl)-, [2S-(2Alpha,5Alpha,6S)]-[CAS]	63358-49-6	GB 1533413	Penicillin, injectable	Infection, respiratory tract, general
AST-120	AST 120 [CAS]	90597-58-3		Urological	Renal failure
Asenizole		68844-77-9			
asulacrine	4-Acridinecarboxamide, 9-[[2-methoxy-4-[(methylsulfonyl)amino]phenyl]amino]-N,5-dimethyl- [CAS]	80841-47-0 80841-48-1	EP 39224	Anticancer, other	Cancer, general
AT-1015	(N-[2-[4-(5H-Dibenzo[a,d]cyclohepten-5-ylidene)-piperidino]ethyl]-1-formyl-4-piperidinecarboxamide monohydrochloride monohydrate			Antithrombotic	Thrombosis, general
atamestane	Androsta-1,4-diene-3,17-dione, 1-methyl-[CAS]	96301-34-7	DE 3338212	Anticancer, hormonal	Cancer, breast
atazanavir	2,5,6,10,13-Pentaazetatetradecanedioic acid, 3,12-bis(1,1-dimethylethyl)-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-6-((4-(2-pyridinyl)phenyl)methyl)- dimethyl ester, (3S,8S,9S,12S)-, sulfate (1:1) (salt) [CAS]	229975-97-7		Antiviral, anti-HIV	Infection, HIV/AIDS
atenolol	Benzeneacetamide, 4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]- [CAS]	29122-68-7 73677-19-7	GB 1285038	Antihypertensive, adrenergic	Hypertension, general
atenolol + chlorthalidone	Benzeneacetamide, 4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]-, mixt. with 2-chloro-5-(2,3-dihydro-1-hydroxy-3-oxo-1H-isoindol-1-yl)benzenesulfonamide [CAS]	73677-19-7	US 3836671	Formulation, fixed-dose combinations	Hypertension, general
atenolol + nifedipine	Benzeneacetamide, 4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]- + 4-(2'-nitrophenyl)-2,6-dimethyl-3,5-dicarbomethoxy-1,4-dihydropyridine			Formulation, fixed-dose combinations	Hypertension, general
a-Terpineol		98-55-5			
Atevirdine		136816-75-6			

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
atipamezole	1H-Imidazole, 4-(2-ethyl-2,3-dihydro-1H-inden-2-yl)- [CAS]	104054-27-5	EP 183492	Reproductive/gonadal, general	Sexual dysfunction, female
atiprimod dimaleate	2-Azaspiro[4.5]decane-2-propanamine, N,N-diethyl-8,8-dipropyl, dimaleate	130065-61-1	US 5744495	Antiarthritic, immunological	Arthritis, rheumatoid
ATL-146e			US 6232297	Imaging agent	Unspecified
a-Tocopherol		59-02-9			
atomoxetine	Benzenepropanamine, N-methyl-Gamma-(2-methylphenoxy)-, (R)- [CAS]	82248-59-7 83015-26-3	EP 52492	Neurological	Attention deficit disorder
atorvastatin	1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-3, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[[phenylamino]carbonyl]- [CAS]	134523-03-8 134523-00-5	EP 409281	Hypolipaeic/Antiatherosclerosis	Hypercholesterolaemia
atosiban	Oxytocin, 1-(3-mercaptopropanoic acid)-2-(O-ethyl-D-tyrosine)-4-L-threonine-8-L-ornithine- [CAS]	90779-69-4	EP 112809	Labour inhibitor	Labour, preterm
atovaquone	1,4-Naphthalenedione, 2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-, trans- [CAS]	95233-18-4	EP 123238	Antifungal	Infection, Pneumocystis jiroveci
atovaquone + proguanil	1,4-Naphthalenedione, 2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-, trans + N-(4-chloro-phenyl)-N-(1-methylethyl)imidodicarbonimidic diamide			Antimalarial	Infection, malaria
atracurium	Isoquinolinium, 2,2'-[1,5-pentanediy]bis[oxy(3-oxo-3,1-propanediyl)]bis[1-[(3,4-dimethoxyphenyl)methyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl- [CAS]	64228-81-5	US 4179557	Muscle relaxant	Surgery adjunct
atrasentan	3-Pyrrolidinecarboxylic acid, 4-(1,3-benzodioxol-5-yl)-1-[2-(dibutylamino)-2-oxoethyl]-2-(4-methoxyphenyl)-, (2R,3R,4S)- [CAS]	173937-91-2	WO 9730045	Anticancer, other	Cancer, prostate
Atrial Natriuretic Peptide		85637-73-6			
Atrolactamide		2019-68-3			
Atropine		51-55-8			

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Augmentin		74469-00-4		Formulation, modified-release, other	Infection, respiratory tract, general
auranofin	Gold, (1-thio-β-D-glucopyranose 2,3,4,6-tetraacetato-S)(triethylphosphine)-[CAS]	34031-32-8	US 3708579	Antiarthritic, other	Arthritis, rheumatoid
Aurothiogluucose		12192-57-3			
avasimibe	Sulfamic acid, [[2,4,6-tris(1-methylethyl)phenyl]acetyl]-, 2,6-bis(1-methylethyl)phenyl ester [CAS]	166518-60-1	US 5491172	Hypolipaeamic/Antiatherosclerosis	Atherosclerosis
Avobenzone		70356-09-1			
AWD-12-281	AWD 12-281 [CAS]	257892-33-4		Antiallergic, non-asthma	Rhinitis, allergic, general
Azacitidine		320-67-2			
Azacyclonol		115-46-8			
azanidazole	2-Pyrimidinamine, 4-[2-(1-methyl-5-nitro-1H-imidazol-2-yl)ethenyl]-, (E)- [CAS]	62973-76-6	US 3882105	Antibacterial, other	Infection, trichomoniasis
azapropazone	1H-Pyrazolo[1,2-a][1,2,4]benzotriazine-1,3(2H)-dione, 5-(dimethylamino)-9-methyl-2-propyl- [CAS]	13539-59-8	FR 1440629	Anti-inflammatory	
Azaserine		115-02-6			
azasetron	2H-1,4-Benzoxazine-8-carboxamide, N-1-azabicyclo[2.2.2]oct-3-yl-6-chloro-3,4-dihydro-4-methyl-3-oxo-, monohydrochloride- [CAS]	123040-16-4 123040-94-8 123040-96-0 123040-69-7	EP 313393	Antiemetic	Nausea and vomiting, general
Azatadine		3964-81-6			
azathioprine	6-[(1-Methyl-4-nitro-1H-imidazol-5-yl)thio]-1H-purine	446-86-6		Formulation, oral, other	Transplant rejection, bone marrow
AZD-4282	glycine			Analgesic, other	Pain, neuropathic
AZD-6140	3,4-Difluorophenylcyclopropylamine			Antithrombotic	Thrombosis, arterial
azelaic acid	Nonanedioic acid [CAS]	123-99-9		Antiacne	Acne
azelastine	1(2H)-Phthalazinone, 4-[(4-chlorophenyl)methyl]-2-(hexahydro-1-methyl-1H-azepin-4-yl)-, monohydrochloride [CAS]	58581-89-8 79307-93-0	GB 1377231	Antialsthma	Asthma

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
azelnidipine	3,5-Pyridinedicarboxylic acid, 2-amino-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-, 3-[1-(diphenylmethyl)-3-azetidinyl] 5-(1-methylethyl)ester, (+/-)- [CAS]	123524-52-7	EP	266922	Antihypertensive, other	Hypertension, general
Azidamfenicol		13838-08-9				
Azidocillin		17243-38-8				
Azimilide		149908-53-2				
Azintamide		1830-32-6				
azithromycin	9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin-A	76801-85-9 83905-01-5 92395-24-9	US	4328334	Macrolide antibiotic	Infection, respiratory tract, lower
azlocillin	4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6-[[[(2-oxo-1-imidazolidinyl)carbonyl]amino]phenylacetyl]amino]-, [2S-{2.alpha.,5Alpha,6beta(S*)}]-[CAS]	37091-65-9 37091-66-0 27589-33-9	GB	1392849	Penicillin, injectable	Infection, general
Azosemide						
aztreonam	Propanoic acid, 2-[[[1-(2-amino-4-thiazolyl)-2-[(2-methyl-4-oxo-1-sulfo-3-azetidinyl)amino]-2-oxoethylidene]amino]oxy]-2-methyl-, [2S-[2Alpha,3beta(Z)]]-[CAS]	104184-69-2 78110-38-0	GB	2071650	Beta-lactam antibiotic	Infection, general
azulene	Sodium 5-isopropyl-3,8-dimethyl-1-azulene sulfonate	6223-35-4	EP	88958	Formulation, modified-release, other	Inflammation, general
bacampicillin	4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[aminophenylacetyl]amino]-3,3-dimethyl-7-oxo-, 1-[(ethoxycarbonyl)oxy]ethyl ester, [2S-[2Alpha,5Alpha,6beta(S*)]]-[CAS]	37661-08-8 50972-17-3 1405-87-4	GB	1363506	Penicillin, oral	Infection, general
Bacitracin						
baclofen	beta-(Aminomethyl)-4-chlorobenzenepropanoic acid [CAS]	1134-47-0 491-67-8			Formulation, implant	Spastic paralysis
Balcalcin						

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
balofloxacin	3-Quinolonecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[3-(methylamino)-1-piperidinyl]-4-oxo- [CAS]	127294-70-6	EP 342675	Quinolone antibacterial	Infection, urinary tract
balsalazide	Benzoic acid, 5-[4-[(2-carboxyethyl)amino]carbonyl]phenyl]azo]-2-hydroxy-, (E)- [CAS]	80573-04-2	US 4412992	GI inflammatory/bowel disorders	Colitis, ulcerative
bambuterol	Carbamic acid, dimethyl-, 5-[2-[(1,1-dimethylethyl)amino]-1-hydroxyethyl]-1,3-phenylene ester, monohydrochloride [CAS]	81732-46-9 81732-65-2	EP 43807	Antiasthma	Asthma
Bamethan		3703-79-5			
Bamifylline		2016-63-9			
Bamipine		4945-47-5			
Barbital		57-44-3			
barnidipine	3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl-1-(phenylmethyl)-3-pyrrolidinyl ester, [S-(R*,R*)]-	104713-75-9 104757-53-1 71863-56-4	US 4220649	Antihypertensive, other	Hypertension, general
BAS-118	N-Methyl-3-[2-(2-naphthyl)acetyl]amino]benzamide			Antibacterial, other	Infection, Helicobacter pylori
Basic Aluminum Carbonate Gel		1339-92-0			
Basiliximab		179045-86-4			
Batimastat		130370-60-4			
Batroxobin		9039-61-6			
Bay-41-2272	5-cyclopropyl-2-[1-(2-fluoro-benzyl)-1H-pyrazolo[3,4-b]pyridine-3-yl]-5-(4-morpholinyl)pyrimidine-4-ylamine			Male sexual dysfunction	Sexual dysfunction, male, general
Bay-41-8543	2-[1-(2-Fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-(4-morpholinyl)pyrimidine-4,6-diamine			Cardiovascular	Unspecified



API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
BAY-43-9006	N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea			Anticancer, other	Cancer, liver
BAY-57-1293	N-[5(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide			Antiviral, other	Infection, herpes simplex virus
bazedoxifen	TSE 424 [CAS]	198481-33-3	EP 802183	Osteoporosis treatment	Osteoporosis
b-Benzalbutyramide		7236-47-7			
BBR-3464	Platinum(4+), hexaaminedichlorobis(μ-(1,6-hexanediamine-N:N'))tri- stereoisomer, tetranitrate [CAS]	172903-00-3	US 5744497	Anticancer, alkylating	Cancer, lung, non-small cell
BBR-3576			US 5519029	Anticancer, antibiotic	Cancer, prostate
BBR-3610			US 6060616	Anticancer, alkylating	Cancer, general
b-Carotene		7235-40-7			
BCH-1868	(-)-2-R-dihydroxyphosphinyol-5-(S)-(guanin-9'-yl-methyl)tetrahydrofuran			Anticancer, antimetabolite	Cancer, general
Bebeerine		477-60-1			
Beclamide		501-68-8			
beclometasone	Pregna-1,4-diene-3,20-dione, 9-chloro-11β,17,21-trihydroxy-16β-methyl, [CAS]	5534-09-8 4419-39-0	WO 0006132	Formulation, inhalable, solution	Asthma
Befloxatone		134564-82-2			
befunolol	Ethanone, 1-[7-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]-2-benzofuranyl]-[CAS]	39543-79-8 39552-01-7		Antiglaucoma	
Bemegride		64-65-3			
Benactyzine		302-40-9			
benazepril	1H-1-Benzazepine-1-acetic acid, 3-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-2,3,4,5-tetrahydro-2-oxo-, [S-(R*,R*)]- [CAS]	86541-74-4 86541-75-5 86541-78-8	EP 72352	Antihypertensive, renin system	Hypertension, general
bencyclane	1-Propanamine, N,N-dimethyl-3-[[1-(phenylmethyl)cycloheptyloxy]-, (E)-2-butenedioate (1:1) [CAS]	14286-84-1 2179-37-5	WO 9829409	Vasodilator, peripheral	

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
bendazac	L-Lysine, mono[[[1-(phenylmethyl)-1H-indazol-3-yl]oxy]acetate] [CAS]	81919-14-4 20187-55-7	GB	2081708	Ophthalmological	
Bendroflumethiazide		73-48-3				
Benexate		78718-25-9				
benfluorex	Ethanol, 2-[[1-methyl-2-[3-(trifluoromethyl)phenyl]ethyl]amino]-, benzoate (ester) [CAS]	23602-78-0 23642-66-2	GB	1175516	Hypolipaeic/Antiatherosclerosis	
Benfotiamine		22457-89-2				
Benfurodil		3447-95-8				
benidipine	3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 1-(phenylmethyl)-3-piperidinyl ester, monohydrochloride (R*,R*)-(+/-)-[CAS]	105979-17-7 91599-74-5	EP	63365	Antihypertensive, other	Hypertension, general
Benorylate		5003-48-5				
Benoxaprofen		67434-14-4				
Benoxinate		99-43-4				
Benperidol		2062-84-2				
Benproperine		2156-27-6				
Benserazide		322-35-0				
bentazepam	2H-[1]Benzothieno[2,3-e]-1,4-diazepin-2-one, 1,3,6,7,8,9-hexahydro-5-phenyl[CAS]	29462-18-8	DE	2005276	Anxiolytic	
Bentiromide		37106-97-1				
Bentoquatam		1340-69-8				
Benzalkonium		8001-54-5				
Benzarone		1477-19-6				
benzbromarone	Methanone, (3,5-dibromo-4-hydroxyphenyl)(2-ethyl-3-benzofuranyl)-[CAS]	3562-84-3	US	3012042	Antigout	
Benzethonium		121-54-0				
Benzetimide		14051-33-3				
Benzilonium		1050-48-2				
Benziodarone		68-90-6				
benznidazole	N-benzyl-2-nitroimidazole-1-acetamide	22994-85-0	GB	1138529	Protozoacide	

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
benzocaine	Benzoic acid, 4-amino-, ethyl ester	94-09-7		Formulation, fixed-dose combinations	Pain, musculoskeletal
Benzocetamine		17243-39-9			
Benzonatate		104-31-4			
Benzoxonium Chloride		19379-90-9			
benzoyl peroxide	Peroxide, dibenzoyl [CAS]	94-36-0		Formulation, other	Acne
Benzoylpas		13898-58-3			
Benzphetamine		156-08-1			
Benzpiperylon		53-89-4			
Benzquinamide		63-12-7			
Benzthiazide		91-33-8			
Benztropine		132-17-2			
	1-Propanamine, N,N-dimethyl-3-[[1-(phenylmethyl)-1H-indazol-3-yl]oxy]- [CAS]	132-69-4 642-72-8		Stomatological, reproductive/gonadal, anti-inflammatory	
benzylamine		120-51-4			
Benzyl Benzoate		1824-50-6			
Benzylhydrochlorothiazide		14297-87-1			
Benzylmorphine		3818-50-6			
Bephenium Hydroxynaphthoate					
	1-Piperidinebutanoic acid, 4-((4-chlorophenyl)-2-pyridinylmethoxy)-, (S)-, monobenzenesulfonate [CAS]	190786-44-8 190786-43-7	WO 9829409	Antiallergic, non-asthma	Allergy, general
bepotastine		64706-54-3 74764-40-2 74764-75-3	EP 146155	Antianginal	Angina, general
bepiridil	1-Pyrrolidineethanamine, β-[[2-methyl(propoxy)methyl]-N-phenyl-N-(phenylmethyl)- [CAS]				
	1H-Cyclopenta[b]benzofuran-5-butanolic acid, 2,3,3a,8b-tetrahydro-2-hydroxy-1-(3-hydroxy-4-methyl-1-octen-6-ynyl)- [CAS]	88475-69-8 88430-50-6	US 4474802	Prostaglandin	Peripheral vascular disease
beraprost		2086-83-1			
Berberine		484-20-8			
Bergapten		78499-27-1			
Bernoprofen					
Besipirdine		119257-34-0			

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
betahistine	2-Pyridineethanamine, N-methyl-, dihydrochloride	5579-84-0 5638-76-6		Formulation, modified-release, <=24hr	Meniere's disease
betaine	Betaine- [CAS]	107-43-7		Metabolic and enzyme disorders	Homocystinuria
betamethasone	Pregna-1,4-diene-3,20-dione, 9-fluoro-11,17,21-trihydroxy-16-methyl-, (11 $\beta$ ,16 $\beta$ )-[CAS]	378-44-9		Formulation, dermal, topical	Psoriasis
Betamipron		3440-28-6			
Betasine		3734-24-5			
betaxolol	2-Propanol, 1-[4-[2-(cyclopropylmethoxy)ethyl]phenoxy]-3-[(1-methylethyl)amino]- [CAS]	63659-18-7 63659-19-8	US 4252984	Antihypertensive, adrenergic	Hypertension, general, glaucoma
Betazole		105-20-4			
Bethanechol		590-63-6			
Bethanidine		55-73-2			
Betoxycaine		3818-62-0			
b-Eucaine		500-34-5			
bevantolol	2-Propanol, 1-[2-(3,4-dimethoxyphenyl)ethyl]amino]-3-(3-methylphenoxy)- [CAS]	42864-78-8 59170-23-9	US 3857891	Antihypertensive, adrenergic	Hypertension, general
Bevonium		5205-82-3			
bexarotene	Benzoic acid, 4-(1-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)ethenyl)- [CAS]	153559-49-0	WO 9321146	Anticancer, other	Cancer, lymphoma, T-cell
bezafibrate	Propanoic acid, 2-[4-[2-(4-chlorobenzoyl)amino]ethyl]phenoxy]-2-methyl- [CAS]	41859-67-0 15301-48-1	GB 1359264	Hypolipaeamic/Antiatherosclerosis	
Bezitramide		166374-48-7		Cardio stimulant	Heart failure
BG-9928					
BIA-2-024	10,11-dihydro-10-hydroxyimino-5H-dibenz[b,f]azepine-5-carboxamide	199997-15-4	WO 9745416	Antiepileptic	Epilepsy, general
BIA-2-093	(S)-(-)-10-acetoxy-10,11-dihydro-5H-dibenzo[b,f]azepine-5-carboxamide- [CAS]	236395-14-5		Antiepileptic	Epilepsy, general

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
BIA-3-202	1-(3,4-dihydroxy-5-nitrophenyl)-2-phenyl-ethanone	274925-86-9	EP 1010688	Antiparkinsonian	Parkinson's disease
Bialamilcol		493-75-4			
biapenem	5H-Pyrazolo[1,2-a][1,2,4]triazol-4-ium, 6-[[2-carboxy-6-(1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-en-3-yl]thio]-6,7-dihydro-, hydroxide, inner salt, [4R-[4Alpha,5beta,6beta(R*)]]- [CAS]	120410-24-4	EP 289801	Beta-lactam antibiotic	Infection, beta-lactamase resistant
Bibenzonium		15585-70-3			
Bibrocathol		6915-57-7			
bicalutamide	Propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methyl-, (+/-)- [CAS]	90357-06-5	EP 100172	Anticancer, hormonal	Cancer, prostate
bicifadine	3-Azabicyclo[3.1.0]hexane, 1-(4-methylphenyl)-, (+/-)- [CAS]	66504-75-4 71195-57-8	DE 2740562 US 6294585	Analgesic, other Dermatological	Pain, general Unspecified
bicyclic monoterpene diols		116078-65-0			
Bidisomide		479-81-2			
Bietamiverine		6888-11-5			
Bietanauiline		53-18-9			
Bietaserpine					
bifemelane	1-Butanamine, N-methyl-4-[2-(phenylmethyl)phenoxy]-, hydrochloride [CAS]	62232-46-6 90293-01-9	GB 1512880	Cognition enhancer	Attention deficit disorder
Bifluranol		34633-34-6			
bifonazole	1H-Imidazole, 1-([1,1'-biphenyl]-4-ylphenylmethyl)- [CAS]	60628-96-8 60629-08-5 60629-09-6	US 4118487	Antifungal	Infection, fungal, general
bimatoprost	5-Heptenamide, 7-(3,5-dihydroxy-2-(3-hydroxy-5-phenyl-1-pentenyl)cyclopentyl)-N-ethyl (1R-(1Alpha(Z)2beta(1E,3S,3Alpha,5Alpha)) [CAS]	155206-00-1	US 5688819	Prostaglandin	Glaucoma



API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
bimoclomol	N-[2-hydroxy-3-(1-piperidinyl)propoxy]-3-pyridinecarboximidoyl chloride, (Z)-2-butanedioate (1:1)	130493-04-8	US 5147874	Symptomatic antidiabetic	Neuropathy, diabetic
bimosiamose	(1,1'-Biphenyl)-3-acetic acid, 3',3''-(1,6-hexanediyloxy)bis(6'-Alpha-D-mannopyranosyloxy)-, [CAS]	187269-40-5	US 5444050	Antiasthma	Asthma
Binifibrate		69047-39-8			
binodenoson	Adenosine, 2-((cyclohexylmethylene)hydrazino)- [CAS]	144348-08-3		Vasodilator, coronary	Diagnosis, coronary
Biomed-101			US 6423744	Anticancer, other	Cancer, renal
Biotin		58-85-5			
Biperiden		514-65-8			
biricodar	2-Piperidinecarboxylic acid, 1-(oxo(3,4,5-trimethoxyphenyl)acetyl)-4-(3-pyridinyl)-1-(3-(3-pyridinyl)propyl)butyl ester, (S)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:2) [CAS]	174254-13-8 159997-94-1		Radio/chemosensitizer	Cancer, breast
biriperone	1-Butanone, 1-(4-fluorophenyl)-4-(3,4,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indol-2(1H)-yl)- [CAS]	42021-34-1	DE 2333922	Neuroleptic	
Bisacodyl		603-50-9			
Bisantrene		78186-34-2			
Bisbentamine		2667-89-2			
Bisdequalinium		52951-36-7			
Bismuth Aluminate		12284-76-3			
Bismuth Butylthiolaurate		53897-25-9			
Bismuth Ethyl Camphorate		52951-37-8			
Bismuth Iodosubgallate		138-58-9			
Bismuth Sodium Iodide		53778-50-0			
Bismuth Sodium Triglycollamate		5798-43-6			
Bismuth Subcarbonate		5892-10-4			
Bismuth Subgallate		22650-86-8			

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Bismuth Subnitrate		1304-85-4			
Bismuth Subsalicylate		14882-18-9			
Bismuth Tribromophenate		5175-83-7			
bisoprolol	2-Propanol, 1-[4-[[2-(1-methylethoxy)ethoxy]methyl]phenoxy]-3-[(1-methylethyl)amino]- [CAS]	104344-23-2 66722-44-9	GB 1532380	Antihypertensive, adrenergic	Heart failure
bisoprolol + HCTZ	2-Propanol, 1-[4-[[2-(1-methylethoxy)ethoxy]methyl]phenoxy]-3-[(1-methylethyl)amino] mixt. with 6-chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide			Formulation, fixed-dose combinations	Hypertension, general
bisoprolol+trichloromethiazide	2-Propanol, 1-[4-[[2-(1-methylethoxy)ethoxy]methyl]phenoxy]-3-[(1-methylethyl)amino] mixt. with 6-chloro-3-(dichloromethyl)-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide			Formulation, fixed-dose combinations	Hypertension, general
Bisoxatin		14008-48-1			
Bithionol		97-18-7			
Bitolterol		30392-40-6			
Bitoscanate		4044-65-9			
BL-3875			WO 0218378	Anti-inflammatory	Unspecified
bleomycin	Bleomycin [CAS]	11056-06-7 9041-93-4		Formulation, transdermal, enhanced	Cancer, head and neck
blonanserin	Cycloocta[b]pyridine, 2-(4-ethyl-1-piperazinyl)-4-(4-fluorophenyl)-5,6,7,8,9,10-hexahydro- [CAS]	132810-10-7	EP 385237	Neuroleptic	Schizophrenia
BMS-184476			EP 639577	Anticancer, other	Cancer, breast
BMS-387032	cls-(+)-2-(Ethylthio)-5,7-dihydroxy-8-(3-hydroxy-1-methyl-4-piperidinyl)-4H-1-benzopyran-4-one		WO 9742949	Anticancer, other	Cancer, general
BN-82451	4-[2-(aminomethyl)-1,3-thiazol-4-yl]-2,6-di-tert-butylphenol, dihydrochloride			Neuroprotective	Unspecified

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
BNP-7787	Ethanesulfonic acid, 2,2'-dithiobis-, disodium salt [CAS]	16208-51-8		Radio/chemoprotective	Chemotherapy-induced nausea and vomiting
BO-653	5-Benzofuranol, 4,6-bis(1,1-dimethylethyl)-2,3-dihydro-2,2-dipentyl- [CAS]	157360-23-1	WO 9408930	Hypolipaeic/Antiatherosclerosis	Atherosclerosis
Bolandiol		19793-20-5			
Bolasterone		1605-89-6			
Boldenone		846-48-0			
bopindolol	2-Propanol, 1-[(1,1-dimethylethyl)amino]-3-[(2-methyl-1H-indol-4-yl)oxy]-, benzoate (ester), (+/-)- [CAS]	62658-63-3 82857-38-3	US 4340541	Antihypertensive, adrenergic	Hypertension, general
Bornyl Chloride		464-41-5			
Bornyl Salicylate		560-88-3			
bortezomib	Boric acid, [(1R)-3-methyl-1-[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]- [CAS]	179324-69-7	US 6271199	Anticancer, other	Cancer, myeloma
bosentan	Benzenesulfonamide, 4-(1,1-dimethylethyl)-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)][2,2'-bipyrimidin]-4-yl]- [CAS]	147536-97-8	EP 633259	Vasodilator, peripheral	Hypertension, pulmonary
BP2.94	Phenol, 2-[[[(1R)-2-(1H-imidazol-4-yl)-1-methylethyl]imino]phenylmethyl]- [CAS]	139191-80-3	WO 9117146	Respiratory	Rhinitis, general
BP4.897	N-[4-{4-(2-methoxyphenyl)-1-piperazinyl}butyl]naphthalene-2-carboxamide				
b-Propiolactone		57-57-8	EP 779284	Dependence treatment	Addiction, cocaine
Bradycor		140661-97-8			
Brain Natriuretic Peptide		114471-18-0			
Brallobarbitol		561-86-4			
brasofensine	8-Azabicyclo(3.2.1)octane-2-carboxaldehyde, 3-(3,4-dichlorophenyl)-8-methyl-, O-methyloxime, (1R-(1Alpha,2beta(E),3Alpha,5Alpha))- [CAS]	171655-91-7	WO 9528401	Antiparkinsonian	Parkinson's disease
Brequinar		96187-53-0			

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Bretylum		61-75-6			
Brilliant Green		633-03-4			
brimonidine	6-Quinoxalinamine, 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)- [CAS]	59803-98-4	DE 2538620	Antiglaucoma	Glaucoma
brinzolamide	2H-Thieno(3,2-e)-1,2-thiazine-6-sulfonamide, 4-(ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-, 1,1-dioxide, (R)- [CAS]	138890-62-7	US 5378703	Antiglaucoma	Glaucoma
brivudin	Uridine, 5-(2-bromoethenyl)-2'-deoxy, (E)- [CAS]	69304-47-8		Antiviral, other	Infection, varicella zoster virus
Brodipropim		56518-41-3			
Bromazepam		1812-30-2			
bromfenac	Benzeneacetic acid, 2-amino-3-(4-bromobenzoyl)- [CAS]	91714-93-1 91714-94-2		Formulation, mucosal, topical	Inflammation, ocular
Bromhexine		3572-43-8			
Bromindione		1146-98-1			
Bromisovalum		496-67-3			
Bromocriptine		25614-03-3			
Bromodiphenhydramine		118-23-0			
Bromoform		75-25-2			
Bromopride		4093-35-0			
Bromosalicylchloranilide		3679-64-9			
bromperidol	1-Butanone, 4-[4-(4-bromophenyl)-4-hydroxy-1-piperidinyl]-1-(4-fluorophenyl)- [CAS]	10457-90-6	US 3438991	Neuroleptic	Psychosis, general
Brompheniramine		86-22-6			
Broparoesol		479-68-5			
Bropiramine		56741-95-8			
brostallicin	4-(2-Bromoacrylamido)-N <sup>m</sup> -(2-guanidinoethyl)-1,1',1'',1'''-tetramethyl-N,4':N',4''':N''',4'''-quater-[pyrrole-2-carboxamide] [CAS]			Anticancer, other	Cancer, general
brotizolam	6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine, 2-bromo-4-(2-chlorophenyl)-9-methyl- [CAS]	57801-81-7	US 4094984	Hypnotic/Sedative	
Brovincamine		57475-17-9			

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Broxuridine		59-14-3			
Broxyquinoline		521-74-4			
Brucine		357-57-3			
b-Sitosterol		83-46-5			
Bucetin		1083-57-4			
Bucillamine		65002-17-7			
Bucindolol		71119-11-4			
buccladesine	Adenosine, N-(1-oxobutyl)-, cyclic 3',5'-(hydrogen phosphate) 2'-butanoate [CAS]	362-74-3	JP 51113896	Cardio stimulant	Wound healing
Bucclizine		82-95-1			
Buclosamide		575-74-6			
Bucolome		841-73-6			
bucrlcaine	9-Acridinamine, N-butyl-1,2,3,4-tetrahydro-, monohydrochloride [CAS]	82636-28-0		Anaesthetic, local	
Bucumolol		58409-59-9			
budesonide	Pregna-1,4-diene-3,20-dione, 16,17-[butylidenebis(oxy)]-11,21-dihydroxy-, (11 $\beta$ ,16 $\alpha$ )- [CAS]	51333-22-3	GB 1429922	Antiasthma	Asthma
budesonide + formoterol	Pregna-1,4-diene-3,20-dione, 16,17-[butylidenebis(oxy)]-11,21-dihydroxy-, (11 $\beta$ ,16 $\alpha$ )- + formamide, N-[2-hydroxy-5-[1-hydroxy-2-[[2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]phenyl]-(R*,R*)-(±)			Formulation, fixed-dose combinations	Asthma
budipine	Piperidine, 1-(1,1-dimethylethyl)-4,4-diphenyl- [CAS]	57982-78-2 63661-61-0	DE 2825322	Antiparkinsonian	Parkinson's disease
Budralazine		36798-79-5			
Bufenlode		22103-14-6			
Bufetolol		53684-49-4			
bufexamac	p-butoxyacetohydroxamic acid	2438-72-4	US 3479396	Anti-inflammatory	
buflomedil	1-Butanone, 4-(1-pyrrolidinyl)-1-(2,4,6-trimethoxyphenyl)- [CAS]	35543-24-9 55837-25-7	GB 1325192	Vasodilator, peripheral	
Buformin		692-13-7			



API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Bufuralol		54340-62-4			
Bumadizon		3583-64-0			
bumetanide	Benzoic acid, 3-(aminosulfonyl)-5-(butylamino)-4-phenoxy- [CAS]	28395-03-1	US 3806534	Antihypertensive, diuretic	Hypertension, general
bunaftine	1-Naphthalenecarboxamide, N-butyl-N-[2-(diethylamino)ethyl]- [CAS]	32421-46-8 1923-76-8	DE 2009894	Antiarrhythmic	
Bunamiodyl Sodium					
bunazosin	1H-1,4-Diazepine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)hexahydro-4-(1-oxobutyl)- [CAS]	52712-76-2 80755-51-7	GB 1398455	Antihypertensive, adrenergic	Hypertension, general
bunitrolol	Benzonitrile, 2-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]- [CAS]	34915-68-9	US 3940489	Antihypertensive, adrenergic	
bupivacaine	2-Piperidinecarboxamide, 1-butyl-N-(2,6-dimethylphenyl)- [CAS]	38396-39-3 2180-92-9 14556-46-8		Formulation, modified-release, >24hr	Anaesthesia
Bupranolol					
buprenorphine	6,14-Ethenomorphinan-7-methanol, 17-(cyclopropylmethyl)-Alpha-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-Alpha-methyl-, [5Alpha,7Alpha(S)]- [CAS]	52485-79-7 53152-21-9	US 3433791	Analgesic, other	
bupropion	1-Propanone, 1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]-, (+/-)- [CAS]	31677-93-7 34911-55-2	US 4425363	Antidepressant	Depression, general
Buramate		4663-83-6			
buserelin	Luteinizing hormone-releasing factor (pig), 6-[O-(1,1-dimethylethyl)-D-serine]-9-(N-ethyl-L-prolinamide)-10-deglycinamide- [CAS]	57982-77-1 68630-75-1	GB 1523623	Releasing hormones	Cancer, prostate
buspirone	8-Azaspiro[4.5]decane-7,9-dione, 8-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-[CAS]	36505-84-7	EP 276536	Anxiolytic	Anxiety, general
busulfan	1,4-Butanediol, dimethanesulfonate [CAS]	55-98-1		Formulation, optimized, microparticles	Cancer, general
busulfan	1,4-Butanediol, dimethanesulfonate- [CAS]	55-98-1		Formulation, parenteral, other	Cancer, leukaemia, acute myelogenous
Butabarbital		143-81-7			
Butacaine		149-16-6			
Butacetin		2109-73-1			

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Butalamine		22131-35-7			
Butalbital		77-26-9			
Butallylonal		1142-70-7			
butamben	4-Aminobenzoic acid butyl ester [CAS]	94-25-7		Formulation, modified-release, other	Pain, cancer
butamirate	Benzeneacetic acid, Alpha-ethyl-, 2-[2-(diethylamino)ethoxy]ethylester, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) [CAS]	18109-80-3 18109-81-4		Antitussive	Cough
Butanillicaine		3785-21-5			
Butaperazine		653-03-2			
Butaverine		55837-14-4			
Butazolamide		16790-49-1			
Butedronic Acid		51395-42-7			
butenafine	1-Naphthalenemethanamine, N-((4-(1,1-dimethylethyl)phenyl)methyl)-N-methyl- [CAS]	101827-46-7 101828-21-1	EP 164697	Antifungal	Infection, dermatological
Butethal		77-28-1			
Butethamate		14007-64-8			
Butethamine		2090-89-3			
Butthalital		510-90-7			
Butthiazide		2043-38-1			
Butibufen		55837-18-8			
Butidrine		1506-12-3			
butobendine	benzoic acid, 3,4,5-trimethoxy-, 1,2-ethanediybis[(methylimino)(2-ethyl-2,1-ethanediy)] ester, [S-(R*,R*)]- [CAS]	55769-64-7 55769-65-8	US 4021473	Antiarrhythmic	Arrhythmia, general
butoconazole	1H-Imidazole, 1-[4-(4-chlorophenyl)-2-[(2,6-dichlorophenyl)thio]butyl]-, (+/-)-[CAS]	64872-76-0 64872-77-1	GB 1567431	Antifungal	Infection, Candida, general
Butoctamide		32838-26-9			
Butoflilolol		64552-17-6			
butorphanol	Morphinan-3,14-diol, 17-(cyclobutylmethyl)-, [S-(R*,R*)]-2,3-dihydroxybutanedioate (1:1) (salt) [CAS]	42408-82-2 58786-99-5	GB 1412129	Analgesic, other	
Butoxycaine		3772-43-8			

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Butriptyline		35941-65-2			
Butropium		29025-14-7			
Buzepide		3691-21-2			
BVT-5182			WO 0208178	Anorectic/Antiobesity	Obesity
BXT-51072	2H-1,2-Benzoselenazine, 3,4-dihydro-4,4-dimethyl-, [CAS]	173026-17-0		GI inflammatory/bowel disorders	Colitis, ulcerative
C-1311	6H-Imidazo[4,5,1-de]acridin-6-one, 5-[[2-(diethylamino)ethyl]amino]-8-hydroxy-, 2HCl, 2H2O				
cabergoline	Ergoline-8-carboxamide, N-{3-(dimethylamino)propyl}-N-[(ethylamino)carbonyl]-6-(2-propenyl)-, (8S)-[CAS]	81409-90-7 85329-89-1	GB 2103603	Antiprolactin	Galactorrhoea
Cabergoline		81409-90-7			
Cacodylic Acid		75-60-5			
Cactinomycin		8052-16-2			
cadexomer iodine	Cadexomer iodine [CAS]	94820-09-4		Anti-infective, other	Ulcer, venostasis
Cadmium Salicylate		19010-79-8			
Cadralazine		64241-34-5			
Cafaminol		30924-31-3			
caffeine	1,2,3,-Propanetricarboxylic acid, 2-hydroxy-mixt. with 3,7-dihydro-1,3,7-trimethyl-1H-purine-2,6-dione [CAS]	69-22-7 08-2	58	Respiratory	Apnoea
Calcifediol		19356-17-3			
Calcipotriene		112965-21-6			
calcipotriol	9,10-Secochola-5,7,10(19),22-tetraene-1,3,24-triol, 24-cyclopropyl-, (1Alpha,3beta,5Z,7E,22E)- [CAS]	112965-21-6	WO 8700834	Antipsoriasis	Psoriasis
calcipotriol+beclometasone	9,10-Secochola-5,7,10(19),22-tetraene-1,3,24-triol, 24-cyclopropyl-, (1Alpha,3beta,5Z,7E,22E) + Pregna-1,4-diene-3,20-dione, 9-chloro-11beta,17,21-trihydroxy-16beta-methyl, 17,21-dipropionate			Formulation, fixed-dose combinations	Psoriasis

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
calcitriol	9,10-Secosteroid-5,7,10(19)-triene-1,3,25-triol, (1 $\alpha$ ,3 $\beta$ ,5 $\alpha$ ,7 $\beta$ ,E)- [CAS]	32222-06-3		Antipsoriasis	Psoriasis
Calcium 3-Aurothio-2-propanol-1-sulfonate		5743-29-3			
Calcium Acetylsalicylate		69-46-5			
Calcium Bromolactobionate		33659-28-8			
Calcium Carbonate		471-34-1			
Calcium Gluconate		299-28-5			
Calcium Glycerophosphate		27214-00-2			
calcium hopanotohenate	Calcium D-(+)-4-(2,4-dihydroxy-3,3-dimethylbutyramido)butyrate (hemihydrate) [CAS]	17097-76-6	EP 117260	Neurological	Attention deficit disorder
Calcium Iodobehenate		1319-91-1			
Calcium Iodostearate		1301-16-2			
Calcium Lactate		814-80-2			
Calcium Levulinat		591-64-0			
Calcium Mesoxalate		21085-60-9			
Calcium N-Carbamoylaspartate		16649-79-9			
calcium polycarbophil	Polycarbophil, calcium salt- [CAS]	126040-58-2		GI Inflammatory/bowel disorders	Irritable bowel syndrome
Calcium Propionate		9003-97-8			
Calcium Succinate		4075-81-4			
		140-99-8			
caldaret	5-methyl-2-(1-piperazinyl)-benzenesulfonic acid monohydrate				
Calusterone		133804-44-1		Cardiosimulant	Heart failure
Camazepam		17021-26-0			
		36104-80-0			
camostat	Benzeneacetic acid, 4-[[4-[(aminoliminomethyl)amino]benzoyl]oxy]-, 2-(dimethylamino)-2-oxoethyl ester, monomethanesulfonate [CAS]	59721-28-7 59721-29-8 71079-09-9	US 4021472	GI Inflammatory/bowel disorders	Pancreatitis
Camphor		76-22-2			
Camphotamide		4876-45-3			

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
camptothecin	4-Ethyl-4-hydroxy-1H-pyrano- [3'4':6,7]indolizino[1,2-b:]quinoline- 3,14(4H,12H)-dione				
Candesartan		139481-59-7		Formulation, optimized, microemulsion	Cancer, general
candesartan cilexetil	1H-Benzimidazole-7-carboxylic acid, 2- ethoxy-1-[[2'-(1H-tetrazol-5-yl)][1,1'-biphenyl]- 4-yl]methyl]-, 1- [[[(cyclohexyloxy)carbonyl]oxy]ethyl ester, (+/-) ]- [CAS]	145040-37-5	EP 520423	Antihypertensive, renin system	Hypertension, general
Candoxatril		123122-55-4			
canertinib	N-[4-(3-(Chloro-4-fluoro-phenylamino)-7-(3- morpholin-4-yl-propoxy)-quinazolin-6-yl]- acrylamide	289499-45-2		Anticancer, other	Cancer, lung, non-small cell
Canrenone		976-71-6			
Cantharidin		56-25-7			
cantuzumab mertansine	Maytansine, N2-deacetyl-N2-(3-mercapto-1- oxopropyl)-, conjugated humanized C242 monoclonal antibody	139504-50-0		Immunotoxin	Cancer, colorectal
capecitabine	Cytidine, 5-deoxy-5-fluoro-N- [[pentyl]oxy]carbonyl]- [CAS]	154361-50-9	EP 602454	Anticancer, antimetabolite	Cancer, breast
Capobenic Acid		21434-91-3			
capravirine	1H-imidazole-2-methanol, 5-(3,5- dichlorophenyl)thio-4-(1-methyl(ethyl)-1-(4- pyridinyl)methyl carbamate (ester) [CAS]	178979-85-6		Antiviral, anti-HIV	Infection, HIV/AIDS
Capromab		151763-64-3			
capsaicin cream	N-[(4-hydroxy-3-methoxyphenyl)methyl]-8- methyl-, (E)- [CAS]	404-86-4		Formulation, dermal, topical	Pain, post-herpetic
Captodiamine		486-17-9			
captopril	L-Proline, 1-(3-mercapto-2-methyl-1- oxopropyl)-, (S)- [CAS]	62571-86-2	US 4105776	Antihypertensive, renin system	Hypertension, general



API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
captopril + HCTZ	L-Proline, 1-(3-mercapto-2-methyl-1-oxopropyl)-, (S)-, mixt. with 6-chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide [CAS]	110075-07-5	US 4217347	Antihypertensive, renin system	
Capuride		5579-13-5			
carabersat	Benzamide, N-(6-acetyl-3,4-dihydro-3-hydroxy-2,2-dimethyl-2H-1-benzopyran-4-yl)-4-fluoro, (3R-trans)- [CAS]	184653-84-7	WO 9811890	Antiepileptic	Epilepsy, general
Caramiphen		77-22-5			
carazolol	2-Propanol, 1-(9H-carbazol-4-yloxy)-3-[(1-methylethyl)amino]- [CAS]	57775-29-8	DE 2240599	Antihypertensive, adrenergic	
Carbachol		51-83-2			
carbamazepine	5H-Dibenz[b,f]azepine-5-carboxamide [CAS]	298-46-4		Formulation, modified-release, other	Epilepsy, general
Carbamide Peroxide		124-43-6			
Carbarsone		121-59-5			
Carbaryl		63-25-2			
Carbazochrome		13051-01-9			
		51460-26-5			
carbendazim	Methyl-2-benzimidazolecarbamate			Anticancer, other	Cancer, general
Carbenicillin		4697-36-3			
Carbenoxolone		5697-56-3			
Carbetapentane		77-23-6			
Carbicarb	Carbonic acid disodium salt, mixt. with monosodium salt- [CAS]	72227-05-5		Alimentary/Metabolic, other	Acidosis
Carbidopa		28860-95-9			
carbidopa+levodopa-1	S-Alpha Hydrazino-3,4-dihydroxy-Alpha methyl benzene propanoic acid monohydrate +3-hydroxy-L-tyrosine			Formulation, fixed-dose combinations	Parkinson's disease
Carbimazole		22232-54-8			
Carbinoxamine		486-16-8			
Carbocloral		541-79-7			
carbocysteine		151756-26-2	EP 546272	Cystic fibrosis treatment	Cystic fibrosis
Carbon Tetrachloride		638-23-3			
		56-23-5			

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
carboplatin	Platinum, diammine[1,1-cyclobutanedicarboxylato(2-)]-, (SP-4-2)- [CAS]	41575-94-4		Anticancer, alkylating	Cancer, ovarian
Carboprost		35700-23-3			
carboprost trometamol	Prosta-5,13-dien-1-oic acid, 9,11,15-trihydroxy-15-methyl-, (5Z,9.alpha.,11Alpha,13E,15S)-, compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol(1:1) [CAS]	58551-69-2 74849-93-7	US 3728382	Prostaglandin	Abortion
Carboquone	2,5-Cyclohexadiene-1,4-dione, 2-[2-[(aminocarbonyloxy]-1-methoxyethyl]-3,6-bis(1-aziridinyl)-5-methyl- [CAS]	24279-91-2	DE 1905224	Anticancer, antibiotic	
Carbromal		77-65-6			
Carbubarb		960-05-4			
Carbutamide		339-43-5			
Carbuterol		34866-47-2			
Carfimate		3567-38-2			
carglumic acid	N-Carbamoyl-L-glutamic acid	1188-38-1		Metabolic and enzyme disorders	Hyperammonaemia
Cargutocin		33605-67-3			
Carindacilin		35531-88-5			
cariporide	Benzamide, N-(aminoiminomethyl)-4-(1-methylethyl)-3-(methylsulfonyl)- [CAS]	159138-80-4 159138-81-5	EP 589336	Antianginal	Angina, general
Cariporide		159138-80-4			
Carisoprodol		78-44-4			
carmofur	1(2H)-Pyrimidinecarboxamide, 5-fluoro-N-hexyl-3,4-dihydro-2,4-dioxo- [CAS]	61422-45-5	US 4071519	Anticancer, antimetabolite	
Carmoxirole		98323-83-2			
camustine	Urea, N,N'-bis(2-chloroethyl)-N-nitroso- [CAS]	154-93-8		Formulation, implant	Cancer, brain
Carnitine		461-06-3			
Caroverine		23465-76-1			
Caroxazone		18464-39-6			
Carphenazine		2622-30-2			
Carpipramine		5942-95-0			

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
carprofen	9H-Carbazole-2-acetic acid, 6-chloro-Alpha-methyl-, (+/-)- [CAS]	53716-49-7	US 3896145	Anti-inflammatory	
Carsalam		2037-95-8			
carteolol	2(1H)-Quinolinone, 5-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-3,4-dihydro-, monohydrochloride [CAS]	51781-06-7 51781-21-6	US 3910924	Antihypertensive, adrenergic	Glaucoma
Carticaine		23964-58-1			
Carubicin		50935-04-1			
Carumonam		87638-04-8			
Carvacrol		499-75-2			
carvedilol	2-Propanol, 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-[CAS]	72956-09-3	EP 4920	Antihypertensive, adrenergic	Hypertension, general
Carvone		99-49-0			
Cascarinil		10118-56-6			
caspofungin	Pneumocandin B0, 1-((4R,5S)-5-((2-aminoethyl)amino)-N2-(10,12-dimethyl-1-oxotetradecyl)-4-hydroxy-L-ornithine)-5-(threo-3-hydroxy-L-ornithine)-, diacetate (salt) [CAS]	162808-62-0 179463-17-3	WO 9421677	Antifungal	Infection, Aspergillus
Catechin		154-23-4			
cathepsin K inhibitors	N-(1-benzothien-2-ylcarbonyl)-N-[2-(2-fluorophenyl)-4-oxo-1,2,3,4-tetrahydropyrimidin-5-yl]-L-leucinamide		WO 9613523	Osteoporosis treatment	Osteoporosis
cathepsin S inhibitors	N-(1-benzothien-2-ylcarbonyl)-N-[2-(2-fluorophenyl)-4-oxo-1,2,3,4-tetrahydropyrimidin-5-yl]-L-leucinamide			Antiasthma	Asthma
CC-401			US 6342595	Immunosuppressant	Arthritis, rheumatoid
CCl-779	Rapamycin 42-(3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate) [CAS]	162635-04-3		Anticancer, antibiotic	Cancer, renal
CCR5 antagonists			WO 9732019	Antiviral, anti-HIV	Infection, HIV/AIDS
CDC-394			US 634061	Anticancer, other	Cancer, myeloma
CDC-801			US 5605914	GI inflammatory/bowel disorders	Crohn's disease

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
CEE-03-310	1H-3-Benzazepin-7-ol, 5-(2,3-dihydro-7-benzofuranyl)-2,3,4,5-tetrahydro-3-methyl-8-nitro, (5S)- [CAS]	128022-68-4	EP 347672	Dependence treatment	Addiction, alcohol
cefaclor	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[(aminophenylacetyl)amino]-3-chloro-8-oxo-, [6R-[6Alpha,7beta(R*)]]- [CAS]	53994-73-3 70356-03-5	GB 1461323	Cephalosporin, oral	Infection, Haemophilus influenzae prophylaxis
cefadroxil	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[amino(4-hydroxyphenyl)acetyl]amino]-3-methyl-8-oxo-, [6R-[6Alpha,7beta(R*)]]- [CAS]	50370-12-2 66592-87-8	GB 1240687	Cephalosporin, oral	Infection, general
cefalexin	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[aminophenylacetyl]amino]-3-methyl-8-oxo-, [CAS]	105879-42-3 15686-71-2	US 4775751	Cephalosporin, oral	Infection, respiratory tract, upper
cefalexin pivoxil	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[aminophenylacetyl]amino]-3-methyl-8-oxo-, (2,2-dimethyl-1-oxopropoxy)methyl ester, monohydrochloride, [6R-[6Alpha,7beta(R*)]]- [CAS]	27726-31-4		Cephalosporin, oral	Infection, general
cefamandole	7-D-mandelamido-3[[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-3-cephem-4-carboxylic acid]	34444-01-4	US 3641021	Cephalosporin, injectable	Infection, general
cefatrizine	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[amino(4-hydroxyphenyl)acetyl]amino]-8-oxo-3-[(1H-1,2,3-triazol-4-ylthio)methyl]-, [6R-[6Alpha,7beta(R*)]]- [CAS]	51627-14-6	GB 1460914	Cephalosporin, oral	Infection, general
Cefazedone		56187-47-4			
Cefazolin		25953-19-9			
Cefbuperazone		76610-84-9			
cefcapene pivoxil	7beta-[(Z)-2-(2-amino-4-thiazolyl)-2-pentenoylamino]-3-carbamoyloxymethyl-3-cephem-4-carboxylic acid, pivaloyloxymethyl ester HCl- [CAS]	105889-45-0 105889-46-1	GB 2173194	Cephalosporin, oral	Infection, respiratory tract, general
Cefclidin		105239-91-6			

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
cefclnir	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[[(2-amino-4-thiazolyl)(hydroxymino)acetyl]amino]-3-ethenyl-8-oxo-, [6R-[6Alpha,7B(Z)]]- [CAS]	91832-40-5	EP 105459	Cephalosporin, oral	Infection, dermatological
	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[[(2-amino-4-thiazolyl)(methoxymino)acetyl]amino]-3-[2-(4-methyl-5-thiazolyl)ethenyl]-8-oxo-, (2,2-dimethyl-1-oxopropoxy)methyl ester, [6R-[3(Z),6Alpha,7B(Z)]]- [CAS]	104145-95-1 104146-53-4 117467-28-4	JP 61178991	Cephalosporin, oral	Infection, general
cefcltoren pivoxil	Pyrrrolidinium, 1-[[7-[[[(2-amino-4-thiazolyl)(methoxymino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-1-methyl-, hydroxide, inner salt, [6R-[6Alpha,7B(Z)]]- [CAS]	107648-80-6 123171-59-5 88040-23-7	EP 531981	Cephalosporin, injectable	Infection, respiratory tract, lower
cefepime		65052-63-3			
Cefetamet					
cefetamet pivoxil	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[[(2-amino-4-thiazolyl)(methoxymino)acetyl]amino]-3-methyl-8-oxo-, (2,2-dimethyl-1-oxopropoxy)methyl ester, monohydrochloride, [6R-[6Alpha,7B(Z)]]- [CAS]	111696-23-2	GB 1581854	Cephalosporin, oral	Infection, general
	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[[(2-amino-4-thiazolyl)(carboxymethoxy)imino]acetyl]amino]-3-ethenyl-8-oxo-, [6R-[6Alpha,7B(Z)]]- [CAS]	79350-37-1	EP 30630	Cephalosporin, oral	Infection, general
cefixime					
cefmenoxime	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[[(2-amino-4-thiazolyl)(methoxymino)acetyl]amino]-3-[[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-oxo-, [6R-[6Alpha,7B(Z)]]- [CAS]	65085-01-0 75738-58-8	GB 1536281	Cephalosporin, injectable	Infection, ocular



API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
cefmetazole	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[[(cyanomethyl)thio]acetyl]amino]-7-methoxy-3-[[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-oxo-, [6R-cis]- [CAS]	56796-20-4 56796-39-5	GB 1449420	Cephalosporin, injectable	Infection, general
cefminox	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[[(2-amino-2-carboxyethyl)thio]acetyl]amino]-7-methoxy-3-[[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-oxo-, [6R-[6Alpha,7Alpha,7(S*)]]- [CAS]	84305-41-9	EP 24879	Cephalosporin, injectable	Infection, urinary tract
cefodizime	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[[(2-amino-4-thiazolyl)(methoxymino)acetyl]amino]-3-[[[(5-carboxymethyl)-4-methyl-2-thiazolyl]thio]methyl]-8-oxo-, [6R-[6Alpha,7(S,Z)]]- [CAS]	69739-16-8 86329-79-5	US 4590267	Cephalosporin, injectable	Infection, respiratory tract, lower
cefonicid	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[[(hydroxyphenylacetyl)amino]-8-oxo-3-[[[(1-sulfomethyl)-1H-tetrazol-5-yl]thio]methyl]-, disodium salt, [6R-[6Alpha,7(S,R*)]]- [CAS]	61270-78-8 61270-58-4	GB 1547473	Cephalosporin, injectable	Infection, general
cefoperazone cefoperazone + sulbactam Ceforanide	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[[(4-ethyl-2,3-dioxo-1-piperazinyl)carbonyl]amino](4-hydroxyphenyl)acetyl]amino]-3-[[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-oxo-, [6R-[6Alpha,7(S,R*)]]- [CAS]	62893-19-0 92739-15-6 60925-61-3	GB 1508071 US 4234579	Cephalosporin, injectable Antibiotic, other	Infection, general Infection, general
cefosells	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[[(2-amino-4-thiazolyl)(methoxymino)acetyl]amino]-3-[[[(2,3-dihydro-2-(2-hydroxyethyl)-3-imino-1H-pyrazol-1-yl]methyl)-8-oxo-, [6R-[6Alpha,7(S,Z)]]	122841-12-7 122841-10-5	EP 307804	Cephalosporin, injectable	Infection, general

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
cefotaxime	(6R,7R)-7-[[[(2-amino-4-thiazolyl)(methoxymino)acetyl]amino]cephalosporanic acid sodium salt	64485-93-4 63527-52-6 69712-56-7	GB 1580621	Cephalosporin, injectable	Infection, general
Cefotetan					
	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[[(2-amino-4-thiazolyl)acetyl]amino]-3-[[[1-[2-(dimethylamino)ethyl]-1H-tetrazol-5-yl]thio]methyl]-8-oxo-, (6R-trans)- [CAS]	61622-34-2 66309-69-1	US 4080498	Cephalosporin, injectable	Infection, general
cefotiam	1-(cyclohexyloxy)carbonyloxyethyl 7β-[2-(2-aminothiazol-4-yl)acetamido]-3-[[[1-(2-dimethylaminoethyl)-1H-tetrazol-5-yl]thio]methyl]ceph-3-em-4-carboxylate 2HCl [CAS]	95789-30-3	EP 128029	Cephalosporin, oral	Infection, respiratory tract, lower
cefotiam hexetil					
	5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 3-(((aminocarbonyloxy)methyl)-7-methoxy-8-oxo-7-((2-thienylacetyl)amino)-, monosodium salt, (6R-cis)- [CAS]	33564-30-6 35607-66-0	GB 1348984	Cephalosporin, oral	Infection, general
cefotitin					
	Imidazo[1,2-b]pyridazinium, 1-[7-[[[(5-amino-1,2,4-thiadiazol-3-yl)(methoxymino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-, hydroxide, inner salt, [6R-[6Alpha,7β(Z)]]- [CAS]	113359-04-9	EP 203271	Cephalosporin, injectable	Infection, general
cefprozopran					
	Pyridinium, 1-[[2-carboxy-7-[[[[(5-carboxy-1H-imidazol-4-yl)carbonyl]amino]phenylacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-4-(2-sulfoethyl)-, hydroxide, inner salt, [6R-[6Alpha,7β(R*)]]- [CAS]	84880-03-5 85287-61-2	EP 60028	Cephalosporin, injectable	Infection, respiratory tract, general
cefpiimizole					

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
cefpiramide	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[[(4-hydroxy-6-methyl-3-pyridinyl)carbonyl]amino](4-hydroxyphenyl)acetyl]amino]-3-[[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-oxo-, [6R-[6Alpha,7beta(R*)]]- [CAS]	70797-11-4	US 4156724	Cephalosporin, injectable	Infection, general
	5H-1-Pyridinium, 1-[[7-[[[(2-amino-4-thiazolyl)(methoxymino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-6,7-dihydro-,hydroxide, inner salt, [6R-[6Alpha,7beta(Z)]]- [CAS]	84957-29-9 98753-19-6	EP 64740	Cephalosporin, injectable	Infection, respiratory tract, lower
		87239-81-4			
Cefpodoxime Proxetil					
cefprozil	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[amino(4-hydroxyphenyl)acetyl]amino]-8-oxo-3-(1-propenyl)-, [6R-[6Alpha,7beta(R*)]]- [CAS]	92665-29-7 121123-17-9	GB 2173798	Cephalosporin, oral	Infection, dermatological
	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[amino-1,4-cyclohexadien-1-ylacetyl]amino]-3-methoxy-8-oxo-, [6R-[6Alpha,7beta(R*)]]- [CAS]	51762-05-1	GB 1435111	Cephalosporin, oral	Infection, general
cefroxadine	Pyridinium, 4-(aminocarbonyl)-1-[[2-carboxy-8-oxo-7-[(phenylsulfoacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-, hydroxide, inner salt, [6R-[6Alpha,7beta(R*)]]- [CAS]	52152-93-9 62587-73-9	GB 1387656	Cephalosporin, injectable	Infection, pseudomonal
	Pyridinium, 1-[[7-[[[(2-amino-4-thiazolyl)[(1-carboxy-1-methylethoxy)imino]acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-, hydroxide, inner salt, [6R-[6Alpha,7beta(Z)]]- [CAS]	72558-82-8 82547-58-8	GB 2025398	Cephalosporin, injectable	Infection, respiratory tract, upper
ceftazidime		26973-24-0			
Cefteram					
Ceftazole					

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
ceftibuten	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[2-(2-amino-4-thiazolyl)-4-carboxy-1-oxo-2-butenyl]amino]-8-oxo-, [6R-[6Alpha,7beta(Z)]]- [CAS]	97519-39-6	EP 136721	Cephalosporin, oral	Infection, respiratory tract, lower
	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[[(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-8-oxo-, [6R-[6Alpha,7beta(Z)]]- [CAS]	68401-81-0 68401-82-1	GB 1600735	Cephalosporin, injectable	Infection, general
ceftizoxime	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[[2-[(2-amino-1-oxopropyl)amino]-4-thiazolyl](methoxyimino)acetyl]amino]-8-oxo-, (2,2-dimethyl-1-oxopropoxy)methyl ester, monohydrochloride, [6R-[6Alpha,7beta(Z(S*))]]- [CAS]	113812-94-5 135767-36-1	JP 62209112	Cephalosporin, oral	Infection, general
	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[[(2-amino-4-thiazolyl)(methoxyimino)acetyl]amino]-8-oxo-3-[[[(1,2,5,6-tetrahydro-2-methyl-5,6-dioxo-1,2,4-triazin-3-yl)thio]methyl]-, [6R-[6Alpha,7beta(Z)]]- [CAS]	73384-59-5 74578-69-1	GB 2022090	Cephalosporin, injectable	Infection, respiratory tract, lower
ceftriaxone	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 3-[[[(aminocarbonyloxy)methyl]-7-[[2-furanyl(methoxyimino)acetyl]amino]-8-oxo-, 1-(acetyloxy)ethyl ester, [6R-[6Alpha,7beta(Z)]]- [CAS]	15686-71-2 64544-07-6	GB 1571683	Cephalosporin, oral	Infection, respiratory tract, upper
	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 3-[[[(aminocarbonyloxy)methyl]-7-[[2-furanyl(methoxyimino)acetyl]amino]-8-oxo-, [6R-[6Alpha,7beta(Z)]]- [CAS]	55268-75-2 56238-63-2 82219-78-1	GB 1453049	Cephalosporin, injectable	Infection, general
Cefuzonam					
celecoxib	Benzenesulfonamide, 4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)- [CAS]	169590-42-5	US 5760068	Antiarthritic, other	Arthritis, rheumatoid

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
celgosivir	Butanoic acid, octahydro-1,7,8-trihydroxy-6-indoliziny ester, [1S-(1Alpha,6S,7Alpha,8S,8aB)]- [CAS]	121104-96-9	US 5017563	Antiviral, other	Infection, hepatitis virus, general
celiprolol	Urea, N'-[3-acetyl-4-{3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy}phenyl]-N,N-diethyl- [CAS]	56980-93-9 57470-78-7	GB 1441359	Antihypertensive, adrenergic	Angina, unstable
Cellulose Ethyl Hydroxyethyl Ether		9004-58-4			
Centchroman		31477-60-8			
CEP-1347	9,12-Epoxy-1H-dlindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid, 5,16-bis((ethylthio)methyl)-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-, methyl ester, (9S,10R,12R)- [CAS]	156177-65-0	WO 9731002	Antiparkinsonian	Parkinson's disease
CEP-701	9,12-Epoxy-1H-dlindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-1-one, 2,3,9,10,11,12-hexahydro-10-hydroxy-10-(hydroxymethyl)-9-methyl-, (9S,10S,12R)- [CAS]	111358-88-4		Anticancer, antimetabolite	Cancer, prostate
Cephacetrile		23239-41-0			
Cephaeline		483-17-0			
Cephalexin		15686-71-2			
Cephaloglycin		3577-1-3			
Cephaloridine		50-59-9			
Cephalosporin C		61-24-5			
Cephalothin		153-61-7			
Cephapirin		24356-60-3			
Cephadrine		38821-53-3			
Cerivastatin		145599-86-6			
Ceronapril		111223-26-8			
certoparin	Heparin [CAS]	9005-49-6		Anticoagulant	Thrombosis, venous
Ceruletide		17650-98-5			
Cerviprost	Prosta-5,13-dien-1-oic acid, 11,15-dihydroxy-9-oxo-, (5Z,11Alpha,13E,-15S)- [CAS]	363-24-6		Formulation, dermal, topical	



API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Cetalkonium		122-18-9			
Cetamolol		34919-98-7			
Cethexonium		1794-74-7			
	2H-Oxacyclotetradecino(4,3-d)oxazole-2,6,8,14(1H,7H,9H)-tetrone 4-ethyloctahydro-3a,7,9,11,13,15-hexamethyl-11-((3-(3-quinolinyl)-2-propenyl)oxy)-10-((3,4,6-trideoxy-3-(dimethylamino)-β-D-xylohexapyranosyl)oxy)-(3a S,4R,7R,9R,10R,11R,13R,15R,15aR)-[CAS]				
cethromycin		205110-48-1	EP 929563	Macrolide antibiotic	Infection, respiratory tract, general
Cetiedil		14176-10-4			
Cetirizine		83881-51-0			
	Acetic acid, [2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-, [CAS]	83881-51-0 83881-52-1	EP 58146	Antiallergic, non-asthma	Allergy, general
cetirizine					
	Acetic acid, [2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-, dihydrochloride, Benzenemethanol, Alpha-[1-(methylamino)ethyl]-, hydrochloride, [S-(R*R*)]-	83881-52-1 90-82-4		Formulation, optimized, microencapsulate	Allergy, general
cetirizine+pseudoephedrine		137-76-8			
Cetotiamine		25394-78-9			
Cetoxime					
	Benzenepropanoic acid, 4-[[[4-(aminomethyl)cyclohexyl]carbonyl]oxy]-, trans-[CAS]	27724-96-5 34675-84-8	JP 48075547	Antilulcer	
cetraxate		57-09-0			
Cetrimonium		120287-85-6			
Cetrorelix		124-03-8			
Cetyldimethylethylammonium		123-03-5			
Cetylpyridinium					
cevimeline	Spiro[1-azabicyclo[2.2.2]octane-3,5'-[1,3]oxathiolane], 2'-methyl-, cis- [CAS]	107220-27-9 107233-08-9	EP 205247	Stomatological	Sjogren's syndrome
	7-phenyl-2,4,6-heptatrienylhydroxamic acid			Anticancer, other	Cancer, general
CG-1521					

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Chaulmoogric Acid		29106-32-9			
Chenodiol		474-25-9			
CHF-3381			EP 951465	Analgesic, other	Pain, neuropathic
Chlophedianol		791-35-5			
Chloracizine		800-22-6			
chloral	1,1-Ethanediol, 2,2,2-trichloro- [CAS]	302-17-0			
		2218-68-0			
		515-82-2		Formulation, transmucosal, systemic	Insomnia
		305-03-3			
		127-52-6			
Chlorambucil		127-65-1			
Chloramine-B		121-30-2			
Chloramine-T		56-75-7			
Chloraminophenamide		500-42-5			
Chloramphenicol		522-18-9			
Chlorazaniil		97-27-8			
Chlorbenzoxamine		82-93-9			
Chlorbetamide		5588-20-5			
Chlorcycizine		58-25-3			
Chlordantoin		500-92-5			
Chlordiazepoxide		3563-58-4			
Chlorguanide					
Chlorhexadol					
chlorhexidine	2,4,11,13-Tetraazatetradecanediiimide, N,N"-bis(4-chlorophenyl)-3,12-dilimino- [CAS]	55-56-1		Formulation, other	Xerostomia, Periodontitis
		69-27-2			
		302-22-7			
		62-37-3			
		80-77-3			
		3689-76-7			
		494-03-1			
		502-98-7			
		1406-65-1			
		52080-57-6			
		3858-89-7			
Chlorisondamine					
Chlormadinone					
Chlormerodrin					
Chlormezanone					
Chlormidazole					
Chlomaphazine					
Chlorazodin					
Chlorophyll					
Chloroprednisone					
Chlorprocaine					

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Chlorpyramine		59-32-5			
Chloroquine		54-05-7			
Chlorothen		148-65-2			
Chlorothiazide		58-94-6			
Chlorotrianisene		569-57-3			
Chloroxine		773-76-2			
Chloroxyfenol		88-04-0			
Chlorozotocin		54749-90-5			
chlorphenamine	2-Pyridinepropanamine, Gamma-(4-chlorophenyl)-N,N-dimethyl- [CAS]	132-22-9		Formulation, modified-release, other	Allergy, general
Chlorphenesin		104-29-0 74-8	886-		
Chlorpheniramine		132-22-9			
Chlorphenoxamide		3576-64-5			
Chlorphenoxamine		77-38-3			
Chlorphentermine		461-78-9			
Chlorproethazine		84-01-5			
Chlorproguanil		537-21-3			
chlorproguanil + dapsone	4,4'-Sulfonyldianiline + 1-(3,4-Dichlorophenyl)5-isopropylbiguanide	537-21-3 80-08-0		Antimalarial	Infection, malaria
Chlorpromazine		50-53-3			
Chlorpropamide		94-20-2			
Chlorprothixene		113-59-7			
Chlorquinaldol		72-80-0			
Chlortetracycline		57-62-5			
Chlorthalidone		77-36-1			
Chlorthenoxazin(e)		132-89-8			
Chlorzoxazone		95-25-0			
Cholic Acid		81-25-4			
Choline		67-48-1 36-6 9	2016- 28319-77-		

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
choline theophyllinate	Ethanaminium, 2-hydroxy-N,N,N-trimethyl-, salt with 3,7-dihydro-1,3-dimethyl-1H-purine-2,6-dione (1:1) [CAS]	4499-40-5		Formulation, modified-release, other	
choline-L-alfoscerate	Ethanaminium, 2-[[[(2,3-dihydroxypropoxy)hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, hydroxide, inner salt, (R)-] [CAS]	28319-77-9	JP 55028955	Cognition enhancer	Amnesia
Chromocarb		4940-39-0			
Chromonar		804-10-4			
Chrysoidine		532-82-1			
CHS-828	Guanidine, N-[6-(4-chlorophenoxy)hexyl]-N'-cyano-N"-4-pyridinyl- [CAS]	200484-11-3	US 5696140	Anticancer, other	Cancer, general
CI-1031	Glycine, N-[2-[5-(aminoiminomethyl)-2-hydroxyphenoxyl]-6-[3-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenoxy]-3,5-difluoro-4-pyridinyl]-N-methyl- [CAS]	183305-24-0	WO 9638421	Antianginal	Angina, unstable
CI-1040	Benzamide, 2-[(2-chloro-4-iodophenyl)amino]-N-(cyclopropylmethoxy)-3,4-difluoro- [CAS]	212631-79-3	WO 9837881	Anticancer, other	Cancer, general
cibenzoline	1H-Imidazole, 2-(2,2-diphenylcyclopropyl)-4,5-dihydro- [CAS]	53267-01-9	GB 1417174	Antiarrhythmic	Arrhythmia, general
ciclesonide	Pregna-1,4-diene-3,20-dione 16,17-((cyclohexylmethylene)bis(oxy))-11-hydroxy-21-(2-methyl-1-oxopropoxy) (11 $\beta$ , 16 $\alpha$ ) [CAS]	126544-47-6	DE 4129535	Antiasthma	Asthma
cicletanine	Furo[3,4-c]pyridin-7-ol, 3-(4-chlorophenyl)-1,3-dihydro-6-methyl-, (+/-)- [CAS]	82747-56-6 89943-82-8	US 4383998	Antihypertensive, other	
ciclopicate	3-Pyridinecarboxylic acid, 3,3,5-trimethylcyclohexyl ester, trans- [CAS]	53449-58-4	DE 1910481	Vasodilator, peripheral	Cancer, lung, small cell
ciclopirox	2(1H)-Pyridinone, 6-cyclohexyl-1-hydroxy-4-methyl-, [CAS]	41621-49-2 29342-05-0	US 3883545	Antifungal	Infection, fungal, general
Ciclosidomine		66564-16-7			

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
ciclosporin A	Cyclosporin A- [CAS]	59865-13-3		Formulation, optimized, microemulsion	Transplant rejection, general
cidofovir	Phosphonic acid, [[2-(4-amino-2-oxo-1(2H)-pyrimidinyl)-1-(hydroxymethyl)ethoxy]methyl]-, (S)- [CAS]	113852-37-2	EP 253412	Antiviral, other	Infection, cytomegalovirus
Cifenline		53267-01-9			
cilansetron	4H-Pyrido[3,2,1-jk]carbazol-11(8H)-one, 5,6,9,10-tetrahydro-10-[[2-methyl-1H-imidazol-1-yl)methyl]-, (R)- [CAS]	120635-74-7	EP 297651	GI inflammatory/bowel disorders	Irritable bowel syndrome
Cilastatin		82009-34-5			
cilazapril	6H-Pyridazino[1,2-a][1,2]diazepine-1-carboxylic acid, 9-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]octahydro-10-oxo-, [1S-[1Alpha,9Alpha(R*)]]- [CAS]	88768-40-5 90139-06-3	GB 2128984	Antihypertensive, renin system	Hypertension, general
cilengitide	Cyclo(L-arginylglycyl-L-Alpha-aspartyl-D-phenylalanyl-N-methyl-L-valyl) [CAS]	188968-51-6	EP 770622	Anticancer, other	Cancer, lung, non-small cell
cilnidipine	3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-methoxyethyl 3-phenyl-2-propenyl ester- [CAS]	102106-21-8 132203-70-4	EP 161877	Antihypertensive, other	Hypertension, general
cilomilast	Cis-4-cyano-4-[3-(cyclopentyloxy)-4-methoxyphenyl]cyclohexane-1-carboxylic acid	153259-65-5	US 5602157	COPD treatment	Chronic obstructive pulmonary disease
cilostazol	2(1H)-Quinolinone, 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-[CAS]	73963-72-1	GB 2033893	Antithrombotic	Peripheral vascular disease
Cimetidine		51481-61-9			
cimetropium	3-Oxa-9-azoniatricyclo[3.3.1.0 <sup>2,4</sup> ]nonane, 9-(cyclopropylmethyl)-7-(3-hydroxy-1-oxo-2-phenylpropoxy)-9-methyl-, [7(S)-(1Alpha,2S,4S,5Alpha,7S)]-[CAS]	51598-60-8	US 3853886	Antispasmodic	Muscle spasm, general
cinacalcet	1-naphthalenemethanamine, Alpha-methyl-N-[3-[3-(trifluoromethyl)phenyl]propyl]-, (AlphaR)-	364782-34-3		Hormone	Hyperparathyroidism



API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Cinchonidine		485-71-2			
Cinchonine		118-10-5			
Cinchophen		132-60-5			
Cinepazet		23887-41-4			
Cinepazide		23887-46-9			
cinepazide	Piperazine, 1-[2-oxo-2-(1-pyrrolidinyl)ethyl]-4-[1-oxo-3-(3,4,5-trimethoxyphenyl)-2-propenyl]-, (Z)-2-butenedioate (1:1) [CAS]	26328-04-1	GB 1218591	Vasodilator, peripheral	Peripheral vascular disease
Cinitapride		66564-14-5			
Cinmetacin		20168-99-4			
Cinnamedrine		90-86-8			
Cinnarizine		298-57-7			
cinolazepam	1H-1,4-Benzodiazepine-1-propanenitrile, 7-chloro-5-(2-fluorophenyl)-2,3-dihydro-3-hydroxy-2-oxo- [CAS]	75696-02-5	DE 2950235	Hypnotic/Sedative	Insomnia
cinoxacin	[1,3]Dioxolo[4,5-g]cinnoline-3-carboxylic acid, 1-ethyl-1,4-dihydro-4-oxo- [CAS]	28657-80-9	GB 1296753	Quinolone antibacterial	Infection, urinary tract
Cinoxate		104-28-9			
Cinromide		58473-74-8			
Cioteronel		89672-11-7			
cipamfyliline	1H-Purine-2,6-dione, 8-amino-1,3-bis(cyclopropylmethyl)-3,7-dihydro- [CAS]	132210-43-6	EP 389282	Antipruritic/Inflamm, allergic	Eczema, atopic
cipralisant	1H-Imidazole, 4-[(1R,2R)-2-(5,5-dimethyl-1-hexynyl)cyclopropyl]- [CAS]	213027-19-1	US 6008240	Psychostimulant	Attention deficit disorder
ciprofibrate	Propanoic acid, 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methyl- [CAS]	52214-84-3	GB 1385828	Hypolipaeamic/Antiatherosclerosis	Hyperlipidaemia, general
ciprofloxacin	3-Quinolincarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)- [CAS]	85721-33-1	US 4670444	Quinolone antibacterial	Infection, general

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
ciprofloxacin+fluocinolone,SAL	3-Quinolnecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)- + (6Alpha, 11beta, 16Alpha)-6,9-Difluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]-pregna-1,4-diene-3,20-dione			Formulation, fixed-dose combinations	Otitis
Cirramadol		63269-31-8			
disapride	Benzamide, 4-amino-5-chloro-N-[1-[3-(4-fluorophenoxy)propyl]-3-methoxy-4-piperidinyl]-2-methoxy-, cis- [CAS]	81098-60-4	EP 76530	Gastroprokinetic	
cisatracurium	Isoquinolinium, 2,2'-[1,5-pentanediy]bis[oxy(3-oxo-3,1-propanediyl)]bis[1'-(3,4-dimethoxyphenyl)methyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-, [1R-[1Alpha,2Alpha(1'R*,2'R*)]]-, [CAS]	96946-42-8	US 5453510	Muscle relaxant	Surgery adjunct
cisplatin	Platinum, diamminedichloro-, (SP-4-2)-[CAS]	15663-27-1	US 4177263	Anticancer, alkylating	
citalopram	5-Isobenzofurancarboxitrile, 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro- [CAS]	59729-32-7 59729-33-8	GB 1526331	Antidepressant	Depression, general
citicoline	Cytidine 5'-(trihydrogen diphosphate), P'-[2-(trimethylammonio)ethyl]ester, hydroxide, inner salt [CAS]	987-78-0	JP 39006541	Cognition enhancer	Infarction, cerebral
Citfolone		1195-16-0			
Citric Acid		77-92-9			
Citrulline		372-75-8			
cizolirine	Ethanamine, N,N-dimethyl-2-[(1-methyl-1H-pyrazol-5-yl)phenylmethoxy]-, 2-hydroxy-1,2,3-propanetricarboxylate [CAS]	142155-44-0		Urological	Incontinence
CJ-13610	4-(3-[4-(2-Methylimidazol-1-yl)-phenylsulfanyl]-phenyl)-tetrahydro-pyran-4-carboxylic acid amide			COPD treatment	Chronic obstructive pulmonary disease

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
CKD-602	1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, 4-ethyl-4-hydroxy-11-[2-[(1-methylethyl)amino]ethyl]-, monohydrochloride, (4S)- [CAS]	213819-48-8	WO	9902530	Anticancer, other	Cancer, ovarian
cladribine	Adenosine, 2-chloro-2'-deoxy- [CAS]	4291-63-8	EP	173059	Anticancer, antimetabolite	Cancer, leukaemia, hairy cell
Clanobutin		30544-61-7				
clarithromycin	Erythromycin, 6-O-methyl- [CAS]	81103-11-9	EP	41355	Macrolide antibiotic	Infection, respiratory tract, lower
Clavulanate, Disodium						
Clavulanic Acid		58001-44-8				
Clebopride		55905-53-8				
Clemastine		15686-51-8				
Clemizole		442-52-4				
Clenbuterol		37148-27-9				
Clentiazem		96125-53-0				
clevudipine	3,5-Pyridinedicarboxylic acid, 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-, methyl (1-oxobutoxy)methyl ester (±) [CAS]	167221-71-8	WO	9512578	Antihypertensive, other	Hypertension, general
clevudine	2,4(1H,3H)-Pyrimidin-5-one, 1-(2-deoxy-2-fluoro-β-L-arabinofuranosyl)-5-methyl- [CAS]	163252-36-6			Antiviral, other	Infection, hepatitis-B virus
Clidanac		28968-07-2				
Clidinium		3485-62-9				
Clinafloxacin		105956-97-6				
Clindamycin		18323-44-9				
clindamycin + tretinoin	L-threo-Alpha-D-galacto-Octopyranoside, methyl 7-chloro-6,7,8-trideoxy-6-[[[(1-methyl-4-propyl-2-pyrrolidinyl)carbonyl]amino]-1-thio-, (2S-trans)- + retinoic acid				Formulation, fixed-dose combinations	Acne

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
clindamycin	L-Threo-Alpha-D-galacto-octopyranoside, methyl 7-chloro-6,7,8-trideoxy-6-[[[(1-methyl-4-propyl-2-pyrrolidinyl)carbonyl]amino]-1-thio-, 2-(dihydrogen phosphate), (2S-trans)-	18323-44-9 24729-96-2		Formulation, parenteral, other	Infection, gynaecological
Clinofibrate		30299-08-2			
Clinprost		88931-51-5			
clobazam	1H-1,5-Benzodiazepine-2,4(3H,5H)-dione, 7-chloro-1-methyl-5-phenyl- [CAS]	22316-47-8	GB 1214662	Anxiolytic	
Clobenfurol		3611-72-1			
Clobenoxide		29899-95-4			
Clobenzepam		1159-93-9			
Clobenzorex		13364-32-4			
Clobenztropine		5627-46-3			
clobetasol	Pregna-1,4-diene-3,20-dione, 21-chloro-9-fluoro-11,17-dihydroxy-16-methyl-, (11 $\beta$ ,16 $\beta$ )- [CAS]	25122-41-2		Formulation, dermal, topical	Psoriasis
clobetasone	Pregna-1,4-diene-3,11,20-trione, 21-chloro-9-fluoro-16-methyl-17-(1-oxobutoxy)-, (16 $\beta$ )-[CAS]	25122-57-0 54063-32-0	GB 1253831	Antipruritic/inflam, allergic	
Clobutinol		14860-49-2			
Clocapramine		47739-98-0			
Clocinazine		298-55-5			
Cloconazole		77175-51-0			
Clocortolone		4828-27-7			
clodronate	Phosphonic acid, (dichloromethylene)bis-[CAS]	22560-50-5		Osteoporosis treatment, Anticancer, hormonal	Pain, cancer, Hypercalcaemia of malignancy
Clodronic Acid		10596-23-3			
clofarabine	2-chloro-9-(2-deoxy-2-fluoro- $\beta$ -D-arabinofurasonyl)adenine			Anticancer, antimetabolite	Cancer, leukaemia, chronic lymphocytic

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
clofazimine	3-(p-chloroanilo)-10-(p-chlorophenyl)-2,10-dihydro-2-(isopropylimino)-phenazine	2030-63-9		Formulation, optimized, microencapsulate	Infection, tuberculosis
Clofenamide		671-95-4			
Clofibrate		637-07-0			
Clofibric Acid		882-09-7			
Cloflucarban		369-77-7			
Clofoctol		37693-01-9			
Cloforex		14261-75-7			
Clomacran		5310-55-4			
Clomestrone		4091-75-2			
Clometacin		25803-14-9			
Clomethiazole		533-45-9			
Clometocillin		1926-49-4			
Clomiphene		911-45-5			
Clomipramine		303-49-1			
Clomocycline		1181-54-0			
clonazepam	2H-1,4-Benzodiazepin-2-one, 5-(2-chlorophenyl)-1,3-dihydro-7-nitro- [CAS]	1622-61-3	US 4316897	Antiepileptic	Epilepsy, general
clonidine	1H-Imidazol-2-amine, N-(2,6-dichlorophenyl)-4,5-dihydro- [CAS]	4205-90-7	US 4060084	Formulation, transdermal, patch	Hypertension, general
Clonitazene		3861-76-5			
Clonitrate		2612-33-1			
Clonixin		17737-65-4			
Clopamide		636-54-4			
Clopenthixol		982-24-1			
Cloperastine		3703-76-2			
clopidogrel	Thieno[3,2-c]pyridine-5(4H)-acetic acid, Alpha-(2-chlorophenyl)-6,7-dihydro-, methyl ester, (S)- [CAS]	120202-48-4 90055-48-4 113665-84-2	EP 99802	Antithrombotic	Infarction, myocardial
Clopirac		42779-82-8			
Cloprednol		5251-34-3			
cloranolol	2-Propanol, 1-(2,5-dichlorophenoxy)-3-[(1,1-dimethylethyl)amino]- [CAS]	39563-28-5 54247-25-5	US 4310549	Antihypertensive, adrenergic	



API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Clorazepic Acid		23887-31-2			
Clorexolone		2127-1-7			
cloricromene	Acetic acid, [[8-chloro-3-[2-(diethylamino)ethyl]-4-methyl-2-oxo-2H-1-benzopyran-7-yl]oxy]-, ethyl ester [CAS]	68206-94-0	US 4349566	Vasodilator, coronary	Peripheral vascular disease
Clorindione		1146-99-2			
Clorprenaline		3811-25-4			
Clortermine		10389-73-8			
Clospirazine		24527-27-3			
Clostebol		1093-58-9			
Clothiapine		2058-52-8			
clotiazepam	2H-Thieno[2,3-e]-1,4-diazepin-2-one, 5-(2-chlorophenyl)-7-ethyl-1,3-dihydro-1-methyl-[CAS]	33671-46-4	US 3849405	Anxiolytic	Anxiety, general
clotrimazole	1-[(2-chlorophenyl)diphenylmethyl]-1H-imidazole	23593-75-1	US 3705172	Antifungal	
clotrimazole + betamethasone	Pregna-1,4-diene-3,20-dione, 9-fluoro-11-hydroxy-16-methyl-17,21-bis(1-oxopropoxy)-, (1R,16R)-, mixt. with 1-[(2-chlorophenyl)diphenylmethyl]-1H-imidazole [CAS]	92522-91-3		Formulation, fixed-dose combinations	Infection, fungal, general
Cloxacinil		61-72-3			
cloxazolam	Oxazolo[3,2-d][1,4]benzodiazepin-6(5H)-one, 10-chloro-11b-(2-chlorophenyl)-2,3,7,11b-tetrahydro- [CAS]	24166-13-0	US 3772371	Anxiolytic	
Cloxotestosterone		53608-96-1			
Cloxyquin		130-16-5			
clozapine	5H-Dibenzo[b,e][1,4]diazepine, 8-chloro-11-(4-methyl-1-piperazinyl)- [CAS]	5786-21-0	US 3539573	Neuroleptic	Schizophrenia
CMI-392	Trans-2-[3-methoxy-4-(2-p-chlorophenylthio)ethoxy-5-(N'-methyl-N'-hydroxyureidyl)methylphenyl]-5-(3,4,5-trimethoxyphenyl)tetrahydrofuran	193739-23-0	US 5648486	Antipsoriasis	Psoriasis

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
CMT-3	2-Naphthacene-carboxamide, 1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4aS,5aR,12aS)- [CAS]	15866-90-7	US 5837696	Anticancer, other	Cancer, sarcoma, Kaposi's
CNI-1493	Decanediamide, N,N'-bis[3,5-bis[1-[(aminiminomethyl)hydrazono]ethyl]phenyl], tetrahydrochloride [CAS]	164301-51-3	US 5750573	Anti-inflammatory	Psoriasis
CNS-5161	N'-[2-chloro-5-(methylthio)phenyl]-N-methyl-N-[3-(methylthio)phenyl]guanidine [CAS]	160754-76-7	WO 9427591	Analgesic, other	Pain, neuropathic
Cobamamide		13870-90-1			
Cocaeethylene		529-38-4			
Cocaine		50-36-2			
Codeine		76-57-3 52-28-8			
CoFactor	5,10 methylene - tetrahydrofolate			Anticancer, antimetabolite	Cancer, colorectal
Colchicine		64-86-8			
colesevelam	1-Hexanaminium, N,N,N-trimethyl-6-(2-propenylamino)-, polymer with (chloromethyl)oxirane, 2-propen-1-amine and N-2-propenyl-1-decanamine, hydrochloride [CAS]	182815-44-7	US 5607669	Hypolipemic/Antiatherosclerosis	Hyperlipidaemia, general
colestilan	1H-Imidazole, 2-methyl-, polymer with (chloromethyl)oxirane [CAS]	95522-45-5	JP 59155421	Hypolipemic/Antiatherosclerosis	Hypercholesterolaemia
Colestipol		26658-42-4			
colforsin daropate	6-(3-dimethylaminopropionyl)forskolin- [CAS]	138605-00-2	EP 222413	Cardio stimulant	Heart failure
colfosceril	3,5,9-Trioxa-4-phosphapentacosan-1-aminium, 4-hydroxy-N,N,N-trimethyl-10-oxo-7-[(1-oxohexadecyl)oxy]-, hydroxide, inner salt, 4-oxide, (R)- [CAS]	63-89-8 99732-49-7	US 4826821	Lung Surfactant	Respiratory distress syndrome, Infant
Collagraft		138331-02-9		Formulation, implant	Regeneration, bone
Colocynthin		1398-78-3			
Colpormon		1247-71-8			

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
coluracetam	1-Pyrrolidineacetamide, 2-oxo-N-(5,6,7,8-tetrahydro-2,3-dimethylfuro[2,3-b]quinolin-4-yl)- [CAS]	135463-81-9	EP	427636	Cognition enhancer	Alzheimer's disease
combretastatin A-4 prodrug compound B, Pharmacor	disodium combretastatin-A-4-3-O-phosphate					
			US	6362165	Anticancer, other Antiviral, anti-HIV	Cancer, thyroid Infection, HIV/AIDS
convivaptin	[1,1'-Biphenyl]-2-carboxamide, N-[4-{(4,5-dihydro-2-methylimidazo[4,5-d][1-benzazepin-6(1H)-yl)carbonyl]phenyl}-, [CAS]	168626-94-6	WO	9503305	GI inflammatory/bowel disorders	Hyponatraemia
Connetivina	Hyaluronic acid [CAS]	9004-61-9			Vulnerary	
Convallatoxin		508-75-8				
Coparaffinate		8001-60-3				
Corticorelin Ovine Triflutate						
Corticosterone		50-22-6				
Cortisone		53-06-5				
Cortivazol		1110-40-3				
Cosyntropin		16960-16-0				
Cotamine		82-54-2				
Cotinine		486-56-6				
co-trimazine	Benzenesulfonamide, 4-amino-N-2-pyrimidinyl-, mixt. with 5-[(3,4,5-trimethoxyphenyl)methyl]-2,4-pyrimidinediamine [CAS]	39474-58-3			Trimethoprim and analogues	Infection, urinary tract
Coumetarol		4366-18-1				
CP-248	1H-Indene-3-acetamide, 5-fluoro-2-methyl-N-(phenylmethyl)-1-[(3,4,5-trimethoxyphenyl)methylene]-, (1Z)- [CAS]	200803-37-8	WO	9747303	Anticancer, other	Barrett's oesophagus
CP-461			US	5948779	Anticancer, other	Cancer, prostate
CPC-211	Acetic acid, dichloro-, sodium salt [CAS]	2156-56-1			Neuroprotective	Acidosis, lactic
CPI-1189	CPI 1189 [CAS]	210475-67-5	WO	9631462	Cognition enhancer	Dementia, AIDS-related
CRA-0450			WO	0202549	Anxiolytic	Unspecified
creatinol-O-phosphate	Guanidine, N-methyl-N-[2-(phosphonoxy)ethyl]- [CAS]	6903-79-3			Antianginal	

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
CRL-5861	Oxirane, methyl-, polymer with oxirane, block [CAS]	106392-12-5	US 4837014	Antisickling	Anaemia, sickle cell
crobenetine	(2R,6S)-3-[2(S)-Benzyloxypropyl]-6,11,11-trimethyl-1,2,3,4,5,6,-hexahydro-2,6-methano-3-benzazocin-10-ol		WO 9914199	Neuroprotective	Ischaemia, cerebral
croconazole	1H-Imidazole, 1-[1-[2-[(3-chlorophenyl)methoxy]phenyl]ethenyl]-[CAS]	77175-51-0	DE 3021467	Antifungal	Infection, fungal, general
cromoglicic acid	4H-1-Benzopyran-2-carboxylic acid, 5,5'-[(2-hydroxy-1,3-propanediyl)bis(oxy)]bis[4-oxo-][CAS]	53736-52-0		Formulation, mucosal, topical	Conjunctivitis
cromolyn	4H-1-Benzopyran-2-carboxylic acid, 5,5'-[(2-hydroxy-1,3-propanediyl)bis(oxy)]bis[4-oxo-][CAS]	15826-37-6 16110-51-3		Formulation, inhalable, solution	Asthma
Cropropamide		633-47-6			
Crotamilon		483-63-6			
Crotethamide		6168-76-9			
Crystacide			US 4557935	Formulation, dermal, topical	Infection, dermatological
CS-502	□		EP 799823	Analgesic, other	Pain, general
CS-758	4-[(1E,3E)-4-[trans-5-[[1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]thio]-1,3-dioxan-2-yl]-1,3-butadienyl]-3-fluorobenzonitrile			Antifungal	Infection, fungal, general
CS-834	1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 6-[[1R)-1-hydroxyethyl]-4-methyl-7-oxo-3-[[[(3R)-5-oxo-3-pyrrolidinyl]thio]-, (2,2-dimethyl-1-oxopropoxy)methyl ester, (4R,5S,6S)- [CAS]	157542-49-9	EP 599512	Beta-lactam antibiotic	Infection, general
CT-052923	[[[2H-benzo[d]1,3-dioxalan-5-methyl)amino][4-(6,7-dimethoxyquinazolin-4-yl)piperazinyl]methane-1-thione			Cardiovascular	Restenosis

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
CT-32228	N-(4-bromophenyl)-6-(5-chloro-2-methylphenyl)-[1,3,5]triazine-2,4-diamine			Anticancer, other	Cancer, general
Cupric Citrate		866-82-0			
Cuproxoline		13007-93-7			
	Ethanol, 2,2'-[[6-[[[4-methoxyphenyl)methyl]amino]-9-(1-methylethyl)-9H-purin-2-yl]imino]bis-[CAS]				
CVT-2584	((S)-6-amino-5-(6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxamido)-3-methyl-1-phenyl-2,4-(1H,3H)-pyrimidinedione	199986-75-9	WO 9805335	Cardiovascular	Restenosis
CX-659S					
Cyacetamide		140-87-4		Dermatological	Eczema, general
Cyamemazine		3546-03-0			
Cyanidin		528-58-5			
CYC400			WO 00172745	Anticancer, other	Cancer, general
Cyclacillin		3485-14-1			
Cyclandelate		456-59-7			
Cyclazocine		3572-80-3			
Cyclexanone		15301-52-7			
Cyclexedrine		532-52-5			
cyclidrol	3-Cyclohexene-1-methanol, 5-hydroxy-Alpha,Alpha,4-trimethyl- [CAS]	498-71-5		COPD treatment, Respiratory	Bronchitis, chronic
cyclin D1 inhibitors			US 6033843	Anticancer, hormonal	Cancer, breast
Cyclizine		82-92-8			
Cyclobarbitol		52-31-3			
Cyclobendazole		31431-43-3			
cyclobenzaprine	1-Propanamine, 3-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-N,N-dimethyl-[CAS]	303-53-7		Formulation, modified-release, other	Muscle spasm, general
Cyclobutylol		512-16-3			
Cyclocumamol		518-20-7			
Cyclodrine		52109-93-0			



API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Cyclofenil		2624-43-3			
Cycloguanil		516-21-2			
Cyclomethycaine		139-62-8			
Cyclonium iodide		6577-41-9			
Cyclopentamine		102-45-4			
Cyclopenthiiazide		742-20-1			
Cyclopentobarbital		76-68-6			
Cyclopentolate		512-15-2			
cyclophosphamide	N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine-2-oxide monohydrate	50-18-0 6055-19-2		Formulation, parenteral, targeted	Cancer, general
cyclopiroxalamine	2(1H)-Pyridinone, 6-cyclohexyl-1-hydroxy-4-methyl-, compd with 2-aminoethanol(1:1) [CAS]	41621-49-2		Formulation, transdermal, other	Vaginitis
Cycloserine		68-41-7			
Cyclothiazide		2259-96-3			
Cyclovalone		579-23-7			
Cymarin		508-77-0			
cymserine	Carbamic acid, [4-(1-methylethyl)phenyl]-, (3aS,8aR)-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo[2,3-b]indol-5-yl ester [CAS]	145209-39-8	WO 9902154	Cognition enhancer	Alzheimer's disease
Cynarin(e)		30964-13-7			
CYP26 inhibitors			US 6063606	Dermatological	Unspecified
Cyproheptadine		129-03-3			
cyproterone	(1R,2R)-6-Chloro-1,2-dihydro-17-hydroxy-3'H-cyclopropa[1,2]pregna-1,4,6-triene-3,20-dione [CAS]	2098-66-0		Radio/chemoprotective	Chemotherapy-induced injury, general
Cysteamine		60-23-1			
cystic fibrosis ther	[[4-[[3-[[4-[1-(4-hydroxyphenyl)-1-methyl-ethyl]phenoxy]methyl]phenyl]methoxy]-phenyl]iminomethyl]-, ethyl ester			Cystic fibrosis treatment	Cystic fibrosis

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
cytarabine	2(1H)-Pyrimidinone, 4-amino-1-[5-O-[hydroxy(octadecyloxy)phosphinyl]-β-D-arabinofuranosyl]-, [CAS]	65093-40-5 147-94-4	EP 239015	Anticancer, antimetabolite	Myelodysplastic syndrome
D-24851	N-(Pyridin-4-yl)-(1-(4-chlorobenzyl)-indol-3-yl)-glyoxy-l-amide			Anticancer, other	Cancer, general
D-4418	8-Methoxyquinoline-5-[N-(2,5-dichloropyridin-3-yl)]carboxamide			Antlasthma	Asthma
DA-5018	Benzeneacetamide, 4-(2-aminoethoxy)-N-(3-(3,4-dimethylphenyl)propyl)-3-methoxy-, monohydrochloride [CAS]	174661-97-3	US 5242944	Analgesic, other	Pain, musculoskeletal
DA-6034			US 6025387	GI inflammatory/bowel disorders	Crohn's disease
DA-7867			KR 9957803	Antibacterial, other	Infection, general
DA-7911			KR 56034	Antiarthritic, other	Arthritis, rheumatoid
DA-8159	3-(1-Methyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo-[4,3-d]pyrimidin-5-yl)-N-[2-(1-methylpyrrolidin-2-yl)ethyl]-4-propoxybenzenesulfonamide		KR 353014	Male sexual dysfunction	Sexual dysfunction, male, general
Dacarbazine		4342-3-4			
Daclizumab		152923-56-3			
Dactinomycin		50-76-0			
dalbavancin	5,31-Dichloro-38-de(methoxycarbonyl)-7-demethyl-19-deoxy-56-O-[2-deoxy-2-(10-methylundecanamido)-β-D-glucopyranosyl]-38-[N-[3-(dimethylamino)propyl]carbamoyl]-42-O-Alpha-D-mannopyranosyl-N15-methylristomycin A aglycone	171500-79-1 112362-50-2		Peptide antibiotic	Infection, dermatological
Dalfopristin					

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
dalfopristin + quinupristin	Virginiamycin M1, 26-((2-(diethylamino)ethyl)sulfonyl)-26,27-dihydro-, (26R,27S)-, mixt with 4-(4-(dimethylamino)-N-methyl-L-phenylalanine)-5-(5-((1-azabicyclo(2.2.2)oct-3-ylthio)methyl)-4-oxo-L-2-piperidinecarboxylic acid) virginiamycin S1- [CAS]	126602-89-9	EP 248703	Antibiotic, other	Infection, respiratory tract, general
dalteparin	Heparin-, [CAS]	9041-08-1	US 4303651	Anticoagulant	Thromboprophylaxis
Daltroban		79094-20-5			
d-Aminolevulinic Acid		106-60-5			
danaparoid			EP 66908	Anticoagulant	Thrombosis, venous
danazol	Pregna-2,4-dien-20-yno[2,3-d]isoxazol-17-ol, (17Alpha)- [CAS]	17230-88-5	GB 905844	Menstruation disorders	
Danthron		117-10-2			
Dantrolene		7261-97-4			
dapiprazole	1,2,4-Triazolo[4,3-a]pyridine, 5,6,7,8-tetrahydro-3-[2-[4-(2-methylphenyl)-1-piperazinyl]ethyl]- [CAS]	72822-12-9 72822-13-0	US 4252721	Ophthalmological	Glaucoma
dapivirine	4-[[4-(2,4,6-trimethylphenyl)amino]pyrimidin-2-yl]amino]benzonitrile	244767-67-7		Antiviral, anti-HIV	Infection, HIV/AIDS
dapoxetine	(+)-(S)-N,N-dimethyl-Alpha-[2-(1-naphthyl-oxy)ethyl]benzylamine HCl	119356-77-3	EP 288188	Male sexual dysfunction	Premature ejaculation
dapsone	4,4'-Sulfonyldianiline	80-08-0		Formulation, dermal, topical	Acne
daptomycin	Daptomycin [CAS]	103060-53-3	EP 178152	Peptide antibiotic	Infection, dermatological
Darbepoetin Alfa					
darifenacin	3-Pyrrolidineacetamide, 1-[2-(2,3-dihydro-5-benzofuranyl)ethyl]-Alpha,Alpha-diphenyl-, (S)- [CAS]	133099-04-4	EP 388054	Urological	Overactive bladder
daunorubicin	5,12-Naphthacenedione, 8-acetyl-10-[(3-amino-2,3,6-trideoxy-Alpha-L-lyxohexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S-cis)- [CAS]	20830-81-3	US 5441745	Formulation, optimized, liposomes	Cancer, sarcoma, Kaposi's

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
DAX, SciClone	3-diallyl-8-cyclohexylxanthine			Cystic fibrosis treatment	Cystic fibrosis
DB-67	7-tert-Butyldimethylsilyl-10-hydroxycamptothecin			Anticancer, other	Cancer, general
d-Camphocarboxylic Acid		18530-30-8			
DCF-987	Dextran		US 5514665	Formulation, other	Cystic fibrosis
DDT		50-29-3			
Deaminoxyclofen		113-78-0			
Deanol		108-01-0			
Debrisoquin		1131-64-2			
Decamethonium		541-22-0			
Declmethide		14817-09-5			
dectabine	1,3,5-Triazin-2(1H)-one, 4-amino-1-(2-deoxy-β-D-erythro-pentofuranosyl)-[CAS]	23339-46-0 2353-33-5		Anticancer, antimetabolite	Myelodysplastic syndrome
declopramide	Benzamide, 4-amino-3-chloro-N-(2-(diethylamino)ethyl)- [CAS]	891-60-1	WO 9732582	Anticancer, other	Cancer, colorectal
Deferiprone		30652-11-0			
Deferoxamine		70-51-9			
deflazacort	5'H-Pregna-1,4-dieno[17,16-d]oxazole-3,20-dione, 21-(acetyloxy)-11-hydroxy-2'-methyl-, (11β,16β)- [CAS]	14484-47-0 74712-90-6	GB 1077393	Hormone	Asthma
Defosamide		3733-81-1			
degarelix	N-acetyl-3-(naphthalen-2-yl)-D-alanyl-4-chloro-D-phenylalanyl-3-(pyridin-3-yl)-D-alanyl-L-seryl-4-[[[(4S)-2,6-dioxahexahydropyrimidin-4-yl]carbonyl]amino]-L-phenylalanyl-4-(carbamoylamino)-D-phenylalanyl-L-leucyl-N6-(1-methylethyl)-L-lysyl-L-prolyl-D-alaninamide	214766-78-6		Anticancer, hormonal	Cancer, prostate
dehydroascorbic acid	L-threo-2,3-Hexodiolulosonic acid gamma-lactone	490-83-5		Cognition enhancer	Alzheimer's disease
Dehydrocholic Acid		81-23-2			
Dehydroemetine		4914-30-1			

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
delapril	Glycine, N-(2,3-dihydro-1H-inden-2-yl)-N-[N-[1-(ethoxycarbonyl)-3-phenylpropyl]-L-alanyl]-, (S)- [CAS]	83435-66-9 83435-67-0	EP 51391	Antihypertensive, renin system	Hypertension, general
delapril+manidipine	Glycine, N-(2,3-dihydro-1H-inden-2-yl)-N-[N-[1-(ethoxycarbonyl)-3-phenylpropyl]-L-alanyl]-, (S)-3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-[4-(diphenylmethyl)-1-piperazinyl]ethyl methyl ester [CAS]		FR 2733911	Formulation, fixed-dose combinations	Hypertension, general
delavirdine	Piperazine, 1-[3-[(1-methylethyl)amino]-2-pyridinyl]-4-[[5-[(methylsulfonyl)amino]-1H-indol-2-yl]carbonyl]- [CAS]	136817-59-9 13698-49-2 79874-76-3	WO 9109849	Antiviral, anti-HIV	Infection, HIV/AIDS
Delmadinone					
Delmopinol	2H-1,4-Benzodiazepin-2-one, 7-chloro-5-(2-chlorophenyl)-1,3-dihydro- [CAS]	2894-67-9	CH 408029	Anxiolytic	
delorazepam	3,3-Bis-(m-fluorophenyl)-N-methylpropylamine [CAS]	186495-99-8 6909-62-2 56-94-0		Neuroprotective	Ischaemia, cerebral
demecarium					
demeclocycline	2-Naphthacene-carboxamide, 7-chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-1,1,1-dioxo-, [4S-(4Alpha,4aAlpha,5aAlpha,6Beta,12aAlpha)]-[CAS]	127-33-3 477-30-5 10116-22-0 24701-51-7		Formulation, modified-release, <=24hr	Infection, general
Demecolcine					
Demegestone					
Demexiptiline					
denaverine	Benzeneacetic acid, Alpha-(2-ethylbutoxy)-Alpha-phenyl-, 2-(dimethylamino)ethyl ester, [CAS]	3321-06-0 173146-27-5 71771-90-9 22006-84-4	DE 4133785	Analgesic, NSAID	Pain, musculoskeletal
Denileukin Difitox					
Denopamine					
Denopterin					



API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Deoxycholic Acid		83-44-3			
Deoxycorticosterone		64-85-7 47-3	56-		
Deoxydihydrostreptomycin		26086-49-7			
Deoxyepinephrine		501-15-5			
Depreotide		161982-62-3			
depsipeptide	L-Valine, N-[(3S,4E)-3-hydroxy-7-mercapto-1-oxo-4-heptenyl]-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoyl-, (4-1)-lactone, cyclic (1-2)-disulfide [CAS]	128517-07-7	EP 352646	Anticancer, antibiotic	Cancer, general
Deptropine		604-51-3			
Dequalinium		522-51-0			
dersalazine	Benzoic acid, 2-hydroxy-5-[[4-[3-[4-(2-methyl-1H-imidazol[4,5-c]pyridin-1-yl)methyl]-1-piperidinyl]-3-oxo-1-phenyl-1-propenyl]phenyl]azo] (Z) [CAS]	188913-57-7 188913-58-8	US 5747477	Anti-inflammatory	Colitis, ulcerative
Deserpidine		131-01-1			
desferrioxamine	Butanediamide, N'-[5-[[4-[[5-(acetylhydroxyamino)pentyl]amino]-1,4-dioxobutyl]hydroxyamino]pentyl]-N-(5-aminopentyl)-N-hydroxy- [CAS]	70-51-9		Antidote	Poisoning, metal
Desflurane		57041-67-5			
Desipramine		50-47-5			
Deslanoside		17598-65-1			
desloratadine	5H-Benzo(5,6)cyclohepta(1,2-b)pyridine, 8-chloro-6,11-dihydro-11-(4-piperidinylidene)- [CAS]	100643-71-8	US 5595997	Antiallergic, non-asthma	Rhinitis, allergic, perennial
deslorelin	Luteinizing hormone-releasing factor (pig), 6-D-tryptophan-9-(N-ethyl-L-prolinamide)-10-deglycinamide- [CAS]	57773-65-6	US 4034082	Releasing hormones	Cancer, prostate
desmopressin	Vasopressin, 1-(3-mercaptopropanoic acid)-8-D-arginine- [CAS]	16679-58-6	DE 2948345	Hormone	Enuresis
Desogestrel		54024-22-5			
desogestrel + estradiol	Estra-1,3,5(10)-triene-3,17-diol (17 $\beta$ )-, mixt. with (17 $\alpha$ )-13-ethyl-11-methylene-18,19-dinorpregn-4-en-20-yn-17-ol [CAS]	122364-17-4		Menopausal disorders	Hormone replacement therapy

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
desogestrel, Akzo Nobel	18,19-Dinorpregn-4-en-20-yn-17-ol, 13-ethyl-11-methylene-, (17Alpha)- [CAS]	54024-55-5		Formulation, oral, other	Contraceptive, female
desogestrel+ethinylestrad (1)	18,19-Dinorpregn-4-en-20-yn-17-ol, 13-ethyl-11-methylene-, (17Alpha)- [CAS]	54024-22-5 71138-35-7	US 3927046	Formulation, oral, other	Contraceptive, female
Desomorphine		427-00-9			
Desonide		638-94-8			
Desoximetasone		382-67-2			
Detaxtran		9015-73-0			
Devacade			WO 9308176	Analgescic, other	Pain, general
dexamethasone	Pregna-1,4-diene-3,20-dione,9-fluoro-11,17,21-trihydroxy-16-methyl-, (11β,16Alpha)- [CAS]	50-02-2 2392-39-4 312-93-6		Formulation, other	Inflammation, ocular
dexanabinol	6H-Dibenzo[b,d]pyran-9-methanol, 3-(1,1-dimethylheptyl)-6a,7,10,10a-tetrahydro-1-hydroxy-6,6-dimethyl-, (6aS-trans)- [CAS]	112924-45-5	EP 427518	Neuroprotective	Head trauma
dexecadotril	Glycine, N-[2-[(acetylthio)methyl]-1-oxo-3-phenylpropyl]-, phenylmethyl ester, (R)- [CAS]	112573-72-5	EP 318377	Alimentary/Metabolic, other	Unspecified
dexefaroxan	1H-Imidazole, 2-(2-ethyl-2,3-dihydro-2-benzofuranyl)-4,5-dihydro- [CAS]	89197-00-2 89197-32-0	EP 71368	Cognition enhancer	Alzheimer's disease
Dexetilimide		21888-98-2			
dexibuprofen	Benzeneacetic acid, Alpha-methyl-4-(2-methylpropyl)-, (AlphaS)- [CAS]	51146-56-6		Analgesic, NSAID	Pain, general
dexketoprofen	Benzeneacetic acid, 3-benzoyl-Alpha-methyl-, (S)- [CAS]	22161-81-5		Anti-inflammatory	Inflammation, general
dexloxiglumide	Pentanoic acid, 4-[(3,4-dichlorobenzoyl)amino]-5-[(3-methoxypropyl)pentylamino]-5-oxo-, (R)- [CAS]	119817-90-2	EP 0344184	GI Inflammatory/bowel disorders	Iritable bowel syndrome
dexmedetomidine	1H-Imidazole, 4-[1-(2,3-dimethylphenyl)ethyl]-, (R)- [CAS]	113775-47-6 86347-15-1	EP 187471	Hypnotic/Sedative	Anaesthesia
dexmethyphenidate	2-Piperidineacetic acid, Alpha-phenyl-, methyl ester, (AlphaR,2R)-	19262-68-1		Psychostimulant	Attention deficit disorder
Dexpanthenol		81-13-0			
dexrazoxane	2,6-Piperazinedione, 4,4'-(1-methyl-1,2-ethanediy)bis-, (S)- [CAS]	24584-09-6	DE 1910283	Radio/chemoprotective	Chemotherapy-induced injury, general

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Dextran-1	Dextran [CAS]	9004-54-0		Plasma substitute	
Dextranomer		56087-11-7			
Dextroamphetamine		51-64-9			
dextromethorphan	Morphinan, 3-methoxy-17-methyl-, (9Alpha,13Alpha,14Alpha)-,	6700-34-1			
Dextromoramide	(9Alpha,13Alpha,14Alpha)-,	125-71-3	US 4221788	Formulation, oral, other	Cough, Emotional lability
		357-56-2			
	Benzeneethanol, Alpha-[2-(dimethylamino)-1-methylethyl]-Alpha-phenyl-, propanoate (ester), [S-(R*,S*)]- [CAS]				
dextropropoxyphene		469-62-5		Formulation, modified-release, other	Pain, general
Dezocine		53648-55-8			
DF-1012	N-Tropyl 7-azaindol-3-ylcarboxamide	163220-65-3	WO 9504742	Respiratory	Respiratory disease, general
DFA-IV	di-D-fructofuranose 2,6':6,2' dianhydride				
d-Fenchone		4695-62-9	US 5700832	Antianaemic	Anaemia, aplastic
D-Glucuronolactone		32449-92-6			
Diab II	Diab II	309956-85-2	US 6153632	Antidiabetic	Diabetes, Type II
diacerein	2-Anthracenecarboxylic acid, 4,5-bis(acetyloxy)-9,10-dihydro-9,10-dioxo-[CAS]	13739-02-1	US 4244968	Antiarthritic, other	Arthritis, rheumatoid
Diampromide		552-25-0			
Diamthazole		136-96-9			
Diathymosulfone		5964-62-5			
Diatrizoate		737-31-5			
diazepam	2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-1-methyl-5-phenyl- [CAS]	439-14-5		Formulation, transmucosal, systemic	Anxiety, epilepsy, general
Diaziquone		57998-68-2			
Diazoxide		364-98-7			
dibekacin	D-Streptamine, O-3-amino-3-deoxy-Alpha-D-glucopyranosyl-(1-6)-O-[2,6-diamino-2,3,4,6-tetra-deoxy-Alpha-D-erythro-hexopyranosyl-(1-4)]-2-deoxy-, sulfate (salt)[CAS]	34493-98-6	GB 1349302	Aminoglycoside antibiotic	Infection, general
Dibenzepin		58580-55-5			
		4498-32-2			

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Dibromopropamide		496-00-4			
Dibucaine		61-12-1			
Dichloralphenazone		480-30-8			
Dichloramine T		473-34-7			
Dichlorisone		7008-26-6			
Dichlorobenzyl Alcohol		1777-82-8			
Dichlorophen		97-23-4			
Dichlorophenarsine		536-29-8			
Dichlorophenamide		120-97-8			
diclofenac + HA	Hyaluronic acid + benzeneacetic acid, 2- [[2,6-dichlorophenyl]amino]- [CAS]			Formulation, transdermal, systemic	Keratosis
diclofenac	Benzeneacetic acid, 2-[(2,6- dichlorophenyl)amino]-, [CAS]	15307-79-6 15307-86-5 15307-81-0		Formulation, modified-release, <=24hr	Pain, general
Dicloxacillin		3116-76-5			
Dicumarol		66-76-2			
Dicyclomine		77-19-0			
didanosine	Inosine, 2',3'-dideoxy- [CAS]	69655-05-6	US 4861759	Antiviral, anti-HIV	Infection, HIV/AIDS
Dideoxyadenosine		4097-22-7			
didox	Benzamide, N,3,4-trihydroxy- [CAS]	69839-83-4	US 4263322	Anticancer, antimetabolite	Cancer, general
Dienestrol		84-17-3			
dienogest	19-Norpregna-4,9-diene-21-nitrile, 17- hydroxy-3-oxo-, (17Alpha)- [CAS]	65928-58-7	GB 1524917	Menstruation disorders	Endometriosis
dienogest+estradiol	19-Norpregna-4,9-diene-21-nitrile, 17- hydroxy-3-oxo-, (17Alpha) + Estra-1,3,5(10)- triene-3,17-diol(17B)			Formulation, fixed-dose combinations	Contraceptive, female
Diethadione		702-54-5			
Diethazine		60-91-3			
Diethylbromoacetamide		511-70-6			
Diethylcarbamazine		90-89-1			
diethylpropion	1-Propanone, 2-(diethylamino)-1-phenyl- [CAS]	90-84-6		Formulation, modified-release, <=24hr	Obesity
Diethylstilbestrol		56-53-1			
Difemerine		80387-96-8			

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Difenamizole		20170-20-1			
Difenoxin		28782-42-5			
Difenpiramide		51484-40-3			
	(5R)-5-Ethyl-9,10-difluoro-1,4,5,13-tetrahydro-5-hydroxy-3H,15H-oxepino[3',4':6,indolizino[1,2-b]quinoline-3,15-dione				
diflomotecan		220997-97-7		Anticancer, other	Cancer, general
diflorasone	Pregna-1,4-diene-3,20-dione, 17,21-bis(acetyloxy)-6,9-difluoro-11-hydroxy-16-methyl-, (6Alpha,11Beta,16Beta)- [CAS]	33564-31-7 2557-49-5	US 3980778	Antipsoriasis	
Difloxacin		98106-17-3			
Difluocortolone		2607-6-9			
diflunisal	2',4'-difluoro-4-hydroxy[1,1'-biphenyl]-3-carboxylic acid	23674-86-4 22494-42-4	GB 1175212	Analgesic, NSAID	Pain, post-operative
Difluprednate		23674-86-4			
Digitalin		752-61-4			
Digitoxin		71-63-6			
digoxin	Card-20(22)-enolide, 3-[(O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy]-12,14-dihydroxy-, (3beta,5beta,12beta)- [CAS]	20830-75-5	US 4088750	Formulation, oral, enteric-coated	Heart failure
Dihexyverine		561-77-3			
Dihydralazine		484-23-1			
Dihydrocodeine		125-28-0			
Dihydrocodeinone Enol		466-90-0			
dihydroergocryptine	Ergocryptine, dihydro- [CAS]	25447-66-9		Formulation, other	Depression, general
dihydroergotamine	Ergotaman-3',6',18-trione, 9,10-dihydro-12'-hydroxy-2'-methyl-5'-(phenylmethyl)-, (5'Alpha,10Alpha)- [CAS]	511-12-6	6495535	Formulation, modified-release, other	Migraine
Dihydromorphine		509-60-4			
Dihydrostreptomycin		128-46-1			
Dihydrotachysterol		67-96-9			



API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Dihydroxyaluminum		13682-92-3 539-68-4			
Diisopromine		5966-41-6			
Diisopropyl Paraoxon		3254-66-8			
Diisopropylamine		660-27-5			
dilazep	Benzolic acid, 3,4,5-trimethoxy-, (tetrahydro-1H-1,4-diazepine-1,4(5H)-dilyl)di-3,1-propanediyl ester [CAS]	35898-87-4	JP 51095086	Vasodilator, coronary	
Dilevalol		75659-07-3			
difloxanide	2-Furancarboxylic acid, 4-[(dichloroacetyl)methylamino]phenyl ester [CAS]	3736-81-0 579-38-4		Amoebicide	
diltiazem	1,5-Benzothiazepin-4(5H)-one, 3-(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-, (2S-cis)- [CAS]	33286-22-5 42399-41-7	US 4721619 US 5529791 EP 322277	Antianginal	Angina, hypertension, general
Dimecrotic Acid		7706-67-4			
Dimefline		1165-48-6			
Dimemorfan		36309-01-0			
Dimenhydrinate		523-87-5			
Dimenoxadol		509-78-4			
Dimepheptanol		545-90-4			
Dimercaprol		59-52-9			
Dimetacrine		4757-55-5			
Dimethadione		695-53-4			
Dimethazan		519-30-2			
Dimethindene		5636-83-9			
Dimethisoquin		86-80-6			
Dimethisterone		79-64-1			
Dimethocaine		94-15-5			
Dimethoxanate		477-93-0			
Dimethyl Sulfoxide		67-68-5			
Dimethylthiambutene		524-84-5			
Dimetofrine		22950-29-4			
Dimorpholamine		119-48-2			

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
dinoprostone	Prosta-5,13-dien-1-olc acid, 11,15-dihydroxy-9-oxo-, (5Z,11Alpha,13E,15S)-[CAS]	363-24-6			Formulation, modified-release, <=24hr	Labour, induction
diosmectite	Smecta- [CAS]	110070-78-5	FR	2770778	Antidiarrhoeal	Diarrhoea, general
diosmin	4H-1-Benzopyran-4-one, 7-[[6-O-(6-deoxy-Alpha-L-mannopyranosyl)-beta.-D-glucopyranosyl]oxy]-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)- [CAS]	520-27-4	DE	2602314	Vasoprotective, systemic	
Dioxadrol		6495-46-1				
Dioxaphetyl		467-86-7				
Dioxethedrine		497-75-6				
Dioxybenzone		131-53-3				
Diphe-manil		62-97-5				
Diphenadione		82-66-6				
Diphenacyprone		886-38-4				
Diphenhydramine		58-73-1				
Diphenidol		972-02-1				
Diphenoxylate		915-30-0				
Diphenylpyraline		147-20-6				
Diphetarson		515-76-4				
Diphtheria & Tetanus Toxoids And Acellular Pertussis Vaccine Adsorbed						
Dipipanone		467-83-4				
dipivefrin	Propanoic acid, 2,2-dimethyl-, 4-[1-hydroxy-2-(methylamino)ethyl]-1,2-phenylene ester, (+/-)- [CAS]	52365-63-6	US	3809714	Antiglaucoma	Glaucoma
Dipyridamole		58-32-2				
Dipyrocetyl		486-79-3				
Dipyrone		5907-38-0				
diquafosol	Uridine 5'-(pentahydrogen tetraphosphate)-5'-ester with uridine, [CAS]	211427-08-6			Ophthalmological	Dry eye syndrome

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
dirithromycin	Erythromycin, 9-deoxy-11-deoxy-9,11-[imino[2-(2-methoxyethoxy)ethylidene]oxy]-, [9S(R)]- [CAS]	62013-04-1	DE 2515075	Macrolide antibiotic	Tonsillitis
disodium pamidronate	Phosphonic acid, (3-amino-1-hydroxypropylidene)bis-, disodium salt [CAS]	57248-88-1	EP 177443	Osteoporosis treatment	Hypercalcaemia of malignancy
Disofenin		65717-97-7			
disopyramide	2-Pyridineacetamide, Alpha-[2-bis(1-methylethyl)amino]ethyl]-Alpha-phenyl- [CAS]	3737-09-5		Formulation, modified-release, <=24hr	Arrhythmia, general
Distigmine		15876-67-2			
Disulfamide		671-88-5			
Disulfiram		97-77-8			
Ditazol		18471-20-0			
Dithiazanine		514-73-8			
dithranol	9(10H)-Anthracenone, 1,8-dihydroxy- [CAS]	1143-38-0		Formulation, dermal, topical	Psoriasis
Ditlocarb		148-18-5			
Dixanthogen		502-55-6			
Dixyrazine		2470-73-7			
DJ-927			WO 01027115	Anticancer, other	Cancer, general
DK-507k	(-)-7-[(7S)-7-Amino-5-azaspiro[2,4]heptan-5-yl]-6-fluoro-1-[(1R,2S)-2-fluoro-1-cyclopropyl]-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid hydrochloride monohydrate			Quinolone antibacterial	Infection, general
DL-Lactic Acid		598-82-3			
DMDC	Cytidine, 2'-deoxy-2'-methylene-, monohydrochloride [CAS]	113648-25-2	WO 8807049	Anticancer, antimetabolite	Cancer, general
DMXAA	5,6-dimethylxanthenone-4-acetic acid			Anticancer, other	Cancer, lung, general
DNA Stealth Nucleosides			US 6132776	Antiviral, anti-HIV	Infection, HIV/AIDS
Dobesilate		20123-80-2			

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
dobutamine	1,2-Benzenediol, 4-[2-[[3-(4-hydroxyphenyl)-1-methylpropyl]amino]ethyl]-, (+/-)- [CAS]	34368-04-2 49745-95-1	US 3987200	Cardio stimulant	
Docarpamine		74639-40-0			
	(2R,3S)-N-Carboxy-3-phenylisoserine, N-tert-butyl ester, 13-ester with 5β,20-epoxy-1,2Alpha,4,7β,10β,13Alpha-hexahydroxytax-11-en-9-one 4-acetate 2-benzoate- [CAS]	114977-28-5 148408-66-6	EP 253738 EP 707487	Anticancer, other Hypolipaeimic/Antiatherosclerosis	Cancer, breast Hyperlipidaemia, general
docetaxel					
docosaheptaenoic acid					
docosanol	1-Docosanol [CAS]	661-19-8 128-49-4 577-11-7	EP 469064 US 4752617	Antiviral, other Formulation, dermal, topical	Infection, herpes simplex virus Infection, herpes simplex virus prophylaxis
docusate					
dofetilide	Methanesulfonamide, N-[4-[2-[methyl[2-[(methanesulfonyl)amino]phenoxy]ethyl]amino]ethyl]phenyl]- [CAS]	115256-11-6	EP 245997	Antiarrhythmic	Fibrillation, atrial
	1H-Indole-3-carboxylic acid, octahydro-3-oxo-2,6-methano-2H-quinolizin-8-yl ester, (2Alpha,6Alpha,8Alpha,9Alphaβ)-, monomethanesulfonate- [CAS]	115956-13-3 115956-12-2 61869-07-6	EP 266730	Antiemetic	Chemotherapy-induced nausea and vomiting
dolasetron mesilate					
Domiodol		538-71-6			
Domiphen		112966-96-8			
Domitroban					
	2H-Benzimidazol-2-one, 5-chloro-1-[1-[3-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)propyl]-4-piperidinyl]-1,3-dihydro- [CAS]	57808-66-9	US 4066772	Antiemetic	
domperidone	1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-((1-(phenylmethyl)-4-piperidinyl)methyl)-, [CAS]	120011-70-3 120014-06-4	EP 296560	Cognition enhancer	Alzheimer's disease
donepezil					
	Piperazine, 1-(((3-(2-aminoethyl)-1H-indol-5-yl)oxy)acetyl)-4-(4-cyanophenyl)- [CAS]	170912-52-4 51-61-6		Antimigraine	Migraine
donitriptan					
Dopamine					
Dopexamine		86197-47-9			

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
doramipimod	urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[4-[2-(4-morpholinyl)ethoxy]-1-naphthalenyl]-	285983-48-4		Antiarthritic, immunological	Arthritis, rheumatoid
doranidazole	(±)-1,2,4-Butanetriol, 3-((2-nitro-1H-imidazol-1-yl)methoxy)- [CAS]	137339-64-1	WO 9414778	Radio/chemosensitizer	Surgery adjunct
doripenem	(1R,5S,6S)-2-[(3S,5S)-5-(sulfamoylaminoethyl)pyrrolidin-3-yl]thio-6-[[[(1R)-1-hydroxyethyl]-1-methylcarbapen-2-em-3-carboxylic acid]	148016-81-3	EP 528678	Beta-lactam antibiotic	Infection, urinary tract
dorzolamide	4H-Thieno(2,3-b)thiopyran-2-sulfonamide, 4-(ethylamino)-5,6-dihydro-6-methyl-, 7,7-dioxide (4S-trans)- [CAS]	120279-96-1	EP 296879	Antiglaucoma	Glaucoma
dorzolamide + timolol	4H-Thieno(2,3-b)thiopyran-2-sulfonamide, 4-(ethylamino)-5,6-dihydro-6-methyl-, 7,7-dioxide (4S-trans) + ethyl 2-propanol, 1-dioxide [[[(1,1-dimethylamino)-3-[[4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl]oxy]-, (S), (Z)-2-butenedioate (1:1) (salt) [CAS]	120279-96-1 26839-75-8 26921-17-5		Formulation, fixed-dose combinations	Glaucoma
dosmalfate	Aluminium, (μ7-(7-((6-O-(6-deoxy-2,3,4-tri-O-sulfo-Alpha-L-mannosylpyranosyl)-2,3,4-tri-O-sulfo-β-D-glucopyranosyl)oxy)-5-hydroxy-2-(4-methoxy-3-(sulfooxy)phenyl-4H-1-benzopyran-4-onato(7-)))tetradeca-μ-hydroxyhenicosahydroxytetradeca- [CAS]	122312-55-4		Antilulcer	Ulcer, gastric
dosulepine	1-Propanamine, 3-dibenzo[b,e]thiepin-11(6H)-ylidene-N,N-dimethyl-, [CAS]	113-53-1		Antidepressant	
Dotarizine		84625-59-2			
Dothiepin		113-53-1			
Doxacurium		106819-53-8			
Doxapram		309-29-5			



API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
doxazosin	Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-[(2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl]- [CAS]	74191-85-8	GB 2007656	Antihypertensive, adrenergic	Hypertension, general
Doxefazepam		40762-15-0			
Doxenitoin		3254-93-1			
doxepin	1-Propanamine, 3-dibenz[b,e]oxepin-11(6H)ylidene-N,N-dimethyl-	1668-19-5		Formulation, dermal, topical	Pruritus
doxercalciferol	9,10-secoergosta-5,7,10(19),22-tetraene-1,3-diol (1Alpha, 3B, 5Z, 7E, 22E) [CAS]	54573-75-0	US 5104854	Hormone	Hyperparathyroidism
doxifluridine	Uridine, 5'-deoxy-5-fluoro- [CAS]	3094-09-5	US 4071680	Anticancer, antimetabolite	Cancer, colorectal
doxofylline	1H-Purine-2,6-dione, 7-(1,3-dioxolan-2-ylmethyl)-3,7-dihydro-1,3-dimethyl-[CAS]	69975-86-6	US 4187308	Antiasthma	Asthma
doxorubicin	5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-Alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)- [CAS]	23214-92-8	EP 191824	Formulation, optimized, liposomes	Cancer, general
doxycycline	2-Naphthacenecarboxamine, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-[4S-(4Alpha,4aAlpha,5Alpha,5aAlpha,6Alpha,12aAlpha)]- [CAS]	564-25-0 17086-28-1		Formulation, modified-release, immediate	Periodontitis
doxylamine	N,N-Dimethyl-2-[1-phenyl-1-(2-pyridinyl)ethoxy]ethanamine	469-21-6		Formulation, transmucosal, systemic	Rhinitis, allergic, general
DPC-817	B-D-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine			Antiviral, anti-HIV	Infection, HIV/AIDS
DPI-3290			US 5681830	Analgesic, other	Pain, general

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
DQ-113	5-Amino-7-[(3S,4R)-(1-aminocyclopropyl)-3-fluoropyrrolidin-1-yl]-1-[(1R,2S)-2-fluoro-1-cyclopropyl]-1,4-dihydro-8-methyl-4-oxo-3-quinolinecarboxylic acid			Quinolone antibacterial	Infection, general
Drofenine		1679-76-1			
Droloxifene		82413-20-5			
Drometizole		2440-22-4			
Dromostanolone		58-19-5			
dronabinol	6H-Dibenzo[b,d]pyran-1-ol, 6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-, (6aR-trans)- [CAS]	1972-08-3		Antiemetic	Chemotherapy-induced nausea and vomiting
dronedarone	2-n-Butyl 3-[4-(3-di-n-butylamino-propoxy)benzoyl]5-methylsulfonamidobenzofuran			Antiarrhythmic	Arrhythmia, general
Droperidol		548-73-2			
Droperilamine		57653-27-7			
Dropropizine		17692-31-8			
Drospirenone		67392-87-4			
Drotaverine		14009-24-6			
Drotebanol		03/02/3176			
droxycam	2H,5H-1,3-Oxazino[5,6-c][1,2]benzothiazine-2,4(3H)-dione, 5-methyl-3-(2-pyridinyl)-, 6,6-dioxide [CAS]	90101-16-9	EP 99770	Anti-inflammatory	Inflammation, general
droxidopa	L-Tyrosine, β,3,3-dihydroxy-, threo- [CAS]	23651-95-8	EP 128684	Antiparkinsonian	Parkinson's disease
Droxidopa		23651-95-8			
DU-125530	1,2-Benzisothiazol-3(2H)-one, 2-[4-(7-chloro-2,3-dihydro-1,4-benzodioxin-5-yl)-1-piperazinyl]butyl-, 1,1-dioxide [CAS]	161611-99-0	EP 633260	Anxiolytic	Anxiety, general
duloxetine	2-Thiophenepropanamine, N-methyl-Gamma-(1-naphthalenyloxy)-, hydrochloride, (S)- [CAS]	136434-34-9 116539-59-4	US 5362886	Antidepressant	Depression, general

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
duramycin			WO 9428726	Formulation, inhalable, solution	Cystic fibrosis
Durapatite		1306-06-5			
dutasteride	4-Azaandrost-1-ene-17-carboxamide, N-(2,5-bis(trifluoromethyl)phenyl)-3-oxo-, (5Alpha,17beta)- [CAS]	164656-23-9	US 5565467	Prostate disorders	Benign prostatic hyperplasia
DW-1141	N,N-dilisopropyl-4-[4-(3-aminobenzo[d]isoxazol-6-yloxy)butoxy]-3-methoxybenzamide			Osteoporosis treatment	Osteoporosis
DW-286a	(R)-(-)-7-((4-aminomethyl-4-methyl-3-(Z)-methyloxyimino)pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro[1,8]naphthyridine-3-carboxylic acid			Quinolone antibacterial	Infection, general
DW-471			US 5922871	Antiviral, other	Infection, hepatitis-B virus
DX-9065a	2-Naphthalenepropanoic acid, 7-(aminoliminomethyl)-Alpha-[4-[[1-(1-iminoethyl)-3-pyrrolidinyloxy]phenyl]-, monohydrochloride, pentahydrate, [S-(R*,R*)]- [CAS]	155204-81-2		Antithrombotic	Thrombosis, general
DY-9760e	1H-Indazole, 3-[2-[4-(3-chloro-2-methylphenyl)-1-piperazinylethyl]-1-(1H-imidazol-4-yl)methyl]-5,6-dimethoxy- [CAS]	160522-00-9	US 5681954	Neuroprotective	Ischaemia, cerebral
Dyclonine		586-60-7			
Dydrogesterone		152-62-5			
Dymanthine		124-28-7			
Dyphylline		479-18-5			
E-1010	1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 6-[[1(R)-1-hydroxyethyl]-3-[[[(3S,5S)-5-[(R)-hydroxy(3R)-3-pyrrolidinymethyl]-3-pyrrolidiny]thio]-4-methyl-7-oxo-, monohydrochloride, (4R,5S,6S)- [CAS]	186319-97-1		Beta-lactam antibiotic	Infection, general

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
E-2101	N-Ethyl-(1-[1-(2-fluorophenethyl)piperidin-4-yl]-1H-indol-6-yl)acetamide			Muscle relaxant	Muscle spasm, general
E2F antagonists			WO 9606943	Anticancer, other	Cancer, general
E-3620	Benzamide, 4-amino-5-chloro-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-2-[(1-methyl-2-butyryloxy]-, monohydrochloride, [3(S)-endo]- [CAS]	151213-86-4	EP 554794	Antacid/Antiflatulent	Dyspepsia
E-5564	Alpha-D-Glucopyranose, 3-O-decyl-2-deoxy-6-O-(2-deoxy-3-O-((3R)-3-methoxydecyl)-6-O-methyl-2-(((11Z)-1-oxo-11-octadeceny)amino)-4-O-phosphono-β-D-glucopyranosyl)-2-((1,3-dioxotetradecyl)amino)- 1-(dihydrogen phosphate), tetrasodium salt [CAS]	185954-98-7	EP 536969	Septic shock treatment	Sepsis
E-5842	Pyridine, 4-(4-fluorophenyl)-1,2,3,6-tetrahydro-1-[4-(1H-1,2,4-triazol-1-yl)butyl]-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) [CAS]	220120-14-9		Neuroleptic	Schizophrenia
E-6259	1-(4-Aminosulfonylphenyl)-5-(2,4-difluorophenyl)-4,5-dihydro-3-trifluoromethyl-1H-pyrazole			Antiarthritic, other	Unspecified
EAA-90	[2-(8,9-Dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)-ethyl]phosphonic acid			Analgesic, other	Pain, neuropathic
e-Acetamidocaproic Acid		57-08-9			
e-Aminocaproic Acid		60-32-2			
ebastine	1-Butanone, 1-[4-(1,1-dimethylethyl)phenyl]-4-[4-(diphenylmethoxy)-1-piperidinyl]- [CAS]	90729-43-4	EP 134124	Antiallergic, non-asthma	Rhinitis, allergic, seasonal
eberconazole	1H-Imidazole, 1-(2,4-dichloro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)- [CAS]	128326-82-9 130104-32-4	ES 2012297	Antifungal	Infection, dermatological

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
ebrotidine	Benzenesulfonamide, N-[[2-[[[2-[(aminomethyl)amino]-4-thiazolyl]methyl]thio]ethyl]amino]methylene]-4-bromo- [CAS]	100981-43-9	EP 159012	Antitumor	Ulcer, duodenal
ebrosen	1,2-Benzisoxazolin-3(2H)-one, 2-phenyl- [CAS]	60940-34-3	EP 44971	Neuroprotective	Haemorrhage, subarachnoid
Ebumamone		474-00-0			
Ecabapide		104775-36-2			
ecabet	1-Phenanthrenecarboxylic acid, 1,2,3,4,4a,9,10,10a-octahydro-1,4a-dimethyl-7-(1-methylethyl)-6-sulfo-, [1R-(1 $\alpha$ ,4 $\alpha$ ,10 $\alpha$ )]- [CAS]	33159-27-2 86408-72-2	DE 3239172	Antitumor	Ulcer, gastric
ecadotril	Glycine, N-[2-[(acetylthio)methyl]-1-oxo-3-phenylpropyl]-,phenylmethyl ester, (S)- [CAS]	112573-73-6	EP 318377	Antihypertensive, other	Hypertension, general
Ecgonidine		484-93-5			
Ecgonine		481-37-8			
Echothiophate		513-10-0			
Econazole		27220-47-9			
ecopipam	5H-Benzo[d]naphth[2,1-b]azepin-12-ol, 11-chloro-6,6a,7,8,9,13b-hexahydro-7-methyl-, (6aS-trans)- [CAS]	112108-01-7	EP 230270	Anorectic/Antiobesity	Obesity
ecraprost	Prosta-8,13-dien-1-oic acid, 11,15-dihydroxy-9-(1-oxobutoxy)-, butyl ester, (11 $\alpha$ ,13 $\alpha$ ,15 $\alpha$ )- [CAS]	136892-64-3	EP 423697	Vasodilator, peripheral	Peripheral vascular disease
Ectylurea		95-04-5			
ED-71	9,10-Secocholesta-5,7,10(19)-triene-1,3,25-triol, 2-(3-hydroxypropoxy)-, (1 $\alpha$ ,2 $\beta$ ,3 $\beta$ ,5Z,7E)- [CAS]	104121-92-8	EP 184206	Osteoporosis treatment	Osteoporosis
edaravone	3H-Pyrazol-3-one, 2,4-dihydro-5-methyl-2-phenyl- [CAS]	89-25-8	JP 62108814	Neuroprotective	Infarction, cerebral
Edatrexate		80576-83-6			
Edetate Calcium Disodium		62-33-9			
Edetate Disodium		139-33-3			
Edetate Sodium		64-02-8			
Edetate Trisodium		150-38-9			



API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
edonentan	Butanamide, N-[[2'-[4,5-dimethyl-3-isoxazolyl]amino]sulfonyl]-4-(2-oxazolyl)][1,1'-biphenyl]-2-yl[methyl]-N,3,3-trimethyl-, monohydrate	210891-04-6		Cardio stimulant	Heart failure
edotreotide	[N-[2-[4,7-Bis[(carboxy-kappaO)methyl]-10-(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl-kappaN1,kappaN4,kappaN10]acetyl]-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-threonyl-L-cysteinyl-L-threoninol cyclic (2-7)-disulfidato(3-)]yttrium	204318-14-9	US 6183721	Anticancer, hormonal	Cancer, lung, small cell
edoxudine	Uridine, 2'-deoxy-5-ethyl- [CAS]	15176-29-1	GB 1170565	Antiviral, other	Infection, herpes virus, general
Edrecolomab		156586-89-9			
Edrophonium		116-38-1			
Efalith	Butanedioic acid, lithium salt [CAS]	16090-09-8		Antipruritic/inflamm, allergic	Eczema, seborrheic
efaproxiral	Propanoic acid, 2-[4-{2-[(3,5-dimethylphenyl)amino]-2-oxoethyl]phenoxy}-2-methyl- [CAS]	131179-95-8	US 5705521	Radio/chemosensitizer	Cancer, brain
efavirenz	2H-3,1-Benzoxazin-2-one, 6-chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-, (S)- [CAS]	154598-52-4	WO 9403440	Antiviral, anti-HIV	Infection, HIV/AIDS
efletirizine	[2-[4-[Bis(p-fluorophenyl)methyl]-1-piperazinyl]ethoxy]acetic acid	150756-35-7	GB 2311940	Antiallergic, non-asthma	Allergy, general
eflornithine	DL-Ornithine, 2-(difluoromethyl)- [CAS]	70052-12-9	US 4413141	Protozoacide, dermal, topical	Infection, trypanosomiasis, African, Hirsutism
Eflorate		119-41-5			
eflucimibe	Benzeneacetamide, Alpha-(dodecylthio)-N-(4-hydroxy-2,3,5-trimethylphenyl)- (S)- [CAS]	202340-45-2		Hypoipaeamic/Antiatherosclerosis	Hyperlipidaemia, general
efonidipine	3-pyridinecarboxylic acid, 5-(5,5-dimethyl-1,3,2-dioxaphosphorinan-2-yl)-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-(phenyl(phenylmethyl)amino)ethyl ester, P-oxide [CAS]	111011-53-1 111011-63-3 111011-76-8	EP 230944	Antihypertensive, other	Hypertension, general

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
EGIS-7229	5-Chloro-4-[3-[N-[2-(3,4-dimethoxyphenyl)ethyl]-N-methylamino]propylamino]-3-(2H)-pyridazinone fumarate [CAS]	150800-12-7 190333-92-7	DE 4243381	Antiarrhythmic	Arrhythmia, general
eglumegad	Bicyclo[3.1.0]hexane-2,6-dicarboxylic acid, 2-amino-, (1S,2S,5R,6S)- [CAS]	176199-48-7 209216-09-1		Anxiolytic	Anxiety, general
egualen	1-Azulenenesulfonic acid, 3-ethyl-7-(1-methylethyl)-	97683-31-3 99287-30-6 10417-94-4	EP 147915	Antilulcer	Ulcer, gastric
Eicosapentaenoic Acid					
elarofiban	3-Pyridinepropanoic acid, $\beta$ -[[(3R)-1-[1-oxo-3-(4-piperidinyl)propyl]-3-piperidinyl]carbonyl]amino]-, ( $\beta$ S)- [CAS]	198958-88-2 60731-46-6 69-25-0	WO 9741102	Antithrombotic	Thrombosis, general
Elcatonin					
Elidoisin					
eletriptan	1H-Indole, 3-[(1-methyl-2-pyrrolidinyl)methyl]-5-(2-(phenylsulfonyl)ethyl)- (R)- [CAS]	143322-58-1 119413-55-7 476-66-4	US 5607951	Antimigraine	Migraine
Elgodipine		58337-35-2			
Ellagic Acid		98224-03-4			
Elliptinium					
Eltoprazine	$\beta$ -L-2',3'-Didehydro-2',3'-dideoxy-5-fluorocytidine	181785-84-2		Antiviral, other	Infection, hepatitis-B virus
elvucitabine	(2Z)-4-(3,4-dichlorophenyl)-2-[2-(4-methylpiperazin-1-yl)benzylidene]thiomorpholin-3-one monohydrochloride- [CAS]	220322-05-4 361343-20-6 550-24-3 3565-72-8		Antidepressant	Depression, general
elzasonan					
Embellin					
Embramine	1H-Benzimidazole, 1-(2-ethoxyethyl)-2-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-, (E)-2-butenedioate (1:2) [CAS]	87233-61-2 87233-62-3 3614-30-0 483-18-1 110690-43-2	EP 79545	Antiallergic, non-asthma	Rhinitis, allergic, general
emedastine					
Emepronium					
Emetine					
Emitetur					

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
EMM-210525	17Alpha-Acetoxy-6Alpha-methyl-19-nor-1 $\beta$ ,2 $\beta$ -dihydrocyclopropa[1,2]pregn-4-ene-3,20-dione+Estra-1,3,5(10)-triene-3,17-diol(17 $\beta$ )			Formulation, fixed-dose combinations	Hormone replacement therapy
Emodin		518-82-1			
emorfazone	3(2H)-Pyridazinone, 4-ethoxy-2-methyl-5-(4-morpholinyl)- [CAS]	38957-41-4	JP 7224030	Anti-inflammatory	
EMR-62203			WO 9806722	Male sexual dysfunction	Impotence
emtricitabine	2(1H)-Pyrimidinone, 4-amino-5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-, (2R-cis)- [CAS]	143491-57-0	WO 9214743	Antiviral, anti-HIV	Infection, HIV/AIDS
Emylcamate		78-28-4			
enalapril	L-Proline, 1-[N-[1-(ethoxycarbonyl)-3-phenylpropyl]-L-alanyl]-, (S)-, (Z)-2-butenedioate [CAS]	76095-16-4	US 4374829	Antihypertensive, renin system	
Enalaprilat		76420-72-9			
Enallypropymal		1861-21-8			
Encainide		66778-36-7			
Enciprazine		68576-86-3			
Endralazine		39715-02-1			
enfenamic acid	Benzoic acid, 2-[(2-phenylethyl)amino]- [CAS]	23049-93-6	IN 103066	Anti-inflammatory	
enflurane	Ethane, 2-chloro-1-(difluoromethoxy)-1,1,2-trifluoro- [CAS]	13838-16-9	US 3469011	Anaesthetic, inhalation	Anaesthesia
Enilconazole		35554-44-0			
Eniluracil		59989-18-3			
ENMD-0995	S-3-amino-phthalidoglutaramide		US 5712291	Anticancer, other	Cancer, myeloma
Enocitabine		55726-47-1			
Enol-3-IPA	1H-Indole-3-propanoic acid, Alpha-oxo- [CAS]	392-12-1	EP 106813	Hypnotic/Sedative	Insomnia
enoxacin	1,8-Naphthyridine-3-carboxylic acid, 1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)- [CAS]	74011-58-8	US 4359578	Quinolone antibacterial	Infection, general

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
enoxaparin	Heparin, [CAS]	9005-49-6 9041-08-1	EP 40144	Antithrombotic	Thrombosis, venous
enoximone	2H-Imidazol-2-one, 1,3-dihydro-4-methyl-5-[4-(methylthio)benzoyl]- [CAS]	77671-31-9	EP 59948	Cardio stimulant	Heart failure
Enoxolone		471-53-4			
enprostil	4,5-Heptadienoic acid, 7-[3-hydroxy-2-(3-hydroxy-4-phenoxy-1-butenyl)-5-oxocyclopentyl]-, methyl ester, [1Alpha,2Beta(1E,3R*),3Alpha]- [CAS]	73121-56-9	GB 2025431	Prostaglandin	Ulcer, duodenal
enrasentan	1H-Indene-2-carboxylic acid, 1-(1,3-benzodioxol-5-yl)-2,3-dihydro-3-(2-(2-hydroxyethoxy)-4-methoxyphenyl)-5-propoxy-, (1S-(1Alpha,2Beta,3Alpha))- [CAS]	167256-08-8	US 5817693	Antihypertensive, other	Hypertension, pulmonary
entacapone	2-Propenamide, 2-cyano-3-(4,5-dihydroxy-3-nitrophenyl)-N,N-diethyl- [CAS]	130929-57-6	EP 426468	Antiparkinsonian	Parkinson's disease
entecavir	6H-Purin-6-one, 2-amino-1,9-dihydro-9-((1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl)- [CAS]	142217-69-4	EP 481754	Antiviral, other	Infection, hepatitis-B virus
Enviomycin		33103-22-9			
epalrestat	3-Thiazolidineacetic acid, 5-(2-methyl-3-phenyl-2-propenylidene)-4-oxo-2-thioxo-, (E,E)- [CAS]	82159-09-9	EP 47109	Symptomatic antidiabetic	Neuropathy, diabetic
Epavir	L-lysine-cis-5,8,11,14,17-eicosapentanoate with L-lysine-cis-4,7,10,13,16,19-doahexanoate			Antiviral, other	Infection, herpes simplex virus
EPC-K1	L-ascorbic acid 2-[3,4-dihydro-2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-2H-1-benzopyran-6-yl]-hydrogen phosphate[potassium- [CAS]	127061-56-7	EP 127471	Neuroprotective	Infarction, cerebral
eperisone	1-Propanone, 1-(4-ethylphenyl)-2-methyl-3-(1-piperidinyl)- [CAS]	64840-90-0	US 3995047	Muscle relaxant	Spastic paralysis
eparvudine	Uridine, 2'-deoxy-5-(1-methylethyl)- [CAS]	60136-25-6	DE 2918260	Antiviral, other	Infection, herpes simplex virus
Ephedrine		299-42-3			
Epicillin		26774-90-3			

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Epimestrol		7004-98-0			
epinastine	1H-Dibenz[c,f]imidazo[1,5-a]azepin-3-amine, 9,13b-dihydro- [CAS]	80012-43-7	DE 3008944	Antialsthma	Asthma
epinephrine	(R)-4-[1-hydroxy-2-(methylamino)-ethyl]-1,2-benzenediol	51-43-4		Formulation, inhalable, dry powder	Anaphylaxis
Epirizole		18694-40-1			
	5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-Alpha-L-arabino-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)- [CAS]	56390-09-1 56420-45-2 2363-58-8	GB 1457632	Anticancer, antibiotic	
epirubicin					
Epitiosanol					
	Pregn-4-ene-7,21-dicarboxylic acid, 9,11-epoxy-17-hydroxy-3-oxo-,Gamma-lactone, methyl ester (7Alpha,11Alpha,17Alpha)-[CAS]	107724-20-9	EP 122232	Antihypertensive, diuretic	Hypertension, general
epiprenone					
	1-Propanone, 1-(2-fluorophenyl)-3-(4-hydroxyphenyl)-, O-(2-(dimethylamino)ethyl)oxime, (Z)-, (E)-2-butenedioate (2:1) (salt) [CAS]	130580-02-8	EP 373998	Anxiolytic	Schizophrenia
epilivanserlin					
	Prosta-5,13-dien-1-olc acid, 6,9-epoxy-11,15-dihydroxy-, (5Z,9Alpha,11Alpha,13E,15S)-[CAS]	35121-78-9 61849-14-7	DE 2720999	Prostaglandin	Hypertension, pulmonary
epoprostenol		80471-63-2			
Epostane		10402-90-1			
Eprazinone		119169-78-7			
Epristeride					
	3-[2-Butyl-1-(4-carboxybenzyl)-1H-imidazol-5-yl]-2-(2-thienylmethyl)-2-(E)-propenoic acid	133040-01-4 32665-36-4	EP 403159	Antihypertensive, renin system	Hypertension, general
eprosartan					
Eprozinol					
	4-methyl-2-[4-(4-(pyrimidin-2-yl)-piperazino)-butyl]-2H,4H-1,2,4-triazin-3,5-dione	179756-85-5		Antidepressant	Depression, general
eptapirone					



API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
eptaplatin	Platinum, [(4R,5R)-2-(1-methylethyl)-1,3-dioxolane-4,5-dimethanamine-kappaN4,kappaN5][propanedioato(2-)-kappaO1,kappaO3]-, (SP-4-2)- [CAS]	146665-77-2	WO 9216539	Anticancer, alkylating	Cancer, lung, small cell
Eptastigmine		101246-68-8			
eptazocine	1,6-Methano-1H-4-benzazonin-10-ol, 2,3,4,5,6,7-hexahydro-1,4-dimethyl-, (1S)- [CAS]	72522-13-5	US 4082744	Analgesic, other	
Eptifibatide		188627-80-7			
Equilenin		517-09-9			
Equilin		474-86-2			
ERA-923	ERA 923 [CAS]	352233-89-7	EP 802183	Female contraceptive	Contraceptive, female
erdosteine	Acetic acid, [(2-oxo-2-[(tetrahydro-2-oxo-3-thienyl)amino]ethyl]thio]- [CAS]	84611-23-4	EP 61386	Respiratory	Respiratory disease, general
Ergocornine		564-36-3			
Ergocorninine		564-37-4			
Ergoloid Mesylates		8067-24-1			
Ergonovine		60-79-7			
Ergosterol		57-87-4			
ergotamine	(5'Alpha)-12'-Hydroxy-2'methyl-(phenylmethyl)ergotaman-3',6', 18-trione	113-15-5		Formulation, inhalable, systemic	Migraine
Eritadenine		23918-98-1			
erlotinib	4-Quinazolinamine, N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-, monohydrochloride [CAS]	183319-69-9	WO 9630347	Anticancer, other	Cancer, lung, non-small cell
ertapenem	1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 3-[[[(3S,5S)-5-[[[(3-carboxyphenyl)amino]carbonyl]-3-pyrrolidinyl]thio]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-], [CAS]	153773-82-1 153832-46-3	WO 9315078	Beta-lactam antibiotic	Infection, GI tract
Erythrityl Tetranitrate		7297-25-8			
Erythrocentaurin		50276-98-7			
erythromycin acistrate	Erythromycin, 2'-acetate, octadecanoate (salt) [CAS]	96128-89-1	US 4599326	Macrolide antibiotic	Infection, general
Erythromycin Estolate		3521-62-8			

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Erythromycin Glucoheptonate		23067-13-2			
Erythromycin Lactobionate		3847-29-8			
Erythromycin Propionate		134-36-1			
Erythromycin Stearate		643-22-1			
erythromycin stinoprate	Erythromycin, 2'-propanoate, compd. with N-acetyl-L-cysteine (1:1) [CAS]	84252-03-9	EP 57489	Macrolide antibiotic	Infection, respiratory tract, lower
erythromycin	Erythromycin [CAS]	114-07-8		Formulation, dermal, topical	Acne
Erythrophleine		36150-73-9			
Esaprazole		64204-55-3			
escitalopram	5-Isobenzofurancarboxitrile, 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-, (S)- [CAS]	128196-01-0	EP 347066	Antidepressant	Depression, general
Esculin		531-75-9			
Eseridine		25573-43-7			
esmolol	Benzenepropanoic acid, 4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]-, methyl ester, (+/-)- [CAS]	81147-92-4	US 4387103	Antihypertensive, adrenergic	Tachycardia, supraventricular
esomeprazole	bis (5-methoxy-2-(((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)sulfinyl))-1H-benzimidazolato	161973-10-0	US 5877192	Antispasmodic	Gastro-oesophageal reflux
estazolam	4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-6-phenyl-[CAS]	29975-16-4	US 3987052	Hypnotic/Sedative	
estradiol	Androst-4-en-3-one, 17-hydroxy-, (17 $\beta$ )-[CAS]	58-22-0	US 5460820	Formulation, transdermal, patch	Sexual dysfunction, female
estradiol	Estra-1,3,5(10)-triene-3,17-diol (17 $\beta$ )-[CAS]	50-28-2	EP 430491	Formulation, transdermal, systemic	Menopausal symptoms, general
estramustine	Estra-1,3,5(10)-triene-3,17-diol (17 $\beta$ )-3-[bis(2-chloroethyl)carbamate] 17- [CAS]	2998-57-4 4891-15-0 52205-73-9		Anticancer, alkylating	Cancer, prostate
Estriol		50-27-1			
estrogen			WO 9924041	Menopausal disorders	Menopausal symptoms, general
Estrone		53-16-7			

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
eszopiclone	1-Piperazinecarboxylic acid, 4-methyl- 6-(5-chloro-2-pyridinyl)-6,7-dihydro-7-oxo-5H-pyrrolo(3,4-b)pyrazin-5-yl ester (S)- [CAS]	138729-47-2	US	5786357	Hypnotic/Sedative	Insomnia
Etafedrine		7681-79-0				
Etafenone		90-54-0				
Etamiphyllin		314-35-2				
Etanercept		185243-69-0				
Etanidazole		22668-01-5				
Etaqualone		7432-25-9				
Eterobarb		27511-99-5				
Ethacridine		442-16-0				
Ethacrynic Acid		58-54-8				
Ethadione		520-77-4				
Ethambutol		74-55-5				
Ethamivan		304-84-7				
Ethamsylate		2624-44-4				
Ethanolamine		141-43-5				
Ethaverine		486-47-5				
Ethchlorvynol		113-18-8				
Ethenzamide		938-73-8				
Ethiazide		1824-58-4				
Ethinamate		126-52-3				
Ethinyl Estradiol		57-63-6				
ethinyl estradiol	19-Norpregna-1,3,5(10)-trien-20-yne-3,17-diol, 3-(2-propanesulfonate), (17Alpha)-[CAS]	28913-23-7	DE	1949095	Formulation, modified-release, >24hr	Cancer, prostate
Ethionamide		536-33-4				
Ethisterone		434-03-7				
Ethioheptazine		77-15-6				
Ethopropazine		522-00-9				
Ethosuximide		77-67-8				
Ethotoin		86-35-1				
Ethoxzolamide		452-35-7				
Ethybenztropine		524-83-4				

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Ethyl Alcohol		64-17-5			
Ethyl Biscoumaracetate		548-00-5			
Ethyl Chloride		75-00-3			
Ethyl Dibunate		5560-69-0			
Ethyl Ether		60-29-7			
ethyl icosapentate	5,8,11,14,17-Eicosapentaenoic acid, ethyl ester, (all-Z)- [CAS]	86227-47-6	JP 61043143	Antithrombotic	Peripheral vascular disease
ethyl loflazepate	1H-1,4-Benzodiazepine-3-carboxylic acid, 7-chloro-5-(2-fluorophenyl)-2,3-dihydro-2-oxo-, ethyl ester [CAS]	29177-84-2	US 3657223	Anxiolytic	Anxiety, general
Ethyl Loflazepate		29177-84-2			
Ethylamine		75-04-7			
Ethylene		74-85-1			
Ethylestrenol		965-90-2			
Ethylidene Dicumaryl		1821-16-5			
Ethylmethythiambutene		441-61-2			
Ethylmorphine		76-58-4			
Ethynorepinephrine		536-24-3			
Ethynodiol		1231-93-2			
ethynylcytidine	Uridine, 3'-C-ethynyl- [CAS]	180300-49-6	WO 9618636	Anticancer, antimetabolite	Cancer, general
Etidocaline		36637-18-0			
etidronate	Phosphonic acid, (1-hydroxyethylidene)bis-, [CAS]	2809-21-4 7414-83-7	US 4137309	Osteoporosis treatment	Osteoporosis
Etidronic Acid		2809-21-4			
Etifelmin		341-00-4			
etifoxine	4H-3,1-Benzoxazin-2-amine, 6-chloro-N-ethyl-4-methyl-4-phenyl- [CAS]	21715-46-8	US 3725404	Anxiolytic	
Etilefrin		709-55-7			
etillevodopa	L-Tyrosine, 3-hydroxy-, ethyl ester [CAS]	37178-37-3	US 5354885	Antiparkinsonian	Parkinson's disease
etiprednol	androsta-1,4-diene-17-carboxylic acid, 17-[(dichloroacetyl)oxy]-11-hydroxy-3-oxo-, ethyl ester, (11 $\beta$ ,17 $\alpha$ )-	199331-40-3		GI inflammatory/bowel disorders	Crohn's disease
Etiroxate		17365-01-4			
Etizolam		40054-69-1			





API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Etoxadrol		28189-85-7			
Etozolin		73-09-6			
etretinate	2,4,6,8-Nonatetraenoic acid, 9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-, ethyl ester, (all-E)- [CAS]	54350-48-0	US 4215215	Antiporiasis	
Ethptamine		2235-90-7			
Etymemazine		523-54-6			
Eucatropine		100-91-4			
Eugenol		97-53-0			
EUK-134	Manganese, chloro[[2,2'-(1,2-ethanediyldis[(nitrilo-kappaN)methylidene]]bis(6-methoxyphenolato-kappaO)]]-, (SP-5-13)- [CAS]	81065-76-1	US 6046188	Cardiovascular	Unspecified
EUK-189			US 6046188	Radio/chemoprotective	Chemotherapy-induced injury, general
Evan's Blue		314-13-6			
everolimus	Rapamycin, 42-O-(2-hydroxyethyl)- [CAS]	159351-69-6	WO 9409010	Immunosuppressant	Transplant rejection, general
exalamide	Benzamide, 2-(hexyloxy)- [CAS]	53370-90-4	GB 726786	Antifungal	Infection, fungal, general
Exametazime		105613-48-7			
exatecan	10H,13H-Benzof[de]pyrano[3',4':6,7]indolizino[1,2-b]quinoline-10,13-dione, 1-amino-9-ethyl-5-fluoro-1,2,3,9,12,15-hexahydro-9-hydroxy-4-methyl-, (1S,9S)-, [CAS]	171335-80-1		Anticancer, other	Cancer, pancreatic
exemestane	Androsta-1,4-diene-3,17-dione, 6-methylene- [CAS]	107868-30-4	DE 3622841	Anticancer, hormonal	Cancer, breast
Exifone		52479-85-3			
exisulind	1H-Indene-3-acetic acid 5-fluoro-2-methyl-1-(((4-(methylsulfonyl)phenyl)methylene)-, (Z)- [CAS]	59973-80-7		Anticancer, other	Polyp
Exosurf®		99732-49-7			

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
ezetimibe	2-Azetidinone, 1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-, (3R,4S)- [CAS]	163222-33-1	US 5846966	Hypolipaeic/Antiatherosclerosis	Hypercholesterolaemia
Factor IX		9001-28-9			
Factor VIII		9001-27-8			
Factor XIII		9013-56-3			
fadolimide	1H-Inden-5-ol, 2,3-dihydro-3-(1H-imidazol-4-ylmethyl)-, monohydrochloride [CAS]	189353-32-0	WO 9712874	Analgesic, other	Pain, general
Fadrozole		102676-47-1			
falecalcitriol	9,10-Secocholesta-5,7,10(19)-triene-1,3,25-triol, 26,26,26,27,27,27-hexafluoro-, (1 $\alpha$ ,3 $\beta$ ,5 $\beta$ ,7E)- [CAS]	83805-11-2	JP 03099022	Osteoporosis treatment	Hyperparathyroidism
famciclovir	1,3-Propanediol, 2-[2-(2-amino-9H-purin-9-yl)ethyl]-, diacetate (ester)- [CAS]	104227-87-4	JP 61085388	Antiviral, other	Infection, gynaecological
famotidine	Propanimidamide, 3-[[[2-[(aminoiminomethyl)amino]-4-thiazolyl]methyl]thio]-N-(aminosulfonyl)- [CAS]	76824-35-6	US 4283408	Antilulcer	Ulcer, duodenal
fampridine	4-pyridinamine	504-24-5		Neuroprotective	Spinal cord injury
fandofloxacin	3-Quinolonecarboxylic acid, 6-fluoro-1-(5-fluoro-2-pyridinyl)-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo-, [CAS]	164150-85-0 164150-99-6	US 5496947	Quinolone antibacterial	Infection, urinary tract
Fantofarone		114432-13-2			
faropenem daloxate	(5R,6S)-6-[1(R)-Hydroxyethyl]-2-[2(R)-tetrahydrofuryl]-2-penam-3-carboxylic acid-5-methyl-2-oxo-1,3-dioxol-4-ylmethyl ester			Beta-lactam antibiotic	Infection, general
faropenem	4-Thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 6-(1-hydroxyethyl)-7-oxo-3-(tetrahydro-2-furanyl)-, [5R-[3(R*),5 $\alpha$ ,6 $\alpha$ ]-6 $\alpha$ -(R*)]-[CAS]	122547-49-3	EP 410727	Beta-lactam antibiotic	Infection, ocular
fasidotril	L-Alanine, N-[(2S)-3-(acetylthio)-2-(1,3-benzodioxol-5-ylmethyl)-1-oxopropyl]-, phenylmethyl ester [CAS]	135038-57-2	EP 419327	Antihypertensive, renin system	Hypertension, general
fasudil	1H-1,4-Diazepine, hexahydro-1-(5-Isoquinolinesulfonyl)- [CAS]	103745-39-7 105628-07-7	EP 187371	Neuroprotective	Vasospasm, general

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Fazadinium Bromide		49564-56-9			
febarbamate	2,4,6-(1H,3H,5H)-Pyrimidinetrione, 1-[2-[(aminocarbonyloxy)-3-butoxypropyl]-5-ethyl-5-phenyl- [CAS]	13246-02-1	US 3075983	Psychostimulant	
Febuprol		3102-00-9			
febuxostat	5-Thiazolecarboxylic acid, 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methyl- [CAS]	144060-53-7	WO 9209279	Antigout	Hyperuricaemia
Fedotozine		123618-00-8			
felbamate	1,3-Propanediol, 2-phenyl-, dicarbamate [CAS]	25451-15-4	US 4868327	Antiepileptic	Epilepsy, general
felbinac	[1,1'-Biphenyl]-4-acetic acid [CAS]	5728-52-9	EP 127840	Anti-inflammatory, topical	
felodipine	3,5-Pyridinedicarboxylic acid, 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-, ethyl methyl ester [CAS]	72509-76-3	US 4264611	Antihypertensive, other	Hypertension, general
Felypressin		56-59-7			
Femoxetine		59859-58-4			
Fenbenicillin		1926-48-3			
fenbufen	[1,1'-Biphenyl]-4-butanolic acid, Gamma-oxo [CAS]	36330-85-5	US 3784701	Anti-inflammatory	
Fenbutrazate		4378-36-3			
Fencamfamine		1209-98-9			
Fencamine		28947-50-4			
Fenclozic Acid		17969-20-9			
Fendiline		13042-18-7			
Fendosal		53597-27-6			
Fenethylline		3736081			
Fenfluramine		458-24-2			
Fenipentol		583-03-9			
fenofibrate	Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester [CAS]	26129-32-8 49562-28-9		Formulation, modified-release, <=24hr	Hyperlipidaemia, general
fenoldopam	1H-3-Benzazepine-7,8-diol, 6-chloro-2,3,4,5-tetrahydro-1-(4-hydroxyphenyl)-[CAS]	67227-56-9 67227-57-0	EP 22330	Antihypertensive, other	Hypertension, general
Fenoprofen		31879-05-7			

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Fenofenol		13392-18-2			
fenoverine	10H-Phenothiazine, 10-[[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]acetyl]-[CAS]	37561-27-6	FR 2092639	Antispasmodic	
Fenoxazoline		4846-91-7			
Fenoxedil		54063-40-0			
Fenozolone		15302-16-6			
Fenpentadiol		15687-18-0			
Fenpiprane		3540-95-2			
Fenpiverinium Bromide		125-60-0			
Fenproporex		15686-61-0			
Fenquizone		20287-37-0			
fenretinide	Retinamide, N-(4-hydroxyphenyl)- [CAS]	65646-68-6	BE 847942	Anticancer, other	Cancer, breast
Fenspiride		5053066			
fentanyl	Propanamide, N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]- [CAS]	437-38-7		Formulation, transmucosal, systemic	Anaesthesia, adjunct
Fentiazac		18046-21-4			
Fenticlor		97-24-5			
fenticonazole	1H-Imidazole, 1-[2-(2,4-dichlorophenyl)-2-[[4-(phenylthio)phenyl]methoxy]ethyl]- [CAS]	72479-26-6 73151-29-8	US 4221803	Antifungal	Infection, gynaecological
Fentonium Bromide		5868064			
fephradinal	Benzenemethanol, Alpha-[[[(2-hydroxy-1,1-dimethylethyl)amino]methyl]-, (+/-)- [CAS]	36981-91-6 67704-50-1 63075-47-8		Anti-inflammatory, topical	
Feprazone		30748-29-9			
Ferric Sodium Edetate		15708-41-5			
ferrinoxamine B			WO 9426263	Septic shock treatment	Respiratory distress syndrome, adult
Ferrocholinate		1336-80-7			
Ferrous Gluconate		299-29-6			
ferumoxytol	Polyglucose sorbitol carboxymethyl ether-coated non-stoichiometric magnetite			Imaging agent	Diagnosis, cancer

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
fesoterodine	2-((1R)-3-(bis(1-methylethyl)amino)-1-phenylpropyl)-4-(hydroxymethyl)phenyl ester, (2E)-2-butenedioate (1:1) (Salt) - [CAS]	286930-03-8		Urological	Incontinence
fexofenadine	Benzeneacetic acid, 4-[1-hydroxy-4-[4(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-Alpha,Alpha-dimethyl-, [CAS]	153439-40-8 83799-24-0 138452-21-8	US 5375693	Antiallergic, non-asthma	Rhinitis, allergic, seasonal
Fibrostat			CA 2132416	Vulnerary	Wound healing
fidarestat	Spiro(4H-1-benzopyran-4,4'-imidazolidine)-2-carboxamide, 6-fluoro-2,3-dihydro-2',5'-dioxo-, (2S-cis)-, [CAS]	136087-85-9	EP 418834	Symptomatic antidiabetic	Neuropathy, diabetic
fiduxosin	8-Phenyl-3-[4-[(3aR,9bR)-1,3a,4,9b-tetrahydro-9-methoxy[1]benzopyrano[3,4-c]pyrrol-2(3H)-yl]butyl]pyrazino[2',3':4,5]thieno[3,2-d]pyrimidine-2,4(1H,3H)-dione	208993-54-8		Prostate disorders	Benign prostatic hyperplasia
finasteride	4-Azaandrost-1-ene-17-carboxamide, N-(1,1-dimethylethyl)-3-oxo-, (5Alpha,17beta)-[CAS]	98319-26-7	EP 155096	Prostate disorders	Benign prostatic hyperplasia
finrozole	Benzonitrile, 4-(3-(4-fluorophenyl)-2-hydroxy-1-(1H-1,2,4-triazol-1-yl)-propyl)-[CAS]	160146-16-7	EP 476944	Urological	Urinary retention
Fipexide		34161-24-5			
FK-960	N-(4-Acetyl-1-piperazinyl)-4-fluorobenzamide monohydrate- [CAS]	133920-70-4	WO 9101979	Cognition enhancer	Alzheimer's disease
Flavopiridol		146426-40-6			
flavoxate	4H-1-Benzopyran-8-carboxylic acid, 3-methyl-4-oxo-2-phenyl-, 2-(1-piperidinyl)ethyl ester [CAS]	15301-69-6 3717-88-2	US 2921070	Urological	
flecainide	Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)-, [CAS]	54143-55-4 54143-56-5		Formulation, modified-release, <=24hr	Fibrillation, atrial
floxacin	3-Quinolonecarboxylic acid, 6,8-difluoro-1-(2-fluoroethyl)-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo- [CAS]	79660-53-0 79660-72-3	US 4398029	Quinolone antibacterial	Infection, general



API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Flesinoxan	2H-Benzimidazol-2-one, 1,3-dihydro-1-(2-(4-(3-(trifluoromethyl)phenyl)-1-piperazinyl)ethyl)- [CAS]	98206-10-1			
flibanserin	Benzoic acid, 2-[[8-(trifluoromethyl)-4-quinolinyl]amino]-, 2,3-dihydroxypropyl ester [CAS]	167933-07-5		Reproductive/gonadal, general	Sexual dysfunction, female
floclafenine		23779-99-9	US 3644368	Analgesic, NSAID	
flomoxef	5-Oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[[(difluoromethyl)thio]acetyl]amino]-3-[[[1-(2-hydroxyethyl)-1H-tetrazol-5-yl]thio]methyl]-7-methoxy-8-oxo-, (6R-cis)- [CAS]	92823-03-5 99665-00-6	EP 128536	Cephalosporin, injectable	Infection, general
Flopropione		2295-58-1			
Florantyrone		519-95-9			
Flosequinan		76568-02-0			
Floxacinil		5250-39-5			
Floxuridine		50-91-9			
Fluacizine		30223-48-4			
Fluanisone		1480-19-9			
fluasterone	Androst-5-en-17-one, 16-fluoro-, (16Alpha)-[CAS]	112859-71-9	EP 246650	Cardiovascular	Keratosis
fluazacort	5H-Pregna-1,4-dieno[17,16-d]oxazole-3,20-dione, 21-(acetyloxy)-9-fluoro-11-hydroxy-2'-methyl-, (11R,16R)- [CAS]	19888-56-3	US 3461119	Antipruritic/inflam, non-allergic	
Flucoronide		3693-39-8			
flucloxacillin		1847-24-1 34214-51-2		Formulation, other	Infection, general
fluconazole	1H-1,2,4-Triazole-1-ethanol, Alpha-(2,4-difluorophenyl)-Alpha-(1H-1,2,4-triazol-1-ylmethyl)- [CAS]	86386-73-4	EP 96569	Antifungal	Infection, dermatological
Flucytosine		2022-85-7			
fludarabine	9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-β-D-arabinofuranosyl)- [CAS]	75607-67-9 21679-14-1	US 4357324	Anticancer, antimetabolite	Cancer, leukaemia, chronic lymphocytic
Fludeoxyglucose F18		105851-17-0			
Fludiazepam		3900-31-0			

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Fludrocortisone		127-31-1			
Flufenamic Acid		530-78-9			
Fluindione		957-56-2			
flumazenil	4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylic acid, 8-fluoro-5,6-dihydro-5-methyl-6-oxo-, ethyl ester [CAS]	78755-81-4	EP 27214	Neurological	
Flumecinol		56430-99-0			
Flumequine		42835-25-6			
Flumethasone		2135-17-3			
Flumethiazide		148-56-1			
flunarizine	Piperazine, 1-[bis(4-fluorophenyl)methyl]-4-(3-phenyl-2-propenyl)-(E)- [CAS]	30484-77-6 52468-60-7 27848-84-6	GB 1268710	Antimigraine	
flunisolide	Pregna-1,4-diene-3,20-dione, 6-fluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]-, (6Alpha,11beta,16Alpha)- [CAS]	3385-03-3	US 3124571	Antiasthma	Rhinitis, allergic, general
flunitrazepam	2H-1,4-Benzodiazepin-2-one, 5-(2-fluorophenyl)-1,3-dihydro-1-methyl-7-nitro- [CAS]	1622-62-4	US 3116203	Hypnotic/Sedative	
Flunoxaprofen		66934-18-7			
Fluocinolone Acetonide		67-73-2			
Fluocinonide		356-12-7			
Fluocortin Butyl		41767-29-7			
Fluocortolone		152-97-6			
Fluorescein		2321-07-5			
Fluoresone		2924-67-6			
Fluorometholone		426-13-1			
Fluorosalan		4776061			
fluorouracil	2,4(1H,3H)-Pyrimidinedione, 5-fluoro- [CAS]	51-21-8		Formulation, transdermal, enhanced	Keratosiis
fluoxetine	Benzenepropanamine, N-methyl-Gamma-[4-(trifluoromethyl)phenoxy]-, (+/-)- [CAS]	54910-89-3 56296-78-7	US 4314081	Antidepressant	Depression, general
Fluoxymesterone		76-43-7			
Flupentixol		2709-56-0			

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Fluprednolone		2119-75-7			
Fluphenazine		69-23-8			
flupirtine	Carbamic acid, [2-amino-6-[[4-fluorophenyl)methyl]amino]-3-pyridinyl]-ethyl ester [CAS]	33400-45-2 56995-20-1 75507-68-5	US 4481205	Analgescic, other	Pain, post-operative
Fluprednidene Acetate		1255-35-2			
Fluprednisolone		53-34-9			
Fluproquazone		40507-23-1			
Flurandrenolide		1524-88-5			
Flurazepam		17617-23-1			
flurbiprofen	[1,1'-Biphenyl]-4-acetic acid, 2-fluoro-Alpha-methyl- [CAS]	5104-49-4	US 3793457	Anti-inflammatory	
flurithromycin	Erythromycin, 8-fluoro-mono(ethyl butanedioate) (ester)- [CAS]	82730-23-2	EP 56291	Macrolide antibiotic	Infection, respiratory tract, lower
Flurogestone		2529-45-5			
Flurothyl		333-36-8			
Fluroxene		406-90-6			
Fluspirilene		1841-19-6			
flutamide	Propanamide, 2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]- [CAS]	13311-84-7	US 4329364	Anticancer, hormonal	
flutazolam	Oxazolo[3,2-d][1,4]benzodiazepin-6(5H)-one, 10-chloro-11b-(2-fluorophenyl)-2,3,7,11b-tetrahydro-7-(2-hydroxyethyl)- [CAS]	27060-91-9	US 3905956	Anxiolytic	
fluticasone	Androsta-1,4-diene-17-carbothiolc acid, 6,9-difluoro-11,17-dihydroxy-16-methyl-3-oxo-, S-(fluoromethyl) ester, (6Alpha,11B,16Alpha,17Alpha)- [CAS]	80474-14-2 90566-53-3		Formulation, inhalable, solution	Asthma
flutoprazepam	2H-1,4-Benzodiazepin-2-one, 7-chloro-1-(cyclopropylmethyl)-5-(2-fluorophenyl)-1,3-dihydro- [CAS]	25967-29-7	GB 1253368	Anxiolytic	Psychosis, general
flutrimazole	1H-Imidazole, 1-[(2-fluorophenyl)(4-fluorophenyl)phenylmethyl]- [CAS]	119006-77-8	EP 352352	Antifungal	Infection, dermatological
Flutropium Bromide		63516-07-4			

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
fluvastatin	6-Heptenoic acid, 7-[3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxy-, monosodium salt, [R*, S*(E)]-(±)- [CAS]	93957-55-2 93957-54-1	EP 114027	Hypolipaeic/Antiatherosclerosis	Hypercholesterolaemia
fluvoxamine	1-Pentanone, 5-methoxy-1-[4-(trifluoromethyl)phenyl]-O-(2-aminoethyl)oxime, (E)- [CAS]	54739-18-3 61718-82-9	GB 1535226	Antidepressant	Depression, general, Obsessive compulsive disorder
Folic Acid		59-30-3			
Folinic Acid		58-05-9			
Fomepizole		7554-65-6			
fomlnoben	Benzamide, N-[3-chloro-2-[[methyl]2-(4-morpholinyl)-2-oxoethyl]amino]methyl]phenyl]- [CAS]	18053-31-1 24600-36-0	US 3661903	Respiratory stimulant	Eczema, general
Fomivirsen		144245-52-3			
Fomocaine		17692-39-6			
Fonazine		7456-24-8			
fondaparinux	Alpha-D-Glucopyranoside, methyl O-2-deoxy-6-O-sulfo-2-(sulfoamino)-Alpha-D-glucopyranosyl-(1-4)-O-β-D-glucopyranuronosyl-(1-4)-O-2-deoxy-3,6-di-O-sulfo-2-(sulfoamino)-Alpha-D-glucopyranosyl-(1-4)-O-2-O-sulfo-Alpha-L-idopyranuronosyl-(1-4)-2-deoxy-2-(sulfoamino)-,6-(hydrogen sulfate) [CAS]	104993-28-4 114870-03-0		Anticoagulant	Thrombosis, venous
Formebolone		2454117			
formestane	Androst-4-ene-3,17-dione, 4-hydroxy- [CAS]	566-48-3	EP 346953	Anticancer, hormonal	Cancer, breast
Formocortol		2825-60-7			
formoterol	Formamide, N-[2-hydroxy-5-[1-hydroxy-2-[[2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]phenyl]-, (R*, R*)-(+/-) [CAS]	43229-80-7 73573-87-2	GB 1415256	Antiasthma	Asthma

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
fosamprenavir	Carbamic acid, ((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-1-(phenylmethyl)-2-(phosphonoxy)propyl)- C-((3S)-tetrahydro-3-furanyl ester, [CAS]	226700-81-8		Antiviral, anti-HIV	Infection, HIV/AIDS
foscamet	Phosphinecarboxylic acid, dihydroxy-, oxide, trisodium salt [CAS]	34156-56-4 4428-95-9 63585-09-1	US 4839445	Antiviral, other	Infection, cytomegalovirus
Fosfestrol		522-40-7			
fosfluconazole	2,4-difluoro-Alpha,Alpha-bis(1H-1,2,4-triazol-1-ylmethyl)benzyl alcohol, dihydrogen phosphate (ester)	194798-83-9		Antifungal	Infection, fungal, general
fosfomycin	Phosphonic acid, (3-methyloxiranyl)-, (2R-cis)- [CAS]	23155-02-4 26016-98-8	GB 1223923	Antibiotic, other	Infection, general
fosfomycin trometamol	Phosphonic acid, (3-methyloxiranyl)-, (2R-cis)-, compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1)- [CAS]	78964-85-9	EP 27597	Antibiotic, other	Infection, urinary tract
Fosfosal		6064-83-1			
fosinopril	L-Proline, 4-cyclohexyl-1-[[[2-methyl-1-(1-oxopropoxy)propoxy](4-phenylbutyl)phosphiny]acetyl]-, (2Alpha,4S)- [CAS]	88889-14-9 98048-97-6	EP 63896	Antihypertensive, renin system	Hypertension, general
fosphenytoin	2,4-Imidazolidinedione, 5,5-diphenyl-3-[[[phosphonoxy)methyl]- [CAS]	92134-98-0 93390-81-9	US 4260769	Antiepileptic	Epilepsy, generalized, tonic-clonic
fotemustine	Phosphonic acid, [1-[[[2-chloroethyl]nitrosoamino]carbonyl]amino]ethyl]-, diethyl ester [CAS]	92118-27-9	EP 117959	Anticancer, alkylating	Cancer, melanoma
Frophenem		106560-14-9			
frovalatriptan	1H-Carbazole-6-carboxamide, 2,3,4,9-tetrahydro-3-(methylamino)-, (R)- [CAS]	158747-02-5	WO 9922730	Antimigraine	Migraine
Fructose		57-48-7			
Fructose-1,6-diphosphate		488-69-7			
FTC	2(1H)-Pyrimidinone, 4-amino-5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)- (4R)			Antiviral, anti-HIV	Infection, HIV/AIDS



API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
FTY-720	1,3-Propanediol, 2-amino-2-(2-(4-octylphenyl)ethyl)-, hydrochloride [CAS]	162359-56-0	WO 9408943	Immunosuppressant	Transplant rejection, general
fudosteine	Alanine, 3-((3-hydroxypropyl)thio)- [CAS]	13189-98-5	US 5047428	Antitussive	Cough
fulvestrant	Estra-1,3,5(10)-triene-3,17-diol, 7-[9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl]-, (7A) [CAS]	129453-61-8	EP 346014	Anticancer, hormonal	Cancer, breast
fumagiline	2,4,6,8-Decatetraenedioic acid, mono[5-methoxy-4-[2-methyl-3-(3-methyl-2-butenyl)oxiranyl]-1-oxaspiro[2.5]oct-6-yl] ester, [3R-]	23110-15-8		Protozoacide	Infection, GI tract
Fumagillin	[3A]pha,4Apha(2R*,3R*),5B,6B(all-E)]-[CAS]	23110-15-8			
Furaltadone		139-91-3			
Furazabol		1239-29-8			
Furazolidone		67-45-8			
Furazolum Chloride		5118-17-2			
Furonazide		3460-67-1			
furosemide	Benzolic acid, 5-(aminosulfonyl)-4-chloro-2-[[2-furanylmethyl]amino]- [CAS]	54-31-9		Formulation, modified-release, other	Hypertension, general
Fursultiamine		804-30-8			
Furtrethonium		7618-86-2			
Fusidic Acid		06/03/6990			
G1, YM BioSciences	1-(5-bromofur-2-yl)-2-bromo-2-nitroethene			Antifungal	Infection, gynaecological
G25			WO 9804252	Antimalarial	Infection, malaria
GABA-A Alpha5 inverse agonist, Mer			WO 0206285	Cognition enhancer	Alzheimer's disease
gabapentin	Cyclohexanecarboxylic acid, 1-(aminomethyl)- [CAS]	60142-96-3	US 4152326	Antiepileptic	Epilepsy, general
gabexate	Benzoic acid, 4-[[6-[(aminoliminomethyl)amino]-1-oxohexyl]oxy]-, ethyl ester, monomethanesulfonate [CAS]	39492-01-8 56974-61-9	US 3751447	GI inflammatory/bowel disorders	Pancreatitis

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
gaboxadol	Isloxazolo[5,4-c]pyridin-3(2H)-one, 4,5,6,7-tetrahydro- [CAS]	64603-91-4	CA 1125288	Hypnotic/Sedative	Sleep disorder, general
Gadobenate Dimeglumine		127000-20-8			
Gadobutrol		138071-82-6			
Gadodiamide		131410-48-5			
Gadopentetic Acid		80529-93-7			
Gadoteridol		120066-54-8			
Gadoversetamide		131069-91-5			
Gadoxetic Acid		135326-11-3			
galantamine	(4aS,6R,8aS)-6-Hydroxy-3-methoxy-11-methyl-5,6,9,10,11,12-hexahydro-4aH-benzofuro[3a,3,2-e,f][2]benzazepine			Formulation, modified-release, other	Alzheimer's disease
Galanthamine		357-70-0			
galarubicin	$\beta$ -Alanine, 2-[4-[(2,6-dideoxy-2-fluoro-Alpha-L-talopyranosyl)oxy]-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthaceny]-2-oxoethyl ester, [CAS]	140637-82-7 140637-86-1	EP 424899	Anticancer, antibiotic	Cancer, breast
Gallamine Triethiodide		65-29-2			
Gallic Acid		149-91-7			
gallium maltolate	4H-Pyran-4-one, 3-hydroxy-2-methyl-, gallium complex			Anticancer, other	Cancer, myeloma
gallium nitrate	Nitric acid, gallium salt [CAS]	13494-90-1	US 4529593	Osteoporosis treatment	Hypercalcaemia of malignancy
gallopamil	Benzeneacetoneitrile, Alpha-[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]propyl]-3,4,5-trimethoxy-Alpha-(1-methylethyl)-[CAS]	16662-47-8	GB 1367677	Antianginal	Angina, general
g-Aminobutyric Acid		56-12-2			
Ganaxolone		38398-32-2			
ganciclovir	6H-Purin-6-one, 2-amino-1,9-dihydro-9-[[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl]-[CAS]	107910-75-8 82410-32-0	EP 49072	Antiviral, other	Infection, cytomegalovirus

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
ganirelix	[N-Ac-D-Nal,D-pCl-Phe,D-Pal,D-hArg(Et)2,hArg(Et)2,D-Ala]GnRH- [CAS]	124904-93-4	EP 312052	Releasing hormones	Infertility, female
ganstigmine	Carbamic acid, (2-ethylphenyl)-, (3aS,8aS)-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo[2,3-b]indol-5-yl ester, [CAS]	223585-99-7	EP 1023297	Cognition enhancer	Alzheimer's disease
gantofiban	1-Piperazineacetic acid, 4-[[[5R]-3-[4-[imino(methoxycarbonyl)amino]methyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-, ethylester [CAS]	183547-57-1	EP 741133	Antithrombotic	Thrombosis, general
garenoxacin	3-Quinolonecarboxylic acid, 1-cyclopropyl-8-(difluoromethoxy)-7-((1R)-2,3-dihydro-1-methyl-1H-isindol-5-yl)-1,4-dihydro-4-oxo-monomethanesulfonate [CAS]	223652-82-2		Quinolone antibacterial	Infection, respiratory tract, lower
gamocestim	5-73-macrophage inflammatory protein 2Alpha (human gene gro2)- [CAS]	246861-96-1		Radio/chemoprotective	Chemotherapy-induced injury, bone marrow, neutropenia
galifloxacin	3-Quinolonecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-, (+/-)- [CAS]	112811-59-3	EP 230295	Quinolone antibacterial	Infection, respiratory tract, general
Gefamate		51-77-4			
gefitinib	4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy) [CAS]	184475-35-2	WO 9633980	Anticancer, other	Cancer, lung, non-small cell
gemcabene	6,6'-oxybis(2,2-dimethylhexanoate)	209789-08-2		Hypolipidaemic/Antiatherosclerosis	Hyperlipidaemia, general
gemcitabine	Cytidine, 2'-deoxy-2', 2'-difluoro-, [CAS]	122111-03-9 95058-81-4	GB 2136425	Anticancer, antimetabolite	Cancer, pancreatic
gemeprost	Prosta-2,13-dien-1-olic acid, 11,15-dihydroxy-16,16-dimethyl-9-oxo-, methyl ester, (2E,11Alpha,13E,15R)- [CAS]	64318-79-2	GB 1540427	Prostaglandin	
gemfibrozil	Pentanoic acid, 5-(2,5-dimethylphenoxy)-2,2-dimethyl- [CAS]	25812-30-0	US 3674836	Hypolipidaemic/Antiatherosclerosis	Hyperlipidaemia, general

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
gemifloxacin	1,8-Naphthyridine-3-carboxylic acid, 7-(3-(aminomethyl)-4-(methoxymino)-1-pyrroldinyl)-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo- [CAS]	175463-14-6	US 5869670	Quinolone antibacterial	Infection, respiratory tract, general
gentamicin	Gentamicin [CAS]	1403-66-3		Formulation, implant	Infection, general
Gentian Violet		548-62-9			
Gentiopicroin		20831-76-9			
Gentisic Acid		490-79-9			
Gepefrine		18840-47-6			
gepirone	2,6-Piperidinedione, 4,4-dimethyl-1-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]- [CAS]			Formulation, modified-release, other	Depression, general
gestodene	18,19-Dinorepregna-4,15-dien-20-yn-3-one, 13-ethyl-17-hydroxy-, (17Alpha)- [CAS]	109852-02-0 60282-87-3	GB 1569135	Formulation, fixed-dose combinations	Contraceptive, female
gestodene + ethinylest	18,19-Dinorepregna-4,15-dien-20-yn-3-one, 13-ethyl-17-hydroxy-, (17Alpha) mixt with 19 Norpregna-1,3,5(10)-trien-20-yne-13,17-diol (17Alpha)			Formulation, modified-release, >24hr	Contraceptive, female
Gestonorone Caproate		1253-28-7			
Gestrinone		16320-04-0			
g-Hydroxybutyrate		591-81-1			
gimatecan	(4S)-11-[(E)-[(1,1-dimethylethoxy)imino]methyl]-4-ethyl-4-hydroxy-1-12-dihydro-14H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H)-dione	292618-32-7		Anticancer, other	Cancer, brain
Giractide		24870-04-0			
Gitoxin		4562-36-1			
GL-406349	N,N'-Bis[2-[N-[2-(N2,N5-dimethyl-DL-lysylamino)-ethyl]carbamoyl]1H-indol-6-yl]-1H-indole-2,5-dicarboxamide				Infection, fungal, general
Glafenine		3820-67-5		Antifungal	

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
glatiramer	L-Glutamic acid, polymer with L-alanine, L-lysine and L-tyrosine, [CAS]	147245-92-9 28704-27-0	WO 5800808	Multiple sclerosis treatment	Multiple sclerosis, relapsing-remitting
Glibornuride		26944-48-9			
gliclazide	Benzenesulfonamide, N-[[[hexahydrocyclopenta[c]pyrrol-2-(1H)-yl]amino]carbonyl]-4-methyl- [CAS]	21187-98-4	GB 1153982	Antidiabetic	Diabetes, Type II
glimepiride	1H-Pyrrole-1-carboxamide, 3-ethyl-2,5-dihydro-4-methyl-N-[2-[4-[[[[4-methyl(cyclohexyl)amino]carbonyl]amino]sulfonyl]phenyl]ethyl]-2-oxo- [CAS]	93479-97-1 506-26-3	WO 9303724	Antidiabetic	Diabetes, Type II
g-Linolenic Acid					
glipizide	Pyrazinecarboxamide, N-[2-[4-[[[(cyclohexylamino)carbonyl]amino]sulfonyl]phenyl]ethyl]-5-methyl- [CAS]	29094-61-9	US 3669966	Antidiabetic	
gliquidone	Benzenesulfonamide, N-[[[cyclohexylamino]carbonyl]-4-[2-(3,4-dihydro-7-methoxy-4,4-dimethyl-1,3-dioxo-2(1H)-isoquinoliny)ethyl]- [CAS]	33342-05-1	GB 1277847	Antidiabetic	Diabetes, general
glisolamide	3-Isoazolecaboxamide, N-[2-[4-[[[(cyclohexylamino)carbonyl]amino]sulfonyl]phenyl]ethyl]-5-methyl- [CAS]	24477-37-0		Antidiabetic	Diabetes, general
Glisoxepid		25046-79-1			
Glucametacin		52443-21-7			
Glucuheptonic Acid		87-74-1			
Gluconic Acid		526-95-4			
glucosamine	D-Glucose, 2-amino-2-deoxy-, [CAS]	29031-19-4 3416-24-8	DE 1953689	Antiarthritic, other	Arthritis, osteo
Glucosulfone		554-18-7			
glufosfamide	β-D-Glucopyranose, 1-(N,N'-bis(2-chloroethyl)phosphorodiamidate)- [CAS]	132682-98-5	DE 3835772	Anticancer, alkylating	Cancer, general
Glutamic Acid		56-86-0			
Glutaraldehyde		111-30-8			
Glutethimide		77-21-4			
Glyburide		10238-21-8			
Glybuthiazol(e)		535-65-9			
Glybuzole		1492-02-0			



API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Glycerol		56-81-5			
Glycocyanine		352-97-6			
Glycol Salicylate		87-28-5			
Glyconiazide		3691-74-5			
Glycopyrrolate		596-51-0			
Glyhexamide		451-71-8			
Glymidine		339-44-6			
Glypinamide		1228-19-9			
GMDP	N-acetylglucosaminyl-N-acetylmuramyl dipeptide			Anti-infective, other	Infection, general
Gold Sodium Thiomalate		12244-57-4			
Gold Sodium Thiosulfate		10233-88-2			
gosereelin	Luteinizing hormone-releasing factor (pig), 6-[O-(1,1-dimethylethyl)-D-serine]-10-deglycinamide-, 2-(aminocarbonyl)hydrazide [CAS]	65807-02-5	US 4100274	Releasing hormones	Cancer, prostate
GPI-1485	L-Proline, 1-(3,3-dimethyl-1,2-dioxopentyl)-, 3-(3-pyridinyl)propyl ester [CAS]	186452-09-5		Antiparkinsonian	Parkinson's disease
GPI-5693	2-(Phosphonomethyl)pentanedioic acid		US 5672592	Analgesic, other	Pain, neuropathic
Graftskin					
granisetron	1H-Indazole-3-carboxamide, 1-methyl-N-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-, endo-[CAS]	107007-99-8 109889-09-0	EP 200444	Antiemetic	Chemotherapy-induced nausea and vomiting
Grepafloxacin		119914-60-2			
griseofulvin	Spiro[benzofuran-2(3H),1'-[2]cyclohexane]-3,4'-dione, 7-chloro-2',4,6-trimeth-oxy-6'methyl-, (1'S-trans)- [CAS]	126-07-8		Formulation, dermal, topical	Infection, dermatological
Gualacol		90-05-1			
Gualapate		852-42-6			
Gualazulene		489-84-9			
Gualifenesin		93-14-1			
gualimesal	4H-1,3-Benzodioxin-4-one, 2-(2-methoxyphenoxy)-2-methyl- [CAS]	81674-79-5	GB 2098201	Anti-inflammatory	

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Guanecycline		16545-11-2			
Guanabenz		5051-62-7			
Guanadrel		40580-59-4			
Guanethidine		55-65-2			
Guanfacine		29110-47-2			
Guanoxabenz		24047-25-4			
Guanoxan		2165-19-7			
gugulipid	Pregna-4,17(20)-diene-3,16-dione [CAS]	95975-55-6	EP 447706	Hypolipaeic/Antiatherosclerosis	
Gusperimus		104317-84-2			
GW-280430A	(Z)-2-Chlorofumaric acid 1-[3-{[6,7-dimethoxy-2(S)-methyl-1(R)-(3,4,5-trimethoxybenzyl)-1,2,3,4-tetrahydroisoquinolinum-2-yl]propyl}]			Muscle relaxant	Anaesthesia, adjunct
GW-320659	[2S,3S,5R]-2-[3,5-difluorophenyl]-3,5-dimethyl-2-morpholinol			Anorectic/Antiobesity	Obesity
GYKI-16084	(+)-R-2-[3-[N-(2-Benzof[1,4]dioxanylmethyl)amino]-1-propyl]-3(2H)-pyridazinone hydrochloride		US 6194411	Prostate disorders	Benign prostatic hyperplasia
Hachimycin		1394-02-1			
Halazepam		23092-17-3			
Halcinonide		3093-35-4			
halobetasol	Pregna-1,4-diene-3,20-dione, 21-chloro-6,9-difluoro-11-hydroxy-16-methyl-17-(1-oxopropoxy)-, (6Alpha,11beta,16beta)- [CAS]	66852-54-8	US 4619921	Antipsoriasis	Psoriasis
halofantrine	9-Phenanthrenemethanol, 1,3-dichloro-Alpha-[2-(dibutylamino)ethyl]-6-(trifluoromethyl)- [CAS]	36167-63-2 69756-53-2	EP 138374	Antimalarial	Infection, malaria
halometasone	Pregna-1,4-diene-3,20-dione, 2-chloro-6,9-difluoro-11,17,21-trihydroxy-16-methyl-, (6Alpha,11beta,16Alpha)- [CAS]	50629-82-8	US 4076737	Antipruritic/Inflamm, allergic	
Haloperidol		52-86-8			
Halopredone		57781-14-3			

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Haloproglin		777-11-7			
Halopropane		679-84-5			
Halothane		151-67-7			
Haloxazolam		59128-97-1			
harkoseride	2(R)-Acetamido-N-benzyl-3-methoxypropionamide		WO 9733861	Antiepileptic	Epilepsy, general
HE-2000	16Alpha-Bromo-3beta-hydroxy-5Alpha-androstane-17-one			Antiviral, anti-HIV	Infection, HIV/AIDS
Healos			WO 9714376	Musculoskeletal	Regeneration, bone
Hematoporphyrin		14459-29-1			
Hepronicate		7237-81-2			
Heptabarbital		509-86-4			
Heptaminol		372-66-7			
Hetacillin		3511-16-8			
Hetastarch		9004-62-0			
Hexachlorophene		70-30-4			
Hexadimethrine Bromide		28728-55-4			
Hexafluorenilum Bromide		317-52-2			
Hexamethonium		60-26-4			
Hexamidine		3811-75-4			
Hexapropymate		358-52-1			
Hexedine		5980-31-4			
Hexestrol		84-16-2			
Hexestrol Bis(b-diethylaminoethyl ether)		2691-45-4			
Hexethal		144-00-3			
Hexetidine		141-94-6			
Hexobarbital		56-29-1			
Hexobendine		54-03-5			
Hexocyclium Methyl Sulfate		115-63-9			
Hexoprenaline		3215-70-1			
Hextend	Hextend [CAS]	235746-51-7	US 5407428	Plasma substitute	Surgery adjunct
Hexylcaine		532-76-3			

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
HF-0299	11b-hydroxy androstenedione			Osteoporosis treatment	Osteoporosis
HGP-2	Benzeneacetic acid, 4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]-, 2-tricyclo[3.3.1.1 <sup>3,7</sup> dec-1-ylethyl ester, (2Z)-2-butenedioate (1:1) (salt) [CAS]	121009-31-2		Antiglaucoma	Glaucoma
HGP-6A	8-Azoniabicyclo[3.2.1]octane, 3-(3-ethoxy-1,3-dioxo-2-phenylpropoxy)-8,8-dimethyl-, (3-endo)-, methyl sulfate [CAS]	113932-41-5		Antiepileptic	Epilepsy, general
hidrosmin	Hydrosmin- [CAS]	120250-44-4		Vasoprotective, systemic	
histamine	histamine	51-45-6	EP 0493468	Anticancer, immunological	Cancer, melanoma
Histapyrrodine		493-80-1			
histrelin	Luteinizing hormone-releasing factor (pig), 6-[1-(phenylmethyl)-D-histidine]-9-(N-ethyl-L-prolinamide)-10-deglycinamide- [CAS]	76712-82-8	EP 217659	Releasing hormones	Precocious puberty
HM-101	HM 101 [CAS]	217311-70-1		Osteoporosis treatment	Osteoporosis
HMN-214	(E)-4-[2-[2-(p-methoxybenzenesulfonamide)-phenyl]ethenyl]pyridine-1-oxide			Anticancer, other	Cancer, general
Homatropine		87-00-3			
Homocamfin		535-86-4			
Homochlorcyclizine		848-53-3			
Hopantenic Acid		18679-90-8			
HP-228	Glycinamide, N-acetyl-L-norleucyl-L-glutamyl-L-histidyl-D-phenylalanyl-L-arginyl-D-tryptophyl- [CAS]	172617-89-9	EP 759770	Analgesic, other	Pain, post-operative
Huperzine A		102518-79-6			
hyaluronan	Hyaluronic acid [CAS]	9004-61-9		Formulation, other	Restenosis
Hycanthone		3105-97-3			
Hydnocarpic Acid		459-67-6			
Hydralazine		86-54-4			
Hydrastine		118-08-1			
Hydrastinine		6592-85-4			

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Hydrochlorothiazide		58-93-5			
hydrocodone	Morphinan-6-one, 4,5-epoxy-3-hydroxy-17-methyl-, (5Alpha)- [CAS]	466-99-9 125-29-1		Formulation, modified-release, other	Pain, general
Hydrocortamate		76-47-1			
hydrocortisone	Pregn-4-ene-3,20-dione, 21-(acetyloxy)-11-hydroxy-17-(1-oxopropoxy)-, (11B)-[CAS]	74050-20-7 50-23-7	DE 2826257	Dermatological	Unspecified
hydrocortisone butyrate proplo	Pregn-4-ene-3,20-dione, 11-hydroxy-17-(1-oxobutoxy)-21-(1-oxopropoxy)-, (11B)-[CAS]	72590-77-3	DE 2910899	Antipruritic/Inflamm, allergic	
Hydroflumethiazide		135-09-1			
hydromorphone	Morphinan-6-one, 4,5-epoxy-3-hydroxy-17-methyl-, (5Alpha)-, mixt with acetamide, N-(4-hydroxyphenyl)-, mixt with morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-, (5Alpha)-	103-90-2 16590-41-3 466-99-9		Formulation, fixed-dose combinations	Pain, general
Hydroquinidine		1435-55-8			
Hydroquinine		522-66-7			/
Hydroquinone		123-31-9			
Hydroxocobalamin		13422-51-0			
Hydroxyamphetamine		1518-86-1			
Hydroxychloroquine		118-42-3			
Hydroxydione		53-10-1			
Hydroxypethidine		468-56-4			
Hydroxyphenamate		50-19-1			
Hydroxypropyl Cellulose		9004-64-2			
Hydroxystilbamidine		495-99-8			
Hydroxytetracaine		490-98-2			
Hydroxyzine		68-88-2			
Hylan G-F 20					
Hymecromone		90-33-5			



API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
hyoscyamine	benzeneacetic acid, Alpha(hydroxymethyl)-, 8-methyl-8-azabicyclo [3.2.1]oct-3-yl ester, [3(S)-endo],	101-31-5		Formulation, oral, orally-disintegrating	Ulcer, GI, general
hypericin	Phenanthro[1,10,9,8-opqra]perylene-7,14-dione, 1,3,4,6,8,13-hexahydroxy-10,11-dimethyl- [CAS]	548-04-9		Anticancer, other	Cancer, brain
IACFT		180468-34-2			
ibandronic acid	Phosphonic acid, [1-hydroxy-3-(methylpentylamino)propylidene] bis- [CAS]	114084-78-5	EP 252504	Osteoporosis treatment	Hypercalcaemia of malignancy
ibopamine	Propanoic acid, 2-methyl-, 4-[2-(methylamino)ethyl]-1,2-phenylene ester- [CAS]	66195-31-1	GB 1551661	Cardio stimulant	Heart failure
ibopamine	Propanoic acid, 2-methyl-, 4-[2-(methylamino)ethyl]-1,2-phenylene ester- [CAS]	66195-31-1		Formulation, mucosal, topical	Surgery adjunct
Ibritumomab Tiuxetan		206181-63-7			
ibrolipim	Phosphonic acid, [[4-[[[(4-bromo-2-cyanophenyl)amino]carbonyl]phenyl]methyl]-, diethyl ester [CAS]	133208-93-2	EP 402033	Hypolipaeamic/Antiatherosclerosis	Hypertriglyceridaemia
ibudilast	1-Propanone, 2-methyl-1-[2-(1-methylethyl)pyrazolo[1,5-a]pyridin-3-yl]- [CAS]	50847-11-5	EP 215438	Antiasthma	Asthma
Ibufenac		1553-60-2			
Ibuprofen piconol	Benzeneacetic acid, Alpha-methyl-4-(2-methylpropyl)-, 2-pyridinylmethyl ester [CAS]	64622-45-3	DE 2658610	Antipruritic/inflamm, non-allergic	Eczema, contact
ibuprofen	Benzeneacetic acid, Alpha-methyl-4-(2-methylpropyl)- [CAS]	15687-27-1		Formulation, modified-release, other	Inflammation, general
Ibuproxam		53648-05-8			
ibutilide	Methanesulfonamide, N-[4-[4-(ethylheptylamino)-1-hydroxybutyl]phenyl]-, (+/-)-, [CAS]	122647-31-8 122647-32-9	JP 60239458	Antiarrhythmic	Fibrillation, atrial
ICA-17043			US 6288122	Antisickling	Anaemia, sickle cell
Icodextrin	Dextrin- [CAS]	9004-53-9		Urological	Renal failure

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
idarubicin	5,12-Naphthacenedione, 9-acetyl-7-[(3-amino-2,3,6-trideoxy-Alpha-L-lyxohexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-, (7S-cis)- [CAS]	58957-92-9 86189-66-4 79944-58-4	US 4471052	Anticancer, antibiotic	Cancer, leukaemia, acute lymphocytic
idazoxan					
IdB-1016	2-(2,3-dihydro-2-(4-hydroxy-3-methoxyphenyl)-3-(hydroxymethyl)-1,4-benzodioxin-6-yl)-2,3-dihydro-3,5,7-trihydroxy-4H-1-benzopyran-4-one phosphatidylcholine complex	134499-06-2	EP 209038	Anticancer, hormonal	Cancer, ovarian
idebenone	2,5-Cyclohexadiene-1,4-dione, 2-(10-hydroxydecyl)-5,6-dimethoxy-3-methyl- [CAS]	58186-27-9	EP 58057	Neuroprotective	Ischaemia, cerebral
IDN-5109	4-Hexenoic acid, 3-[[[(1,1-dimethylethoxy)carbonyl]amino]-2-hydroxy-5-methyl-, (3aS,4R,7R,8aS,9S,10aR,12aS,12bR,13S,13aS)-7,12a-bis(acetyloxy)-13-(benzoyloxy)-3a,4,7,8,8a,9,10,10a,12,12a,12b,13-dodecahydro-9-hydroxy-5,8a,14,14-tetramethyl-2,8-dioxo-6,13a-methano-13aH-oxeto [2",3",5',6"] benzo[1,2:4,5] cyclodeca [1,2-d] dioxyl-4-yl ester, 2R,3S) [CAS]	186348-05-0 116057-75-1	US 5264591	Anticancer, other	Cancer, colorectal
Idoxifene					
Idraparinux	Alpha-D-Glucopyranoside, methyl O-2,3,4-tri-O-methyl-6-O-sulfo-Alpha-D-glucopyranosyl-(1-4)-O-2,3-di-O-methyl-β-D-glucopyranuronosyl-(1-4)-O-2,3,6-tri-O-sulfo Alpha-D-glucopyranosyl-(1-4)-O-2,3-di-O-methyl-Alpha-L-Idopyranuronosyl-(1-4)-, tris(hydrogen sulfate) nonasodium salt [CAS]	149920-56-9	AU 698456	Antithrombotic	Thrombosis, venous
Idrocilamide	2-Propenamide, N-(2-hydroxyethyl)-3-phenyl- [CAS]	6961-46-2	US 3659014	Anti-inflammatory, topical	

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
ifenprodil	(7)-2-(4-benzyl piperidino)-1-p-hydroxyphenylpropanol tartrate	23210-58-4 23210-56-2	US 3509164	Neuroprotective	
ifosfamide	2H-1,3,2-Oxazaphosphorin-2-amine, N,3-bis(2-chloroethyl)tetrahydro-2-oxide [CAS]	3778-73-2	US 3732340	Anticancer, alkylating	Cancer, lung, general
iguratimod	N-[3-(Formylamino)-4-oxo-6-phenoxo-4H-chromen-7-yl] methanesulfonamide	123663-49-0	DE 3834204	Antiarthritic, other	Arthritis, rheumatoid
ilaprazole	1H-Benzimidazole, 2-(((4-methoxy-3-methyl-2-pyridinyl) methyl)sulfinyl)-5-(1H-pyrrol-1-yl)- [CAS]	172152-36-2	US 5703097	Antilulcer	Ulcer, GI, general
ilomastat	Butanediamide, N4-hydroxy-N1-(1-(1H-indol-3-ylmethyl)-2-(methylamino)-2-oxoethyl)-2-(2-methylpropyl)-, (S-(R*, S*))- [CAS]	142880-36-2	US 5892112	COPD treatment	Emphysema, smoking-related
iloperidone	Ethanone, 1-[4-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxyphenyl]- [CAS]	133454-47-4	US 5776963	Neuroleptic	Schizophrenia
iloprost trometamol	Pentanoic acid, 5-[hexahydro-5-hydroxy-4-(3-hydroxy-4-methyl-1-octen-6-ynyl)-2(1H)-pentalenylidene]- [CAS]	78919-13-8	DE 3417638	Prostaglandin	Peripheral vascular disease
ILX23-7553	1Alpha,25-Hydroxy-16-yne vitamin D3			Anticancer, other	Cancer, general
imatinib	4-(((Methyl-1-piperazinyl)methyl)-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-phenyl]benzamide methanesulfonate	152459-95-5	US 5521184	Anticancer, other	Cancer, leukaemia, chronic myelogenous
imidapril	4-Imidazolidinecarboxylic acid, 3-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1-methyl-2-oxo-, [4S-[3[R*(R*),4R*]]- [CAS]	89371-37-9 89396-94-1	EP 95163	Antihypertensive, renin system, Musculoskeletal	Hypertension, general, Cachexia
imidazole salicylate	Benzoic acid, 2-hydroxy-, compd. with 1H-imidazole (1:1) [CAS]	36364-49-5	US 4329340	Anti-inflammatory	Pain, general

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Imipenem	1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 6-(1-hydroxyethyl)-3-[[2-[[[iminomethyl]amino]ethyl]thio]-7-oxo-, [5R-[5Alpha,6Alpha(R*)]]]- [CAS]	64221-86-9 74431-23-5 81129-83-1	GB 1570990	Beta-lactam antibiotic	Infection, general
Imipramine		50-49-7			
Imipramine N-Oxide		6829-98-7			
Imiquimod	1H-Imidazo[4,5-c]quinolin-4-amine, 1-(2-methylpropyl)- [CAS]	99011-02-6	EP 145340	Antiviral, other	Infection, human papilloma virus
Imolamine		318-23-0			
Impitapide	Benzeneacetamide, Alpha-cyclopentyl-4-((2,4-dimethyl-9H-pyrido(2,3-b)indol-9-yl)methyl)-N-((1R)-2-hydroxy-1-phenylethyl)-(AlphaS)- [CAS]	177469-96-4	EP 705831	Hypolipaeimic/Antiatherosclerosis	Atherosclerosis
Improsulfan		13425-98-4			
Inaperisone		99323-21-4			
Incadronate	Phosphonic acid, [[cycloheptylamino]methylene]bis-, [CAS]	138330-18-4		Musculoskeletal	Hypercalcaemia of malignancy
Incadronic Acid		124351-85-5			
Indalpine		63758-79-2			
Indanazoline		40507-78-6			
Indapamide	4-chloro-N-(2-methylindolin-1-yl)-3-sulfamoylbenzamide	26807-65-8	GB 1203691	Antihypertensive, diuretic	Hypertension, general
Indecainide		74517-78-5			
Indeloxazine	Morpholine, 2-[(1H-inden-7-yloxy)methyl]- [CAS]	60929-23-9 65043-22-3	JP 52083773	Cognition enhancer	Alzheimer's disease
Indeloxazine		65043-22-3			
	2-Propanol, 1-[1H-inden-4(or 7)-yloxy]-3-[(1-methylethyl)amino]- [CAS]	30190-87-5 60607-68-3 68906-88-7	GB 1290343	Antihypertensive, adrenergic	
Indenolol					
Indinavir	D-erythro-Pentonamide, 2,3,5-trideoxy-N-(2,3-dihydro-2-hydroxy-1H-inden-1-yl)-5-(2-(((1,1-dimethylethyl)amino)carbonyl)-4-(3-pyridinylmethyl)-1-piperazinyl)-2-(phenylmethyl), [1S-[1Alpha(R*),2Alpha]]-, [CAS]	150378-17-9 157810-81-6	EP 0541168	Antiviral, anti-HIV	Infection, HIV/AIDS

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Indiplon	Acetamide, N-methyl-N-(3-(2-thienylcarbonyl)pyrazolo(1,5-a)pyrimidin-7-yl)phenyl)- [CAS]	325715-02-4	US 6399621	Hypnotic/Sedative	Insomnia
indisetron	1H-Indazole-3-carboxamide, N-(3,9-dimethyl-3,9-diazabicyclo(3.3.1)non-7-yl)-, diendo- [CAS]	160472-97-9		Antiemetic	Nausea and vomiting, general
indisulam	1,4-Benzenedisulfonamide, N-(3-chloro-1H-indol-7-yl)- [CAS]	165668-41-7		Anticancer, other	Cancer, lung, non-small cell
Indobufen		63610-08-2			
Indocyanine Green		3599-32-4			
indometacin	1H-Indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl- [CAS]	53-86-1		Formulation, modified-release, other	Inflammation, general
Indoprofen		31842-01-0			
Indoramin	Benzamide, N-[1-[2-(1H-indol-3-yl)ethyl]-4-piperidinyl]- [CAS]	26844-12-2	GB 1218570	Antihypertensive, adrenergic	
Inducterm		38821-52-2	US 5993810	Labour Inducer	Labour, Induction
Infliximab		170277-31-3			
Inosine Pranobex		36703-88-5			
Inositol		87-89-8			
Inositol Niacinate		6556112			
Iobenguane		80663-95-2			
Iobenzamic Acid		3115057			
Iobitridol		136949-58-1			
Iocamic Acid		10397-75-8			
Iocetamic Acid		16034-77-8			
Iodamide		440-58-4			
Iodine	Iodine [CAS]	7553-56-2		Formulation, oral, other	Fibrocystic breast disorder
Iodipamide		606-17-7			
Iodixanol		92339-11-2			
Iodoalphonic Acid		577-91-3			
iodochlorhydroxyquin	5-Chloro-7-iodo-8-quinolinol	130-26-7		Cognition enhancer	Alzheimer's disease
Iodoform		75-47-8			
Iodopyracet		300-37-8			
Iodopyrrole		87-58-1			



API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Iodoquinol		83-73-8			
Iofetamine 123I		75917-92-9			
Ioglycamic Acid		2618-25-9			
Iohexol		66108-95-0			
Iomeglamic Acid		25827-76-3			
Iomeprol		78649-41-9			
Iopamidol		60166-93-0			
Iopanolc Acid		96-83-3			
Iopentol		89797-00-2			
Iophendylate		99-79-6			
Iophenoxic Acid		96-84-4			
Iopromide		73334-07-3			
Iopronic Acid		41473-08-9			
Iopydol		5579-92-0			
Iopydone		5579-93-1			
Iothalamic Acid		2276-90-6			
Iotrolan		79770-24-4			
Ioversol		87771-40-2			
Ioxaglic Acid		59017-64-0			
Ioxilan		107793-72-6			
IP-751	(3R,4R)-(delta6)-THC-DMH-11-olc acid		WO 9401429	Analgesic, other	Pain, neuropathic
Ipidacrine		62732-44-9			
IPL-576092	Stigmastan-15-one, 22,29-epoxy-3,4,6,7,29-pentahydroxy-, (3Alpha,4Beta,5Alpha,6Alpha,7Beta,14Beta,22S)-[CAS]				
		137571-30-3	US 6046185	Antiasthma	Asthma
		5587-89-3			
Ipodate		66985-17-9			
		22254-24-6		Formulation, inhalable, solution	Chronic obstructive pulmonary disease
Ipratropium bromide					
Ipratropium	(endo,syn)-(+)-3-(3-Hydroxy-1-oxo-2-phenylpropoxy)-8-methyl-8-(1-methylethyl)-8-azoniabicyclo[3.2.1]octane			Formulation, inhalable, topical	Asthma

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
iprazochrome	Hydrazinecarboxamide, 2-[1,2,3,6-tetrahydro-3-hydroxy-1-(1-methylethyl)-6-oxo-5H-indol-5-ylidene]- [CAS]	7248-21-7		Haemostatic	
ipriflavone	4H-1-Benzopyran-4-one, 7-(1-methylethoxy)-3-phenyl- [CAS]	35212-22-7	EP 214647	Osteoporosis treatment	Osteoporosis
iprindole		5560-72-5			
iproclazide		3544-35-2			
iproniazid		54-92-2			
ipsapirone		95847-70-4			
irbesartan	2-n-butyl-4-spirocyclopentane-1-[[2'-(tetrazol-5-yl)biphenyl-4-yl)methyl]-2-imidazolyl-5-one	138402-11-6	WO 9114679	Antihypertensive, renin system	Hypertension, general
IRFI-042	Butanedioic acid, mono[2-[2-(acetylthio)ethyl]-2,3-dihydro-4,6,7-trimethyl-5-benzofuranyl] ester, (+/-) [CAS]	134867-62-2	US 5114966	Cardiovascular	Atherosclerosis
IRFI-165	N-Cyclopentyl-1-methylimidazo[1,2-a]quinoxalin-4-amine	191349-26-5	EP 865442	Antidepressant	Depression, general
Iridomyrmecin		485-43-8			
Irindalone	-Imidazolidinone, 1-[2-[4-[3-(4-fluorophenyl)-2,3-dihydro-1H-inden-1-yl]-1-piperazinyl]ethyl]-, (1R-trans)- [CAS]	104113-57-7 96478-43-2	EP 183349	Antidepressant	Depression, general
Irinotecan		97682-44-5			
Irofulven	Spiro[cyclopropane-1,5'-[5H]inden]-7'(6'H)-one, 6'-hydroxy-2',4',6'-trimethyl-, (R)- [CAS]	125392-76-9	US 5563176	Anticancer, other	Cancer, prostate
Iron Sorbitex		1338-16-5			
Irsogladiine	1,3,5-Triazine-2,4-diamine, 6-(2,5-dichlorophenyl)- [CAS]	57381-26-7 57381-28-9 57381-33-6	US 4657907	Antihypertensive, diuretic	Hypertension, general
IS-741	Cyclohexanecarboxamide, N-[2-[(ethylsulfonyl)amino]-5-(trifluoromethyl)-3-pyridinyl]- [CAS]	141283-87-6	EP 465913	GI inflammatory/bowel disorders	Pancreatitis
isaglitazone	2,4-Thiazolidinedione, 5-[[6-[(2-fluorophenyl)methoxy]-2-naphthalenyl]methyl]-[CAS]	161600-01-7	US 5594016	Antidiabetic	Diabetes, Type II

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
ISAtx-247			NZ 502362	Immunosuppressant	Transplant rejection, general
Isbogrel		89667-40-3			
isepamicin	D-Streptamine, O-6-amino-6-deoxy-Alpha-D-glucopyranosyl-(1-4)-O-[3-deoxy-4-C-methyl-3-(methylamino)-β-L-arabinopyranosyl-(1-6)]-N1-(3-amino-2-hydroxy-1-oxopropyl)-2-deoxy-, (S)- [CAS]	58152-01-5 58152-03-7	US 4029882	Aminoglycoside antibiotic	Infection, dermatological
Isoaminile		77-51-0			
Isobutyl p-Aminobenzoate		94-14-4			
Isocarboxazid		59-63-2			
isiconazole	1-[2-(2,6-dichlorobenzoyloxy)-2-(2,4-dichlorophenyl)ethyl]	24168-96-5 27523-40-6	GB 1244530	Antifungal	Infection, fungal, general
Isoetharine		530-08-5			
isofloxythepin	1-Piperazineethanol, 4-[3-fluoro-10,11-dihydro-8-(1-methylethyl)dibenzo[b,f]thiepin-10-yl]- [CAS]	106819-39-0 106819-41-4 70931-18-9	GB 2010843	Neuroleptic	
isoflurane	Ethane, 2-chloro-2-(difluoromethoxy)-1,1,1-trifluoro- [CAS]	26675-46-7	US 3535388	Anaesthetic, inhalation	Anaesthesia
Isofluorophate		55-91-4			
Isoladol		530-34-7			
Isomethadone		466-40-0			
Isomethheptene		503-01-5			
Isoniazid		54-85-3			
Isonixin		57021-61-1			
Isopromethazine		303-14-0			
Isopropamide iodide		71-81-8			
Isopropyl Alcohol		67-63-0			
isopropyl unoprostone	5-Heptenoic acid, 7-(3,5-dihydroxy-2-(3-oxodecyl)cyclopentyl)-, 1-methylethylester, (1R-(1Alpha(Z), 2β,3Alpha,5Alpha))- [CAS]	120373-24-2	EP 289349	Prostaglandin	Glaucoma
Isoproterenol		7683-59-2			
Isosorbide		652-67-5			

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Isosorbide dinitrate	D-Glucitol, 1,4:3,6-dianhydro-, dinitrate [CAS]	87-33-2		Formulation, modified-release, other	Angina, general
Isosorbide mononitrate	D-Glucitol, 1,4:3,6-dianhydro-, 5-nitrate [CAS]	16051-77-7		Formulation, modified-release, other	Angina, general
Isohipendyl		482-15-5			
Isotretinoin	Retinoic acid, 13-cis- [CAS]	4759-48-2	US 4843096	Antiacne	Acne
Isovaleryl Diethylamide		533-32-4			
Isoxepac		55453-87-7			
Isoxicam		34552-84-6			
Isoxsuprine		395-28-8			
Isradipine	3,5-Pyridinedicarboxylic acid, 4-(4-benzofurazan-1-yl)-4-dihydro-2,6-dimethyl-, methyl 1-methylethyl ester [CAS]	75695-93-1	GB 2037766	Antihypertensive, other	Hypertension, general
Israpafant	6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine, 4-(2-chlorophenyl)-6,9-dimethyl-2-[2-[4-(2-methylpropyl)phenyl]ethyl]- [CAS]	117279-73-9	EP 268242	Antiasthma	Asthma
ISV-403			US 5447926	Formulation, mucosal, topical	Conjunctivitis
Itasetron		123258-84-4			
ITF-282	ITF 282 [CAS]	93615-44-2	GB 2115821	Antianaemic	Anaemia, general
Itopride	Benzamide, N-[[4-[2-(dimethylamino)ethoxy]phenyl]methyl]-3,4-dimethoxy-, monohydrochloride [CAS]	122892-31-3	EP 306827	Gastroprokinetic	Gastritis
Itraconazole	3H-1,2,4-Triazol-3-one, 4-[4-[4-[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-yl)methyl]-1,3-dioxolan-4-yl]methoxy]phenyl]-1-piperazinyl]phenyl]-2,4-dihydro-2-(1-methylpropyl)- [CAS]	84625-61-6	EP 6711	Antifungal	Infection, fungal, general
Itramin		13445-63-1			
Ittriglumide	1-Naphthalenepropanoic acid, β-[2-[2-(8-azaspiro[4.5]dec-8-ylcarbonyl)-4,6-dimethylphenyl]amino]-2-oxoethyl]-, (SR)- [CAS]	201605-51-8	WO 9800404	Anxiolytic	Anxiety, general

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
iturelix	D-Alaninamide N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-N6-(3-pyridinylcarbonyl)-L-lysyl-N6-(3-pyridinylcarbonyl)-D-lysyl-L-leucyl-N6-(1-methylethyl)-L-lysyl-L-prolyl- [CAS]	112568-12-4	WO 8901944	Fertility enhancer	Infertility, female
ivabradine	7,8-dimethoxy-3-(3-[[[(1S)(4,5-dimethoxybenzocyclobutan-1-yl)methyl]methylamino]propyl]-1,3,4,5-tetrahydro-2H-benzazepin-2-one			Antianginal	Angina, general
ixabepilone	17-Oxa-4-azabicyclo(14.1.0)heptadecane-5,9-dione, 7,11-dihydroxy-8,10,12,16-pentamethyl-3-(1-methyl-2-(2-methyl-4-thiazolyl)ethenyl, (1R,3S,7S,10R,11S,12S,16R) [CAS]	219989-84-1		Anticancer, other	Cancer, breast
J-104132	5H-Cyclopenta[b]pyridine-6-carboxylic acid, 5-(1,3-benzodioxol-5-yl)-2-butyl-7-[2[(2S)-2-carboxypropyl]-4-methoxyphenyl]-6,7-dihydro-, (5S,6R,7R)- [CAS]	198279-45-7	WO 9737665	Antihypertensive, other	Heart failure
J-107088	5H-Indolo(2,3-a)pyrrolo(3,4-c)carbazole-5,7(6H)-dione, 12-β-D-glucopyranosyl-12,13-dihydro-2,10-dihydroxy-6-((2-hydroxy-1-(hydroxymethyl)ethyl)amino- [CAS]	174402-32-5		Anticancer, other	Cancer, bladder
J-113397	1-[(3R,4R)-1-Cyclooctylmethyl-3-hydroxymethyl-4-piperidyl]-3-ethyl-1,3-dihydro-2H-benzimidazole-2-one			Analgesic, other	Pain, general
Janex-1	Phenol, 4-[[6,7-dimethoxy-4-quinazolinyl)amino]-[CAS]	202475-60-3		Anticancer, other	Cancer, leukaemia, general
Josamycin	Leucomycin V, 3-acetate 4B-(3-methylbutanoate) [CAS]	16846-24-5	JP 41021759	Macrolide antibiotic	Infection; general
JTV-519	1,4-Benzothiazepine, 2,3,4,5-tetrahydro-7-methoxy-4-[1-oxo-3-[4-(phenylmethyl)-1-piperidinyl]propyl]- [CAS]	145903-06-6	WO 9212148	Cardiovascular	Infarction, myocardial



API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
K-777			US 6287840	Protozoacide	Infection, trypanosomiasis, American
Kainic Acid		487-79-6			
Kalimate	Kalimate- [CAS]	92354-70-6		Urological	
Kallidin		342-10-9			
KB-130015	Acetic acid (2,6-diiodo-4-((2-methyl-3-benzofuranyl)methyl)phenoxy)- [CAS]	147030-48-6		Antiarrhythmic	Arrhythmia, general
KCB-328	Methanesulfonamide, N-[3-amino-4-[2-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]ethoxy]phenyl]-, monohydrochloride [CAS]	177596-55-3	WO 9604231	Antiarrhythmic	Arrhythmia, general
Kebuzone		853-34-9			
ketamine	2-(2-Chlorophenyl)-2-(methylamino)-cyclohexanone hydrochloride	6740-88-1		Formulation, transmucosal, nasal	Pain, post-operative
ketanserlin	2,4-(1H,3H)-Quinazolin-3-one, 3-[2-{4-(4-fluorobenzoyl)-1-piperidinyl}ethyl]- [CAS]	74050-98-9 83846-83-7	EP 13612	Antihypertensive, other	Hypertension, general
ketazolam	4H-[1,3]Oxazino[3,2-d][1,4]benzodiazepine-4,7(6H)-dione, 11-chloro-8,12b-dihydro-2,8-dimethyl-12b-phenyl- [CAS]	27223-35-4 27762-78-3	GB 1222294	Anxiolytic	
Kethoxal		469-79-4			
Ketobemidone					
ketocanazole	Piperazine, 1-acetyl-4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-yl)methyl]-1,3-dioxolan-4-yl]methoxy]phenyl]-, cis- [CAS]	65277-42-1	US 4335125	Antifungal	Infection, fungal, general
ketoprofen	mono(3-benzoyl-Alpha-methylbenzeneacetate) [CAS]	173011-11-5	EP 502502	Formulation, transdermal, systemic	Pain, general
ketorolac	1H-Pyrrolizine-1-carboxylic acid, 5-benzoyl-2,3-dihydro-, (+/-)- [CAS]	74103-06-3 74103-07-4	EP 53021	Analgesic, NSAID	
Ketorolac Tromethamine					
ketotifen	10-H-Benzo[4,5]cyclohepta[1,2-b]thiophen-10-one, 4,9-dihydro-4-(1-methyl-4-piperidinylidene)-, (E)-2-butenedioate (1:1)- [CAS]	34580-13-7 34580-14-8	GB 1355539	Antiallergic	Asthma
Khellin		82-02-0			

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
kinetin		9001-29-0		Dermatological	Photodamage
KNI-272	4-Thiazolidinecarboxamide, N-(1,1-dimethylethyl)-3-[2-hydroxy-3-[[[5-isoquinolinyl]oxy]acetyl]amino]-3-(methylthio)-1-oxopropyl]amino]-1-oxo-4-phenylbutyl]-, [4R-[3[2S*,3S*(R*)],4R*]]-[CAS]	147318-81-8	US 5644028	Antiviral, anti-HIV	Infection, HIV/AIDS
KP-103	(R,R)-2-(2,4-Difluorophenyl)-3-(4-methylenepiperidin-1-yl)-1-(1,2,4-triazol-1-yl)-2-butanol			Antifungal	Infection, general
KP-157			US 6110961	Antidepressant	Depression, general
KP-544			WO 9919305	Cognition enhancer	Unspecified
KRN-5500	L-glycero-β-L-manno-Heptopyranosylamine, 4-deoxy-4-[[[(2E,4E)-1-oxo-2,4-tetradecadienyl]amino]acetyl]amino]-N-1H-purin-6-yl- [CAS]	151276-95-8	WO 9015811	Anticancer, antibiotic	Cancer, colorectal
KT-136	Alpha-D-Glucopyranoside, β-D-fructofuranosyl, mixt. with 1-ethenyl-2-pyrrolidinone homopolymer compd. with iodine [CAS]	121602-88-8		Formulation, dermal, topical	Ulcer, decubitus
KUL-7211	(-)-2-[(2S)-1,2,3,4-tetrahydro-2-[(2R)-2-hydroxy-2-(4-hydroxyphenyl)ethyl]amino]naphthalen-7-yloxy]-N,N-dimethylacetamide hydrochloride monohydrate			Urological	Urinary calculus
KW-2170	6H-Pyrazolo[4,5,1-de]acridin-6-one, 5-[(3-aminopropyl)amino]-7,10-dihydroxy-2-[[[(2-hydroxyethyl)amino]methyl]-, dihydrochloride [CAS]	207862-44-0		Anticancer, alkylating	Cancer, lung, non-small cell
KW-6002	1H-Purine-2,6-dione, 8-(2-(3,4-dimethoxyphenyl)ethenyl)-1,3-dieethyl-3,7-dihydro-7-methyl- (E)- [CAS]	155270-99-8		Antiparkinsonian	Parkinson's disease

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
KW-7158	3,3,3-Trifluoro-2-hydroxy-2-methyl-N-(10-oxo-4,10-dihydrothieno[3,2-C][1]benzothiepin-9-yl)propanamide 5,5 dioxide			Urological	Incontinence
L-365260	Urea, N-(2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl)-N'-(3-methylphenyl)-, (R)- [CAS]	118101-09-0	EP 284256	Anticancer, other	Cancer, general
L-5-hydroxytryptophan	L-Tryptophan, 5-hydroxy- [CAS]	4350-09-8		Metabolic and enzyme disorders	Unspecified
L-745337	Methanesulfonamide, N-[6-[(2,4-difluorophenyl)thio]-2,3-dihydro-1-oxo-1H-inden-5-yl]- [CAS]	158205-05-1	WO 9413635	Analgesic, NSAID	Pain, general
L-758298	Phosphonic acid, [3-[[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-2,5-dihydro-5-oxo-1H-1,2,4-triazol-1-yl]]- [CAS]	172673-20-0	WO 9523798	Antiemetic	Chemotherapy-induced nausea and vomiting
L-826141			WO 9722585	Antiasthma	Unspecified
labetalol	5-[1-hydroxy-2-[(1-methyl-3-phenylpropyl)amino]ethyl]salicylamide HCl	32780-64-6 36894-69-6	US 4012444	Antihypertensive, adrenergic	
lacidipine	3,5-Pyridinedicarboxylic acid, 4-[2-[3-(1,1-dimethylethoxy)-3-oxo-1-propenyl]phenyl]-1,4-dihydro-2,6-dimethyl-, diethyl ester, (E)- [CAS]	103890-78-4	GB 2164336	Antihypertensive, other	Hypertension, general
Lactic Acid					
lactitol	D-Glucitol, 4-O-β-D-galactopyranosyl- [CAS]	585-86-4		Hepatoprotective	Infection, neurological
Lactulose		4618-18-2			
lafutidine	Acetamide, 2-[(2-furanylmethyl)sulfinyl]-N-[4-[[4-(1-piperidinylmethyl)-2-pyridinyloxy]-2-butenyl]-, (Z)- [CAS]	118288-08-7 169899-19-8	EP 282077	Antilucer	Ulcer, gastric
Lamifiban		144412-49-7			
lamivudine	2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-, (2R-cis)- [CAS]	134678-17-4	EP 513917	Antiviral, anti-HIV	Infection, HIV/AIDS

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
lamotrigine	1,2,4-Triazine-3,5-diamine, 6-(2,3-dichlorophenyl)- [CAS]	84057-84-1	EP	21121	Antiepileptic	Epilepsy, partial (focal, local)
lanidolol	Benzenepropanoic acid, 4-[2-hydroxy-3-[[2-[[4-morpholinyl(carbonyl)amino]ethyl]amino]propoxy]-, (2,2-dimethyl-1,3-dioxolan-4-yl)methyl ester, [S-(R*, R*)]- HCL	133242-30-5	EP	397031	Antiarrhythmic	Tachycardia, general
lanicemine	(S)-Alpha-phenyl-2-pyridine ethanamine dihydrochloride	153322-05-5			Neurological	Unspecified
laniquidar	Methyl 6,11-dihydro-11-[1-[2-[4-(2-quinolylmethoxy)phenyl]ethyl]-4-piperidinylidene]-5H-imidazo[2,1-b][3]benzazepine-3-carboxylate	197509-46-9	WO	9734897	Radio/chemosensitizer	Cancer, general
lanocanazole	1H-Imidazole-1-acetonitrile, Alpha-[4-(2-chlorophenyl)-1,3-dithiolan-2-ylidene]-, (E)- (±)- [CAS]	101530-10-3	US	4738976	Antifungal	Infection, fungal, general
Lanoteplase		171870-23-8				
Lanreotide		108736-35-2				
lansoprazole	1H-Benzimidazole, 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]- [CAS]	103577-45-3	EP	174726	Antiulcer	Ulcer, duodenal
lanthanum carbonate	Carbonic acid, lanthanum(3+) salt (3:2)[CAS]	587-26-8	US	5968976	Urological	Hyperphosphataemia
lapatinib	4-Quinazolinamine, N-[3-chloro-4-[(3-fluorobenzyl)methoxy phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]furan-2-yl]]	388082-78-8			Anticancer, other	Cancer, breast
laquinimod		248281-84-7			Multiple sclerosis treatment	Multiple sclerosis, general
lasofoxfene	2-Naphthalenol, 5,6,7,8-tetrahydro-6-phenyl-5-(4-(2-(1-pyrrolidinyl)ethoxy)phenyl)-(5R-cis)-, (S-(R*, R*)))-2,3-dihydroxybutanedioate [CAS]	190791-29-8	WO	9716434	Menopausal disorders	Hormone replacement therapy

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
latamoxef	5-Oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[carboxy(4-hydroxyphenyl)acetyl]amino]-7-methoxy-3-[[[(1-methyl-1H-tetrazol-5-yl)thio]methyl]-8-oxo- [CAS]	64952-97-2 64953-12-4	GB 1547351	Beta-lactam antibiotic	Infection, general
latanoprost	5-Heptenoic acid, 7-(3,5-dihydroxy-2-(3-hydroxy-5-phenylpentyl)cyclopentyl)-, 1-methylethyl ester, (1R-(1Alpha(Z),2beta(R*),3Alpha,5Alpha))- [CAS]	130209-82-4 135-43-3	WO 9002553	Prostaglandin	Glaucoma
Lauroguadine		146-37-2			
Laurolinium Acetate		83-72-7			
Lawson					
LAX-111	1-(Z,Z,Z,Z-eicosa-5,8,11,14,17-pentaenoyloxy)-3-(Z,Z,Z,Z,Z-eicosa-5,8,11,14,17-pentaenoyloxy)-propane	103878-84-8		Neuroleptic	Schizophrenia
Lazabemide					
LB-30057	Benzenecarboximidic acid, 4-[(2S)-3-(cyclopentylmethylamino)-2-[(2-naphthalenylsulfonyl)amino]-3-oxopropyl]-, hydrazide [CAS]		WO 9749673	Antithrombotic	Thrombosis, venous
L-Cystine					
Lefetamine		7262-75-1			
leflunomide	4-Isoxazolecarboxamide, 5-methyl-N-[4-(trifluoromethyl)phenyl]- [CAS]	75706-12-6	EP 13376	Antiarthritic, immunological	Arthritis, rheumatoid
leflunomide	4-Isoxazolecarboxamide, 5-methyl-N-[4-(trifluoromethyl)phenyl]- [CAS]	104981-93-3 75706-12-6	US 5610173	Anticancer, other	Cancer, ovarian
Lelopyrrole		5633-16-9			
lenampicillin	4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[aminophenylacetyl]amino]-3,3-dimethyl-7-oxo-, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester, [2S-[2Alpha,5Alpha,6beta(S*)]]- [CAS]	80734-02-7 86273-18-9	EP 61206	Penicillin, oral	Infection, general
lentinan	Lentinan [CAS]	37339-90-5		Anticancer, immunological	Cancer, stomach
Lepirudin					



API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
lercanidipine	3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-[(3,3-diphenylpropyl)methylamino]-1,1-dimethylethyl methyl ester-, hydrochloride [CAS]	100427-26-7 132866-11-6	US 4705797	Antihypertensive, other	Hypertension, general
lerisetron	1H-Benzimidazole, 1-(phenylmethyl)-2-(1-piperazinyl)- [CAS]	143257-98-1	US 5256665	Antiemetic	Nausea and vomiting, general
Lesopitron		132449-46-8			
leteprinim	Benzoic acid, 4-((3-(1,6-dihydro-6-oxo-9H-purin-9-yl)-1-oxopropyl)amino)-, monopotassium salt [CAS]				
leteprinin	4-Thiazolidinecarboxylic acid, 2-[2-(2-ethoxy-2-oxoethyl)thioethyl]- [CAS]	138117-50-7	US 6338963	Antiparkinsonian	Parkinson's disease
letosteine	Benzonitrile, 4,4'-(1H-1,2,4-triazol-1-ylmethylene)bis- [CAS]	53943-88-7	US 4032534	COPD treatment	Bronchitis, chronic
letrozole		112809-51-5	EP 236940	Anticancer, hormonal	Cancer, breast
Leucocyanidin		480-17-1			
Leuprolide		53714-56-0			
leuprolide acetate	Luteinizing hormone-releasing factor (pig), 6-D-leucine-9-(N-ethyl-L-prolinamide)-10-deglycinamide-, monoacetate (salt) [CAS]	53714-56-0 74381-53-6		Formulation, implant	Cancer, prostate
leuprorelin	Luteinizing hormone-releasing factor (pig), 6-D-leucine-9-(N-ethyl-L-prolinamide)-10-deglycinamide- [CAS]	53714-56-0		Formulation, implant	Cancer, prostate
Levallorphan		152-02-3			
levamisole	Imidazo[2,1-b]thiazole, 2,3,5,6-tetrahydro-6-phenyl-, (S)- [CAS]	14769-73-4 16595-80-5	US 4584305	Anthelmintic	Infection, helminth, general
Levcromakalim		94535-50-9			
levetiracetam	1-Pyrrolidineacetamide, Alpha-ethyl-2-oxo-, (S)- [CAS]	102767-28-2	EP 162036	Antiepileptic	Epilepsy, general
levobetaxolol	2-Propanol, 1-(4-(2-(cyclopropylmethoxy)ethyl)phenoxy)-3-((1-methylethyl)amino) hydrochloride [CAS]	116209-55-3		Formulation, mucosal, topical	Glaucoma
levobunolol	1(2H)-Naphthalenone, 5-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-3,4-dihydro-, (S)- [CAS]	27912-14-7 47141-42-4	US 3641152	Formulation, mucosal, topical	Glaucoma

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
levobupivacaine	2-Piperidinecarboxamide, 1-butyl-N-(2,6-dimethylphenyl)-, (S)- [CAS]	27262-47-1	WO 9510276	Anaesthetic, injectable	Anaesthesia
levocabastine	4-Piperidinecarboxylic acid, 1-[4-cyano-4-(4-fluorophenyl)cyclohexyl]-3-methyl-4-phenyl-, [3S-[1(cis),3Alpha,4S]]- [CAS]	79449-98-2 79516-68-0 79547-78-7	US 4369184	Antiallergic, non-asthma	Rhinitis, allergic, general
levocetirizine	Acetic acid, (2-(4-(4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)-, (R)- [CAS]	130018-77-8 59-92-7	WO 9406429	Antiallergic, non-asthma	Allergy, general
Levodopa					
levodropropizine	1,2-Propanediol, 3-(4-phenyl-1-piperazinyl)-, (S)- [CAS]	99291-25-5	EP 147847	Antitussive	Cough
levofloxacin	7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid, 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-, (S)- [CAS]	100986-85-4 138199-71-0 1477-40-3	EP 206283	Quinolone antibacterial	Infection, respiratory tract, lower
Levomethadyl Acetate					
levomoprolol	2-Propanol, 1-(2-methoxyphenoxy)-3-[(1-methylethyl)amino]-, (S)- [CAS]	27058-84-0 5741-22-0 77164-20-6	EP 15418	Antihypertensive, adrenergic	
levonorgestrel	18,19-Dinorepregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-, (17Alpha)- [CAS]	797-63-7		Formulation, implant	Contraceptive, female
Levophacetoparane		24558-01-8			
Levopropoxyphene		2338-37-6			
Livorphanol		77-07-6			
levosimendan	Propanedinitrile, [[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]-, (R)- [CAS]	131741-08-7 141505-33-1	EP 383449	Cardio stimulant	Heart failure
levosulpiride	Benzamide, 5-(aminosulfonyl)-N-[(1-ethyl-2-pyrrolidinyl)methyl]-2-methoxy-, (S)- [CAS]	23672-07-3	GB 2014990	Antiemetic	Dyspepsia
Levothyroxine					
levovirin	1-β-L-ribofuranosyl-1,2,4-triazole-3-carboxamide			Antiviral, other	Infection, hepatitis-C virus

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
lexipafant	L-Leucine, N-methyl-N-[[4-[(2-methyl-1H-imidazo[4,5-c]pyridin-1-yl)methyl]phenyl]sulfonyl]-, ethyl ester- [CAS]	139133-26-9	WO 9203423	Neurological	Dementia, AIDS-related
LF-15-0195			WO 9624579	Immunosuppressant	Lupus erythematosus, general
LF-16-0687	2-Pyrrolidinecarboxamide, N-[3-[[4-(aminoininomethyl)benzoyl]amino]propyl]-1-[[2,4-dichloro-3-[[[(2,4-dimethyl-8-quinolinyloxy)methyl]phenyl]sulfonyl]-, (2S)- [CAS]	209733-45-9	FR 2756562	Neuroprotective	Head trauma
LGD-1550	2,4,6-Octatrienoic acid, 7-(3,5-bis(1,1-dimethylethyl)phenyl)-3-methyl- (2E,4E,6E)- [CAS]	178600-20-9		Anticancer, other	Cancer, cervical
LH		9002-67-9			
LH-RH		9034-40-6			
liarozole	1H-Benzimidazole, 5-[(3-chlorophenyl)-1H-imidazol-1-ylmethyl]- [CAS]	115575-11-6		Formulation, other	Psoriasis
licofelone	1H-Pyrrolizine-5-acetic acid, 6-(4-chlorophenyl)-2,3-dihydro-2,2-dimethyl-7-phenyl- [CAS]	156897-06-2		Antiarthritic, other	Arthritis, osteo
Licostinel		153504-81-5			
lidadronate	Phosphonic acid, [1-amino-3-(dimethylamino)propylidene]bis- [CAS]	63132-38-7	WO 9702827	Urological	Unspecified
Lidamidine		66871-56-5			
lidocaine	Acetamide, 2-(diethylamino)-N-(2,6-dimethylphenyl)- [CAS]	137-58-6		Formulation, transdermal, patch	Pain, post-herpetic
Lidofenin		59160-29-1			
Lidoflazine		3416-26-0			
limaprost	Prosta-2,13-dien-1-olc acid, 11,15-dihydroxy-17,20-dimethyl-9-oxo-, (2E,11Alpha,13E,15S,17S)-, [CAS]	74397-12-9	GB 2041368	Prostaglandin	Buerger's syndrome
Lincomycin		154-21-2			
Lindane		58-89-9			
linezolid	Acetamide, N-((3-(3-fluoro-4-(4-morpholinyl)phenyl)-2-oxo-5-oxazolidinyl)methyl)-, (S)- [CAS]	165800-03-3	WO 9507271	Antibiotic, other	Infection, dermatological

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Linoleic Acid		60-33-3			
Linolenic Acid		463-40-1			
Liothyronine		6893023			
Lipase		9001-62-1			
Lipo-dexamethasone palmitate	Pregna-1,4-diene-3,20-dione, 9-fluoro-11,17-dihydroxy-16-methyl-21-[(1-oxohexadecyl)oxy]-, (11 $\beta$ ,16 $\alpha$ )- [CAS]	14899-36-6		Formulation, optimized, microemulsion	Arthritis, rheumatoid
Lipo-flurbiprofen	[1,1'-Biphenyl]-4-acetic acid, 2-fluoro- $\alpha$ -methyl-, 1-(acetoxy)ethyl ester [CAS]	91503-79-6	JP 60208910	Formulation, optimized, microemulsion	Pain, cancer
Lipogel HA			EP 525655	Formulation, optimized, liposomes	Unspecified
LiquiVent	perfluorooctylbromide	423-55-2	US 5437272	Lung Surfactant	Respiratory distress syndrome, adult
Liranaftate	Carbamothioic acid, (6-methoxy-2-pyridinyl)methyl-, O-(5,6,7,8-tetrahydro-2-naphthalenyl) ester [CAS]	88678-31-3	GB 2124617	Antifungal	Infection, dermatological
Lisinopril	L-Proline, 1-[N2-(1-carboxy-3-phenylpropyl)-L-lysyl]-, (S)- [CAS]	76547-98-3 83915-83-7	EP 12401	Antihypertensive, renin system	Hypertension, general
Lisofylline		100324-81-0			
Lisuride	Urea, N'-[(8 $\alpha$ )-9,10-didehydro-6-methylergolin-8-yl]-N,N-diethyl-, [CAS]	19875-60-6 305-13-5 18016-80-3		Antiprolactin	Acromegaly
Lithium Citrate		919-16-4			
Lithium	Carbonic acid, dilithium salt [CAS]	554-13-2		Formulation, modified-release, $\leq 24$ hr	Depression, bipolar
Lixivaptan	Benzamide, N-[3-chloro-4-(5H-pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-ylcarbonyl)phenyl]-5-fluoro-2-methyl- [CAS]	168079-32-1	US 5736540	Cardiovascular	Heart failure
LJP-1082			US 6207160	Immunosuppressant	Thrombosis, venous
LLUAlpha	S-2,7,8-Trimethyl-6-( $\beta$ -carboxyethyl)-6-hydroxychroman			Antihypertensive, other	Hypertension, general
LMP-160			US 5643893	Antiasthma	Asthma
LMP-420			US 5643893	Antiarthritic, other	Arthritis, rheumatoid

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Iobaptatin	Platinum, (1,2-cyclobutanedimethanamine-N,N')bis(2-hydroxypropanoato(2-)-O1,O2)-, [SP 4-3-(S) <sub>2</sub> (trans)]- [CAS]	135558-11-1	DE 4115559	Anticancer, alkylating	Cancer, lung, small cell
Lobeline		90-69-7			
Lobenzarit		63329-53-3			
Iodoxamide	2,2'-(2-chloro-5-cyano-1,3-phenylene)dilimino bis(2-oxoacetate):2-amino-2-(hydroxymethyl)-1,3-propanediol (1:2)	63610-09-3 53882-12-5	US 4439445	Antialsthma	Asthma
Lofentanil		61380-40-3			
Iofepamine	Ethanone, 1-(4-chlorophenyl)-2-[[3-(10,11-dihydro-5H-dibenz[b,f]azepin-5-yl)propyl]methylamino]- [CAS]	23047-25-8 26786-32-3	GB 1177525	Antidepressant	
Iofexidine	1H-Imidazole, 2-[1-(2,6-dichlorophenoxy)ethyl]-4,5-dihydro- [CAS]	31036-80-3	GB 1181356	Antihypertensive, adrenergic	Hypertension, general
Lofluocarban		790-69-2			
Iomefloxacin	3-Quinolincarboxylic acid, 1-ethyl-6,8-difluoro-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4-oxo- [CAS]	98079-51-7 98079-52-8	EP 140116	Quinolone antibacterial	Infection, respiratory tract, lower
Iomerizine	Piperazine, 1-[bis(4-fluorophenyl)methyl]-4-[[2,3,4-trimethoxyphenyl)methyl]-, [CAS]	101477-54-7 101477-55-8	EP 159566	Antimigraine	Migraine
Iomifylline	7-(5-oxohexyl)theophylline	10226-54-7	DE 2207860	Neurological	
Iomustine	Urea, N-(2-chloroethyl)-N'-cyclohexyl-N-nitroso- [CAS]	13010-47-4	JP 48075526	Anticancer, alkylating	
Ionafamib	1-Piperidinecarboxamide, 4-[2-[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl]-1-piperidinyl]-2-oxoethyl]- [CAS]	193275-84-2	US 5874442	Anticancer, other	Cancer, lung, non-small cell
Lonapalene		91431-42-4			
Lonazolac		53808-88-1			
Ionidamine	1H-Indazole-3-carboxylic acid, 1-[(2,4-dichlorophenyl)methyl]- [CAS]	50264-69-2	DE 2310031	Radio/chemosensitizer	Cancer, breast
Ioperamide	4-(p-chlorophenyl)-4-hydroxy-N,N-dimethyl-Alpha,Alpha-diphenyl-1-piperidine butyramide HCl	34552-83-5 53179-11-6	US 3714159	Antidiarrhoeal	Diarrhoea, general



API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
loperamide oxide	1-Piperidinebutanamide, 4-(4-chlorophenyl)-4-hydroxy-N,N-dimethyl-Alpha,Alpha-diphenyl-, 1-oxide, trans- [CAS]	106900-12-3	EP 219898	Antidiarrhoeal	Diarrhoea, general
loprazolam	1H-Imidazo[1,2-a][1,4]benzodiazepin-1-one, 6-(2-chlorophenyl)-2,4-dihydro-2-[(4-methyl-1-piperazinyl)methylene]-8-nitro- [CAS]	61197-73-7 61197-93-1 70111-54-5	GB 1496426	Hypnotic/Sedative	
Loprinone		106730-54-5			
loracarbef	1-Azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[(aminophenylacetyl)amino]-3-chloro-8-oxo-, [6R-[6Alpha,7B(R')]]- [CAS]	76470-66-1 121961-22-6	EP 14475	Cephalosporin, oral	Infection, respiratory tract, lower
Lorajmine		47562-08-3			
loratadine	1-Piperidinecarboxylic acid, 4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)-, ethyl ester- [CAS]	79794-75-5	EP 42544	Antiallergic, non-asthma	Rhinitis, allergic, general
lorazepam	2H-1,4-Benzodiazepin-2-one, 7-chloro-5-(2-chlorophenyl)-1,3-dihydro-3-hydroxy- [CAS]	846-49-1		Formulation, oral, orally-disintegrating	Epilepsy, general
lorcainide	Benzeneacetamide, N-(4-chlorophenyl)-N-[1-(1-methylethyl)-4-piperidinyl]-[CAS]	58934-46-6 59729-31-6	DE 2642856	Antiarrhythmic	
lormetazepam	2H-1,4-Benzodiazepin-2-one, 7-chloro-5-(2-chlorophenyl)-1,3-dihydro-3-hydroxy-1-methyl- [CAS]	848-75-9	US 3296249	Hypnotic/Sedative	Insomnia
lornoxicam	2H-Thieno[2,3-e]-1,2-thiazine-3-carboxamide, 6-chloro-4-hydroxy-2-methyl-N-2-pyridinyl-, 1,1-dioxide- [CAS]	70374-39-9	EP 313935	Analgesic, NSAID	Pain, post-operative
losartan	1H-Imidazole-5-methanol, 2-butyl-4-chloro-1-[[2'-(1H-tetrazol-5-yl)][1,1'-biphenyl]-4-yl]methyl]-, [CAS]	124750-99-8 114798-26-4	EP 253310	Antihypertensive, renin system	Hypertension, general
loteprednol	Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxyl]-11-hydroxy-3-oxo-, chloromethyl ester, (11B,17Alpha)- [CAS]	82034-46-6	GB 2079755	Anti-inflammatory, topical	Uveitis

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Lotrafiban		171049-14-2			
Lovastatin		75330-75-5			
Loxapine		10/02/1977			
loxiglumide	Pentanoic acid, 4-[(3,4-dichlorobenzoyl)amino]-5-[(3-methoxypropyl)pentylamino]-5-oxo-, (±)- [CAS]	107097-80-3	WO 8703869	GI inflammatory/bowel disorders	Pancreatitis
loxoprofen	Benzeneacetic acid, Alpha-methyl-4-[(2-oxocyclopentyl)methyl]- [CAS]	68767-14-6 80382-23-6 87828-36-2	EP 55588	Antiarthritic, other	Arthritis, rheumatoid
Lu-35-138	1-[3[[2-[5-chloro-1-(4-fluorophenyl)-3-1H-indolyl]ethyl]methylamino]propyl]-2-imidazolidinone hydrochloride		WO 9516684	Neuroleptic	Psychosis, general
Lubeluzole		144665-07-6			
lubiprostone	(-)-7-[(2R,4aR,5R,7aR)-2-(1,1-difluoropentyl)-2-hydroxy-6-oxooctahydrocyclopenta[b]pyran-5-yl]heptanoic acid	136790-76-6		Laxative	Constipation
lucanthone	Thioxanthene-9-one, 1-((2-(diethylamino)ethyl)amino-4-methyl)- [CAS]	479-50-5		Radio/chemosensitizer	Cancer, brain
Lucanthone		548-57-2			
Lumefantrine		82186-77-4			
lumiracoxib	Benzeneacetic acid, 2-((2-chloro-6-fluorophenyl)amino)-5-methyl- [CAS]	220991-20-8		Analgesic, NSAID	Pain, general
lurtotecan	11H-1,4-Dioxino[2,3-g]pyranol[3',4':6,7]indolizino[1,2-b]quinoline-9,12[8H,14H]-dione, 8-ethyl-2,3-dihydro-8-hydroxy-15-[[4-methyl-1-piperazinyl]methyl]-, [CAS]	155773-58-3		Formulation, optimized, liposomes	Cancer, ovarian
lutetium texaphyrin	Lutetium, bis(acetato-O)[9,10-diethyl-20,21-bis-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]-4,15-dimethyl-8,11-imino-3,6:16,13-dinitrilo-1,18-benzodiazacycloelcosine-5,14-dipropanolato-N1,N18,N23,N24,N25]-, (PB-7-11-233'2'4')- [CAS]	156436-90-7	WO 9906411	Radio/chemosensitizer	Atherosclerosis

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
LV-216	Zinc[2-(2,6-dichloroanilino)phenyl]acetate			Anti-inflammatory	Arthritis, rheumatoid
LX-104	Hexadecanamide, N-[4-[[2-[2-[2-[O-(N-acetyl-Alpha-neuraminosyl)-(2-3)-O-β-D-galactopyranosyl-(1-4)-O-[6-deoxy-Alpha-L-galactopyranosyl-(1-3)]-β-D-glucopyranosyl]oxy]ethoxy]ethoxy]ethoxy]methyl]phenyl]-2-tetradecyl- [CAS]	158792-45-1		Cognition enhancer	Dementia, senile, general
LY-156735	β-methyl-6-chloromelatonin		EP 655243	Hypnotic/Sedative	Sleep disorder, general
LY-293111	Benzolic acid, 2-[3-[3-[(5-ethyl-4'-fluoro-2-hydroxy[1,1'-biphenyl]-4-yloxy]propoxy]-2-propylphenoxy]- [CAS]	161172-51-6		Anticancer, other	Cancer, melanoma
LY-293558	3-Isoquinolinecarboxylic acid, decahydro-6-[2-(1H-tetrazol-5-yl)ethyl]-, [3S-(3Alpha.,4aAlpha,6β,8aAlpha.)]- [CAS]	154652-83-2		Analgesic, other	Pain, neuropathic
LY-355703	1,4-Dioxo-8,11-diazacyclohexadec-13-ene-2,5,9,12-tetrone, 10-[(3-chloro-4-methoxyphenyl)methyl]-6,6-dimethyl-3-(2-methylpropyl)-16-[(1S)-1-[(2S,3R)-3-phenyloxirany]ethyl]-, (3S,10R,13E,16S)- [CAS]	18256-67-7	WO 9707798	Anticancer, other	Cancer, lung, non-small cell
Lyapolate		25053-27-4			
Lymecycline		992-21-2			
Lynestrenol		52-76-6			
Lypressin		50-57-7			
Lysine Acetylsalicylate		62952-06-1			
lysine salicylate	L-Lysine, 2-hydroxybenzoate [CAS]	59535-08-9	WO 9624331	Analgesic, NSAID	
lysophospholipids			WO 9843093	Diagnostic	Diagnosis, cancer

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
M-40403	Dichloro[(4aR,13aR,17aR,21aR)-1,2,3,4,4a,5,6,12,13,13a,14,15,16,17,17a,18,19,20,21,21a-eicosahydro-1,7-nitro-7H-dibenzo[b,h][1,4,7,10]tetraazacycloheptadecine-kappaN5,kappaN13,kappaN18,kappaN21,kappaN22]manganese		US 6180620	Anticancer, other	Unspecified
mabuprofen	Benzeneacetamide, N-(2-hydroxyethyl)-Alpha-methyl-4-(2-methylpropyl)-, (+/-)-[CAS]	82821-47-4	DE 3121595	Anti-inflammatory	
Mabuterol		56341-08-3			
Macrophage Colony-Stimulating Factor		81627-83-0			
MADU		840-50-6			
mafenide	Benzenesulfonamide, 4-(aminomethyl)-monacetate [CAS]	13009-99-9 138-39-6		Vulninary	Burns
mafosfamide	Ethanesulfonic acid, 2-[[2-bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorin-4-yl]thio]-, P-oxide, cis-(±)-[CAS]	88859-04-5 98845-64-8	EP 393575	Anticancer, alkylating	Cancer, renal
magaldrate	Aluminum magnesium hydroxide sulfate (Al5Mg10(OH)31(SO4)2), hydrate [CAS]	74978-16-8	US 2923660	Antacid/Antiflatulent	
Magenta I		632-99-5			
Magnesium Acetylsalicylate		132-49-0			
Magnesium Carbonate Hydroxide		39409-82-0			
magnesium chloride	Magnesium chloride (MgCl2) [CAS]	7786-30-3		Formulation, oral, enteric-coated	Nutrition
Magnesium Citrate		3344-18-1			
magnesium gluconate	D-Gluconic acid, magnesium salt (2:1) [CAS]	3632-91-5		Formulation, other	Hypertension, general
Magnesium Lactate		18917-93-6			
Magnesium Salicylate		18917-89-0			
Malathion		121-75-5			
Malotilate		59937-28-9			
Mandelic Acid		90-64-2			

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Mandelic Acid Isoamyl Ester		5421045			
Mangafodipir		118248-94-5 (free acid); 155319-91-8 (hexahydrogen)			
manidipine	3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-[4-(diphenylmethyl)-1-piperazinyl]ethyl methyl ester [CAS]	89226-50-6 89226-75-5	EP 94159	Antihypertensive, other	Hypertension, general
Mannomustine		551-74-6			
mannose-6-phosphate	mannose-6-phosphate			Vulnerary	Wound healing
Maprotiline		10262-69-8			
maribavir	1H-Benzimidazol-2-amine, 5,6-dichloro-N-(1-methylethyl)-1-β-L-ribofuranosyl- [CAS]	176161-24-3		Antiviral, other	Infection, cytomegalovirus
marimastat	N-[2,2-Dimethyl-1(S)-(N-methylcarbamoyl)propyl]-N,3(S)-dihydroxy-2(R)-isobutylsuccinamide	154039-60-8	WO 9402447	Anticancer, other	Cancer, pancreatic
maxacalcitol	1,3-Cyclohexanediol, 4-methylene-5-(2-(octahydro-1-(1-(3-hydroxy-3-methylbutoxy)ethyl)-7a-methyl-4H-inden-4-ylidene)ethylidene)-, (1S-(1Alpha(R*),3aβ,4E(1S*,3R*,5Z),7aAlpha))-[CAS]	103909-75-7	US 4891364	Hormone	Hyperparathyroidism
mazindol	3H-Imidazo[2,1-a]isoindol-5-ol, 5-(4-chlorophenyl)-2,5-dihydro- [CAS]	22232-71-9	US 3763178	Anorectic/Antiobesity	Obesity
Mazipredone		13085-08-0			
MC-5723			US 6043259	Cardiovascular	Unspecified
MCC-478	(2-amino-6-(4-methoxyphenylthio)-9-[2-(phosphonomethoxy)ethyl]purine bis(2,2,2-trifluoroethyl) ester)			Antiviral, other	Infection, hepatitis-B virus
MCI-154	3(2H)-Pyridazinone, 4,5-dihydro-6-[4-(4-pyridinylamino)phenyl]-, monohydrochloride [CAS]	98326-32-0 98326-33-1	EP 145019	Cardio stimulant	Heart failure
m-Cresyl Acetate		122-46-3			

Patent US 63/44642



API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
MDAM	Gamma-Methylene-10-deazaaminopterin			Anticancer, antimetabolite	Cancer, general
MDI-101			US 4885311	Antiacne	Acne
MDI-403		403849-94-5	US 4677120	Antiacne	Acne
MDL-100907	4-Piperidinemethanol, Alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-, (R)- [CAS]	139290-65-6		Hypnotic/Sedative	Sleep disorder, general
mebendazole	methyl-5-benzoylbenzimidazole-2-carbamate	31431-39-7	GB 1307306	Anthelmintic	
mebeverine	Benzolic acid, 3,4-dimethoxy-, 4-[ethyl[2-(4-methoxyphenyl)-1-methylethyl]amino]butyl ester [CAS]	3625-06-7		Antispasmodic	Irritable bowel syndrome
Mebhydroline		524-81-2			
Mebrofenin		78266-06-5			
Mebutamate		64-55-1			
mecamylamine	Bicyclo(2.2.1)heptan-2-amine, N,2,3,3-tetramethyl- [CAS]	60-40-2		Neurological	Unspecified
Mechlorethamine		51-75-2			
Mechlorethamine Oxide		302-70-5			
mecillinam	4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[hexahydro-1H-azepin-1-yl)methylene]amino]-3,3-dimethyl-7-oxo-, [2S-(2Alpha,5Alpha,6.beta.)]- [CAS]	32887-01-7 32887-03-9	GB 1293590	Penicillin, injectable	Infection, general
Mecizine		569-65-3			
Meclocycline		2013-58-3			
meclofenamate	Benzoic acid, 2-[(2,6-dichloro-3-methylphenyl)amino]-, monosodium salt [CAS]	6385-02-0 644-62-2		Antiarthritic, other	Arthritis, osteo
Meclofenamic Acid		644-62-2			
Meclofenoxate		51-68-3			
Mecloqualone		340-57-8			
Mecysteine		18598-63-5			
Medazepam		12/06/2898			
medifoxamine	Ethanamine, N,N-dimethyl-2,2-diphenoxy- [CAS]	32359-34-5	FR M5498	Antidepressant	

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Medrogestone		977-79-7			
Medronic Acid		1984-15-2			
medroxyprogesterone	Pregn-4-ene-3,20-dione, 17-(acetyloxy)-6-methyl-, (6 $\alpha$ )	71-58-9 520-85-4		Formulation, fixed-dose combinations	Contraceptive, female
Medrysone		2668-66-8			
Mefenamic Acid		61-68-7			
Mefenorex		17243-57-1			
Mefexamide		1227-61-8			
mefloquine	4-Quinolinemethanol, Alpha-2-piperidinyl-2,8-bis(trifluoromethyl)-, (R*,S*)-( $\pm$ )-[CAS]	51773-92-3 53230-10-7 69191-18-0	GB 1594282	Antimalarial	
Mefruside		7195-27-9			
Megestrol		595-33-5			
Meglumine		22154-43-4 49-7	131-		
meglutol	2-hydroxy-2-methyl-1,3-propanedicarboxylic acid	503-49-1	US 3629449	Hypolipaeic/Antiatherosclerosis	Hyperlipidaemia, general
melagatran	Glycine, N-[(1R)-2-[(2S)-2-[[[4-(aminiminomethyl)phenyl]methyl]amino]carbonyl]-1-azetidinyl]-1-cyclohexyl-2-oxoethyl]-[CAS]	159776-70-2	WO 9616671	Antithrombotic	Thrombosis, general
melanocortin-4 agonist	N-[(3R)-1,2,3,4-Tetrahydroisoquinolinium-3-ylcarbonyl]-(1R)-1-(4-chlorobenzyl)-2-[4-cyclohexyl-4-(1H-1,2,4-triazol-1-ylmethyl)piperidin-1-yl]-2-oxoethylamine(1)			Anorectic/Antiobesity	Obesity
Melarsoprol		494-79-1			
Melengestrol		5633-18-1			
melevodopa	Alanine, 3-(3,4-dihydroxyphenyl)-methyl ester [CAS]	7101-51-1	EP 252290	Antiparkinsonian	Parkinson's disease
Melinamide		14417-88-0			
Melitracen		5118-29-6			

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
meloxicam	2H-1,2-Benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-, 1,1-dioxide- [CAS]	71125-38-7	US 4233299	Antiarthritic, other	Arthritis, rheumatoid
melperone	1-Butanone, 1-(4-fluorophenyl)-4-(4-methyl-1-piperidinyl)- [CAS]	1622-79-3 3575-80-2	BE 651144	Neuroleptic	
Melphalan		148-82-3			
meluadrine	Benzenemethanol, 2-chloro-Alpha-(((1,1-dimethylethyl)amino)methyl)-4-hydroxy-, (R)-, (R*, R*)-2,3-dihydroxybutanedioate (1:1) (salt) [CAS]				
memantine	Tricyclo[3.3.1.1 <sup>3,7</sup> ]decan-1-amine, 3,5-dimethyl [CAS]	134865-37-5 41100-52-1 19982-08-2	EP 420120 EP 392059	Labour inhibitor Cognition enhancer	Labour, preterm Dementia, AIDS-related
MEN-10700	Acetamide, 2-[[[(5R,6S)-6-[(1R)-1-hydroxyethyl]-2-methyl-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-en-3-yl]methyl]methylamino]- [CAS]	195874-55-6	WO 9406803	Beta-lactam antibiotic	Infection, general
MEN-10755	5,12-Naphthacenedione, 7-[[4-O-(3-amino-2,3,6-trideoxy-Alpha-L-lyxo-hexopyranosyl)-2,6-dideoxy-Alpha-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-9-(hydroxyacetyl)-, hydrochloride, (7S,9S)- [CAS]	169317-77-5	WO 9509173	Anticancer, antibiotic	Cancer, breast
Menadiol		481-85-6			
Menadione		58-27-5			
Menadoxime		573-01-3			
Menbutone		3562-99-0			
Menogaril		71628-96-1			
MENT	7Alpha-Methyl-19-nortestosterone			Formulation, transdermal, systemic	Contraceptive, male
menthol	Cyclohexanol, 5-methyl-2-(1-methylethyl)- [CAS]	1490-04-6 89-78-1		Formulation, dermal, topical	Pruritus
Menthyl Valerate		89-47-4			
Meobentine		46464-11-3			
Meparfynol		77-75-8			
mepartricin	Partricin, methyl ester [CAS]	11121-32-7	US 3780173	Antifungal	Infection, Candida, general

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Mepazine		60-89-9			
Mepenzolate Bromide		76-90-4			
Meperidine		57-42-1			
Mephenesin		59-47-2			
Mephenoxalone		70-07-5			
Mephentermine		100-92-5			
Mephénytoin		50-12-4			
Mephobarbital		115-38-8			
Mepindolol		23694-81-7			
Mepitiostane		21362-69-6			
mepivacaine	N-(2,6-Dimethylphenyl)-1-methyl-2-piperidinecarboxamide	96-88-8		Formulation, modified-release, >24hr	Pain, post-operative
Mepixanox		17854-59-0			
Meprednisone		1247-42-3			
Meprobamate		57-53-4			
meprosicillin	Bufa-4,20,22-trienolide, 3-[(6-deoxy-4-O-methyl- $\alpha$ -L-mannopyranosyl)oxy]-14-hydroxy-, (3S)- [CAS]		DE 1910207	Cardio stimulant	Heart failure
mep tazinol	Phenol, 3-(3-ethylhexahydro-1-methyl-1H-azepin-3-yl)- [CAS]	33396-37-1 54340-58-8 59263-76-2	GB 1285025	Analgesic, other	Pain, general
mequitazine	10H-Phenothiazine, 10-(1-azabicyclo[2.2.2]oct-3-ylmethyl)- [CAS]	29216-28-2	GB 1250534	Antiallergic, non-asthma	
Meralein		4386-35-0			
Meralluride		8069-64-5			
Merbromin		129-16-8			
Mercaptopimerin		21259-76-7			
Mercurallylic Acid		86-36-2			
Mercuric Chloride, Ammoniated		10124-48-8			
Mercuric Oleate		1191-80-6			
Mercuric Oxycyanide		1335-31-5			

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
merimepodib	Carbamic acid, ((3-(((3-methoxy-4-(5-oxazolyl)phenyl)amino)carbonyl)amino)phenyl)methyl)- (3S)-tetrahydro-3-furanyl ester [CAS]	198821-22-6	US 5807876	Antiviral, other	Infection, hepatitis-C virus
meropenem	1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 3-[[5-[(dimethylamino)carbonyl]-3-pyrrolidinyl]thio]-6-(1-hydroxyethyl)-4-methyl-7-oxo-, [4R-(3(3S*,5S*),4A]pha,5B,6B(R*)]-[CAS]	96036-03-2	EP 126587	Beta-lactam antibiotic	Infection, respiratory tract, lower
Mersalyl		492-18-2			
Mesalamine		89-57-6			
mesalazine	Benzoic acid, 5-amino-2-hydroxy- [CAS]	89-57-6	WO 5541170	Formulation, oral, other	Colitis, ulcerative
Mesna		19767-45-4			
Mesoridazine		5588-33-0			
Mestanolone		521-11-9			
Mesterolone		1424-00-6			
Mestranol		72-33-3			
Mesulfen		135-58-0			
Metaclozepam		84031-17-4			
Metampicillin		6489-97-0			
Metapramine		21730-16-5			
Metaproterenol		586-06-1			
Metaraminol		54-49-9			
Metazocine		3734-52-9			
metergoline	Carbamic acid, [[(8S)-1,6-dimethylergolin-8-yl]methyl]-, phenylmethyl ester [CAS]	17692-51-2 21631-37-8 2706-42-5	GB 1401935	Antiprolactin	Amenorrhoea
metformin	Imidodicarbonimidic diamide, N,N-dimethyl-[CAS]	657-24-9		Formulation, modified-release, <=24hr	Diabetes, Type II
Methacholine		62-51-1			
Methacycline		914-00-1			
Methadone		76-99-3			
Methafurylene		531-06-6			
Methamphetamine		537-46-2			



API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Methandriol		521-10-8			
Methandrostenolone		72-63-9			
Methantheline		53-46-3			
Methapyriene		91-80-5			
Methaqualone		72-44-6			
Metharbital		50-11-3			
Methazolamide		554-57-4			
Methdilazine		1982-37-2			
Methenamine		100-97-0			
Methenolone		153-00-4			
Methestrol		130-73-4			
Methetoin		5696-06-0			
Methicillin		132-92-3			
Methimazole		60-56-0			
Methiodal		126-31-8			
Methioninic Acid		503-40-2			
Methionine		63-68-3			
Methisazone		1910-68-5			
Methitural		467-43-6			
Methixene		02/02/4969			
Methocarbamol		532-03-6			
Methohexital		22151-68-4			
methotrexate	L-Glutamic acid, N-[4-[[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-[CAS]	59-05-2	US 2512572	Anticancer, antimetabolite	Cancer, general
Methotrimeprazine		60-99-1			
Methoxamine		390-28-3			
Methoxsalen		298-81-7			
Methoxyflurane		76-38-0			
Methoxyphenamine		93-30-1			
Methoxypromazine		61-01-8			
Methscopolamine		155-41-9			
Methsuximide		77-41-8			
Methyclothiazide		135-07-9			

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Methyl Blue		28983-56-4			
Methyl Nicotinate		93-60-7			
Methyl Propyl Ether		557-17-5			
Methyl Salicylate		119-36-8			
Methyl tert-Butyl Ether		1634-04-4			
Methylbenzethonium Chloride		25155-18-4			
Methylcobalamin		13422-55-4			
methyl dopa	L-Tyrosine, 3-hydroxy-Alpha-methyl- [CAS]	555-30-6		Formulation, modified-release, <=24hr	Hypertension, general
Methylene Blue		61-73-4			
Methylergonovine		113-42-8			
Methylhexanamine		105-41-9			
methylphenidate	2-Piperidineacetic acid, Alpha-phenyl-, methyl ester [CAS]	113-45-1		Formulation, modified-release, multi	Attention deficit disorder
Methylprednisolone		298-59-9			
		83-43-2			
methylprednisolone aceponate	Pregna-1,4-diene-3,20-dione, 21-(acetyloxy)-11-hydroxy-6-methyl-17-(1-oxopropoxy)-, (6Alpha,11Beta) [CAS]		EP 72547	Antipruritic/Inflamm, allergic	Pruritus
	Pregna-1,4-diene-3,20-dione, 11,17-dihydroxy-6-methyl-21-[[8-[methyl(2-sulfoethyl)amino]-1,8-dioxoctyl]oxy]-, monosodium salt, (6Alpha,11Beta) [CAS]				
methylprednisolone suleptanate		90350-40-6	JP 59137500	Antiasthma	Asthma
Methylthiouracil		56-04-2			
Methyltrienolone		965-93-5			
Methypyrylon		125-64-4			
Methysergide		361-37-5			
Metiazinic Acid		13993-65-2			
metipranolol	Phenol, 4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]-2,3,6-trimethyl-, 1-acetate [CAS]				
		22664-55-7	GB 1206148	Antihypertensive, adrenergic	
metoclopramide	Benzamide, 4-amino-5-chloro-N-[2-(diethylamino)ethyl]-2-methoxy- [CAS]	364-62-5		Formulation, modified-release, <=24hr	Gastro-oesophageal reflux
Metocurine Iodide		7601-55-0			
Metofenazate		388-51-2			

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
metolazone	6-Quinazolinylsulfonamide, 7-chloro-1,2,3,4-tetrahydro-2-methyl-3-(2-methylphenyl)-4-oxo- [CAS]	17560-51-9	US 4517179	Antihypertensive, diuretic	
Metopimazine		14008-44-7			
Metopon		143-52-2			
metoprolol	2-Propanol, 1-[4-(2-methoxyethyl)phenoxy]-3-[(1-methylethyl)amino]-, (+/-)- [CAS]	51384-51-1 56392-17-7 37350-58-6		Formulation, modified-release, other	Hypertension, general
Metralindole		54188-38-4			
Metrizamide		31112-62-6			
Metrizoic Acid		1949-45-7			
Metron S		13946-02-6			
Metyrapone		54-36-4			
Metyrosine		672-87-7			
Mexazolam		31868-18-5			
Mexenone		1641-17-4			
Mexiletine		31828-71-4			
mezlocillin	4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-6-[[[3-(methylethylsulfonyl)-2-oxo-1-imidazolidinyl]carbonyl]amino]phenylacetyl]amino]-7-oxo-, [2S-[2Alpha,5Alpha,6(S*)]]-[CAS]	42057-22-7 51481-65-3 72539-76-5	GB 1301961	Penicillin, injectable	Infection, general
MFH-244	Benzenecarboximidic acid, 3,4,5-trihydroxy-, ethyl ester, hydrochloride	95933-76-9	US 4623659	Cardiovascular	Reperfusion injury
mianserin	Dibenzo[c,f]pyrazino[1,2-a]azepine, 1,2,3,4,10,14b-hexahydro-2-methyl- [CAS]	21535-47-7 24219-97-4	GB 1173783	Antidepressant	Depression, general
Mibefradil		116644-53-2			
Miboplatin		103775-75-3			
Micafungin		235114-32-6			
miconazole	1H-Imidazole, 1-(2,4-dichlorophenyl)-2[2,4-dichlorophenyl)methoxy]ethyl]	22916-47-8		Formulation, modified-release, other	Infection, Candida, general
Micronomicin		52093-21-7			

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
midaxifylline	1H-Purine-2,6-dione, 8-(1-aminocyclopentyl)-3,7-dihydro-1,3-dipropyl- [CAS]	151159-23-8	US 5378844	Cardiovascular	Unspecified
midazolam	4H-imidazo[1,5-a][1,4]benzodiazepine, 8-chloro-6-(2-fluorophenyl)-1-methyl- [CAS]	59467-70-8 59467-94-6	US 4280957	Anaesthetic, injectable	
midecamycin	Leucomycin V, 3,4B-dipropanoate [CAS]	35457-80-8	US 3761588	Macrolide antibiotic	Infection, general
midecamycin acetate	Leucomycin V, 3B,9-diacetate 3,4B-dipropanoate [CAS]	55881-07-7	JP 49124087	Macrolide antibiotic	Infection, general
midesteine	2-Thiophenecarbothioic acid, S-[1-methyl-2-oxo-2-[(tetrahydro-2-oxo-3-thienyl)amino]ethyl] ester [CAS]	94149-41-4	EP 120534	COPD treatment	Emphysema, general
midodrine	Acetamide, 2-amino-N-[2-(2,5-dimethoxyphenyl)-2-hydroxyethyl]- [CAS]	42318-56-0 42794-76-3	EP 164571	Urological	Incontinence
midostaurin	Benzamide, N-(2,3,10,11,12,13-hexahydro-10-methoxy-9-methyl-1-oxo-9,13-epoxy-1H,9H-dindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-11-yl)-N-methyl-, (9Alpha,10B,11B,13Alpha)- [CAS]	120685-11-2	EP 296110	Anticancer, other	Cancer, leukaemia, acute myelogenous
mifepristone	Estra-4,9-dien-3-one, 11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(1-propynyl)-, (11B,17B)- [CAS]	84371-65-3	EP 57115	Abortifacient	Abortion
miglitol	3,4,5-Piperidinetriol, 1-(2-hydroxyethyl)-2-(hydroxymethyl)-, [2R-(2Alpha,3B,4Alpha,5B)]- [CAS]	72432-03-2	EP 55431	Antidiabetic	Diabetes, Type I
miglustat	3,4,5-Piperidinetriol, 1-butyl-2-(hydroxymethyl)-(2R-(2Alpha,3B,4Alpha,5B)) [CAS]	72599-27-0	DE 2758025	Metabolic and enzyme disorders	Gaucher's disease
mildronate	Hydrazinium, 2-(2-carboxyethyl)-1,1,1-trimethyl-, inner salt- [CAS]	76144-81-5	WO 8001068	Cardio stimulant	Heart failure
milnacipran	Cyclopropanecarboxamide, 2-(aminomethyl)-N,N-diethyl-1-phenyl-, cis-(±) [CAS]	101152-94-7 92623-85-3	US 4478836	Antidepressant	Depression, general
Miloxacin		37065-29-5			

API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
milrinone	[3,4'-Bipyridine]-5-carbonitrile, 1,6-dihydro-2-methyl-6-oxo- [CAS]	78415-72-2	US	4313951	Cardio stimulant	Heart failure
miltefosine	Ethaniminium, 2-[[[hexadecyloxy]hydroxyphosphinyloxy]-N,N,N-trimethyl-, hydroxide, inner salt [CAS]	53949-20-5 58066-85-6	EP	225608	Anticancer, other	Cancer, skin, general
minaprine	4-Morpholineethanamine, N-(4-methyl-6-phenyl-3-pyridazinyl)- [CAS]	25905-77-5 25953-17-7	GB	1345880	Antidepressant	Depression, general
minocycline	2-Naphthacene carboxamide, 4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, [4S-(4Alpha,4aAlpha,5a.alpha.,12aAlpha)]-[CAS]	10118-90-8			Formulation, optimized, microparticles	Infection, oral
minodronic acid	Phosphonic acid, (1-hydroxy-2-imidazo(1,2-a)pyridin-3-ylethylene)bis-, [CAS]	180064-38-4	EP	354806	Anticancer, other	Cancer, myeloma
minoxidil	2,4-Pyrimidinediamine, 6-(1-piperidinyl)-, 3-oxide [CAS]	38304-91-5	US	4139619	Vasodilator, peripheral	Hypertension, general
Miokamycin		55881-07-7				
mirtazapine	Pyrazino[2,1-a]pyrido[2,3-c][2]benzazepine, 1,2,3,4,10,14b-hexahydro-2-methyl-[CAS]	85650-52-8 61337-67-5	GB	1543171	Antidepressant	Depression, general
misoprostol	Prost-13-en-1-olc acid, 11,16-dihydroxy-16-methyl-9-oxo-, methyl ester, (11Alpha,13E)-(+)- [CAS]	59122-46-2 59122-48-4	US	4301146	Prostaglandin	Ulcer, gastric
mitemcinal	Erythromycin, 8,9-didehydro-N-demethyl-9-deoxy-6,11-dideoxy-6,9-epoxy-12-O-methyl-N-(1-methylethyl)-11-oxo-, (2E)-2-butenedioate (2:1) [CAS]	154802-96-7	WO	9324509	Gastroprokinetic	Gastro-oesophageal reflux
mitiglinide	Calcium (2S)-2-benzyl-3-(cis-hexahydro-2-isindolinylcarbonyl)propionate, dihydrate-[CAS]	145525-41-3 488-41-5	EP	507534	Antidiabetic	Diabetes, Type II
Mitobronitol						
Mitoguazone		459-86-9				

Patent/USDA/42642



API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
mitolactol	Galactitol, 1,6-dibromo-1,6-dideoxy- [CAS]	10318-26-0	US 3993781	Anticancer, alkylating	Cancer, cervical
mitomycin	Azirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione, 6-amino-8-[[[aminocarbonyloxy)methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methyl-, [1aS-(1aAlpha,8b,8aAlpha,8bAlpha)]- [CAS]	50-07-7		Formulation, parenteral, other	Cancer, stomach
Mitotane		53-19-0			
mitoxantrone	9,10-Anthracenedione, 1,4-dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]- [CAS]	65271-80-9 70476-82-3	US 4197249	Anticancer, other	Cancer, breast
mitoxantrone	9,10-Anthracenedione, 1,4-dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]- [CAS]	65271-80-9 70476-82-9		Formulation, optimized, liposomes	Cancer, general
MIV-210	(3'-Fluoro-2'-3'-dideoxy guanosine)			Antiviral, other	Infection, hepatitis-B virus
mivacurium	Isoquinolinium, 2,2'-[1,8-dioxo-4-octene-1,8-diyl]bis(oxy-3,1-propanediyl)]bis[1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-, dichloride, [R*,R*(E)]- [CAS]	106861-44-3 125472-02-8	EP 181055	Muscle relaxant	Anaesthesia, adjunct
Mivazerol	4(1H)-Pyrimidinone, 2-[[1'-[1-[(4-fluorophenyl)methyl]-1H-benzimidazol-2-yl]-4-piperidinyl]methylamino]- [CAS]	108612-45-9 50924-49-7	EP 217700	Antiallergic, non-asthma	Rhinitis, allergic, general
Mizoribine	(R)-N-(3-quinuclidinyl)-7-oxo-4,7-dihydrothieno[3,2-b]pyridine-6-carboxamide hydrochloride	194093-42-0	JP 09216888	Gastroprokinetic	Gastro-oesophageal reflux
MLN-519	6-Oxa-2-azabicyclo[3.2.0]heptane-3,7-dione, 1-[(1S)-1-hydroxy-2-methylpropyl]-4-propyl-, (1R,4R,5S)- [CAS]	211866-70-5	WO 9915183	Neuroprotective	Ischaemia, cerebral
MLN-576	4-Methoxy-benzo[a]phenazine-11-carboxylic acid (2-(dimethylamino)-1-(R)-methylethyl)-amide			Anticancer, other	Cancer, general

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
moclobemide	Benzamide, 4-chloro-N-[2-(4-morpholinyl)ethyl]- [CAS]	71320-77-9	EP 326023	Antidepressant	Depression, general
modafinil	Acetamide, 2-[(diphenylmethyl)sulfinyl]- [CAS]	68693-11-8	DE 2809625	Psychostimulant	Narcolepsy
moexipril	3-Isoquinolinecarboxylic acid, 2-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-(3S-(2(R*(R*),3R*)))- [CAS]	103775-10-6 103775-14-0	US 4344949	Antihypertensive, renin system	Hypertension, general
Mofarotene		125533-88-2			
Mofebutazone		2210-63-1			
Mofegiline		119386-96-8			
mofezolac	5-Isoazoleacetic acid, 3,4-bis(4-methoxyphenyl)- [CAS]	78967-07-4	EP 26928	Analgesic, NSAID	Pain, post-operative
MOL-6131	N-[4-(aminomethyl)benzyl]-8(S)-[1-[4-{2-(4-aminophenyl)-acetamido]butyl]piperidin-4-yl]-2-(naphthalen-1-ylmethyl)-1,3-dioxo-2,3,5,8-tetrahydro-1H-[1,2,4]triazolo[1,2-a]pyridazine-5(R)-carboxamide			Antiasthma	Asthma
Molindone		7416-34-4			
molsidomine	Sydhone Imine, N-(ethoxycarbonyl)-3-(4-morpholinyl)- [CAS]	25717-80-0	US 3769283	Vasodilator, coronary	
mometasone	Pregna-1,4-diene-3,20-dione, 9,21-dichloro-11,17-dihydroxy-16-methyl-, (11 $\beta$ ,16 $\alpha$ ) [CAS]	105102-22-5 83919-23-7	EP 57401	Antipruritic/Inflamm, allergic	Psoriasis
Monatepil		103377-41-9			
Monobenzzone		103-16-2			
monolaurin	Dodecanolic acid, monoester with 1,2,3-propanetriol [CAS]	27215-38-9	US 4885282	Dermatological	Ichthyosis
montelukast	Cyclopropaneacetic acid, 1-[[[1-[3-[2-(7-Chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]-, [CAS]	151767-02-1 158966-92-8		Antiasthma	Asthma
Monteplase		122007-85-6			
Moperone		1050-79-9			

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Mopidamol		13665-88-8			
Moprolol		5741-22-0			
moracizine	Carbamic acid, [10-[3-(4-morpholinyl)-1-oxopropyl]-10H-phenothiazin-2-yl]-, ethyl ester [CAS]	29560-58-5 31883-05-3	US 3864487	Antiarrhythmic	Tachycardia, ventricular
Morazone		6536-18-1			
Moricizine		31883-05-3			
Moroxydine		3731-59-7			
Morphazinamide		952-54-5			
morphine	Morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl- (5Alpha,6Alpha)-, [CAS]	57-27-2 6055-06-7 64-31-3		Formulation, parenteral, other	Pain, cancer
morphine-6-glucuronide	morphine-6-glucuronide			Formulation, inhalable, systemic	Pain, general
mosapramine	Spiro[imidazo[1,2-a]pyridine-3(2H),4'-piperidin]-2-one, 1'-[3-(3-chloro-10,11-dihydro-5H-dibenz[b,f]azepin-5-yl)propyl]hexahydro-, (+/-)- [CAS]	89419-40-9 98043-60-8	US 4337260	Neuroleptic	
mosapride	Benzamide, 4-amino-5-chloro-2-ethoxy-N-(((4-((4-fluorophenyl)methyl)-2-morpholinyl)methyl)- [CAS]	112885-41-3 112885-42-4	EP 243959	GI inflammatory/bowel disorders	Gastritis
motexafin gadolinium	Gadolinium, bis(acetato-kappaO)(9,10-diethyl-20,21-bis(2-(2-methoxyethoxy)ethoxy)-4,15-dimethyl-8,11-imino-3,16:16,13-dinitrilo-1,18-benzodiazacycloelcosine-5,14-dipropanalato-kappaN1, kappaN18, kappaN23, kappaN24, kappaN25), (PB-7-11-233'2'4) [CAS]	246252-06-2		Radio/chemosensitizer	Cancer, brain
Motretinide		56281-36-8			
Movelipiril		85856-54-8			
Moxalactam		64952-97-2			
Moxastine		3572-74-5			
Moxaverine		10539-19-2			
Moxestrol		34816-55-2			

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
moxifloxacin	3-Quinolnecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(octahydro-6H-pyrrolo(3,4-b)pyridin-6-yl)-4-oxo-, hydrochloride (4aS-cl)s- [CAS]	186826-86-8 151096-09-2	DE 19546249	Quinolone antibacterial	Infection, respiratory tract, general
moxisylyte	Phenol, 4-[2-(dimethylamino)ethoxy]-2-methyl-5-(1-methylethyl)-, acetate (ester), [CAS]	964-52-3 54-32-0		Male sexual dysfunction	Impotence
moxonidine	5-Pyrimidinamine, 4-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-6-methoxy-2-methyl- [CAS]	75438-57-2	DE 2849537	Antihypertensive, other	Hypertension, general
M-PGA	(-)-(S)-2-Methyl-2-(1-oxo-2,3-dihydro-1H-isindol-2-yl)pentanedioic acid		US 5712291	Anticancer, other	Cancer, general
MPI-5010	Platinum diamminedichloro-, (SP-4-2) + (R)-4-[1-hydroxy-2-(methylamino)-ethyl]-1,2-benzenediol		US 6224883	Formulation, parenteral, other	Cancer, head and neck
MPI-5020	2,4(1H,3H)-Pyrimidinedione, 5-fluoro- [CAS]	51-21-8	US 5750146	Formulation, parenteral, other	Cancer, breast
MPL		198076-81-2		Immunostimulant, other	Vaccine adjunct
MRS-1754			US 6060481	Antiasthma	Asthma
MS-209	1-Piperazineethanol, 4-(diphenylacetyl)-Alpha-[(5-quinolinyl)oxy)methyl]-, (2E)-2-butenedioate(2:3) (salt) [CAS]	158681-49-3		Radio/chemosensitizer	Cancer, breast
MS-275	N-(2-Aminophenyl)-4-[N-(pyridin-3-yl-methoxycarbonyl)aminomethyl]benzamide			Anticancer, antimetabolite	Cancer, lung, general
MS-325		201688-00-8			
MS-377			EP 839805	Neuroleptic	Schizophrenia
Mupirocin		12650-69-0			
Muscarine		300-54-9			
Muzollimine		55294-15-0			
MX-1013			US 6153591	Hepatoprotective	Unspecified

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
mycophenolate mofetil	4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-, 2-(4-morpholinyl)ethyl ester, (E)-[CAS]	116680-01-4 128794-94-5	WO 9119498	Immunosuppressant	Transplant rejection, general
mycophenolic acid	4-hexanoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-,	37415-62-6 24280-93-1		Formulation, oral, enteric-coated	Transplant rejection, general
Myrophine		467-18-5			
N-(Hydroxymethyl)nicotinamide		3569-99-1			
N,N,N $\phi$ ,N $\phi$ -Tetraethylphthalamide		83-81-8			
N2-Formylsulfisomidine		795-13-1			
N4-b-D-Glucosylsulfanilamide		53274-53-6			
N4-Sulfanilylsulfanilamide		547-52-4			
Nabilone		51022-71-0			
nabumetone	2-Butanone, 4-(6-methoxy-2-naphthalenyl)-[CAS]	42924-53-8	GB 1476721	Anti-inflammatory	Arthritis, osteo
N-acetylcysteine	L-Cysteine, N-acetyl- [CAS]	616-91-1		Anticancer, other	Cancer, general
N-Acetylmethionine		65-82-7			
nadifloxacin	1H,5H-Benzo[j]quinoline-2-carboxylic acid, 9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-, (+/-)- [CAS]	124858-35-1	US 4399134	Quinolone antibacterial	Acne
nadolol	2,3-Naphthalenediol, 5-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-1,2,3,4-tetrahydro- [CAS]	42200-33-9	US 4346106	Antihypertensive, adrenergic	
Nadoxolol		54063-51-3			
nafamostat	Benzoic acid, 4-[(aminoiminomethyl)amino]-, 6-(aminoiminomethyl)-2-naphthalenyl ester [CAS]	80251-32-7 81525-10-2 82956-11-4	EP 450232	GI inflammatory/bowel disorders	Pancreatitis
nafarelin	Luteinizing hormone-releasing factor (pig), 6-[3-(2-naphthalenyl)-D-alanine]-[CAS]	76932-56-4 86220-42-0	EP 21234	Releasing hormones	Endometriosis



API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Naftillin		147-52-4			
Nafronyl		31329-57-4			
naftidrofuryl	2-Furanpropanoic acid, tetrahydro-Alpha-(1-naphthalenylmethyl)-, 2-(diethylamino)ethyl ester	31329-57-4		Formulation, modified-release, other	Unspecified
naftifine	1-Naphthalenemethanamine, N-methyl-N-(3-phenyl-2-propenyl)-, (E)- [CAS]	65472-88-0 65473-14-5	US 4282251	Antifungal	Infection, dermatological
naftopidil	1-Piperazineethanol, 4-(2-methoxyphenyl)-Alpha-[(1-naphthalenyloxy)methyl]- [CAS]	57149-07-2	US 3997666	Antihypertensive, adrenergic	Hypertension, general
nalbuphine	Morphinan-3,6,14-triol, 17-(cyclobutylmethyl)-4,5-epoxy-, (5Alpha,6Alpha)- [CAS]	20594-83-6 23277-43-2	US 3393197	Analgesic, other	Pain, general
Nalidixic Acid		389-08-2			
nalmeferne	Morphinan-3,14-diol, 17-(cyclopropylmethyl)-4,5-epoxy-6-methylene-, (5Alpha)-[CAS]	55096-26-9	JP 56167687	Dependence treatment	Poisoning, drug
Nalorphine		62-67-9			
naloxone	Morphinan-6-one, 17-allyl-4,5Alpha-epoxy-3,14-dihydroxy-, hydrochloride [CAS]	357-08-4 465-65-6		Septic shock treatment	
naltrexone	Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-, (5Alpha)-[CAS]	16590-41-3 16676-29-2	US 3332950	Dependence treatment	Addiction, narcotic/opiate
NAMI	Imidazolium trans(imidazole)(dimethylsulfoxide)tetrachlororuthenate (III)			Anticancer, other	Cancer, general
naminiidil	Guanidine, N-cyano-N'-(4-cyanophenyl)-N'-[(1R)-1,2,2-trimethylpropyl]-[CAS]	220641-11-2		Dermatological	Alopecia, general
Nandrolone		434-22-0			
Naphazoline		835-31-4			
Naphthalene		91-20-3			
naproxen betainate	Methanaminium, 1-carboxy-N, N, N-trimethyl- salt with (R)-6-methoxy- Alpha-methyl-2-naphthaleneacetic acid (1:1), sodium salt [CAS]	104124-26-7	US 4672077	Antiarthritic, other	Arthritis, rheumatoid

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
naproxen	2-Naphthaleneacetic acid, 6-methoxy-Alpha-methyl-, [CAS]	26159-34-2 22204-53-1	GB 1211134	Analgesic, NSAID	Pain, general
naratriptan	1H-Indole-5-ethanesulfonamide, N-methyl-3-(1-methyl-4-piperidinyl)- [CAS]	121679-13-8	EP 303507	Antimigraine	Migraine
Narceine		131-28-2			
Narcobarbital		125-55-3			
Natamycin		7681-93-8			
nateglinide	D-phenylalanine, N-((4-(1-methylethyl)cyclohexyl)carbonyl)-, trans-[CAS]	105816-04-4	EP 196222	Antidiabetic	Diabetes, Type II
N-Butyldoxynojirimycin		72599-27-0			
N-Butylscopolammonium Bromide		149-64-4			
NC-503			US 5643562	Anti-inflammatory	Amyloidosis
NC-531			US 5643562	Cognition enhancer	Alzheimer's disease
NCX-1000			WO 0061604	Hepatoprotective	Cirrhosis, hepatic
NCX-4016	Benzoic acid, 2-(acetoxy)-, 2-((nitrooxy)methyl)phenyl ester [CAS]	175033-36-0	WO 9716405	Symptomatic antidiabetic	Insulin-related metabolic syndrome
NCX-456	Benzoic acid, 5-amino-2-hydroxy-, 4-(nitrooxy)butyl ester [CAS]	256499-26-0		GI inflammatory/bowel disorders	Inflammatory bowel disease
NCX-950	Alpha'-[[[(1,1-dimethylethyl)amino]methyl]-4-hydroxy]-1,3-benzenedimethanol nitrate			Antiasthma	Asthma
n-Docosanol		661-19-8			
NE-100	Benzeneethanamine, 4-methoxy-3-(2-phenylethoxy)-N,N-dipropyl-, hydrochloride [CAS]	149409-57-4	WO 9307113	Neuroleptic	Schizophrenia
Nealbarbital		561-83-1			
neбиволol	2H-1-Benzopyran-2-methanol, Alpha,Alpha'-[[iminobis(methylene)]bis[6-fluoro-3,4-dihydro]-, (2R*(R*(R*(S*))))-(1+)- [CAS]	118457-14-0 99200-09-6	EP 145067	Antihypertensive, adrenergic	Hypertension, general
nebestinel	N1-(4,4-Dimethylcyclohexyl)-L-isoglutamine	163000-63-3	EP 0688312	Cognition enhancer	Unspecified
Nebracetam		97205-34-0			

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
nedaplatin	Platinum, diammine[hydroxyacetato(2-)-O1,O2]-, (SP-4-3)- [CAS]	95734-82-0	EP 216362	Anticancer, alkylating	
nedocromil	4H-Pyran[3,2-g]quinoline-2,8-dicarboxylic acid, 9-ethyl-6,9-dihydro-4,6-dioxo-10-propyl- [CAS]	69049-73-6 69049-74-7	EP 555718	Antialsthma, Ophthalmological	Rhinitis, allergic, general, Ocular disorder, general
nefazodone	3H-1,2,4-Triazol-3-one, 2-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-5-ethyl-2,4-dihydro-4-(2-phenoxyethyl)-, [CAS]	82752-99-6 83366-66-9	US 4338317	Antidepressant	Depression, general
nefiracetam	1-Pyrrolidineacetamide, N-(2,6-dimethylphenyl)-2-oxo- [CAS]	77191-36-7	US 4341790	Cognition enhancer	Dementia, senile, general
nefopam	1H-2,5-Benzoxazocine, 3,4,5,6-tetrahydro-5-methyl-1-phenyl- [CAS]	13669-70-0 23327-57-3 33404-78-3	US 3487153	Analgesic, NSAID	
Negamycin					
nelfinavir	3-Isoquinolinecarboxamide, N-(1,1-dimethylethyl)decahydro-2-(2-hydroxy-3-((3-hydroxy-2-methylbenzoyl)amino)-4-(phenylthio)butyl)-, (3S-(2(2S*,3S*),3Alpha,4aB,8aB))-, [CAS]	159989-65-8 159989-64-7 75272-39-8		Antiviral, anti-HIV	Infection, HIV/AIDS
Nemonapride		59-99-4			
Neostigmine					
nepadutant	Cyclo[3-amino-L-alanyl-L-leucyl-N-[2-(acetylamino)-2-deoxy-β-D-glucopyranosyl]-L-asparaginyl-L-Alpha-aspartyl-L-tryptophyl-L-phenylalanyl], (4-1)-lactam [CAS]	183747-35-5	WO 9628467	Antialsthma	Asthma
neramexane	1,3,3,5,5-pentamethylcyclohexylamine	202807-80-5 219810-59-0		Dependence treatment	Addiction, alcohol
neridronic acid	Phosphonic acid, (6-amino-1-hydroxyhexylidene)bis- [CAS]	79778-41-9 466-07-9 457-87-4		Musculoskeletal	Osteogenesis imperfecta
Nerifolin					
N-Ethylamphetamine					
neticonazole	1H-Imidazole, 1-[2-(methylthio)-1-[2-(pentyloxy)phenyl]ethenyl]-, monohydrochloride, (E)- [CAS]	130773-02-3 130726-68-0	EP 445540	Antifungal	Infection, Candida, general

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
netilmicin	D-Streptamine, O-3-deoxy-4-C-methyl-3-(methylamino)-β-L-arabinopyranosyl-(1-6)-O-[2,6-diamino-2,3,4,6-tetra-deoxy-Alpha-D-glycero-hex-4-enopyranosyl-(1-4)]-2-deoxy-N1-ethyl- [CAS]	56391-56-1 56391-57-2	GB 1473733	Aminoglycoside antibiotic	Infection, general
nevirapine	6H-Dipyrro[3,2-b:2',3'-e][1,4]diazepin-6-one, 11-cyclopropyl-5,11-dihydro-4-methyl-[CAS]	129618-40-2	EP 429987	Antiviral, anti-HIV	Infection, HIV/AIDS
NGD-98-2			WO 9635689	Anxiolytic	Anxiety, general
Nialamide		51-12-7			
Niaprazine		27367-90-4			
Nicametate		3099-52-3			
nicaraven	3-Pyridinecarboxamide, N,N'-(1-methyl-1,2-ethanediy))bis- [CAS]	79455-30-4	EP 29602	Neuroprotective	Haemorrhage, subarachnoid
nicardipine	3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 2-[methyl(phenylmethyl)amino]ethyl ester [CAS]	54527-84-3 55985-32-5	US 3985758	Neuroprotective	Hypertension, general
nicergoline	Ergoline-8-methanol, 10-methoxy-1,6-dimethyl-, (8b)-, 5-bromo-3-pyridinecarboxylate(ester)	27848-84-6		Formulation, modified-release, other	Unspecified
Niceritol		5868053			
Niclosamide		50-65-7			
Niccloclonate		10571-59-2			
Nicofuranose		15351-13-0			
Nicomol		27959-26-8			
Nicomorphine		639-48-5			
nicorandil	3-Pyridinecarboxamide, N-[2-(nitrooxy)ethyl] [CAS]	65141-46-0	US 4792564	Vasodilator, coronary	Hypertension, general
Nicotinamide		98-92-0			
nicotine	Pyridine, 3-(1-methyl-2-pyrrolidinyl)-, (S)- [CAS]	54-11-5		Formulation, inhalable, other	Addiction, nicotine
Nicotinic Acid		59-67-6			
Nicotinic Acid Benzyl Ester		94-44-0			
Nicotinyl Alcohol		100-55-0			

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
nifedipine	4-(2'-nitrophenyl)-2,6-dimethyl-3,5-dicarbomethoxy-1,4-dihydropyridine	21829-25-4	GB 1173862	Vasodilator, coronary	Hypertension, general
nifekalant	2,4-(1H,3H)-Pyrimidinedione, 6-[[2-(2-hydroxyethyl)][3-(4-nitrophenyl)propylamino]ethylamino]-1,3-dimethyl-, [CAS]	130636-43-0 130656-51-8	EP 369627	Antiarrhythmic	Arrhythmia, general
Nifenalol		7413-36-7			
Niflumic Acid		4394-00-7			
Nifuratel		4936-47-4			
Nifurfoline		3363-58-4			
Nifuroxazide		965-52-6			
Nifuroxime		6236051			
Nifurpirinol		13411-16-0			
Nifurprazine		1614-20-6			
Nifurtimox		23256-30-6			
Nifurtinol		1088-92-2			
nifurzide	2-Thiophenecarboxylic acid, 5-nitro-, [3-(5-nitro-2-furanyl)-2-propenyldene]hydrazide [CAS]	39978-42-2	US 3847911	Antidiarrhoeal	Infection, GI tract
NIK-254	Gentamicin, sulfate (salt) [CAS]	1405-41-0		Formulation, other	Infection, general
Nikethamide		59-26-7			
nilutamide	2,4-Imidazolidinedione, 5,5-dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]-[CAS]	63612-50-0	US 4472382	Anticancer, hormonal	Cancer, prostate
nilvadipine	3,5-Pyridinedicarboxylic acid, 2-cyano-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-, 3-methyl 5-(1-methylethyl) ester [CAS]	75530-68-6	US 4338322	Antihypertensive, other	Hypertension, general
nimesulide	Methanesulfonamide, N-(4-nitro-2-phenoxyphenyl)- [CAS]	51803-78-2	US 3840597	Anti-inflammatory	Pain, general
Nimetazepam		2011-67-8			
nimodipine	3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-methoxyethyl 1-methylethyl ester [CAS]	66085-59-4	EP 533014	Neuroprotective	
Nimorazole		6506-37-2			



API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
nimustine	Urea, N'-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-N-(2-chloroethyl)-N-nitroso-[CAS]	103745-00-2 42471-28-3 55661-38-6	GB 1374344	Anticancer, alkylating	Cancer, brain
Ninoplerin		2179-16-0			
NIP-142	N-[4(S)-(Cyclopropylamino)-3-(R)-hydroxy-2,2-dimethyl-7-nitro-3,4-dihydro-2H-1-benzopyran-6-yl]-4-methoxybenzeneacetamide		WO 9804542	Antiarrhythmic	Fibrillation, atrial
NIP-531	N'-[3,5-Bis(trifluoromethyl)benzyl]-N-[3-{(1-(4-fluorobenzyl)benzimidazol-2-yl)-amino]propyl-N-methylurea hydrochloride			Antipruritic/inflamm, allergic	Eczema, atopic
niperotidine	N-[2-[[5-[(dimethylamino)methyl]furfuryl]thio]ethyl]-2-nitro-N'-piperonyl-1,1-ethenediamine	84845-75-0	GB 2104071	Antilulcer	Ulcer, GI, general
nipradilol	2H-1-Benzopyran-3-ol, 3,4-dihydro-8-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]-, 3-nitrate [CAS]	81486-22-8 86247-86-1	EP 42299	Formulation, mucosal, topical	Glaucoma
Niridazole		61-57-4			
nisoldipine	3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-, methyl 2-methylpropyl ester- [CAS]	63675-72-9	GB 1516793	Antihypertensive, other	Hypertension, general
nitazoxanide	Benzamide, 2-(acetyloxy)-N-(5-nitro-2-thiazolyl)- [CAS]	55981-09-4	US 5387598	Protozoacide	Infection, GI tract
nitisinone	1,3-Cyclohexanedione, 2-[2-nitro-4-(trifluoromethyl)benzoyl]- [CAS]	104206-65-7	EP 186118	Metabolic and enzyme disorders	Cirrhosis, hepatic
nitracrine	1,3-Propanediamine, N,N-dimethyl-N'-(1-nitro-9-acridinyl)- [CAS]	4533-39-5 6514-85-8	FR 1458183	Anticancer, other	Cancer, ovarian
Nitrazepam		146-22-5			
nitrendipine	3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, ethyl methyl ester- [CAS]	39562-70-4	GB 1358951	Antihypertensive, other	Hypertension, general

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
nitroflurbiprofen	(1,1'-Biphenyl)-4-acetic acid, 2-fluoro-Alpha-methyl-, 4-(nitrooxy)butyl ester [CAS]	158836-71-6	EP 670825	Urological	Incontinence
Nitrofurantoin		67-20-9			
Nitrofurazone		59-87-0			
nitroglycerin	1,2,3-Propanetriol, trinitrate [CAS]	55-63-0		Formulation, transdermal, patch	Angina, general
Nitromersol		133-58-4			
nitronaproxen	2-Napthaleneacetic acid, 6-methoxy-Alpha-methyl 4-(nitrooxy)butyl ester (AlphaS)-[CAS]	163133-43-5	WO 9509831	Analgesic, NSAID	Pain, post-operative
nitroxazepine	Dibenz[b,f][1,4]oxazepin-11(10H)-one, 10-[3-(dimethylamino)propyl]-2-nitro-, monohydrochloride [CAS]	16398-39-3	NL 6608671	Antidepressant	
Nitroxoline		4008-48-4			
nizatidine	1,1-Ethenediamine, N-[2-[[[2-[(dimethylamino)methyl]-4-thiazolyl]methyl]thio]ethyl]-N'-methyl-2-nitro-[CAS]	76963-41-2	EP 49618	Antiulcer	Ulcer, duodenal
Nizofenone		54533-85-6			
NM-3	3-(2-methylcarboxymethyl)-6-methoxy-8-hydroxy-isocoumarin		JP 08176138	Anticancer, other	Cancer, general
NM-702	4-Bromo-5-(3-pyridylmethylamino)-6-[3-(4-chlorophenyl)propoxy]-3(2H)pyridazinone hydrochloride			Antithrombotic	Peripheral vascular disease
N-Methylephedrine		552-79-4			
N-Methylepinephrine		554-99-4			
N-Methylglucamine		6284-40-8			
NN-414	6-chloro-3-(1-methylcyclopropylamino)-4H-thieno[3,2-e]-[1,2,4]thiadiazine-1,1-dioxide			Antidiabetic	Diabetes, Type II
NNC-05-1869	(R)-1-(3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-3-piperidine carboxylic acid			Symptomatic antidiabetic	Neuropathy, diabetic

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Nogalamycin		1404-15-5			
nolatrexed	4(1H)-Quinazolinone, 2-amino-6-methyl-5-(4-pyridinylthio)-, [CAS]	152946-68-4 147149-76-6	WO 9320055	Anticancer, antimetabolite	Cancer, liver
nolomirole	Propanoic acid, 2-methyl-, 5,6,7,8-tetrahydro-6-(methylamino)-1,2-naphthalenediyl ester, hydrochloride, (+/-)- [CAS]	138531-51-8	WO 9529147	Cardio stimulant	Heart failure
nolpitantium	1-Azoniabicyclo[2.2.2]octane, 1-[2-{3-(3,4-dichlorophenyl)-1-[[3-(1-methylethoxy)phenyl]acetyl]-3-piperidinyl]ethyl]-4-phenyl-, chloride, (S)- [CAS]	153050-21-6	EP 591040	GI inflammatory/bowel disorders	Inflammatory bowel disease
nomegestrol	19-Norpregna-4,6-diene-3,20-dione, 17-(acetyloxy)-6-methyl- [CAS]	58652-20-3	DE 2522533	Menstruation disorders	Menstrual disorder, general
Nomifensine		24526-64-5			
Noprylsulfamide		576-97-6			
Norbolethone		1235-15-0			
Nordazepam		1088-11-5			
Nordefrin		6539-57-7 (unspecified); 74812-63-8 (R*,S*) (±)-form			
Nordihydroguaiaretic Acid		27686-84-6 (meso-form); 500-38-9 (unspecified)			
Norelgestromin, Ethinyl Estradiol					
Norepinephrine		51-41-2			
Norethandrolone		52-78-8			
Norethindrone		68-22-4			
Norethynodrel		68-23-5			
Norfenefrine		536-21-0			
norfloxacin	3-Quinolonecarboxylic acid, 1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)- [CAS]	68077-27-0 70458-96-7	US 4146719	Quinolone antibacterial	Infection, general
Norgesterone		13563-60-5			

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Norgestimate		35189-28-7			
Norgestrel		6533-00-2			
Norgestrienone		848-21-5			
Norlevorphanol		1531-12-0			
Normethadone		467-85-6			
Normethandrone		514-61-4			
Normorphine		466-97-7			
Norphenazone		89-25-8			
Noripipanone		561-48-8			
Norpseudoephedrine		492-39-7			
Nortriptyline		72-69-5			
Norvinisterone		6795-60-4			
Noscapine		128-62-1			
Novembichin		1936-40-9			
Novobiocin		303-81-1			
Noxiptilin		3362-45-6			
Noxythiolin		15599-39-0			
NS-1209	Butanoic acid, 2-[[[5-[4- [[dimethylamino)sulfonyl]phenyl]-1,2,6,7,8,9- hexahydro-8-methyl-2-oxo-3H-pyrrolo[3,2- h]isoquinolin-3-ylidene]amino]oxy]-3- hydroxy- [CAS]	254751-28-5	WO 9426747	Antiepileptic	Epilepsy, general
NS-1231	5-(4-chlorophenyl)-6,7,8,9-tetrahydro-1H- pyrrolo-(3,2-h)naphthalene-2,3-dione-3- oxime			Neuroprotective	Ischaemia, cerebral
NS-126			US 5063222	Antiallergic, non-asthma	Rhinitis, allergic, general
NS-220	2-Methyl-c-5-[4-[5-methyl-2-(4- methylphenyl)-4-oxazoly]butyl]-1,3-dioxane- r-2-carboxylic acid			Hypolipaeic/Antiatherosclerosis	Atherosclerosis
NS-2330	NS 2330 [CAS]	402856-42-2		Cognition enhancer	Alzheimer's disease
NS5A Inhibitors			US 6030785	Antiviral, other	Infection, hepatitis-C virus
NS-7	Pyrimidine, 4-(4-fluorophenyl)-2-methyl-6- [[5-(1-piperidinyl)pentyl]oxy]-; monohydrochloride [CAS]	178429-67-9	WO 9607641	Neuroprotective	Ischaemia, cerebral

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
NS-8	2-Amino-5-(2-fluorophenyl)-4-methyl-1H-pyrrole-3-carbonitrile			Urological	Incontinence
NSC-330507	17-Allylaminogeldanamycin			Anticancer, antituberc	Cancer, general
NSC-619534	2-chloroethyl phenyl selenone			Anticancer, alkylating	Cancer, general
NSC-697726	2,5-diazinidinyl-3-[hydroxymethyl]6-methyl-1,4-benzoquinone			Anticancer, antituberc	Cancer, general
N-Sulfamyl-3,4-xylamide		120-34-3			
NU-6027	2,4-Pyrimidinediamine, 6-(cyclohexylmethoxy)-5-nitroso- [CAS]	220036-08-8		Anticancer, other	Cancer, general
NV-07	2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-sec-pentyl-, 2-oxime [CAS]	53745-16-7	US 6455032	Antipruritic/inflamm, non-allergic	Keratosis
NVP-SRA880	[(3R,4aR,10aR)-1,2,3,4,4a,5,10,10a-Octahydro-6-methoxy-1-methyl-benz[g]quinoline-3-carboxylic acid-4-(4-nitrophenyl)piperazine amide, hydrogen maleate				
	(S)-(+)-2-[4-(2-fluorobenzoyloxy)benzylamino]propanamide methansulfonate			Neurological	Unspecified
NW-1029				Analgesic, other	Pain, general
NXY-059	CPI 22 [CAS]	168021-79-2	US 5780510	Neuroprotective	Ischaemia, cerebral
Nylidrin		447-41-6			
NZ-314	1-Imidazolidineacetic acid, 3-[(3-nitrophenyl)methyl]-2,4,5-trioxo- [CAS]	128043-99-2	EP 353198	Symptomatic antidiabetic	Neuropathy, diabetic
NZ-419	5-hydroxy-1-methylimidazolidine-2,4-dione		EP 412940	Urological	Renal failure
Obidoxime Chloride		114-90-9			
OC-108	OC 108 [CAS]	162602-62-2		Vasoprotective, topical	Venous insufficiency
ocinaplon	Methanone, 2-pyridinyl[7-(4-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]-[CAS]	96604-21-6	EP 129847	Anxiolytic	Generalized anxiety disorder
Octabenzone		1843-05-6			
Octacaine		13912-77-1			



API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Octamoxin		4684-87-1			
Octaverine		549-68-8			
octenidine	1-Octanamine, N,N'-(1,10-decanediyl-di-1(4H)-pyridinyl-4-ylidene)bis- [CAS]	70775-75-6 71251-02-0 86767-75-1	WO 8705501	Stomatological	Periodontitis
Octodrine		543-82-8			
Octopamine		104-14-3			
Octolamine		137-86-0			
octreotide	L-Cysteineamide, D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-[2-hydroxy-1-(hydroxymethyl)propyl]-, cyclic (2-7)-disulfide, [R-(R*, R*)]- [CAS]	83150-76-9		Formulation, fixed-dose combinations	Cancer, general
Octyl Methoxycinnamate		5466-77-3			
ofloxacin	7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid, 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-, (+/-)- [CAS]	82419-36-1	EP 47005	Quinolone antibacterial	
o-Iodohippurate		133-17-5			
olanzapine	10H-Thieno(2,3-b)(1,5)benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)- [CAS]	132539-06-1	EP 454436	Neuroleptic	Schizophrenia
Oleandrin		465-16-7			
Oleic Acid		112-80-1			
olmesartan medoxomil	1H-Imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-, (5-methyl-2-oxo-1,3-dioxol-4-yl) methyl ester [CAS]	144689-63-4	EP 503785	Antihypertensive, renin system	Hypertension, general
olopatadine	11-[(Z)-3-(Dimethylamino)propylidene]-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid, monohydrochloride	113806-05-6 140462-76-6	EP 235796	Ophthalmological	Conjunctivitis
olpadronic acid	Monosodium 3-dimethylamino-1-(hydroxypropylidene)-1,1-bisphosphonate	63132-39-8	WO 9619998	Osteoporosis treatment	Osteoporosis

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
oisalazine	Benzolic acid, 3,3'-azobis[6-hydroxy- [CAS]	15722-48-2	US 4559330	GI inflammatory/bowel disorders	Colitis, ulcerative
olipraz	3H-1,2-Dithiole-3-thione, 4-methyl-5-pyrazinyl- [CAS]	53200-51-4	DE 2705641	Anticancer, other	Cancer, general
OM-294DP	2-[3(R)-(Dodecanoyloxy)tetradecanamido]-N-[4-[3(R)-hydroxytetradecanamido]-5-(phosphonoxy)pentyl]-4-(phosphonoxy)butyramide	64224-21-1			
Omacor	ethyl (5Z,8Z,11Z,14Z,17Z)-eicosa-5,8,11,14,17-pentaenoate + ethyl (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoate	81926-94-5 86227-47-6		Anticancer, immunological	Unspecified
omapatrilat	7H-Pyrido(2,1-b)(1,3)thiazepine-7-carboxylic acid, octahydro-4-((2-mercapto-1-oxo-3-phenylpropyl)amino)-5-oxo, (4S-(4Alpha(R*),7Alpha,10aß))- [CAS]	167305-00-2	US 5508272	Hypolipaeimic/Antiatherosclerosis	Hypertiglyceridaemia
omeprazole	1H-Benzimidazole, 5-methoxy-2-[[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]- [CAS]	73590-58-6	US 4255431	Antihypertensive, renin system	Hypertension, general
omiloxetine	Ethanone, 2-[(3R,4S)-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-1-piperidinyl]-1-(4-fluorophenyl)-, rel- [CAS]	176894-09-0		Antidiuretic	Depression, general
omoconazole	1H-Imidazole; 1-[2-[2-(4-chlorophenoxy)ethoxy]-2-(2,4-dichlorophenyl)-1-methylethenyl]-, (Z)- [CAS]	74512-12-2	EP 8804	Antifungal	Infection, dermatological
Onapristone		96346-61-1			
ondansetron	4H-Carbazol-4-one, 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]- [CAS]	99614-01-4 99614-02-5	US 4847281	Antiemetic	Chemotherapy-induced nausea and vomiting

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
ONO-3403	Benzoic acid, 4-[(1E)-3-[(2-ethoxy-2-oxoethyl)-2-propenylamino]-2-methyl-3-oxo-1-propenyl]-, 4-(aminoiminomethyl)phenyl ester, monomethanesulfonate [CAS]	181586-07-2		GI Inflammatory/bowel disorders	Unspecified
ONO-4128	1,4,9-Triazaspiro(5.5)undecane-2,5-dione, 1-butyl-3-(cyclohexylmethyl)-9-[(2,3-dihydro-1,4-benzodioxin-6-yl)methyl]- [CAS]	342394-93-8		Antiviral, anti-HIV	Infection, HIV/AIDS
ONO-8815 Ly	L-lysine (Z)-7-[(1R,2R,3R,5R)-5-chloro-3-hydroxy-2-[(E)-(S)-4-(1-ethylcyclobutyl)-4-hydroxy-1-butenyl]cyclopentyl]-5-heptenoate			Labour inhibitor	Labour, preterm
ONT-093			US 5756527	Radio/chemosensitizer	Cancer, general
OPC-14523	2(1H)-Quinolnolone, 1-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-3,4-dihydro-5-methoxy- [CAS]	145969-30-8	EP 512525	Antidepressant	Depression, general
OPC-31260	Benzamide, N-[4-[[5-(dimethylamino)-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl]carbonyl]phenyl]-2-methyl-	137975-06-5	WO 9105549	Urological	Unspecified
OPC-51803	(5R)-2-[1-(2-chloro-4-(1-pyrrolidinyl)benzoyl)-2,3,4,5-tetrahydro-1H-1-benzazepin-5-yl]-N-isopropylacetamide			Antidiabetic	Diabetes, insipidus
OPC-6535	2-Pyridinecarboxylic acid, 6-[2-(3,4-dithoxyphenyl)-4-thiazolyl]- [CAS]	145739-56-6	WO 9209586	GI Inflammatory/bowel disorders	Inflammatory bowel disease
Opiniazide		2779-55-7			
opioid analgesics	2-(4-trifluoromethylphenyl)-N-methyl-[1-phenyl-2-(1-pyrrolidinyl)ethyl]acetamide			Analgesic, other	Pain, general
Opi Pramol		315-72-0			
Orazamide		2574-78-9			
orazipone	2,4-Pentanedione, 3-((4-methylsulfonyl)phenyl)methylene)- [CAS]	137109-78-5	EP 440324	Antiasthma	Unspecified

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Org-12962	Piperazine, 1-[6-chloro-5-(trifluoromethyl)-2-pyridinyl]-, monohydrochloride [CAS]	210821-63-9		Antidepressant	Depression, general
Org-24448			US 6166008	Neuroleptic	Schizophrenia
oritavancin	Vancomycin, 22-O-(3-amino-2,3,6-trideoxy-3-C-methyl-Alpha-L-arabino-hexopyranosyl)-N3"-[(4'-chloro[1,1'-biphenyl]-4-yl)methyl]-, (4"R)- [CAS]	171099-57-3	US 5840684	Peptide antibiotic	Infection, dermatological
orlistat	L-Leucine, N-formyl-, 1-[(3-hexyl-4-oxo-2-oxetanyl)methyl]dodecyl ester, [2S-[2Alpha(R*),3S]]- [CAS]	96829-58-2	EP 129748	Anorectic/Antiobesity	Obesity
ormeloxifene	Pyrolidine, 1-[2-(p-(7-methoxy-2,2-dimethyl-3-phenyl-4-chromanyl)phenoxy)ethyl]-, trans [CAS]	31477-60-8	DE 2329201	Female contraceptive	Contraceptive, female
Ornidazole		16773-42-5			
Omlipressin		3397-23-7			
Omlithine		70-26-8			
ornoprostil	Prost-13-en-1-oic acid, 11,15-dihydroxy-17,20-dimethyl-6,9-dioxo-, methyl ester, (11Alpha,13E,15S,17S)- [CAS]	70667-26-4	US 4278688	Prostaglandin	Ulcer, gastric
Orotic Acid		65-86-1			
Orphenadrine		83-98-7			
Orthocaine		536-25-4			
Osalmid		526-18-1			
osanetan	Acetamide, N-[1-[3-[(3R)-1-benzoyl-3-(3,4-dichlorophenyl)-3-piperidinyl]propyl]-4-phenyl-4-piperidinyl]-N-methyl- [CAS]	160492-56-8	EP 673928	Neuroleptic	Schizophrenia
osaterone	2-Oxapregna-4,6-diene-3,20-dione, 17-(acetyloxy)-6-chloro- [CAS]	105149-00-6	EP 193871	Prostate disorders	Benign prostatic hyperplasia
oseltamivir	1-Cyclohexene-1-carboxylic acid, 4-(acetylamino)5-amino-3-(1-ethylpropoxy)-, ethyl ester, (3R-(3Alpha,(4S,5Alpha))-[CAS]	196618-13-0	WO 9626933	Antiviral, other	Infection, influenza virus
OSI-7836	4'-Thio-β-D-arabinofuranosylcytosine			Anticancer, antimetabolite	Cancer, general

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
OSI-7904	Pentanedioic acid, 2-[5-[[[1,2-dihydro-3-methyl-1-oxobenzof[quinazolin-9-yl)methyl]amino]-1,3-dihydro-1-oxo-2H-isindol-2-yl]-, (S)- [CAS]	139987-54-5	WO 9119700	Formulation, optimized, liposomes	Cancer, general
ospemifene	Ethanol, 2-[4-[(1Z)-4-chloro-1,2-diphenyl-1-butenyl]phenoxy]- [CAS]	128607-22-7	WO 9607402	Menopausal disorders	Osteoporosis
otilonium bromide	Ethanaminium, N,N-diethyl-N-methyl-2-[[4-[[2-(octyloxy)benzoyl]amino]benzoyl]oxy]-, bromide [CAS]	26095-59-0	GB 1181406	Antispasmodic	Irritable bowel syndrome
Ouabain		630-60-4			
Oxaceprol		33996-33-7			
Oxacillin		66-79-5			
Oxafozane		26629-87-8			
oxaliplatin	Platinum, (1,2-cyclohexanediamine-N,N'')ethanedioato(2-)-O,O'-, [SP-4-2-(1R-trans)]- [CAS]	61825-94-3	EP 393575	Anticancer, alkylating	Cancer, colorectal
Oxalyt-C	1,2,3-Propanetricarboxylic acid, 2-hydroxy-, potassium sodium salt [CAS]	28060-67-5	DE 2249274	Urological	
Oxamarin		15301-80-1			
Oxametacine		27035-30-9			
Oxamniquine		21738-42-1			
oxandrolone	2-Oxaandrostane-3-one, 17-hydroxy-17-methyl-, (5Alpha,17beta)- [CAS]	53-39-4	US 3128283	Reproductive/gonadal, general	Sex-chromosome abnormality, Turner's syndrome
Oxantel		36531-26-7			
Oxapropanium		541-66-2			
oxaprozoin	2-Oxazolepropanoic acid, 4,5-diphenyl- [CAS]	21256-18-8	GB 1206403	Antiarthritic, other	Arthritis, osteo
oxatomide	2H-Benzimidazol-2-one, 1-[3-[4-(diphenylmethyl)-1-piperazinyl]propyl]-1,3-dihydro- [CAS]	60607-34-3	GB 1579365	Antiallergic, non-asthma	Rhinitis, allergic, general
oxazepam	7-Chloro-1,3-dihydro-3-hydroxy-5-phenyl-2H-1,4-benzodiazepin-2-one	604-75-1		Formulation, oral, orally-disintegrating	Anxiety, general



API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
oxazolam	Oxazol[3,2-d][1,4]benzodiazepin-6(5H)-one, 10-chloro-2,3,7,11b-tetrahydro-2-methyl-11b-phenyl- [CAS]	27167-30-2	US	3772371	Anxiolytic	
oxcarbazepine	5H-Dibenz[b,f]azepine-5-carboxamide, 10,11-dihydro-10-oxo- [CAS]	28721-07-5 29331-92-8	DE	2011087	Antiepileptic	Epilepsy, general
Oxeladin		468-61-1				
Oxendolone		33765-68-3				
Oxethazaine		126-27-2				
Oxetorone		26020-55-3				
oxiconazole	Ethanone, 1-(2,4-dichlorophenyl)-2-(1H-imidazol-1-yl)-, O-[(2,4-dichlorophenyl)methyl]oxime, (Z)- [CAS]	64211-45-6	GB	1514870	Antifungal	Infection, fungal, general
Oxidronic Acid		15468-10-7				
Oxiniacic Acid		2398-81-4				
Oxiracetam		62613-82-5				
oxitropium	3-Oxa-9-azoniatricyclo[3.3.1.0 <sup>2,4</sup> ]nonane, 9-ethyl-7-(3-hydroxy-1-oxo-2-phenylpropoxy)-9-methyl-, bromide, [7(S)-(1 $\alpha$ ,2 $\beta$ ,4 $\beta$ ,5 $\alpha$ )-7 $\beta$ ]- [CAS]	30286-75-0	GB	1178305	Antiasthma	
Oxolamine		959-14-8				
Oxolinic Acid		14698-29-4				
Oxophenarsine		538-03-4				
Oxprenolol		6452-71-7				
Oxybenzone		131-57-7				
oxybutynin	Benzeneacetic acid, Alpha-cyclohexyl-Alpha-hydroxy-, 4-(diethylamino)-2-butynyl ester- [CAS]	5633-20-5			Formulation, modified-release, other	Incontinence
Oxycinchophen		485-89-2				
oxycodone	Morphinan-6-one, 4,5-epoxy-14-hydroxy-3-methoxy-17-methyl-, (5 $\alpha$ )-	76-42-6			Formulation, transmucosal, nasal	Pain, general
Oxyfedrine		15687-41-9				

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Oxygent	Octane, 1-bromo-1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8-heptadecafluoro- [CAS]	423-55-2		Haematological	Surgery adjunct
Oxymesterone		145-12-0			
Oxymetazoline		1491-59-4			
oxymetholone	Androstan-3-one, 17-hydroxy-2-(hydroxymethylene)-17-methyl-, (5 $\alpha$ ), 17 $\beta$ - [CAS]	434-07-1		Hormone	Anaemia, general
Oxymethurea		140-95-4			
oxymorphone	(5 $\alpha$ ), 4,5-Epoxy-3,14-dihydroxy-17-methylmorphinan-6-one [CAS]	76-41-5		Formulation, modified-release, immediate	Pain, general
Oxypendyl		5585-93-3			
Oxypertine		153-87-7			
Oxyphenbutazone		129-20-4			
Oxyphencyclimine		125-53-1			
Oxyphenisatin		115-33-3			
Oxyphenonium		50-10-2			
Oxyphlocamphone		10136-65-9			
oxypurinol	1H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione [CAS]	2465-59-0		Antigout	Hyperuricaemia
Oxytetracycline		79-57-2			
ozagrel	2-Propenoic acid, 3-[4-(1H-imidazol-1-ylmethyl)phenyl]-, (E)- [CAS]	78712-43-3 82571-53-7	GB 2025946	Antithrombotic	Vasospasm, cerebral
p-(Benzylsulfonamido)benzoic Acid		536-95-8			
P-100			US 6313177	Antiviral, anti-HIV	Infection, HIV/AIDS
P-1202	Pentanoic acid, 5-amino-4-oxo, methyl ester, hydrochloride [CAS]	79416-27-6	US 6034267	Dermatological	Keratosis
P32/98	Di-(3N-[(2S,3S)-2-amino-3-methylpentanoyl]-1,3-thiazolidine)fumarate			Antidiabetic	Diabetes, Type II
PA-824			WO 9701562	Antimycobacterial	Infection, tuberculosis
PACAP 38	Pituitary adenylate cyclase-activating peptide-38 [CAS]	128606-20-2	US 5128242	Neuroprotective	Nerve injury, general

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
pacifloxel	5β,20-Epoxy-1,2Alpha,4,7β,10β,13Alpha-hexahydroxytax-11-en-9-one-4,10-diacetate-2-benzoate-13-(Alpha-phenylhippurate)	33069-62-4		Formulation, optimized, nanoparticles	Cancer, breast
PADRE			US 6413935	Immunostimulant, other	Vaccine adjunct
pagoclone	1H-Isolindol-1-one, 2-(7-chloro-1,8-naphthyridin-2-yl)-2,3-dihydro-3-(5-methyl-2-oxohexyl)- (R)- [CAS]	133737-32-3	US 4960779	Anxiolytic	Panic disorder
PAI Inhibs			WO 9404512	Antithrombotic	Thrombosis, venous
palindore	8H-1,4-dioxino[2,3-e]indol-8-one,2,3,7,9-tetrahydro-2-[(phenylmethyl)amino]methyl]-, 2(S)-, (2E)-2-butendioate (1:1)	189681-71-8		Neuroleptic	Schizophrenia
Palivizumab		188039-54-5			
palonosetron	3aS-2-[(S)-1-Azabicyclo[2.2.2]oct-3-yl]-2,3,3a,4,5,6-hexahydro-1-oxo-1H-benz[de]isoquinoline hydrochloride	135729-62-3	US 5202333	Antiemetic	Chemotherapy-induced nausea and vomiting
Pamabrom		606-04-2			
Pamaquine		491-92-9			
pamicrogel	1H-Pyrrole-1-acetic acid, 2-[4,5-bis(4-methoxyphenyl)-2-thiazolyl]-, ethyl ester [CAS]	101001-34-7	EP 159677	Antithrombotic	Thrombosis, cerebral
pamidronate	(3-Amino-1-hydroxypropylidene)diphosphonic acid- [CAS]	40391-99-9		Formulation, implant	Hypercalcaemia of malignancy
p-Aminobenzoic Acid		150-13-0			
p-Aminohippuric Acid		61-78-9			
p-Aminopropiophenone		70-69-9			
p-Aminosalicylic Acid		65-49-6			
Panavir	4,4'-isopropylidenedithiobis-2,6-di-t-butylphenol			Neuroprotective	Vasospasm, cerebral
Pancuronium		15500-66-0			
Panipenem		87726-17-8			

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Pantethine		16816-67-4			
pantoprazole	1H-Benzimidazole, 5-(difluoromethoxy)-2-[[[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]-[CAS]				
Pantothenic Acid		102625-70-7	EP 166287	Antiulcer	Ulcer, duodenal
Papain		79-83-4			
Papaverine		58-74-2			
paracetamol	Acetamide, N-(4-hydroxyphenyl)- [CAS]	103-90-2		Formulation, oral, other, modified-release	Pain, general
Paraflutizide		1580-83-2			
Paraldehyde		123-63-7			
Paramethadione		115-67-3			
Paramethasone		53-33-8			
Paranyline		1729-61-9			
Parathyroid Hormone		9002-64-6			
parecoxib	Propanamide, N-((4-(5-methyl-3-phenyl-4-isoxazolyl)phenyl)sulfonyl)-, sodium salt [CAS]	198470-85-8	WO 9738986	Analgesic, NSAID	Pain, post-operative
Parethoxycaine		94-23-5			
Pargyline		555-57-7			
paricalcitol	19-Nor-9,10-secoergosta-5,7,22-triene-1,3,25-triol, (1 $\alpha$ ,3 $\beta$ ,7 $\alpha$ ,22 $\alpha$ )- [CAS]	131918-61-1	EP 387077	Hormone	Hyperparathyroidism
paromomycin	O-2-Amino-2-deoxy-Alpha-D-glucopyranosyl-(1-4)-O-[O-2,6-diamino-2,6-dideoxy- $\beta$ -L-idopyranosyl-(1-3)- $\beta$ -D-ribofuranosyl-(1-5)]-2-deoxy-D-streptamine				
		7542-37-2		Protozoacide	Infection, leishmaniasis
paroxetine	Piperidine, 3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-, (3S-trans)- [CAS]				
Paroxypropione		61869-08-7	EP 223403	Antidepressant, formulation, oral, orally-disintegrating	Depression, general
Parsalmide		70-70-2			
		30653-83-9			
PaTrin-2	4-Bromothienylguanine			Radio/chemosensitizer	Cancer, melanoma
Pazinacone		103255-66-9			

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
pazufloxacin	7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid, 10-(1-aminocyclopropyl)-9-fluoro-2,3-dihydro-3-methyl-7-oxo-, (S)- [CAS]	127045-41-4 127046-45-1 136905-87-8 103-88-8	DE 3913245	Quinolone antibacterial	Infection, general
p-Bromoacetanilide			US 4918063	Formulation, other	Arthritis, general
PC-NSAIDs	6-(2,6-Dichlorophenyl)-2-[4-(diethylaminoethoxy)-phenylamino]-8-pyrido[2,3-D]pyrimidine-7-one			Anticancer, other	Cancer, general
PD-0166285		19504-77-9			
Pecilocin	3-Quinolonecarboxylic acid, 1-ethyl-6-fluoro-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo [CAS]	70458-92-3	GB 1598915	Quinolone antibacterial	Infection, urinary tract
pefloxacin	Somatotropin (18-aspartic acid, 21-asparagine, 120-lysine, 167-asparagine, 168-alanine, 171-serine, 172-arginine, 174-serine, 179-threonine (human), pegylated [CAS]	218620-50-9 4396-1-4		Somatostatin	Acromegaly
pegvisomant					
Pelletierine					
pemetrexed	L-Glutamic acid, N-[4-[2-(2-amino-4,7-dihydro-4-oxo-1H-pyrido[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-, disodium salt [CAS]	137281-23-3 150399-23-8	US 5248775	Anticancer, antimetabolite	Cancer, mesothelioma
pemilolast	4H-Pyrido[1,2-a]pyrimidin-4-one, 9-methyl-3-(1H-tetrazol-5-yl)- [CAS]	100299-08-9 69372-19-6 2152-34-3 79-55-0	US 4457932	Antiasthma	Asthma
Pemoline					
Pempidine			US 5955446	Antiviral, other	Infection, human papilloma virus
PEN-203		983-85-7			
Penamecillin	2-Propanol, 1-(2-cyclopentylphenoxy)-3-[(1,1-dimethylethyl)amino]-, (S)-, sulfate (2:1) (salt) [CAS]	38363-32-5 38363-40-5	GB 1215751	Antihypertensive, adrenergic	
penbutolol	6H-Purin-6-one, 2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)butyl]- [CAS]	39809-25-1 808-71-9	JP 60058982	Antiviral, other	Infection, herpes simplex virus
peniclovir					
Penethamate					



API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
penflutidol	4-Piperidinol, 1-[4,4-bis(4-fluorophenyl)butyl]-4-[4-chloro-3-(trifluoromethyl)phenyl]- [CAS]	26864-56-2	DE 2040231	Neuroleptic	
Penicillamine		52-67-5			
Penicillin G		61-33-6			
Penicillin G Benzathine		1538-09-6			
Penicillin G Procaine		6130-64-9			
Penicillin N		525-94-0			
Penicillin O		87-09-2			
Penicillin V		87-08-1			
Penimepicycline		4599-60-4			
Pennuss			US 4221778	Formulation, modified-release, other	Rhinitis, allergic, general
Pentaerythritol Chloral		78-12-6			
Pentaerythritol Dichlorohydrin		2209-86-1			
Pentaerythritol		597-71-7			
Pentagastrin		5534-95-2			
Pentagestrone		7001-56-1			
Pentalyle	Starch, 2-hydroxyethyl ether [CAS]	9005-27-0	US 5407428	Plasma substitute	Surgery adjunct
Pentamethonium		541-20-8			
pentamidine	Benzenecarboximidamide, 4,4'-[1,5-pentanediy]bis(oxy)]bis- [CAS]	100-33-4		Formulation, inhalable, systemic	Infection, Pneumocystis jiroveci prophylaxis
Pentazocine		359-83-1			
Pentetate		12111-24-9			
Pentetic Acid		67-43-6			
Pentetreotide		138661-02-6			
Penthienate		60-44-6			
Pentifylline		1028-33-7			
Pentigetide		62087-72-3			
Pentisomide		78833-03-1			
Pentobarbital		76-74-4			
Pentolinium		52-62-0			
Pentorex		434-43-5			
pentosan	Xylan, [CAS]	37319-17-8	US 5180715	Urological	Inflammation, urinary tract

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
pentostatin	Imidazo[4,5-d][1,3]diazepin-8-ol, 3-(2-deoxy- $\beta$ -D-erythro-pentofuranosyl)-3,6,7,8-tetrahydro-, (R)- [CAS]	53910-25-1	US 3923785	Anticancer, antimetabolite	Cancer, leukaemia, hairy cell
pentoxifylline	1H-Purine-2,6-dione, 3,7-dihydro-3,7-dimethyl-1-(5-oxohexyl)- [CAS]			Neuroprotective	Amyotrophic lateral sclerosis
Pentoxyl		147-61-5			
Pentritinrol		1607-17-6			
Pentylenetetrazole		54-95-5			
peplomycin	Bleomycinamide, N1-[3-[(1-phenylethyl)amino]propyl]-, (S)- [CAS]	68247-85-8	US 4195018	Anticancer, antibiotic	
Perazine		84-97-9			
Perflubron		423-55-2			
Perfosfamide		62435-42-1; 39800-16-3 (unspecified)			
pergolide	Ergoline, 8-[(methylthio)methyl]-6-propyl-, (8 $\beta$ )-, monomethanesulfonate- [CAS]	66104-22-1 66104-23-2	US 4797405	Antiparkinsonian	Parkinson's disease
Perhexiline		6621-47-2			
Pericyazine		2622-26-6			
perifosine	Piperidinium, 4-[[[hydroxy(octadecyloxy)phosphinyloxy]-1,1-dimethyl-, inner salt [CAS]	157716-52-4	EP 594999	Anticancer, other	Cancer, prostate
perillyl alcohol	1-Cyclohexene-1-methanol, 4-(1-methylethenyl)- [CAS]	536-59-4	US 5110832	Anticancer, other	Cancer, breast
Permethazine		13093-88-4			
perindopril	1H-Indole-2-carboxylic acid, 1-[2-[[1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro-, [2S-[1[R*(R*)],2Alpha,3a $\beta$ ,7a $\beta$ ]]-, compd. with 2-methyl-2-propanamine (1:1) [CAS]	107133-36-8 2139-25-5 2055-44-9 95153-31-4	EP 49658	Antihypertensive, renin system	Hypertension, general
Peritodyl		53586-99-5			
perisoxal	1-Piperidineethanol, Alpha-(5-phenyl-3-isoxazolyl)-, 2-hydroxy-1,2,3-propanetricarboxylate (2:1) (salt) [CAS]	2139-25-5 2055-44-9	JP 04217925	Anti-inflammatory	
Perlapine		1977-11-3			
Permethrin		52645-53-1			

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
perospirone	1H-Isindole-1,3(2H)-dione, 2-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butyl]hexahydro-, cis- [CAS]	129273-38-7 150915-41-6	CA 2167004	Neuroleptic	Schizophrenia
Perphenazine		58-39-9			
Petroleum Benzln		8030-30-6			
PH-10			US 6331286	Antipsoriasis	Psoriasis
Phanquinone		84-12-8			
Pharmaprojects No. 4994			WO 9638482	Immunological	Unspecified
Pharmaprojects No. 5325			WO 9703986	Neuroleptic	Schizophrenia
Pharmaprojects No. 5972			WO 0204426	Antiasthma	Asthma
Pharmaprojects No. 6362			US 6057346	Antiviral, anti-HIV	Infection, HIV/AIDS
	(R)-N-[4-[2-[[2-Hydroxy-2-(3-pyridinyl)ethyl]amino]ethyl]phenyl]-4-[4-(4-(trifluoromethyl)phenyl]thiazol-2-yl]benzenesulfonamide			Anorectic/Antiobesity	Obesity
Pharmaprojects No. 6446					
Pharmaprojects No. 6590			WO 0206223	Psychostimulant	Attention deficit disorder
Pharmaprojects No. 6656			US 6455026	Genomics-based drug discovery	Cancer, brain
Pharmaprojects No. 6691			US 6299900	Formulation, other	Pain, general
	3-(6-Aminopyridin-3-yl)-N-methyl-N-[(1-methyl-1H-indol-2-yl)methyl]acrylamide			Antibacterial, other	Infection, general
Pharmaprojects No. 6743					
	1,2,3,4,10,14b-Hexahydro-6-methoxy-2-methylidibenzo[c,flpyrazino[1,2-a]azepin			Antidepressant	Depression, general
Pharmaprojects No. 6748					
Phenacaine		620-99-5			
Phenacemide		63-98-9			
Phenacetin		62-44-2			
Phenadoxone		467-84-5			
Phenallymal		115-43-5			
Phenamet		3819-34-9			
Phenazocine		127-35-5			
Phenazopyridine		136-40-3			
Phenbutamide		3149-00-6			

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Phencyclidine		77-10-1			
Phendimetrazine		634-03-7			
Phenelzine		51-71-8			
Phenesterine		3546-10-9			
Phenetharbital		357-67-5			
Phenethicillin		132-93-4			
Pheneturide		90-49-3			
Phenformin		114-86-3			
Phenglutarimide		1156-05-4			
Phenindamine		82-88-2			
Phenindione		83-12-5			
Pheniprazine		55-52-7			
Pheniramine		86-21-5			
Phenmetrazine		134-49-6			
Phenobarbital		50-06-6			
Phenobutiodil		554-24-5			
Phenocoll		103-97-9			
Phenocide		78-05-7			
Phenolphthalein		77-09-8			
Phenolphthalol		81-92-5			
Phenolsulfonphthalein		143-74-8			
Phenoltetrachlorophthalein		639-44-1			
Phenoperidine		562-26-5			
Phenosulfazole		515-54-8			
Phenoxybenzamine		59-96-1			
Phenoxypropazine		3818-37-9			
Phenprobamate		673-31-4			
Phenprocoumon		435-97-2			
pheneserine	Pyrrolo(2,3-b)Indol-5-ol, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-, phenylcarbamate (ester), (3aS-cis)- [CAS]				
		101246-66-6		Cognition enhancer	Alzheimer's disease
		86-34-0			
Phensuximide					
Phentermine		122-09-8			

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Phentetatein		18265-54-8			
phenolamine	Phenol, 3-(((4,5-dihydro-1H-imidazol-2-yl)methyl)(4-methylphenyl)amino)-, monomethanesulfonate (salt) [CAS]	65-28-1 50-60-2		Formulation, oral, other	Impotence
Phenyl Acetylsalicylate		134-55-4			
Phenyl Aminosalicylate		133-11-9			
Phenyl Salicylate		118-55-8			
Phenylbutazone		50-33-9			
Phenylephrine		61-76-7			
Phenylethanolamine		7568-93-6			
Phenylmercury		102-98-7			
Phenylmethylbarbituric Acid		76-94-8			
phenylpropanolamine	Benzenemethanol, Alpha-(1-aminoethyl)-, (R*,S*)-(+/-)- [CAS]	14838-15-4		Anorectic/Antiobesity, formulation, optimized, microparticles	
Phenylpropylmethylamine		93-88-9			
Phenyltoloxamine		92-12-6			
Phenylramidol		553-69-5			
phenytoin	2,4-imidazolidinedione, 5,5-diphenyl- [CAS]	57-41-0		Formulation, oral, other	Epilepsy, general
Phethenylate		510-34-9			
Phloroglucinol		108-73-6			
Pholcodine		509-67-1			
Pholedrine		370-14-9			
Phosphocreatine		67-07-2			
Phosphocysteamine		5746-40-7			
Phosphorylcholine		107-73-3			
Phthalylsulfacetamide		131-69-1			
Phthalylsulfathiazole		85-73-4			
p-Hydroxyephedrine		365-26-4			
Phylloquinone		84-80-0			
Physostigmine		57-47-6			
Phytic Acid		83-86-3			



API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
PI-88	D-Mannose, O-6-O-phosphono-Alpha-D-mannopyranosyl-(1-3)-O-Alpha-D-mannopyranosyl-(1-3)-O-Alpha-D-mannopyranosyl-(1-3)-O-Alpha-D-mannopyranosyl-(1-2)-hydrogen sulphate [CAS]	185077-23-0		Anticancer, other	Cancer, melanoma
Piberaline		39640-15-8			
plboserod	2H-(1,3)Oxazino(3,2-a)indole-10-carboxamide, N-((1-butyl-4-piperidinyl)methyl)-3,4-dihydro- [CAS]	152811-62-6	WO 9318036	Antiarrhythmic	Fibrillation, atrial
Piclorex		62510-56-9			
Picloxydine		5636-92-0			
Picoperine		21755-66-8			
Picosulfate		10040-45-6			
Picotamide		32828-81-2			
Picumast		39577-19-0			
pidotimod	4-Thiazolidinecarboxylic acid, 3-[(5-oxo-2-pyrrolidinyl)carbonyl]- [CAS]	121808-62-6	EP 276752	Immunomodulator, anti-infective	Infection, respiratory tract, lower
Pifamine		56208-01-6			
piketoprofen	Benzeneacetamide, 3-benzoyl-Alpha-methyl-N-(4-methyl-2-pyridinyl)- [CAS]	60576-13-8	GB 1436502	Anti-inflammatory, topical	
Pildralazine		64000-73-3			
pilocarpine	2(3H)-Furanone, 3-ethylidhydro-4-[(1-methyl-1H-imidazol-5-yl)methyl]-, (3S-cis)- [CAS]	92-13-7		Formulation, Implant, Stomatological	
Piloplex	2-Propenoic acid, 2-methyl-, dodecyl ester, polymer with 2-propenolacid, compd. with (3S-cis)-3-ethylidhydro-4-[(1-methyl-1H-imidazol-5-yl)methyl]-2(3H)-furanone [CAS]	62783-28-2	DE 2636559	Formulation, mucosal, topical	Glaucoma
pilsicainide	1H-Pyrrolizine-7a(5H)-acetamide, N-(2,6-dimethylphenyl)tetrahydro-, monohydrochloride [CAS]	88069-49-2 88069-67-4	US 4564624	Antiarrhythmic	Arrhythmia, general
Pimeclone		534-84-9			

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
pimecrolimus	15,19-Epoxy-3H-pyrido(2,1-c)(1,4)oxazacyclicotricosine-1,7,20,21(4H,23H)-tetrone, 3-(2-(4-chloro-3-methoxycyclohexyl)-1-methylethenyl)-8-ethyl-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5,19-dihydroxy-14,16-dimethoxy-4,10,12,18-tetramethyl-(3S-(3R*E(1S*,3S*,4R*)), 4S*,5R*,8S*,9E*,12R*,14R*,16R*,18S,19S*,26aR*))-[CAS]	137071-32-0	EP 626385	Antipruritic/Inflamm, allergic	Eczema, atopic
Pimefylline		10001-43-1			
pimiliprost	Acetic acid, [2-[octahydro-5-hydroxy-6-(3-hydroxy-5-methyl-1-nonanyl)-2-pentalenyl]ethoxy]-, methyl ester, [2R-[2Alpha,3Alpha,4Alpha(1E,3S*,5S*),5beta,6aAlpha]]-[CAS]	139403-31-9		Dermatological	Ulcer, general
Piminodine		13495-09-5			
Pimobendan		74150-27-9			
pimozide	2H-Benzimidazol-2-one, 1-[1-[4,4-bis(4-fluorophenyl)butyl]-4-piperidinyl]-1,3-dihydro [CAS]	2062-78-4	FR M3695	Neuroleptic	
Pinacidil		85371-64-8			
pinaverium	Morpholinium, 4-[(2-bromo-4,5-dimethoxyphenyl)methyl]-4-[2-[2-(6,6-dimethylbicyclo[3.1.1]hept-2-yl)ethoxy]ethyl]-. [CAS]	53251-94-8 59995-65-2	EP 406743	Antispasmodic	Irritable bowel syndrome
pinazepam	2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-5-phenyl-1-(2-propynyl)-[CAS]	52463-83-9	DE 2339790	Anxiolytic	
Pindolol		13523-86-9			
pioglitazone	2,4-Thiazolidinedione, 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-, monohydrochloride (+/-)- [CAS]	111025-46-8 112529-15-4	EP 193256	Antidiabetic	Diabetes, Type II
Pipacycline		1110-80-1			
Pipamazine		84-04-8			
Pipamperone		1893-33-0			

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Pipazethate		2167-85-3			
Pipebuzone		27315-91-9			
Pipecurium		52212-02-9			
pipecuronium	Piperazinium, 4,4'- [[2R,3Alpha,5Alpha,16R,17R]-3,17-bis(acetyloxy)androstane-2,16-diy]bis[1,1]-dimethyl-, [CAS]	52212-02-9 68399-57-5	GB 1398050	Muscle relaxant	Anaesthesia, adjunct
pipemidic acid	Pyrido[2,3-d]pyrimidine-6-carboxylic acid, 8-ethyl-5,8-dihydro-5-oxo-2-(1-piperazinyl)- [CAS]	51940-44-4	GB 1451911	Antibacterial, other	Infection, urinary tract
Pipenzolate Bromide		125-51-9			
Piperacetazine		3819-00-9			
piperacillin	4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[(4-ethyl-2,3-dioxo-1-piperazinyl)carbonyl]amino]phenylacetyl]amino]-3,3-dimethyl-7-oxo-, [2S]-[2Alpha,5Alpha,6R(S*)]- [CAS]	59703-84-3 61477-96-1	GB 1508062	Penicillin, injectable	Infection, general
Piperazine Adipate		142-88-1			
Piperidione		77-03-2			
Piperidolate		82-98-4			
Piperilate		4546-39-8			
piperine analogues			WO 002544	Dermatological	Vitiligo
Piperocaine		136-82-3			
Piperonal		120-57-0			
Piperoxan		59-39-2			
Piperylone		25 31-4-6			
Pipobroman		54-91-1			
Piposulfan		2608-24-4			
pipotiazine	Hexadecanoic acid, 2-[1-[3-[2-[(dimethylamino)sulfonyl]-10H-phenothiazin-10-yl]propyl]-4-piperidinyl]ethyl ester [CAS]	37517-26-3 39860-99-6	US 4782077	Neuroleptic	
Pipoxolan		18174-58-8			
Pipradrol		467-60-7			

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
piprozolin	Acetic acid, [3-ethyl-4-oxo-5-(1-piperidinyl)-2-thiazolidinylidene], ethyl ester [CAS]	17243-64-0	US 3971794	GI inflammatory/bowel disorders	Motility dysfunction, GI, general
Piracetam		7491-74-9			
pirarubicin	5,12-Naphthacenedione, 10-[[3-amino-2,3,6-trideoxy-4-O-(tetrahydro-2H-pyran-2-yl)-Alpha-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, [8S-[8Alpha,10Alpha(S*)]]- [CAS]	72496-41-4	US 4303785	Anticancer, antibiotic	Cancer, breast
Pirazolac		71002-09-0			
pirbuterol	2,6-Pyridinedimethanol, Alpha6-[[[(1,1-dimethyl[ethyl]amino)methyl]-3-hydroxy-, monoacetate (salt) [CAS]	38029-10-6 38677-81-5 65652-44-0	US 3786160	Antiasthma	Asthma
Pirenoxine		1043-21-6			
pirenzepine	6H-Pyrido[2,3-b][1,4]benzodiazepin-6-one, 5,11-dihydro-11-[[4-methyl-1-piperazinyl]acetyl]- [CAS]	28797-61-7 29868-97-1	FR 1505795	Antilucer	
piretanide	Benzoic acid, 3-(aminosulfonyl)-4-phenoxy-5-(1-pyrrolidinyl)- [CAS]	55837-27-9	US 4010273	Antihypertensive, diuretic	Hypertension, general
pirfenidone	2(1H)-Pyridinone, 5-methyl-1-phenyl- [CAS]	53179-13-8		Respiratory	Fibrosis, pulmonary
piribedil	Pyrimidine, 2-[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]- [CAS]	3605-01-4	US 3299067	Vasodilator, peripheral	Parkinson's disease
Piridocaine		87-21-8			
Pirifibrate		55285-45-5			
Piritramide		302-41-0			
Piritrexim		72732-56-0			
pirindole	1H-Pyrazino[3,2,1-k]carbazole, 2,3,3a,4,5,6-hexahydro-8-methyl- [CAS]	16154-78-2 60762-57-4	SU 276060	Antidepressant	Depression, general
pirmenol	(2-Pyridinemethanol, Alpha-[3-(2,6-dimethyl-1-piperidinyl)propyl]-Alpha.phenyl-, cis-(+)- [CAS]	61477-94-9 68252-19-7	US 4112103	Antiarrhythmic	Tachycardia, supraventricular
Piroctone		50650-76-5			
Piroheptine		16378-21-5			

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Piromidic Acid		19562-30-2			
piroxicam	2H-1,2-Benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-N-2-pyridinyl-, 1,1-dioxide [CAS]	36322-90-4	US 3862319	Anti-inflammatory	
piroxicam betadex	$\beta$ -Cyclodextrin, compd. with 4-hydroxy-2-methyl-N-2-pyridinyl-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide- [CAS]	121696-62-6 96684-39-8	EP 153998	Formulation, other	Pain, musculoskeletal
piroxicam cinnamate	2-Propenoic acid, 3-phenyl-, 2-methyl-3-[(2-pyridinylamino)carbonyl]-2H-1,2-benzothiazin-4-yl ester, S,S-dioxide [CAS]	87234-24-0	EP 79639	Antiarthritic, other	Inflammation, general
Pirozadil		54110-25-7			
Piprofen		31793-07-4			
pitavastatin	6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, calcium salt (2:1), [S-(R*, S*-(E))]- [CAS]	147526-32-7	EP 304063	Hypolipaeimic/Antiatherosclerosis	Hyperlipidaemia, general
pivagabine	N-trimethylacetyl-4-aminobutyric acid	69542-93-4		Neurological	Anxiety, general
pivaloyloxymethyl	Butanoic acid, (2,2-dimethyl-1-oxopropoxy)methyl ester [CAS]	122110-53-6	EP 302349	Anticancer, other	Cancer, lung, non-small cell
Pivalylbenzhydrazine		306-19-4			
Pivampicillin		33817-20-8			
pivampicillin/pivmecillinam		98445-47-7		Penicillin, oral	Infection, general
Pivcefalexin		63836-75-9			
pivmecillinam	4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[(hexahydro-1H-azepin-1-yl)methylene]amino]-3,3-dimethyl-7-oxo-, (2,2-dimethyl-1-oxopropoxy)methyl ester, [2S-(2Alpha,5Alpha,6S)]- [CAS]	32886-97-8	GB 1293590	Penicillin, oral	Infection, general
pixantrone	Benz[glisoquinoline-5,10-dione, 6,9-bis[(2-aminoethyl)amino]-, (2Z)-2-butenedioate(1:2) [CAS]	144675-97-8	EP 503537	Anticancer, other	Cancer, lymphoma, non-Hodgkin's



API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
pizotifen	4-(9,10-dihydro-4H-benzo[4,5]cyclohepta[1,2-b]thien-4-ylidene)-1-methylpiperidine	15574-96-6	DE 2346747	Antimigraine	
Pizotyline		15574-96-6			
PKI-166	Phenol, 4-(4-(((1R)-1-phenylethyl)amino)-1H-pyrrolo[2,3-d]pyrimidin-6-yl)- [CAS]	187724-61-4		Anticancer, other	Cancer, general
p-Lactophenetide		539-08-2			
Plafibride		63394-05-8			
plasminogen activator	Plasminogen activator [CAS]	105913-11-9	EP 151996	Fibrinolytic	Infarction, myocardial
Plasmodid		551-01-9			
Platonin		3571-88-8			
Plaunotol		64218-02-6			
PLD-118	Cyclopentanecarboxylic acid, 2-amino-4-methylene-, (1R,2S)- [CAS]	198022-65-0	EP 805145	Antifungal	Infection, Candida, general
PLD-147	(OC-6-43)-Bis(acetato)(1-adamantylamine)ammine-dichloro-platinum (IV)			Anticancer, alkylating	Cancer, general
pleconanil	1,2,4-Oxadiazole, 3-(3,5-dimethyl-4-(3-(3-methyl-5-isoxazolyl)propoxy)phenyl)-5-(trifluoromethyl)- [CAS]	153168-05-9	US 5464848	Antiviral, other	Infection, respiratory tract, general
Plicamycin		18378-89-7			
p-Methyldiphenhydramine		19804-27-4			
PMS-601			WO 0001677	Antiviral, anti-HIV	Infection, HIV/AIDS
<i>Pneumococcal Vaccine, Diphtheria Conjugate</i>					
<i>Pneumococcal Vaccine, Polyvalent</i>					
PNU-288034	N-[[[(5s)-3[4[(1,1-dioxido-4-thiomorpholinyl)3,5-difluorophenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide]			Antibiotic, other	Infection, general
Podophyllotoxin		518-28-5			
polaprezinc	Zinc, bis(N-β-alanyl-L-histidinato-N3,Oαpha)-, (T-4)- [CAS]	107667-60-7	EP 303380	Antitumor	Ulcer, duodenal
Poldine Methylsulfate		545-80-2			

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Pollcresulen		9011-2-3			
Polidexide		9064-92-0			
polidocanol	Polyethylene glycol monododecyl ether	3055-99-0 9002-92-0		Vasoprotective, systemic	Venous insufficiency
<i>Poliovirus Vaccine Inactivated</i>					
poly-ADPRT inhibitors			WO 9845253	Anticancer, other	Cancer, general
Polyestradiol Phosphate		28014-46-2			
Polyphenon E	Polyphenon E [CAS]	188265-33-0			Infection, human papilloma virus
Polythiazide		346-18-9		Antiviral, other	
porfimer	Photofrin [CAS]	87806-31-3	US 4882234	Anticancer, other	Cancer, lung, non-small cell
Porfiromycin		801-52-5			
posaconazole	D-threo-Pentitol, 2,5-anhydro-1,3,4-trideoxy-2-C-(2,4-difluorophenyl)-4-((4-(4-(1(1S,2S)-1-ethyl-2-hydroxypropyl)-1,5-dihydro-5-oxo-4H-1,2,4-triazol-4-yl)phenyl)-1-piperazinyl)phenoxy)methyl)-1-(1H-1,2,4-triazol-1-yl)- [CAS]	171228-49-2	US 5714490	Antifungal	Infection, fungal, general
Posatirelin		78664-73-0			
potassium chloride	Potassium chloride (KCl) [CAS]	7447-40-7		Formulation, oral, enteric-coated	
Potassium Gluconate		299-27-4			
Potassium Gualacolsulfonate		1321-14-8			
Potassium p-Aminobenzoate		138-84-1			
Potassium Permanganate		7722-64-7			
Povidone		9003-39-8			
Povidone-Iodine		25655-41-8			
PP-117	3-Pyridinemethanol, hydrofluoride [CAS]	62756-44-9	DE 2633028	Formulation, oral, other	Unspecified
PR-2699	(-)-(E)-[4-(2,4-dichlorophenyl)-1,3-dithiolan-2-ylidene]-1-imidazolylacetoneitrile			Antifungal	Infection, fungal, general

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
PR-608	(S)-(-)-1-[4,4-bis(4-fluorophenyl)butyl]-4-(2-hydroxy-3-phenylaminopropyl)piperazine trihydrochloride			Antiparkinsonian	Parkinson's disease
Practolol		6673-35-4			
Praimalline		35080-11-6			
Pralidoxime		51-15-0			
pralnacasan	6H-Pyridazino(1,2-a)(1,2)diazepine-1-carboxamide, N-((2R,3S)-2-ethoxytetrahydro-5-oxo-3-furanyl)octahydro-9-((1-isoquinolinylcarbonyl)amino)-6,10-dioxo-, (1S,9S)- [CAS]	192755-52-5		Antiarthritic, Immunological	Arthritis, rheumatoid
pramipexole	2,6-Benzothiazolediamine, 4,5,6,7-tetrahydro-N6-propyl-, (S)- [CAS]	104632-26-0	EP 186087	Antiparkinsonian	Parkinson's disease
pramiracetam	1-Pyrrolidineacetamide, N-[2-bis(1-methylethyl)amino]ethyl]-2-oxo-, monohydrochloride [CAS]	68497-62-1 72869-16-0 75733-50-5	US 4145347	Cognition enhancer	Amnesia
Pramiverin		14334-40-8			
pramlintide	1,2-Dithia-5,8,11,14,17-pentaazacycloicosane, cyclic peptide deriv. [CAS]	151126-32-8	US 5124314	Antidiabetic	Diabetes, Type I
Pramoxine		140-65-8			
pranidipine	3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 3-phenyl-2-propenyl ester, (E)- [CAS]	99522-79-9	EP 173126	Antihypertensive, other	Hypertension, general
Pranlukast		103177-37-3			
pranoprofen	5H-[1]Benzopyrano[2,3-b]pyridine-7-acetic acid, Alpha-methyl-, [CAS]	52549-17-4		Formulation, mucosal, topical	Ocular disorder, general
prasterone	Androst-5-en-17-one, 3-hydroxy-, (3β)- [CAS]	53-43-0		Labour inducer	
prazosin	4(3H)-Cycloheptimidazolone, 5,6,7,8-tetrahydro-2-propyl-3-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- [CAS]	153804-05-8	US 5409947	Antihypertensive, renin system	Hypertension, general

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
pravastatin	1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro- $\beta$ ,delta,6-trihydroxy-2-methyl-8-(2-methyl-1-oxobutoxy)-, monosodium salt, [1S- [1 $\alpha$ pha( $\beta$ S*,deltaS*),2 $\alpha$ pha,6 $\alpha$ pha,8 $\beta$ (R*),8a $\alpha$ pha]]- [CAS]	81093-37-0 81131-70-6	US 4346227	Hypolipaeic/Antiatherosclerosis	Atherosclerosis
Prazepam		2955-38-6			
praziquantel	4H-Pyrazino[2,1-a]isoquinolin-4-one, 2-(cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro- [CAS]	55268-74-1	US 4001411	Schistosomicide	
prazosin	Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)-[CAS]	19216-56-9 19237-84-4	US 4092315	Antihypertensive, adrenergic	Hypertension, general
Prednicarbate		73771-04-7			
prednimustine	Pregna-1,4-diene-3,20-dione, 21-[4-[4-bis(2-chloroethyl)amino]phenyl]-1-oxobutoxy]-11,17-dihydroxy-, (11 $\beta$ )- [CAS]	29069-24-7	GB 1272841	Anticancer, alkylating	
Prednisolone		50-24-8			
Prednisolone 21-Diethylaminoacetate		5626-34-6			
prednisolone farnesil	Pregna-1,4-diene-3,20-dione, 11,17-dihydroxy-21-[(3,7,11-trimethyl-1-oxo-2,6,10-dodecatienyl)oxy]-, [11 $\beta$ ,21(2E,6E)]- [CAS]	118244-44-3	EP 332143	Antiarthritic, other	Arthritis, rheumatoid
Prednisolone Sodium Phosphate		125-02-0			
Prednisone		53-03-2			
Prednival		15180-00-4			
Prednylidene		599-33-7			
pregabalin	Hexanoic acid, 3-(aminomethyl)-5-methyl, (S)- [CAS]	148553-50-8		Antiepileptic	Epilepsy, general
Pregnan-3 $\alpha$ -ol-20-one		128-20-1			
Premarin + trimegestone	Estra-4,9-dien-3-one, 17-(2-hydroxy-1-oxopropyl)-17-methyl-, [17 $\beta$ (S)]- [CAS]	74513-62-5		Menopausal disorders	Hormone replacement therapy
prenalterol	Phenol, 4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]-, hydrochloride, (S)-[CAS]	57526-81-5 61260-05-7	GB 1470039	Cardio stimulant	

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Prenoxdiazine		982-43-4			
Prenylamine		390-64-7			
prezatide	Cuprate(1-), (N2-(N-glycyl-L-histidyl)-L-lysinate)(N2-(N-glycyl-L-histidyl)-L-lysinate(2-))-, hydrogen, [CAS]	130120-57-9		Vulnerary	Wound healing
Pridinol		511-45-5			
Prifinium		4630-95-9			
Prilocaine		721-50-6			
Primaquine		90-34-6			
Primidone		125-33-7			
Prinomastat		192329-42-3			
PRO-2000			US 5614599	Antiviral, anti-HIV	Infection, HIV prophylaxis
Probenecid		57-66-9			
Probucof		23288-49-5			
procainamide	Benzamide, 4-amino-N-[2-(diethylamino)ethyl]- [CAS]	51-06-9 614-39-1		Formulation, other	Arrhythmia, general
Procaine		59-46-1			
Procarbazine		671-16-9			
procatenol	2(1H)-Quinolinone, 8-hydroxy-5-[1-hydroxy-2-[(1-methylethyl)amino]butyl]-, monohydrochloride [CAS]	59828-07-8 60443-17-6 72332-33-3	GB 1496766	Antisthma	
prochlorperazine	10H-Phenothiazine, 2-chloro-10-[3-(4-methyl-1-piperazinyl)propyl]-, (Z)-2-butenedioate	58-38-8 84-02-6		Formulation, oral, other	Nausea and vomiting, general
procodazol	1H-Benzimidazole-2-propanoic acid [CAS]	23249-97-0	ES 407882	Anticancer, immunological	Cancer, general
Procyclidine		77-37-2			
Procymate		13931-64-1			
Prodipine		31314-38-2			
Proflavine		92-62-6			
Progabide		62666-20-0			
progesterone	Pregn-4-ene-3,20-dione [CAS]	57-83-0		Formulation, transmucosal, systemic	Amenorrhoea



API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
proglumetacin	1H-Indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-, 2-(4-(3-((4-(benzoylamino)-5-(diisopropylamino)-1,5-dioxopentyl)oxy)propyl)-1-piperazinyl)ethyl ester, (+/-)- [CAS]	57132-53-3 59209-40-4	GB 1467568	Anti-inflammatory	Inflammation, general
proglumide	Pentanoic acid, 4-(benzoylamino)-5-(diisopropylamino)-5-oxo-, (+/-)- [CAS]	6620-60-6	DE 1518125	Antitumor	Ulcer, gastric
Proheptazine		77-14-5			
Prolactin		9002-62-4			
Prolintane		493-92-5			
Prolonium		123-47-7			
Promazine		58-40-2			
Promedol		64-39-1			
Promegestone		34184-77-5			
promestriene	Estra-1,3,5(10)-triene, 17-methoxy-3-propoxy-, (17 $\beta$ )- [CAS]	39219-28-8	GB 1337198	Reproductive/gonadal, general	Acne
Promethazine		60-87-7			
Pronethalol		54-80-8			
propacetamol	Glycine, N,N-diethyl-, 4-(acetamidino)phenyl ester [CAS]	66532-85-2 66532-86-3	US 4127671	Formulation, parenteral, other	
propafenone	1-Propanone, 1-[2-[2-hydroxy-3-(propylamino)propoxy]phenyl]-3-phenyl- [CAS]	54063-53-5	GB 1307455	Antiarrhythmic	Fibrillation, ventricular
Propagermanium		12758-40-6			
Propallylinal		545-93-7			
Propamidine		104-32-5			
propane-1,2-diol	1,2-propanediol	57-55-6		Formulation, dermal, topical	Infection, fungal, general
Propanidid		1421-14-3			
Propantheline		50-34-0			
Proparacaine		499-67-2			
Propatyl		2921-92-8			
propenidazole	ethyl trans-Alpha-acetyl-1-methyl-5-nitroimidazole-2-acrylate	76448-31-2		Antifungal	infection, trichomoniasis
propentofylline	1H-Purine-2,6-dione, 3,7-dihydro-3-methyl-1-(5-oxohexyl)-7-propyl- [CAS]	55242-55-2	GB 1470220	Neuroprotective	Ischaemia, cerebral

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Propicillin		551-27-9			
Propiomazine		362-29-8			
Propionic Acid		79-09-4			
propionyl L-carnitine	1-Propanaminium, 3-carboxy-N,N,N-trimethyl-2-(1-oxopropoxy)-, chloride, (R)- [CAS]	119793-66-7 20084-19-1	GB 2008578	Vasodilator, peripheral	Peripheral vascular disease
Propiopocaine		3670-68-6			
Propiram		15686-91-6			
propiverine	2,2-diphenyl-2-(1-propoxy)acetic acid (1-methylpiperid-4-yl) ester hydrochloride	54556-98-8 60569-19-9		Urological	Incontinence
Propizepine		10321-12-7			
propofol	Phenol, 2,6-bis(1-methylethyl)- [CAS]	2078-54-8	US 4056635	Anaesthetic, injectable	Anaesthesia
Propoxycaine		550-83-4			
Propoxyphene		469-62-5			
propranolol	2-Propanol, 1-[(1-methylethyl)amino]-3-(1-naphthalenyloxy)- [CAS]	318-98-9 525-66-6		Formulation, modified-release, <=24hr	Hypertension, general
Propylhexedrine		101-40-6			
Propylidone		587-61-1			
Propylthiouracil		51-52-5			
Propyphenazone		479-92-5			
Proquazone		22760-18-5			
Proscillaridin		466-06-8			
Prostacyclin		35121-78-9			
Prostaglandin E1		745-65-3			
Prostaglandin E2		363-24-6			
Prostaglandin F2a		551-11-1			
Prosultiamine		59-58-5			
Protein C		60202-16-6			
Prothecbromine		50-39-5			
Prothipendyl		303-69-5			
Protiofate		58416-00-5			
Protonamide		14222-60-7			

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
protiznic acid	10H-Phenothiazine-2-acetic acid, 7-methoxy-Alpha, 10-dimethyl-, (+/-)- [CAS]	13799-03-6	US 3450698	Anti-inflammatory	
Protoanemonin		108-28-1			
Protokylol		136-70-9			
Protoporphyrin IX		553-12-8			
Protriptyline		438-60-8			
Pro-Urokinase		82657-92-9			
Proxazole		5696-9-3			
Proxibarbal		2537-29-3			
proxigermanium	Propionic acid, 3,3'-(1,3-dioxo-1,3-digermoxanediyl)bis- [CAS]	12758-40-6	FR 2005110	Antiviral, other	Infection, hepatitis-B virus
Proxyphylline		603-00-9			
Prozapine		3426-8-2			
Prucalopride		179474-81-8			
prullifloxacin	1H,4H-[1,3]Thiazeto[3,2-a]quinoline-3-carboxylic acid, 6-fluoro-1-methyl-7-[4-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl]-1-piperazinyl]-4-oxo- [CAS]	123447-62-1	EP 315828	Quinolone antibacterial	Infection, respiratory tract, general
Pseudococaine		478-73-9			
pseudoephedrine + triprolidine	Benzenemethanol, Alpha-[1-(methylamino)ethyl]-, hydrochloride, [S-(R*,R*)]-, mixt. with (E)-2-[1-(4-methylphenyl)-3-(1-pyrrolidinyl)-1-propenyl]pyridine monohydrochloride [CAS]			Formulation, modified-release, other	Rhinitis, allergic, general
pseudoephedrine	Benzenemethanol, Alpha-[1-(methylamino)ethyl]-, [S-(R*,R*)]- [CAS]	90-82-4, 8054-27-1, 345-78-8		Formulation, oral, other	Infection, respiratory tract, general
Psilocybin		520-52-5			
PSK-3841	Benzonitrile, 4-[3-(4-hydroxybutyl)-4,4-dimethyl-2,5-dioxo-1-imidazolidinyl]-2-(trifluoromethyl)- [CAS]	154992-24-2		Dermatological	Alopecia, general
p-Sulfanilylbenzylamine		4393-19-5			
PT-141			US 6051555	Male sexual dysfunction	Impotence
Pteropterin		89-38-3			
Puromycin		53-79-2			

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
PX-12	1-Methylpropyl 2-mercaptoimidazolyl disulfide			Anticancer, other	Cancer, general
Pyrantel		15686-83-6			
Pyrazinamide		98-96-4			
Pyridinol Carbamate		1882-26-4			
Pyridostigmine Bromide		101-26-8			
Pyridoxal 5-Phosphate		54-47-7			
Pyridoxine		58-56-0			
Pyrimidine		91-84-9			
Pyrimethamine		58-14-0			
Pyrimidine		1740-22-3			
Pyrisuccideanol		33605-94-6			
Pyritnone		1121-30-8			
Pyritnone		77-04-3			
Pyritnone		1098-97-1			
Pyrocatechol		120-80-9			
Pyrogallol		87-66-1			
Pyronaridine		74847-35-1			
Pyrovalerone		3563-49-3			
Pyroxilin		9004-70-0			
Pyrobutamine		91-82-7			
Pyrocarine		2210-77-7			
Pyrolnitrin		1018-71-9			
Pyvinium Pamoate		3546-41-6			
quazepam	2H-1,4-Benzodiazepine-2-thione, 7-chloro-5-(2-fluorophenyl)-1,3-dihydro-1-(2,2,2-trifluoroethyl)- [CAS]	36735-22-5	US	Hypnotic/Sedative	Insomnia
Quercetin		117-39-5			
quetiapine	Ethanol, 2-[2-(4-dibenzo[b,f][1,4]thiazepin-11-yl-1-piperazinyl)ethoxy]-, (E)-2-butenedioate (2:1) (salt) [CAS]	111974-69-7 111974-72-2	EP	Neuroleptic	Schizophrenia
Quinacilin		1596-63-0			

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
quinacrine	N-(6-Chloro-2-methoxy-9-acridinyl)-N,N-diethyl-1,4-pentanediamine + 10H-Phenothiazine-10-propanamine, 2-chloro-N,N-dimethyl	83-89-6		Neurological	Creutzfeldt-Jakob disease
quinagolide	Sulramide, N,N-diethyl-N'-(1,2,3,4,4a,5,10,10a-octahydro-6-hydroxy-1-propylbenzo[g]quinolin-3-yl)-, (3A)pha,4aAlpha,10aß)- (+/-)- [CAS]	87056-78-8 94424-50-7 97805-49-7	EP 77754	Antiprolactin	Hyperprolactinaemia
quinapril	3-Isoquinolinecarboxylic acid, 2-[2-[[1-(ethoxycarbonyl)-3-phenylpropylamino]-1-oxopropyl]-1,2,3,4-tetrahydro-, [3S-[2[R*(R*),3R*]]- [CAS]	82586-55-8 85441-61-8 90243-99-5	EP 49605	Antihypertensive, renin system	Hypertension, general
quinaprilat	3-Isoquinolinecarboxylic acid, 2-[2-[[1-carboxy-3-phenylpropyl)amino]-1-oxopropyl]-1,2,3,4-tetrahydro-, [3S-[2[R*(R*),3R*]]- [CAS]	82768-85-2	EP 46953	Antihypertensive, renin system	Hypertension, general
Quinapyramine		20493-41-8			
Quinbolone		2487-63-0			
Quinestradiol		1169-79-5			
Quinestrol		152-43-2			
Quinethazone		73-49-4			
quinfamide	2-Furancarboxylic acid, 1-(dichloroacetyl)-1,2,3,4-tetrahydro-6-quinolinyl ester [CAS]	62265-68-3	US 3997542	Amoebicide	
quinidine	Cinchonan-9-ol, 6'-methoxy-, (9S)-, sulfate (1:1) (salt) [CAS]	747-45-5 56-54-2		Formulation, modified-release, other	Arrhythmia, general
Quinine		130-95-0			
Quinocide		525-61-1			
Quinupramine		31721-17-2			
Quinupristin		120138-50-3			
R-107500	cis-2,3,3a,8-tetrahydro-N,N-dimethyldibenz[c,f]isoxazolo[2,3-a]azepine-2-methanamine		WO 9614320	Anxiolytic	Anxiety, general
R-667			WO 0204439	COPD treatment	Emphysema, general



API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
rabaprazole	1H-Benzimidazole, 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]methyl]sulfinyl]-, sodium salt- [CAS]	117976-89-3 117976-90-6	EP 268956	Antilulcer	Ulcer, gastric
racecadotril	Glycine, N-[2-[(acetylthio)methyl]-1-oxo-3-phenylpropyl]-, phenylmethyl ester, (+/-)- [CAS]	112573-72-5 81110-73-8	EP 38758	Antidiarrhoeal	Diarrhoea, general
Racemethorphan		510-53-2			
raloxifene	Methanone, [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]-, hydrochloride [CAS]	82640-04-8 84449-90-1	EP 62503	Osteoporosis treatment	Osteoporosis
ralitrexed	L-glutamic acid, N-[[5-[[[1,4-dihydro-2-methyl-4-oxo-6-quinazolinyl)methyl]methylamino]-2-thienyl]carbonyl]- [CAS]	112887-68-0	EP 239362	Anticancer, antimetabolite	Cancer, colorectal
ramatroban	9H-Carbazole-9-propanoic acid, 3-[[[4-(fluorophenyl)sulfonyl]amino]-1,2,3,4-tetrahydro-, (R)- [CAS]	116649-85-5 3615-24-5	EP 242518	Antiallergic, non-asthma	Rhinitis, allergic, perennial
Ramifenazone					
ramipril	Cyclopenta[b]pyrrole-2-carboxylic acid, 1-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydro-, [2S-[1R*(R*)], 2Alpha,3aß,6aß]]-[CAS]	87269-97-4 87333-19-5	EP 79022	Antihypertensive, renin system	Heart failure
ramosetron	Methanone, (1-methyl-1H-indol-3-yl)(4,5,6,7-tetrahydro-1H-benzimidazol-5-yl)-, monohydrochloride, (R)- [CAS]	132907-72-3 132036-88-5	EP 381422	Antiemetic	Nausea and vomiting, general
Ramot project No. 1097			US 5730992	Dermatological	Unspecified
Ranimustine		58994-96-0			
ranitidine	1,1-Ethenediamine, N-[2-[[[5-[(dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl]-N'-methyl-2-nitro- [CAS]	66357-35-5	US 4128658	Antilulcer	Ulcer, duodenal

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
ranitidine bismuth citrate	1,2,3-Propanetricarboxylic acid, 2-hydroxy-bismuth(3+) salt (1:1), compd. with N-(2-(((5-((dimethylamino)methyl)-2-furanyl)methyl)thio)ethyl)-N'-methyl-2-nitroethenediamine (1:1))- [CAS]	128345-62-0	EP 533281	Antilulcer	Ulcer, duodena
ranolazine	1-Piperazineacetamide, N-(2,6-dimethylphenyl)-4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]-, (+/-) [CAS]	95635-55-5 95635-56-6	EP 126449	Antianginal	Angina, general
Ranpirnase		133737-96-9			
Rapacuronium		156137-99-4			
rasagiline	1H-Inden-1-amine, 2,3-dihydro-N-2-propynyl-, (R)-, [CAS]	161735-79-1	US 5457133	Antiparkinsonian	Parkinson's disease
Raubasine		483-04-5			
ravuconazole	Benzonitrile, 4-[2-[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-4-thiazolyl]- [CAS]	182760-06-1		Antifungal	Infection, meningitis, general
raxofelast	2-Benzofuranacetic acid, 5-(acetyloxy)-2,3-dihydro-4,6,7-trimethyl-, (+)- [CAS]	128232-14-4	US 4999350	Symptomatic antidiabetic	Nephropathy, diabetic
razoxane	2,6-Piperazinedione, 4,4'-(1-methyl-1,2-ethanedyl)bis- [CAS]	21416-67-1, 21416-87-5	GB 1234935	Anticancer, other	Cancer, general
RC-529	Tetradecanoic acid (1R)-1-(2-((2-deoxy-3-O-((3R)-1-oxo-3-((1-oxotetradecyl)oxy)tetradecyl)amino-4-O-phosphono-β-D-glucopyranosyl)oxy)ethyl)amino)-2-oxoethyl)dodecyl ester, compd. with N,N-diethylethylamine (1:1) [CAS]	216014-46-9		Immunostimulant, other	Vaccine adjunct
rebamipide	4-Quinolonepropanoic acid, Alpha-[(4-chlorobenzoyl)amino]-1,2-dihydro-2-oxo- [CAS]	90098-04-7	DE 3324034	Antilulcer	
rebimastat	L-Valinamide, N-((2S)-2-mercapto-1-oxo-4-(3,4,4-trimethyl-2,5-dioxo-1-imidazolidinyl)butyl)-L-leucyl-N,3-dimethyl- [CAS]	259188-38-0		Anticancer, other	Cancer, lung, non-small cell
reboxetine	Morpholine, 2-[(2-ethoxyphenoxy)phenylmethyl]-, (R*,S*)- [CAS]	71620-89-8, 98769-81-4	US 4229449	Antidepressant	Depression, general

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Remacemide		128298-28-2			
remifentanyl	1-Piperidinepropanoic acid, 4-(methoxycarbonyl)-4-((1-oxopropyl)phenylamino)-methyl ester- [CAS]	132539-07-2, 132875-61-7	EP 383579	Analgesic, other	Pain, general
remimetant	Tricyclo[3.3.1.1 <sup>3,7</sup> ]decane-2-carboxylic acid, 2-[[[1-(7-chloro-4-quinolinyl)-5-(2,6-dimethoxyphenyl)-1H-pyrazol-3-yl]carbonyl]amino]- [CAS]	146362-70-1 80125-14-0	EP 699438	Neuroleptic	Schizophrenia
Remoxipride					
renzapride	Benzamide, 4-amino-N-1-azabicyclo[3.3.1]non-4-yl-5-chloro-2-methoxy- [CAS]	109872-41-5 88721-77-1	JP 58188885	Gastroprokinetic	Irritable bowel syndrome
repaglinide	Benzoic acid, 2-ethoxy-4-[2-[[3-methyl-1-[2-(1-piperidinyl)phenyl]butyl]amino]-2-oxoethyl]-, (S)- [CAS]	135062-02-1	WO 9300337	Antidiabetic	Diabetes, Type II
repertaxin L-lysine salt	2(R)-4-Isobutylphenylpropionyl methanesulfonamide L-lysine salt		WO 0024710	Cardiovascular	Reperfusion injury
replintan	1,2-Benzisothiazol-3(2H)-one, 2-(4-(((3,4-dihydro-2H-1-benzopyran-2-yl)methyl)amino)butyl)-, 1,1-dioxide, monohydrochloride [CAS]	144980-29-0 144980-77-8	US 5137901	Neuroprotective	Ischaemia, cerebral
repirinast	4H-Pyran[3,2-c]quinoline-2-carboxylic acid, 5,6-dihydro-7,8-dimethyl-4,5-dioxo-, 3-methylbutyl ester [CAS]	73080-51-0 3625-25-0	US 4298610	Antiasthma	
Reposal					
reproterol	1H-Purine-2,6-dione, 7-[3-[2-(3,5-dihydroxyphenyl)-2-hydroxyethyl]amino]propyl]-3,7-dihydro-1,3-dimethyl- [CAS]	13055-82-8 54063-54-6	FR M5969	Antiasthma	Asthma
Rescimetol		73573-42-9			
Rescinnamine		24815-24-5			
Reserpiline		131-02-2			
Reserpine		50-55-5			
Resibufogenin		465-39-4			

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
resiquimod	1H-imidazo(4,5-c)quinoline-1-ethanol(ethoxymethyl)-Alpha, Alpha-dimethyl- [CAS]	144875-48-9	US 5389640	Antiviral, other	Infection, hepatitis-C virus
Resorcinol		108-46-3			
Releplase		133652-38-7			
retigabine	Carbamic acid, (2-amino-4-(((4-fluorophenyl)methyl)amino)phenyl)-, ethyl ester [CAS]	150812-12-7	DE 4200259	Antiepileptic	Epilepsy, general
retinoic acid	Retinoic acid [CAS]	302-79-4		Formulation, parenteral, other	Cancer, leukaemia, acute myelogenous
Revimid			US 6281230	Anticancer, other	Cancer, myeloma
R-flurbiprofen	[1,1'-Biphenyl]-4-acetic acid, 2-fluoro-Alpha-methyl	5104-49-4		Anticancer, other	Cancer, prostate
Rho (D) Immune Globulin (Human)					
Rho-kinase Inhibitors			WO 0156988	Antiasthma	Unspecified
ribavirin	1H-1,2,4-Triazole-3-carboxamide, 1-β-D-ribofuranosyl- [CAS]	36791-04-5	US 4211771	Antiviral, other	Infection, haemorrhagic fever
Riboflavin		146-17-8			
ribostamycin	D-Streptamine, O-2,6-diamino-2,6-dideoxy-Alpha-D-glucopyranosyl-(1-4)-O-β-D-ribofuranosyl-(1-5)]-2-deoxy- [CAS]	25546-65-0	GB 1254883	Aminoglycoside antibiotic	Infection, general
Ricinoleic Acid		141-22-0			
Ridogrel		110140-89-1			
rifabutin	Rifamycin XIV, 1',4-didehydro-1-deoxy-1,4-dihydro-5'-(2-methylpropyl)-1-oxo-[CAS]	72559-06-9	US 4219478	Antimycobacterial	Infection, Mycobacterium avium complex
rifalazil	Rifamycin VIII, 1',4-didehydro-1-deoxy-1,4-dihydro-3'-hydroxy-5'-[4-(2-methylpropyl)-1-piperazinyl]-1-oxo- [CAS]	129791-92-0 129791-94-2 133633-12-2	EP 366914	Antimycobacterial	Infection, tuberculosis
rifametane	Rifamycin, 3-[[1-(diethylamino)ethylidene]hydrazono]methyl]-[CAS]				
Rifamide		94168-98-6 2750-76-7	EP 119571	Antimycobacterial	Infection, general

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
rifampicin + trimethoprim	Rifamycin, 3-[[[(4-methyl-1-piperazinyl)imino]methyl]-, mixt. with 5-[(3,4,5-trimethoxyphenyl)methyl]-2,4-pyrimidinediamine [CAS]	61498-94-0		Formulation, fixed-dose combinations	Infection, general
		13292-46-1			
		6998-60-3			
Rifamycin SV					
rifapentine	Rifamycin, 3-[[[(4-cyclopentyl-1-piperazinyl)imino]methyl]- [CAS]	61379-65-5	DE 2608218	Antibiotic, other	Infection, tuberculosis
rifaximin	Epoxy-pentadeca[1,11,13]trienimino)benzofuro[4,5-e]-pyrido[1,2-a]benzimidazole-1,15(2H)-dione, 25-(acetyloxy)-5,6,21,23-tetrahydro-27-methoxy-2,4,11,16,20,22,24,26-octamethyl-, [2S-(2R*,16Z,18E,20R*,22S*,23S*,24S*,25R*,26S*,27R*,28E)]	80621-81-4	GB 2079270	Antibiotic, other	Infection, GI tract
rifaximine cream	4-deoxy-4'-methylpyrido[1',2'-1,2]imidoazo[5,4-c]rifamycin SV	80621-81-4	BE 888895	Formulation, dermal, topical	Infection, dermatological
Rilmazafone		99593-25-6			
rilmentidine	2-Oxazolamine, N-(dicyclopropylmethyl)-4,5-dihydro- [CAS]	54187-04-1		Antihypertensive, adrenergic	Hypertension, general
		54249-57-9	DE 2362754		
riluzole	2-Benzothiazolamine, 6-(trifluoromethoxy)- [CAS]	1744-22-5	EP 50551	Neuroprotective	Amyotrophic lateral sclerosis
Rimantadine		13392-28-4			
rimazolium	4H-Pyrido[1,2-a]pyrimidinium, 3-(ethoxycarbonyl)-6,7,8,9-tetrahydro-1,6-dimethyl-4-oxo-, [CAS]	28610-84-6		Analgesic, NSAID	
		35615-72-6	DE 2461349		
rimexolone	Androsta-1,4-dien-3-one, 11-hydroxy-16,17-dimethyl-17-(1-oxopropyl)-, (11R,16A)alpha,17B)- [CAS]	49697-38-3	DE 2301317	Ophthalmological	Inflammation, ocular
		32953-89-2			
Rimiterol					
rimonabant	1H-Pyrazole-3-carboxamide, 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-1-piperidinyl-, monohydrochloride [CAS]	158681-13-1	US 5624941	Anorectic/Antiobesity	Obesity
riodoxol	1,3-Benzenediol, 2,4,6-triiodo- [CAS]	19403-92-0	US 3755251	Antiviral, other	



API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Rioprostil		77287-05-9			
risedronate	Phosphonic acid, (1-hydroxy-2-(3-pyridinyl)ethylidene)bis-, monosodium salt	115436-72-1	EP 304961	Osteoporosis treatment	Paget's disease
Risedronic Acid		105462-24-6			
risperidone	4H-Pyrido[1,2-a]pyrimidin-4-one, 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl- [CAS]	106266-06-2	EP 196132	Neuroleptic, formulation, optimized, microencapsulate	Schizophrenia
Ritanserlin		87051-43-2			
Ritipenem		84845-57-8			
ritodrine	Benzenemethanol, 4-hydroxy-Alpha-[1-[2-(4-hydroxyphenyl)ethyl]amino]ethyl]-, (R*,S*)- [CAS]	23239-51-2 26652-09-5	US 3410944	Labour inhibitor	Labour, preterm
ritonavir	2,4,7,12-Tetraazatridecan-13-olc acid, 10-hydroxy-2-methyl-5-(1-methylethyl)-1-(2-(1-methylethyl)-4-thiazolyl)-3,6-dioxo-8,11-bis(phenylmethyl)-, 5-thiazolyl-methyl ester, (5S-(5R*,8R*,10R*,11R*))- [CAS]	155213-67-5	WO 9414436	Antiviral, anti-HIV	Infection, HIV/AIDS
Rituximab		174722-31-7			
rivastigmine	Carbamic acid, ethylmethyl-, 3-[1-(dimethylamino)ethyl]phenyl ester, (S)- [CAS]	123441-03-2 129101-54-8	DE 3805744	Cognition enhancer	Alzheimer's disease
rizatriptan	1H-Indole-3-ethanamine, N,N-dimethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-, [CAS]	145202-66-0 159776-67-7 144034-80-0	EP 497512	Antimigraine	Migraine
RJR-2403	3-Buten-1-amine, N-methyl-4-(3-pyridinyl)-, (3E)-, (2E)-2-butenedioate (1:1) [CAS]	183288-99-5		Cognition enhancer	Alzheimer's disease
RNA Stealth Nucleosides	5-Formyluridine			Antiviral, other	Infection, hepatitis-C virus
Ro-0094889	2',3'-Di-O-acetyl-5'-vinylcytidine			Anticancer, antimetabolite	Cancer, general

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Ro-61-1790	2-Pyridinesulfonamide, N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-[2-(1H-tetrazol-5-yl)-4-pyridinyl]-4-pyrimidinyl]-5-methyl- [CAS]	180384-56-9	WO 9619459	Cardiovascular	Haemorrhage, subarachnoid
Rociverine		53716-44-2			
rocuronium	Pyrrolidinium, 1- [(2S,3A)pha,5A]pha,16S,17S)-17-(acetyloxy)-3-hydroxy-2-(4-morpholinyl)androstan-16-yl]-1-(2-propenyl)-, bromide- [CAS]	104855-17-6 104884-91-5 119302-91-9 143558-00-3	EP 287150	Muscle relaxant	Muscle spasm, general
rofecoxib	2(5H)-Furanone, 4-(4-(methy/sulfonyl)phenyl)-3-phenyl- [CAS]	162011-90-7	US 5474995	Analgesic, NSAID	Arthritis, osteo
roflumilast	Benzamide, 3-(cyclopropylmethoxy)-N-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy)- [CAS]	162401-32-3	WO 9501338	COPD treatment	Chronic obstructive pulmonary disease
rokitamycin	Leucomycin V, 4B-butanate 3B-propanoate [CAS]	74014-51-0	US 4242504	Macrolide antibiotic	Infection, general
Rolipram		61413-54-5			
Rolitetracycline		751-97-3			
Romurtide		78113-36-7			
Ronifibrate		42597-57-9			
ropinirole	2H-Indol-2-one, 4-[2-(dipropylamino)ethyl]-1,3-dihydro-, monohydrochloride- [CAS]	91374-20-8 91374-21-9	EP 266033	Antiparkinsonian	Parkinson's disease
ropivacaine	2-Piperidinecarboxamide, N-(2,6-dimethylphenyl)-1-propyl-, (S)- [CAS]	84057-95-4 98717-15-8	EP 239710	Anaesthetic, local	Anaesthesia
Roquinimex		84088-42-6			
rosaprostol	Cyclopentaneheptanoic acid, 2-hexyl-5-hydroxy- [CAS]	56695-65-9	GB 1523355	Prostaglandin	
Rosaramicin		35834-26-5			
Rose Bengal		632-68-8			
rosiglitazone	2,4-Thiazolidinedione, 5-((4-(2-(methyl-2-pyridinylamino)ethoxy)phenyl)methyl)-, (Z)-2-butenedioate (1:1) [CAS]	122320-73-4 155141-29-0	US 5002953	Antidiabetic	Diabetes, Type II
rosoxacin	3-Quinolonecarboxylic acid, 1-ethyl-1,4-dihydro-4-oxo-7-(4-pyridinyl)- [CAS]	40034-42-2	US 3753993	Quinolone antibacterial	Infection, gonorrhoea

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
rosapofin	Tin, dichloro[ethyl 3,4,20,21-tetrahydro-4,9,14,19-tetraethyl-18,19-dihydro-3,8,13,18-tetramethyl-20-phorbinecarboxylato(2-)-kappaN23,kappaN24,kappaN25,kappaN26], (OC-6-13)- [CAS]	114494-17-6		Ophthalmological	Macular degeneration
rosuvastatin	6-Heptenoic acid, 7-(4-(4-fluorophenyl)-6-(1-methylethyl)-2-methyl(methylsulfonyl)amino)-5-pyrimidinyl)-3,5-dihydroxy- (S-(R*, S*(E))) [CAS]	147098-20-2	JP 2648897	Hypolipaeic/Antiatherosclerosis	Hyperlipidaemia, general
roligotine	1-Naphthalenol, 5,6,7,8-tetrahydro-6-[propyl[2-(2-thienyl)ethyl]amino]-, (S)- [CAS]	99755-59-6	US 4564628	Antiparkinsonian	Parkinson's disease
Rotraxate		92071-51-7			
Roxarsone		121-19-7			
roxatidine	Acetamide, 2-(acetyloxy)-N-[3-[3-(1-piperidinylmethyl)phenoxy]propyl]-, [CAS]	78628-28-1 93793-83-0	EP 24510	Antilulcer	Ulcer, gastric
roxifiban	L-Alanine, 3-(((3-(4-(aminoliminomethyl)phenyl)-4,5-dihydro-5-isoxazolyl)acetyl)amino)-N-(butoxycarbonyl)-, methyl ester, (R)-, [CAS]	176022-59-6	US 5849736	Antithrombotic	Thrombosis, general
Roxindole		112192-04-8			
roxithromycin	Erythromycin, 9-[O-[(2-methoxyethoxy)methyl]oxime] [CAS]	80214-83-1 80214-86-4	EP 33255	Macrolide antibiotic	Infection, general

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
RPR-109881A	Benzenepropanoic acid, β-(((1,1-dimethylethoxy)carbonyl)amino)-Alpha-hydroxy-(1S,2S,4S,7R,8aR,9aS,10aR,12aS,12bR)-7,12a-bis(acetyloxy)-1-(benzoyloxy)-1,3,4,7,8,9,9a,10,10a,12,12a,12b-dodecahydro-2-hydroxy-5,13,13-trimethyl-8-oxo-2,6-methano-2H-cyclodeca(3,4) cyclopropa (4,5) benz (1,2-b) oxet-4-yl ester, dihydrate Alpha R, betaS [CAS]	192573-38-9		Anticancer, other	Cancer, lung, general
RPR-130401	4,9-Ethano-3aH-benz[fi]indole-3a-carboxylic acid, 1,2,3,4,9,9a-hexahydro-2-[2-(2-methoxyphenyl)-1-oxo-2-propenyl]-9-(4-methylphenyl)-, (3aR,4S,9S,9aR)-rel- [CAS]	210282-69-2	WO 9829390	Anticancer, other	Cancer, general
R-roscovitine	N,N'-bis(3-hydroxyphenyl)pyridazine-3,6-diamine		US 6316456	Anticancer, other	Cancer, lung, non-small cell
RS-0406		131179-95-8		Neuroprotective	Alzheimer's disease
RSR-13		79-58-3			
Rubijervine					
rubitecan	1H-Pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione, 4-ethyl-4-hydroxy-10-nitro-, (S)- [CAS]	91421-42-0	US 6485514	Anticancer, other	Cancer, pancreatic
ruboxistaurin	9H,18H-5,21:12,17-Dimethenodibenzo(e,k)pyrrolo(3,4-h)(1,4,13)oxadiazacyclohexadecine-18,20(19H)-dione,9-((dimethylamino)methyl)-6,7,10,11-tetrahydro-, (S)- [CAS]	169939-94-0		Symptomatic antidiabetic	Retinopathy, diabetic
Rufinamide		106308-44-5			
rufloxacin	7H-Pyrido[1,2,3-de]-1,4-benzothiazine-6-carboxylic acid, 9-fluoro-2,3-dihydro-10-(4-methyl-1-piperazinyl)-7-oxo- [CAS]	101363-10-4 102052-47-1 106017-08-7	EP 165375	Quinolone antibacterial	Infection, general

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
rupatadine	5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-[[1-[(5-methyl-3-pyridinyl)methyl]-4-piperidinylidene]-, trihydrochloride- [CAS]	156611-76-6	EP 0577957	Antiallergic, non-asthma	Rhinitis, allergic, seasonal
Rutin		153-18-4			
RWJ-54428	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[[(2Z)-(2-amino-5-chloro-4-thiazolyl)(hydroxymino)acetyl]amino]-3-[[[(2-aminoethyl)thio]methyl]-4-pyridinyl]thio]-8-oxo-, (6R,7R)- [CAS]	189448-35-9	WO 9713772	Cephalosporin, injectable	Infection, beta-lactamase resistant
S-0139	Olean-12-en-28-oic acid, 27-[[3-[5-hydroxy-2-[(4-methoxy-1,4-dioxo-2-butenyl)amino]phenyl]-1-oxo-2-propenyl]oxy]-3-oxo- [CAS]	193969-54-9	WO 9727314	Cardiovascular	Ischaemia, cerebral
S-15535	Piperazine, 1-(2,3-dihydro-1,4-benzodioxin-5-yl)-4-(2,3-dihydro-1H-inden-2-yl)- [CAS]	146998-34-7		Cognition enhancer	Cognitive disorder, general
S-18886	1-Naphthalenepropanoic acid, 6-(((4-chlorophenyl)sulfonyl)amino)-5,6,7,8-tetrahydro-2-methyl [CAS]	165537-73-5		Antithrombotic	Thrombosis, general
S-34730	7-chloro-6-sulfamoyl-2-(1H)-quinoleinone-3-phosphonic acid			Neuroprotective	Unspecified
S-3578	7β-[2-(5-amino-1,2,4-thiadiazol-3-yl)-2(Z)-ethoxyiminoacetamido]-3-(1-(N-methylaminopropyl)-1H-imidazol[4,5-b]pyridinium-4-methyl-3-cephem-4-carboxylate monosulfate			Cephalosporin, injectable	Infection, general
S-36496	2-{N-[4-(4-Chlorophenylsulfonylamino)butyl]-N-{3-[(4-isopropylthiazol-2-yl)methyloxy]benzyl}sulfamoyl}benzoic acid			Antiasthma	Asthma



API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
S-36527	2-{N-[4-(4-Chlorophenylsulfonylamino)butyl]-N-[3-{2-(4-cyclobutylthiazol-2-yl)ethyl]benzyl}sulfamoyl}benzoic acid			Antiasthma	Asthma
S-5751	(1R,2R,3S,5S)-7-[2-(5-Hydroxybenzothiofophen-3-ylcarboxamido)-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-5(Z)-heptenoic acid			Antiallergic, non-asthma	Allergy, general
S-8510	Imidazo[4,5-d]pyrano[4,3-b]pyridine, 1,6,7,9-tetrahydro-2-(3-isoxazolyl)-, phosphate (1:1) [CAS]	151466-23-8	EP 556008	Cognition enhancer	Alzheimer's disease
S-8921	2-Naphthalenecarboxylic acid, 1-(3,4-dimethoxyphenyl)-3-(3-ethyl-1-oxopentyl)-4-hydroxy-6,7,8-trimethoxy-, methyl ester [CAS]	151165-96-7	WO 9308155	Hypolipaeamic/Antiatherosclerosis	Hypercholesterolaemia
Sabcomeline		159912-53-5			
Sabeluzole		104383-17-7			
S-Adenosylmethionine		29908-03-0			
safinamide	(S)-(+)-2-[4-(3-fluorobenzoyloxy)benzylamino]propanamide methansulfonate	133865-89-1	AU 711309	Antiepileptic	Epilepsy, general
Salacetamide		487-48-9			
Salazosulfadimidine		2315-8-4			
salbutamol	1,3-Benzenedimethanol, Alpha 1-[[[(1,1-dimethylethyl)amino]methyl]-4-hydroxy-[CAS]	18559-94-9	EP 451745	Formulation, Inhalable, topical, dry powder	Asthma
Salicin		138-52-3			
Salicyl Alcohol		90-01-7			
Salicylamide		65-45-2			
Salicylamide O-Acetic Acid		25395-22-6			
Salicylanilide		87-17-2			
Salicylic Acid		69-72-7			
Salicylsulfuric Acid		89-45-2			
Salinazid		495-84-1			

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
salmeterol	1,3-Benzenedimethanol, 4-hydroxy-Alpha 1- [[[6-(4-phenylbutoxy)hexyl]amino]methyl]-, (±)- 1-hydroxy-2-naphthalenecarboxylate [CAS]	89365-50-4 94749-08-3	WO 9006775	Antiasthma	Asthma
Salsalate		552-94-3			
Salverine		6376-26-7			
Samarium 153Sm Lexidronam		154427-83-5			
sampatrilat	L-Tyrosine, N2-(methylsulfonyl)-L-lysyl-1- [(2S)-3-amino-2- carboxypropyl]cyclopentanecarbonyl- [CAS]	129981-36-8	EP 358398	Antihypertensive, renin system	Hypertension, general
Sancycline		808-26-4			
Saperconazole		110588-57-3			
sapropterin	4(1H)-Pteridinone, 2-amino-6-(1,2- dihydroxypropyl)-5,6,7,8-tetrahydro-, dihydrochloride, [6R-[6R*(1R*,2S*)]]- [CAS]	69056-38-8 62989- 33-7	EP 191335	Antidepressant	Hyperphenylalaninaemia
saquinavir	Butanediamide, N1-[3-[3-[[[(1,1- dimethylethyl)amino]carbonyl]octahydro- 2(1H)-isoquinolinyl]-2-hydroxy-1- (phenylmethyl)propyl]-2-[(2- quinolinylcarbonyl)amino]-, [3S- [2(1R*(R*),2S*),3Alpha,4aβ,8aβ]]- [CAS]	127779-20-8 34273-10-4	EP 432695	Antiviral, anti-HIV	Infection, HIV/AIDS
Saralasin					
saredutant	Benzamide, N-[4-[4-(acetylamino)-4-phenyl- 1-piperidinyl]-2-(3,4-dichlorophenyl)butyl]-N- methyl-, (S)- [CAS]	142001-63-6	EP 474561	Antiasthma	Asthma
sarizotan	3-Pyridinemethanamine, N-((3,4-dihydro-2H- 1-benzopyran-2-yl)methyl)-5-(4- fluorophenyl)- [CAS]	177975-08-5		Antiparkinsonian	Parkinson's disease
sarpogrelate	Butanedioic acid, mono[2-(dimethylamino)- 1-[[2-[2-(3- methoxyphenyl)ethyl]phenoxy]methyl]ethyl] ester [CAS]	125926-17-2	EP 398326	Antithrombotic	
Satigrel		111753-73-2			

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
satraplatin	Platinum, bis(acetato-O)amminedichloro(cyclohexanamine)-, (OC-6-43)- [CAS]	129580-63-8	EP 328274	Anticancer, alkylating	Cancer, prostate
Satumomab		144058-40-2			
SB-237376	N-[3-[[2-(3,4-dimethoxyphenyl)ethyl]amino]propyl]-4-nitrobenzamide, HCl			Antiarrhythmic	Fibrillation, atrial
SB-238039	(5-(2-phenylamino-4-pyrimidinyl)-4-)(4-fluorophenyl)-1-(4-piperidinyl)imidazole			Anticancer, other	Cancer, general
SB-277011	trans-N-[4-[2-(6-Cyano-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl]cyclohexyl]-4-quinolinecarboxamide			Neuroleptic	Schizophrenia
Scarlet Red		85-83-6			
SCH-00013	Benzonitrile, 4-[2-[3,6-dihydro-4-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)-1(2H)-pyridinyl]-1-hydroxyethyl]- [CAS]	217963-18-3	EP 618204	Cardio stimulant	Heart failure
Sch-23863	(2-[10,11-Dihydro-5-ethoxy-5H-dibenzo[a,d] cyclohepten-S-yl]-N, N-dimethylethanamine			Immunosuppressant	Inflammation, general
Sch-57790	1-Piperazineacetoneitrile, 4-cyclohexyl-alpha-[4-[(S)-(4-methoxyphenyl)sulfinyl]phenyl]- [CAS]	221660-80-6		Cognition enhancer	Alzheimer's disease
Sch-63390	7H-Pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine, 2-(2-furanyl)-7-(3-phenylpropyl)- [CAS]	174648-45-4		Antiparkinsonian	Parkinson's disease
Scillarenin		465-22-5			
Scopolamine		51-34-3			
Scopolamine N-Oxide		97-75-6			

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
scopolamine	Benzeneacetic acid, Alpha-(hydroxymethyl)-, 9-methyl-3-oxa-9-azatricyclo[3.3.1.0 <sup>2,4</sup> ]non-7-yl ester, [7(S)-(1 $\alpha$ ,2 $\beta$ ,4 $\beta$ ,5 $\alpha$ )-[CAS]	51-34-3	US 4262003	Formulation, transdermal, other	Nausea and vomiting, general
SCS technology			US 6046188	Antiasthma	Unspecified
secalciferol	9,10-Secosteroid-5,7,10(19)-triene-3,24,25-triol, (3 $\beta$ ,5Z,7E,24R)- [CAS]	55721-11-4	EP 301167	Osteoporosis treatment	Osteodystrophy
secnidazole	1H-Imidazole-1-ethanol, Alpha,2-dimethyl-5-nitro- [CAS]	3366-95-8	FR M3270	Protozoicide	Infection, trichomoniasis
Secobarbital		309-43-3			
selegiline	Benzeneethanamine, N,Alpha-dimethyl-N-2-propynyl-, (R)- [CAS]	14611-51-9	GB 1153578	Antiparkinsonian	
Selenomethionine		1464-42-2			
Sematilide		101526-83-4			
Semotiadil		116476-13-2			
seocalcitol	1,3-Cyclohexanediol, 5-((1-(6-ethyl-6-hydroxy-1-methyl-2,4-octadienyl)octahydro-7a-methyl-4H-inden-4-ylidene)ethylidene)-4-methylene-, (1R-(1 $\alpha$ ,1R*,2E,4E),3a $\beta$ ,4E(1R*,3S*,5Z),7a $\alpha$ )- [CAS]	134404-52-7	WO 9100855	Anticancer, other	Cancer, liver
Sepimostat		103926-64-3			
seratrodast	Benzeneheptanoic acid, zeta-(2,4,5-trimethyl-3,6-dioxo-1,4-cyclohexadien-1-yl)-, (+/-)- [CAS]	103187-07-1 112665-43-7	EP 232089	Antiasthma	Asthma
sertaconazole	1H-Imidazole, 1-[2-[(7-chlorobenzo[b]thien-3-yl)methoxy]-2-(2,4-dichlorophenyl)ethyl]- [CAS]	99592-32-2	EP 151477	Antifungal	Infection, dermatological
sertindole	2-Imidazolidinone, 1-[2-[4-[5-chloro-1-(4-fluorophenyl)-1H-indol-3-yl]-1-piperidinyl]ethyl]- [CAS]	106516-24-9	EP 392959	Neuroleptic	Schizophrenia
sertraline	1-Naphthalenamine, 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-, (1S-cis)- [CAS]	79559-97-0 79617-96-2 79617-97-3	EP 30081	Antidepressant	Depression, general
Setastine		64294-95-7			

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
sevelamer	2-Propen-1-amine polymer with (chloromethyl)oxirane, hydrochloride [CAS]	152751-57-0 52757-95-6	US 5496545	Urological	Renal failure
sevoflurane	Propane, 1,1,1,3,3,3-hexafluoro-2-(fluoromethoxy)- [CAS]	28523-86-6	DE 1954268	Anaesthetic, inhalation	Anaesthesia
SG-210	2H-1,4-Benzothiazine-2-acetic acid, 3,4-dihydro-3-oxo-4-((4,5,7-trifluoro-2-benzothiazolyl)methyl)- [CAS]	143162-65-6		Symptomatic antidiabetic	Neuropathy, diabetic
sibutramine	Cyclobutanemethanamine, 1-(4-chlorophenyl)-N,N-dimethyl-Alpha-(2-methylpropyl)- [CAS]	106650-56-0 84485-00-7	GB 2098602	Anorectic/Antiobesity	Obesity
siccanin	(4aS-(4aAlpha,6aAlpha,11bAlpha,13aR*,13bAlpha)-1,2,3,4,4a,5,6a,11b,13b-decahydro-4,4,6a,9-tetramethyl-13H-benzo[a]furo[2,3,4-mn]xanthen-11-yl)	22733-60-4	JP 37003548	Antifungal	
sildenafil	Piperazine, 1-((3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo(4,3-d)pyrimidin-5-yl)-4-ethoxyphenyl)sulfonyl)-4-methyl, 2-hydroxy-1,2,3-propanetricarboxylate- (1:1) [CAS]	171599-83-0 139755-83-2	WO 9428902	Male sexual dysfunction	Impotence
sildenafil	1H-Indole-7-carboxamide, 2,3-dihydro-1-(3-hydroxypropyl)-5-[(2R)-2-[[2-(2,2,2-trifluoroethoxy)phenoxy]ethylamino]propyl]- [CAS]	160970-54-7	EP 600675	Urological	Dysuria
Silver Lactate		128-00-7			
Silver Picrate		146-84-9			
silver sulfadiazine	N'-2-pyrimidinylsulfanilamide monosilver salt	22199-08-2 68-35-9		Anti-infective, other	Infection, general
Simeotide		154-82-5			
Simvastatin		14929-11-4			



API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
simvastatin	Butanoic acid, 2,2-dimethyl-, 1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1-naphthalenyl ester, [1S-[1Alpha,3Alpha,7B,8B(2S*,4S*),8aB]]-[CAS]	79902-63-9	US 4444784	Hypolipaeic/Antiatherosclerosis	Hyperlipidaemia, general
Sinacalide		25126-32-3			
Sintropium Bromide		79467-19-9			
Sisomicin		32385-11-8			
sitafloxacin	3-Quinolonecarboxylic acid, 7-(7-amino-5-azaspiro[2.4]hept-5-yl)-8-chloro-6-fluoro-1-(2-fluorocyclopropyl)-1,4-dihydro-4-oxo-, [1R-[1Alpha(S*),2Alpha]]-, hydrate	127254-12-0	EP 341493	Quinolone antibacterial	Infection, general
sitamaquine	1,6-Hexanediamine, N,N-diethyl-N'-(6-methoxy-4-methyl-8-quinolinyl)- [CAS]	5330-29-0 57695-04-2		Protozoacide	Infection, leishmaniasis
sitaxsentan	N-(4-Chloro-3-methyl-5-isoxazolyl)-2-[[4,5-(methylenedioxy)-o-tolylacetyl]-3-thiophenesulfonamide	184036-34-8	US 5464853	Antihypertensive, other	Hypertension, pulmonary
sivelestat	Glycine, N-[2-[[[4-(2,2-dimethyl-1-oxopropoxy)phenyl]sulfonyl]amino]benzoyl]-[CAS]	127373-66-4	EP 347168	Respiratory	Systemic inflammatory response syndrome
SJA-6017	Butanamide, 2-[[[4-fluorophenyl]sulfonyl]amino]-N-[[1S)-1-formyl-3-methylbutyl]-, -3-methyl-, (2S)-[CAS]	190274-53-4	EP 771565	Ophthalmological	Cataract
SL-65-1498	6-Fluoro-9-methyl-2-phenyl-4-pyrrolidin-1-ylcarbonyl)-2,9-dihydro-1H-pyrido[3,4-b]indole-1-one				
SLV-306	(3S,2'R)-3-[1-[2'-(Ethoxycarbonyl)-4'-phenylbutyl]-cyclopentan-1-carboxylamino]-2,3,4,5-tetrahydro-2-oxo-1H-benzapin-1-acetic acid		EP 607076	Anxiolytic	Anxiety, general
				Antihypertensive, diuretic	Hypertension, general

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
SLV-308	2(3H)-Benzoxazolone, 7-(4-methyl-1-piperazinyl)-, monohydrochloride	269718-83-4		Antiparkinsonian	Parkinson's disease
Sm153 leixidronam	Samarate(5-)-153Sm, (((1,2-ethanediybis(nitrolobis(methylene)))tetrakis(phosphonato))(8-)-N,N',OP,OP',OP'',OP'''), pentasodium, (OC-6-21)- [CAS]	160369-78-8		Analgesic, other	Pain, cancer
S-Methylmethionine		4727-40-6			
SMP-300	N-(Aminoininomethyl)-11-chloro-5,6,7,8-tetrahydro-8-oxo-4H-pyrrolo[3,2,1-kl][1]benzazocine-2-carboxamide monomethanesulfonate monohydrate			Antianginal	Angina, general
SN-38	(4S)-4,7,11-triethyl-3,4,12,14-tetrahydro-4,10-dihydroxy-3,14-dioxo-1H-pyranol[3',4':6,7]indolizino[1,2-b]quindin-9-yl	100286-90-6		Formulation, optimized, liposomes	Cancer, colorectal
SNAP-7941	((+)-methyl (4S)-3-(((3-{4-{3-(acetylamino)phenyl}-1-piperidinyl)propyl}amino) carbonyl)-4-(3,4-difluorophenyl)-6-(methoxymethyl)-2-oxo-1,2,3,4-tetrahydro-5-pyrimidinecarboxylate hydrochloride)			Anxiolytic	Anxiety, general
SOA-132	2-Naphthalenecarboxamide, N-[2-[4-(diphenylmethoxy)-1-piperidinylethyl]-3-hydroxy-5-(3-pyridinylmethoxy)- [CAS]	143964-80-1		Formulation, inhalable, topical	Asthma
soblidotin	L-vallinamide, N,N-dimethyl-L-valyl-N-[2-methoxy-4-[2-[1-methoxy-2-methyl-3-oxo-3-[(2-phenylethyl)amino]propyl]-1-pyrrolidinyl]-1-(2-methylpropyl)-4-oxobutyl]-N-methyl-, [2S-[1R*(R*),2S],2R*(1S*,2S*)]]- [CAS]	149606-27-9	WO 9303054	Anticancer, other	Cancer, lung, non-small cell
Sobrerol		498-71-5			

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
sobuzoxane	Carbonic acid, 1,2-ethanediylbis[(2,6-dioxo-4,1-piperazinediyl)methylene]bis(2-methylpropyl) ester [CAS]	98631-95-9	EP 140327	Anticancer, other	Cancer, lymphoma, T-cell
Sodium Arsanilate		127-85-5			
Sodium Arphenamine		1936-28-3			
Sodium Chloride					
Sodium Dibunate		14992-59-7			
Sodium Folate		6484-89-5			
Sodium Formaldehydesulfoxylate		149-44-0			
Sodium Glycerophosphate		1334-74-3			
Sodium Hyaluronate					
Sodium Iodomethamate		519-26-6			
Sodium Nitrite		7632-00-0			
Sodium Nitroprusside		14402-89-2			
sodium oxybate	Butyric acid, 4-hydroxy monosodium salt [CAS]	502-85-2		Psychostimulant	Narcolepsy
Sodium Phenolsulfonate		1300-51-2			
sodium phenylbutyrate	Butyric acid, 4-phenyl-, sodium salt- [CAS]	1716-12-7		Formulation, other	Hyperammonaemia
sodium phosphate	Sodium phosphate monobasic monohydrate + sodium phosphate dibasic anhydrous		US 6162464	Formulation, oral, other	Surgery adjunct
sodium prasterone sulfate	3 $\beta$ -hydroxy-5-androsten-17-one(sodium sulfate dihydrate)		EP 380036	Formulation, mucosal, topical	Labour, induction
Sodium Propionate		137-40-6			
sodium salicylate	Benzoic acid, 2-hydroxy-, monosodium salt [CAS]	54-21-7		Formulation, oral, solubility-enhanced	Pain, general
Sodium Tetradecyl Sulfate		139-88-8			
sofalcone	Acetic acid, [5-[(3-methyl-2-butenyl)oxy]-2-[3-{4-[(3-methyl-2-butenyl)oxy]phenyl}-1-oxo-2-propenyl]phenoxy]- [CAS]	64506-49-6	GB 1523241	Antitumor	
Solasulfone		133-65-3			

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
solifenacin	Butanedioic acid compd with (1S)-(3R)-1-azabicyclo(2.2.2)oct-3-yl 3,4-dihydro-1-phenyl-2(1H)-isoquinolinecarboxylate (1:1) [CAS]	242478-38-2		Urological	Overactive bladder
Sorbinicate	D-Glucitol, hexa-3-pyridinecarboxylate [CAS]	6184-06-1	BE 883352	Hypolipaeamic/Antiatherosclerosis	
Sorbitol		50-70-4			
Sorvudine		77181-69-2			
sotalol	Methanesulfonamide, N-[4-[1-hydroxy-2-[(1-methylethyl)amino]ethyl]phenyl]- [CAS]	3930-20-9 959-24-0		Antiarrhythmic	
Soterenol		13642-52-9			
Sozoiodolic Acid		554-71-2			
spaglumatic acid	L-Glutamic acid, N-(N-acetyl-L-Alpha-aspartyl)- [CAS]	3106-85-2 80619-64-3		Formulation, mucosal, topical	Conjunctivitis
sparfloxacin	3-Quinolonecarboxylic acid, 5-amino-1-cyclopropyl-7-(3,5-dimethyl-1-piperazinyl)-6,8-difluoro-1,4-dihydro-4-oxo-, cis- [CAS]	110871-86-8	EP 221463	Quinolone antibacterial	Infection, respiratory tract, general
Sparteine		90-39-1			
SPA-S-843	Candicin D, 18-decarboxy-40-demethyl-3,7-dideoxo-N3'-((dimethylamino)acetyl)-18-(((2-(dimethylamino)ethyl)amino)carbonyl)-3,7-dihydroxy-N47-methyl-5-oxo cyclic 15,19-hemiacetal, comp with L-ascorbic acid (1:2) [CAS]	202748-83-2	US 5298495	Antifungal	Infection, fungal, general
Spasmolytol		25333-96-4			
SPD-754	2(1H)-Pyrimidinone, 4-amino-1-(2-(hydroxymethyl)-1,3-oxathiolan-4-yl- (2R-cis)-	160707-69-7	US 6228860	Antiviral, anti-HIV	Infection, HIV/AIDS
Spectinomycin		1695-77-8			
SPI-339	4-[3-(4-Oxo-4,5,6,7-tetrahydroindol-yl)propionylamino]benzoic acid ethyl ester			Cognition enhancer	Alzheimer's disease

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Spiperone		749-02-0			
spiralpril	1,4-Dithia-7-azaspiro[4.4]nonane-8-carboxylic acid, 7-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-, [8S-[7[R*(R*),8R*]]- [CAS]	83647-97-6	EP 50800	Antihypertensive, renin system	Hypertension, general
Spirogermanium		41992-23-8			
spironolactone	Pregn-4-ene-21-carboxylic acid, 7-(acetylthio)-17-hydroxy-3-oxo-, Gamma-lactone,(7Alpha,17Alpha)- [CAS]	52-01-7	EP 124147	Formulation, dermal, topical	Acne
SR-121463	Benzamide, N-(1,1-dimethylethyl)-4-[[cis-5'-ethoxy-4-[2-(4-morpholinyl)ethoxy]-2'-oxospiro[cyclohexane-1,3'-[3H]indol]-1'(2'H)-yl]sulfonyl]-3-methoxy- [CAS]	185913-78-4	WO 9715556	Cardio stimulant	Heart failure
SR-144190	Morpholine, 4-benzoyl-2-(3,4-difluorophenyl)-2-[2-[4-[[[(dimethylamino)carbonyl]amino]-4-phenyl]-1-piperidinyl]ethyl]-, (2R)- [CAS]	201152-86-5	WO 9623787	Anxiolytic	Anxiety, general
SR-146131	1H-Indole-1-acetic acid, 2-[[[4-(4-chloro-2,5-dimethoxyphenyl)-5-(2-cyclohexylethyl)-2-thiazolyl]amino]carbonyl]-5,7-dimethyl-[CAS]	221671-61-0	WO 9915525	Anorectic/Antiobesity	Obesity
SR-271425	N-[1-[2-(diethylamino)ethylamino]-7-methoxy-9-oxo-9H-thioxanthen-4-ylmethyl]formamide			Anticancer, alkylating	Cancer, general
SR-27897	1H-Indole-1-acetic acid, 2-[[[4-(2-chlorophenyl)-2-thiazolyl]amino]carbonyl]-[CAS]	136381-85-6	EP 432040	Anticancer, other	Cancer, pancreatic
SR-31747	Cyclohexanamine, N-(3-(3-chloro-4-cyclohexylphenyl)-2-propenyl)-N-ethyl-, hydrochloride, (Z)- [CAS]	132173-07-0	EP 376850	Anticancer, other	Cancer, myeloma
SR-58611	Acetic acid, [[[7S)-7-[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]-5,6,7,8-tetrahydro-2-naphthalenyl]oxy]-, ethyl ester, hydrochloride [CAS]	121524-09-2	EP 303546	GI inflammatory/bowel disorders	Irritable bowel syndrome



API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
SS732			US 5385900	Formulation, mucosal, topical	Infection, ocular
SS-750	(R)-(-)-2-(2,4-difluorophenyl)-1-(ethylsulfonyl)-1,1-difluoro-3-(1H-1,2,4-triazol-1-yl)-2-propanol				
β-alethine	Propanamide, N, N'(dithiodi-2,1-ethanedily)bis(3-amino)- [CAS]	646-08-2	US 6083968	Antifungal	Infection, fungal, general
	(2S,4R)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxyphenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide			Anticancer, immunological	Cancer, myeloma
SSR-149415	2-(7-chloro-5-methyl-4-oxo-3-phenyl-4,5-dihydro-3H-pyridazino[4,5-b]indol-1-yl)-N,N-dimethylacetamide		WO 0155130	Antidepressant	Depression, general
SSR-180575	(3-Exo)-8-benzoyl-N-[[[(2S)-7-chloro-2,3-dihydro-1,4-benzodioxin-2-yl]methyl]-8-azabicyclo[3.2.1]octane-3-methanamine HCl			Neuroprotective	Unspecified
SSR-181507	(5aS,8S,10aR)-5a,6,9,10-tetrahydro, 7H,11H-8,10a-methanopyrido[2',3':5,6]pyrano[2,3-d]azepine		US 6221879	Neuroleptic	Schizophrenia
SSR-591813	D-Glucitol, 1,4:3,6-dianhydro-, dinitrate [CAS]			Dependence treatment	Addiction, nicotine
SST-101	(-)-(R)-3-Methyl-3-(methylsulfonyl)-1-(1,2,4-triazol-1-yl)-2-[4-(trifluoromethyl)phenyl]-2-butanol	87-33-2		Formulation, transdermal, other	Angina, general
SSY-726	1-Propanaminium, 2-(acetyloxy)-3-carboxy-N,N,N-trimethyl-, chloride, (R)- [CAS]	5080-50-2	US 5147886	Antifungal	Infection, fungal, general
ST-200			DE 3015635	Cognition enhancer	Dementia, senile, general
stachyflin			WO 9711947	Antiviral, other	Infection, Influenza virus
Stallimycin		636-47-5			
Stampidine			US 6350736	Antiviral, anti-HIV	Infection, HIV/AIDS

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Stannous Pyrophosphate		15578-26-4			
stannosoporphin	(OC-6-13)-Dihydrogen dichloro[7,12-diethyl-3,8,13,17-tetramethyl-21H,23H-porphine-2,18-dipropanoato(4-)-N21,N22,N23,N24]stannate(2-)	106344-20-1		Hepatoprotective	Hyperbilirubinaemia
Stanolone		521-18-6			
Stanozolol		10418-03-8 (2 <i>φ</i> H form); 302-96-5 (1 <i>φ</i> H form)			
Staph aureus ther			US 6376652	Genomics-based drug discovery	Infection, MRSA
STAT4 inhibitors			WO 9629341	Immunosuppressant	Unspecified
stavudine	Thymidine, 2',3'-dideoxy-3'-deoxy- [CAS]	3056-17-5	EP 501511	Antiviral, anti-HIV	Infection, HIV/AIDS
Stenbolone		5197-58-0			
stepronin	Glycine, N-[1-oxo-2-[(2-thienylcarbonyl)thio]propyl]- [CAS]	72324-18-6	US 4242354	Antitussive	Cough
Sibocaptate		27279-76-1			
Sibophen		15489-16-4			
Stilbamidine		122-06-5			
stiripentol	1-Penten-3-ol, 1-(1,3-benzodioxol-5-yl)-4,4-dimethyl- [CAS]	49763-96-4		Antiepileptic	Epilepsy, general
Streptodornase		37340-82-2			
Streptomycin		57-92-1			
Streptonicozid		5667-71-0			
Streptonigrin		3930-19-6			
Streptozocin		18863-66-4			
strontium ranelate	3-Thiopheneacetic acid, 5-[bis(carboxymethyl)amino]-2-carboxy-4-cyano-, strontium salt (1:2)- [CAS]	135459-87-9	EP 415850	Osteoporosis treatment	Osteoporosis
strontium-89 chloride	Strontium chloride (89SrCl2) [CAS]	38270-90-5		Analgesic, other	Pain, cancer
Succimer		304-55-2			
Succinimide		123-56-8			
Succinylcholine		55-94-7			
Succinylcholine		71-27-2			
Succinylsulfathiazole		116-43-8			

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Succinylsulfone		5934-14-5			
Suclofenide		30279-49-3			
sucralfate	Aluminium, hexadeca-μ- hydroxytetrahydroxy(μ8-(1,3,4,6-tetra- O-sulfo-β-D-fructofuranosyl-Alpha-D- glucopyranoside tetrakis(hydrogen sulfato)(8-))hexadeca- [CAS]	54182-58-0	JP 58208233	Antitumor, Formulation, oral, other	Ulcer, general
sufentanil	Propanamide, N-[4-(methoxymethyl)-1-[2-(2- thienyl)ethyl]-4-piperidinyl]-N-phenyl- [CAS]	56030-54-7	US 3998834	Analgesic, other, formulation implant	Pain, general
sublactam	4-Thia-1-azabicyclo[3.2.0]heptane-2- carboxylic acid, 3,3-dimethyl-7-oxo-, 4,4- dioxide, (2S-cis)- [CAS]	68373-14-8	GB 2000138	Antibiotic, other	Infection, general
sublactam + ampicillin		117060-71-6	US 4234579	Antibiotic, other	Infection, general
sublencillin	4-Thia-1-azabicyclo[3.2.0]heptane-2- carboxylic acid, 3,3-dimethyl-7-oxo-6- [[phenylsulfoacetyl]amino]-, [2S- [2A]pha,5Alpha,6β(S*)]- [CAS]	28002-18-8 41744-40-5	GB 1289358	Penicillin, injectable	Infection, pseudomonal
Sulbentine		350-12-9			
sublutamine	Propanoic acid, 2-methyl-, dithiobis[3-[1-[[4- amino-2-methyl-5- pyrimidinyl)methyl]formylamino]ethylidene]- 3,1-propanediyl] ester [CAS]	3286-46-2 67-16-3		Neurological	Unspecified
sulconazole	1H-Imidazole, 1-[2-[[4- chlorophenyl)methyl]thio]-2-[2,4- dichlorophenyl)ethyl]-, (+/-)- [CAS]	61318-90-9 61318-91-0	US 4055652	Antifungal	Infection, fungal, general
Sulesomab		167747-19-5			
Sulfabenzamide		127-71-9			
Sulfacetamide		144-80-9			
Sulfachlorpyridazine		80-32-0			
Sulfachrysoidine		485-41-6			
Sulfacytine		17784-12-2			
Sulfadiazine		68-35-9			
Sulfadiazamide		115-68-4			
Sulfadimethoxine		122-11-2			
Sulfadoxine		2447-57-6			

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Sulfaethidole		94-19-9			
Sulfaguanidine		57-67-0			
Sulfaguanole		27031-08-9			
Sulfalene		152-47-6			
Sulfaloxic Acid		14376-16-0			
Sulfamerazine		127-79-7			
Sulfamer		651-06-9			
Sulfamethazine		57-68-1			
Sulfamethizole		144-82-1			
Sulfamethomidine		3772-76-7			
Sulfamethoxazole		723-46-6			
Sulfamethoxypyridazine		80-35-3			
Sulfametrole		32909-92-5			
Sulfamidochrysolidine		103-12-8			
Sulfamoxole		729-99-7			
Sulfanilamide		63-74-1			
Sulfanilic Acid		121-57-3			
Sulfanilylurea		547-44-4			
Sulfaperine		599-88-2			
Sulfaphenazole		526-08-9			
Sulfaproxyline		116-42-7			
Sulfapyrazine		116-44-9			
Sulfapyridine		144-83-2			
Sulfarside		1134-98-1			
Sulfarsphenamine		618-82-6			
sulfasalazine	Benzolic acid, 2-hydroxy-5-[[4-[(2-pyridinylamino)sulfonyl]phenyl]azo]- [CAS]	599-79-1		Formulation, oral, enteric-coated	Arthritis, rheumatoid
Sulfasomizole		632-00-8			
Sulfasymazine		1984-94-7			
Sulfathiazole		72-14-0			
Sulfathiourea		515-49-1			
Sulfinalol		66264-77-5			
Sulfipyrazone		57-96-5			

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Sulfiram		95-05-6			
Sulfisomidine		515-64-0			
Sulfisoxazole		127-69-5			
Sulfobromophthalein		71-67-0			
Sulfonethymethane		76-20-0			
Sulfoniazide		3691-81-4			
Sulfonmethane		115-24-2			
Sulfordazine		14759-06-9			
Sulfoxone		144-75-2			
sulindac	cis-5-fluoro-2-methyl-1-[(p-methylsulfinyl)benzylidene]indene-3-acetic acid	38194-50-2	US 3725548	Anti-inflammatory	Inflammation, general
Sulisatin		54935-03-4			
Sulisobenzone		4065-45-6			
Sulmarin		29334-07-4			
Sulmazole		73384-60-8			
Suloctidil		54063-56-8			
Sulphan Blue		129-17-9			
sulpiride	Benzamide, 5-(aminosulfonyl)-N-[(1-ethyl-2-pyrrolidinyl)methyl]-2-methoxy-[CAS]	15676-16-1		Alimentary/Metabolic, other	
sulprostone	5-Heptenamide, 7-[3-hydroxy-2-(3-hydroxy-4-phenoxy-1-butenyl)-5-oxocyclopentyl]-N-(methylsulfonyl)-, [1R-[1Alpha(Z),2B(1E,3R*),3Alpha]]- [CAS]	60325-46-4	US 4024179	Prostaglandin	Abortion
sultamicillin	4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-((aminophenylacetyl)amino)-3,3-dimethyl-7-oxo-, (((3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)hept-2-yl)carbonyl)oxy)methyl ester, S, S-dioxide, (2S-(2.alpha.(2R*,5S*),5.alpha.,6.beta.(S*))-[CAS]	117060-71-6 76497-13-7	GB 2044255	Penicillin, oral	Infection, general
Sulthiame		61-56-3			



API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
sultopride	Benzamide, N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-(ethylsulfonyl)-2-methoxy-[CAS]	53583-79-2	FR M5916	Neuroleptic	Psychosis, general
Sulfosilic Acid		57775-26-5			
sumanirole	4H-Imidazo[4,5,1-ij]quinolin-2(1H)-one, 5,6-dihydro-5-(methylamino)-, (5R)-, (2Z)-2-butenedioate (1:1) [CAS]	179386-44-8	WO 9514020	Antiparkinsonian	Parkinson's disease
sumatriptan	1H-Indole-5-methanesulfonamide, 3-[2-(dimethylamino)ethyl]-N-methyl-, butanedioate (1:1)- [CAS]	103628-46-2 103628-48-4	EP 147107	Antimigraine	Migraine
SUN-N8075	1-(4-amino-2,3,5-trimethylphenoxy)-3-[4-(4-fluorobenzyl)phenyl]piperazin-1-yl)propan-2(s)-ol dimethanesulfonate			Neuroprotective	Infarction, cerebral
suplatast	Sulfonium, [3-[[4-(3-ethoxy-2-hydroxypropoxy)phenyl]amino]-3-oxopropyl]dimethyl-, [CAS]	94055-76-2	JP 59167564	Antiasthma	Asthma
Suprofen		40828-46-4			
Suramin		129-46-4			
surfactant TA	Beractant [CAS]	108778-82-1	WO 9117766	Lung Surfactant	Respiratory distress syndrome, general
Suriclone		53813-83-5			
Suxibuzone		27470-51-5			
SYM-1010			US 5830998	Antiepileptic	Epilepsy, general
SYM-2081	L-Glutamic acid, 4-methyl-, (4R)- [CAS]	31137-74-3		Analgesic, other	Pain, general
SYM-2207	4-(Aminophenyl)-1-methyl-6,7-(methylenedioxy)-N-butyl-1,2-dihydrophthalazine-2-carboxamide			Neuroprotective	Ischaemia, cerebral
Symclosene		87-90-1			
Syn-1253	1-cyclopropyl-6-fluoro-8-methoxy-7-[3-(4-methyl-1,2,3-triazol-1-yl)pyrrolidin-1-yl]-4-oxo-1,4-dihydroquinoline 3-carboxylic acid			Quinolone antibacterial	Infection, peritoneum
Syn-2190	1-Azetidinesulfonic acid, 3-[[[(2E)-[(1,4-dihydro-1,5-dihydroxy-4-oxo-2-pyridinyl)methoxy]imino]-2-thienylacetyl]amino]-2-methyl-4-oxo-, (2S,3S)- [CAS]	214963-75-4	WO 9847895	Antibacterial, other	Infection, general

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Sym-2869	3H-1,2,4-Triazol-3-one, 4-(4-(4-((1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl)-1-piperazinyl)phenyl)-2,4-dihydro-2((4-(trifluoromethoxy)phenyl)methyl)- [CAS]	210562-98-4	US 6153616	Antifungal	Infection, Aspergillus
Synephrine		94-07-5			
Syrosingopine		84-36-6			
T-1095	1-Propanone, 3-(5-benzofuranyl)-1-(2-hydroxy-6-((6-O-methoxycarbonyl)-β-D-glucopyranosyl)oxy)-4-methylphenyl- [CAS]	209746-59-8	EP 850948	Antidiabetic	Diabetes, general
T-1249	L-Phenylalaninamide, N-acetyl-L-tryptophyl-L-glutamyl-L-Alpha-glutamyl-L-tryptophyl-L-Alpha-glutamyl-L-glutamyl-L-lysyl-L-isoleucyl-L-threonyl-L-alanyl-L-leucyl-L-leucyl-L-Alpha-glutamyl-L-glutamyl-L-alanyl-L-glutamyl-L-isoleucyl-L-glutamyl-L-glutamyl-L-Alpha-glutamyl-L-lysyl-L-Alpha-glutamyl-asparagyl-L-tyrosyl-L-Alpha-glutamyl-L-leucyl-L-glutamyl-L-lysyl-L-leucyl-L-Alpha-aspartyl-L-lysyl-L-tryptophyl-L-ananyl-L-seryl-L-leucyl-L-tryptophyl-L-Alpha-glutamyl-L-tryptophyl- [CAS]	251562-00-2	WO 9959615	Antiviral, anti-HIV	Infection, HIV/AIDS
T-3912	1-cyclopropyl-8-methyl-7-[5-methyl-6-(methylamino)-3-pyridinyl]-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid			Quinolone antibacterial	Infection, dermatological
T-588	Benzo(b)thiophene-5-methanol, Alpha-(2-(diethylamino)ethoxy)methyl)-, hydrochloride, (R)- [CAS]	142935-03-3	EP 565965	Cognition enhancer	Alzheimer's disease
T-67	Benzenesulfonamide, 2,3,4,5,6-pentafluoro-N-(3-fluoro-4-methoxyphenyl)- [CAS]	195533-53-0		Anticancer, other	Cancer, liver
T-82			US 5190951	Cognition enhancer	Alzheimer's disease

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
TA-2005	2(1H)-Quinolone, 8-hydroxy-5-[1-hydroxy-2-[[2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-, monohydrochloride, [R-(R*,R*)]- [CAS]	137888-11-0	US 4579854	Antiasthma	Asthma
	2(1H)-Quinolone, 8-hydroxy-5-[1-hydroxy-2-[[2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-, monohydrochloride, [R-(R*,R*)]- [CAS]		WO 189480	Formulation, Inhalable, solution	Asthma
TA-993	1,5-Benzothiazepin-4(5H)-one, 3-(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-8-methyl-2-(4-methylphenyl)-, (2R,3R)-rel(-), (2Z)-2-butenedioate [CAS]	122024-98-0	JP 01045376	Antithrombotic	Peripheral vascular disease
tabimorelin	(R)-Alpha-[(E)-5-Amino-N,5-dimethyl-2-hexenamido]-N-methyl-N-[(R)-Alpha-(methylcarbamoyl)phenethyl]-2-naphthalenepropionamide	170851-70-4 193079-69-5		Releasing hormones	Growth hormone deficiency
	9,10-Secocholesta-5,7,10(19)-triene-1,3,24-triol, (1Alpha,3β,5Z,7E,24R)- [CAS]	57333-96-7 93129-94-3	EP 129003	Antipsoriasis	Keratosis
tacedinaline	Benzamide, 4-(acetylamino)-N-(2-aminophenyl)- [CAS]	112522-64-2	DE 3613571	Anticancer, other	Cancer, pancreatic
tacrine	9-Acridinamine, 1,2,3,4-tetrahydro- [CAS]	1684-40-8 321-64-2	EP 332147	Cognition enhancer	Alzheimer's disease
Tacrolimus		104987-11-3			
tadalafil	Pyrazino(1',2':1,6)pyrido(3,4-b)indole 1,4-dione, 6-(1,3-benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-methyl-, (6R-trans) [CAS]	171596-29-5	US 6143746	Male sexual dysfunction	Impotence
	1,4-Pentanediamine, N4-[2,6-dimethoxy-4-methyl-5-[3-(trifluoromethyl)phenoxy]-8-quinolinyl]- [CAS]	106635-80-7 106635-81-8 80065-55-0	US 4617394	Antimalarial	Infection, malaria
tafenoquine				Anticancer, other	Cancer, general
tafluposide	(S)-N-[2-(1,6,7,8-Tetrahydro-2H-indeno-[5,4-b]furan-8-yl)]proplonamide	179067-42-6	WO 9612727		
TAK-375				Hypnotic/Sedative	Insomnia

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
TAK-427	2-[6-[[3-[4-(Diphenylmethoxy)-piperidino]imidazo[1,2-b]pyridazin-2-yl]-2-methylpropionic acid dihydrate			Antipruritic/inflamm, allergic	Eczema, atopic
TAK-559	(E)-4-{4-[5-Methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]benzyloxyimino}-4-phenylbutyric acid			Antidiabetic	Diabetes, general
Taka-Diastase		9001-19-8			
talampanel	7H-1,3-Dioxolo[4,5-h][2,3]benzodiazepine, 7-acetyl-5-(4-aminophenyl)-8,9-dihydro-8-methyl-, (8R)- [CAS]	161832-65-1	US 5639751	Antiepileptic	Epilepsy, general
Talampicillin		47747-56-8			
talaporfin	N-[[[(2S,3S)-18-Carboxy-2-(2-carboxy-ethyl)-13-ethyl-2,3-dihydro-3,7,12,17-tetramethyl-8-vinyl porphyrin-20-yl]acetyl]-L-aspartic acid	220201-34-3		Radio/chemosensitizer	Cancer, lung, general
Talastine		16188-61-7			
Talbutal		115-44-6			
Talinolol		57460-41-0			
talipexole	4H-Thiazolo[4,5-d]azepin-2-amine, 5,6,7,8-tetrahydro-6-(2-propenyl)- [CAS]	101626-70-4 36085-73-1	DE 3503963	Antiparkinsonian	Schizophrenia
talnetant	4-Quinolincarboxamide, 3-hydroxy-2-phenyl-N-[(1S)-1-phenylpropyl]- [CAS]	174636-32-9	WO 9532948	GI inflammatory/bowel disorders	Irritable bowel syndrome
talniflumate	3-Pyridinecarboxylic acid, 2-[[3-(trifluoromethyl)phenyl]amino]-, 1,3-dihydro-3-oxo-1-isobenzofuran-yl ester [CAS]	66898-62-2	BE 858864	Anti-inflammatory	Inflammation, ocular
talitirelin	L-Prolinamide, N-[(hexahydro-1-methyl-2,6-dioxo-4-pyrimidinyl)carbonyl]-L-histidyl-, (S)- [CAS]	103300-74-9	JP 61033197	Neurological	Dyskinesia, general
tamoxifen	Ethanamine, 2-[4-(1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethyl-, (Z)- [CAS]	10540-29-1	US 4536516	Anticancer, hormonal	

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
tamsulosin	Benzenesulfonamide, 5-[2-[[2-(2-ethoxyphenoxy)ethyl]amino]propyl]-2-methoxy-, (R)- [CAS]	106133-20-4 80223-99-0	EP 34432	Prostate disorders	Benign prostatic hyperplasia
tandospirone	4,7-Methano-1H-isoindole-1,3(2H)-dione, hexahydro-2-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-, (3aAlpha,4b,7b,7aAlpha), 2-hydroxy-1,2,3-propanetricarboxylate (1:1) [CAS]	112457-95-1 87760-53-0	EP 82402	Anxiolytic	Anxiety, general
Tannoform		9010-29-1			
Taprostene		108945-35-3			
tariquidar	3-Quinolynecarboxamide, N-[2-[[[4-[2-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)ethyl]phenyl]amino]carbonyl]-4,5-dimethoxyphenyl]- [CAS]	206873-63-4	WO 9817648	Radio/chemosensitizer	Cancer, lung, non-small cell
TAS-103	6-[[2-(Dimethyl-amino)ethyl]amino]-3-hydroxy-7H-indeno[2,1-c]quinolin-7-one dihydrochloride	174634-09-4 145733-36-4	WO 9532187	Anticancer, other	Cancer, lung, non-small cell
Tasosartan		81-24-3			
Taurocholic Acid		19388-87-5			
Taurolidine					
tazanolast	Acetic acid, oxo[[3-(1H-tetrazol-5-yl)phenyl]amino]-, butyl ester [CAS]	82989-25-1	US 4778816	Antiasthma	
tazarotene	3-Pyridinecarboxylic acid, 6-[(3,4-dihydro-4,4-dimethyl-2H-1-benzothioopyran-6-yl)ethynyl]-, ethyl ester [CAS]	118292-40-3	EP 284288	Antipsoriasis	Psoriasis
Tazobactam		89786-04-9			
tazobactam + piperacillin			JP 58225091	Antibiotic, other	Infection, general
TBC-3711		374680-51-0		Cardiovascular	Heart failure
TCH-346	N-Methyl-N-propargyl-10-aminomethyl-dibenzo(b,f)oxepin			Neuroprotective	Amyotrophic lateral sclerosis
tebipenem	5-Hexenoic acid, 4-hydroxy-, polymer with 4-ethenyl-1H-imidazole [CAS]	82200-24-6		Beta-lactam antibiotic	Infection, streptococcal
tecadenoson	Adenosine, N-[(3R)-tetrahydro-3-furanyl]- [CAS]	204512-90-3	WO 9808855	Antiarrhythmic	Tachycardia, supraventricular



API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
tecastemizole	1H-Benzimidazol-2-amine, 1-((4-fluorophenyl)methyl)-N-4-piperidinyl- [CAS]	75970-99-9	US 4219559	Antiallergic, non-asthma	Rhinitis, allergic, seasonal
Technetium 99mTc Bicisate		121281-41-2			
Technetium 99mTc Mertiatide		125224-05-7; 104348-91-6			
Technetium 99mTc Sestamibi		109581-73-9			
Technetium 99mTc Teboroxime		104716-22-5			
Teclothiazide		4267-5-4			
Teclozan		5560-78-1			
tedisamil	Spiro[cyclopentane-1,9'-[3,7]diazabicyclo[3.3.1]nonane], 3',7'-bis(cyclopropylmethyl)- [CAS]	90961-53-8	EP 102833	Antiarrhythmic	Fibrillation, atrial
Teflurane		124-72-1			
tegafur	2,4(1H,3H)-Pyrimidinedione, 5-fluoro-1-(tetrahydro-2-furanyl)- [CAS]	17902-23-7	GB 1168391	Anticancer, antimetabolite	Cancer, general
tegafur + uracil	2,4(1H,3H)-Pyrimidinedione, 5-fluoro-1-(tetrahydro-2-furanyl)-, mixt. with 2,4(1H,3H)pyrimidinedione- [CAS]	74578-38-4	EP 224885	Anticancer, antimetabolite	Cancer, breast
tegasero	Hydrazinecarboximidamide, 2-((5-methoxy-1H-indol-3-yl)methylene)-N-pentyl-, (Z)-2-butenedioate [CAS]	189188-57-6 145158-71-0		GI inflammatory/bowel disorders	Irritable bowel syndrome
Telcoplanin		61036-64-4			
telbivudine	$\beta$ -L-2'-deoxythymidine	3424-98-4		Antiviral, other	Infection, hepatitis-B virus
Telenzepine		80880-90-6			
telithromycin	3-De((2,6-dideoxy-3-C-methyl-3-O-methyl-Alpha-L-ribo-hexopyranosyl)oxy)-11,12-dideoxy-6-O-methyl-3-oxo-12,11-(oxycarbonyl)((4-(4-(3-pyridinyl)-1H-imidazol-1-yl)butyl)imino))- [CAS]	191114-48-4	EP 680967	Macrolide antibiotic	Infection, respiratory tract, general
telmestaine	3,4-Thiazolidinedicarboxylic acid, 3-ethyl ester, (R)- [CAS]	122946-43-4		COPD treatment	Bronchitis, chronic
telmisartan	(1,1'-Biphenyl)-2-carboxylic acid, 4'-((1,4-dimethyl-2'-propyl(2,6'-bi-1H-benzimidazol)-1'-yl)methyl)- [CAS]	144701-48-4	EP 502314	Antihypertensive, renin system	Hypertension, general

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use		Example of Indication
telomerase Inhibs			WO 9941261	Anticancer, other	Cancer, general	
temazepam	7-chloro-1,3-dihydro-3-hydroxy-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one	846-50-4	US 3197467	Hypnotic/Sedative	Insomnia	
temiverine	Benzeneacetic acid, Alpha-cyclohexyl-Alpha-hydroxy-, 4-(diethylamino)-1,1-dimethyl-2-butynyl ester, [CAS]	129927-33-9	GB 2222828	Urological	Pollakiuria	
temocapril	1,4-Thiazepine-4(5H)-acetic acid, 6-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]tetrahydro-5-oxo-2-(2-thienyl)-, [2S-[2Alpha,6beta(R*)]]- [CAS]	102090-90-4 110221-44-8 111902-57-9	US 4495188	Antihypertensive, renin system	Hypertension, general	
Temocillin		66148-78-5				
temoporfin	Phenol, 3,3',3'''-(2,3-dihydro-21H,23H-porphine-5,10,15,20-tetrayl)tetrakis- [CAS]	122341-38-2	EP 337601	Radio/chemosensitizer	Cancer, head and neck	
temozolomide	Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3,4-dihydro-3-methyl-4-oxo- [CAS]	85622-93-1	DE 3231255	Anticancer, alkylating	Cancer, brain, general	
tenatoprazole	1H-Imidazo(4,5-b)pyridine, 5-methoxy-2-(((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)sulfinyl)- [CAS]	113712-98-4	US 4808596	Antiulcer	Ulcer, gastric	
Tenecteplase		191588-94-0				
Tenidap		120210-48-2				
teniposide	Furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one, 5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-9-[[4,6-O-(2-thienylmethylene)-beta-D-glucopyranosyl]oxy]-, [5R-[5Alpha,5aBeta,8aAlpha,9Beta(R*)]]- [CAS]	29767-20-2	US 3524844	Anticancer, other	Cancer, lymphoma, non-Hodgkin's	
tenofovir	Phosphonic acid, (((1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy)methyl)- [CAS]	147127-20-6		Antiviral, anti-HIV	Infection, HIV/AIDS	

FOI/US03/41642

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
tenofovir disoproxil	2,4,6,8-tetraoxa-5-phosphanonanedioic acid, 5-(2-(6-amino-9H-purin-9-yl)-1-methylethoxymethyl) bis(1-methylethyl)ester, 5-oxide (R)-, (E)-2-butenedioate	202138-50-9		Antiviral, anti-HIV	Infection, HIV/AIDS
Tenonitroazole		3810-35-3			
tenoxicam	2H-Thieno[2,3-e]-1,2-thiazine-3-carboxamide, 4-hydroxy-2-methyl-N-2-pyridinyl-, 1,1-dioxide [CAS]	59804-37-4	GB 1519811	Antiarthritic, other	
Tenuazonic Acid		610-88-8			
teprenone	5,9,13,17-Nonadecatetraen-2-one, 6,10,14,18-tetramethyl- [CAS]	3796-63-2 6809-52-5		Antitumor	
terazosin	Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-[(tetrahydro-2-furanyl)carbonyl]- [CAS]	63074-08-8 63590-64-7 70024-40-7	US 4112097	Antihypertensive, adrenergic	Hypertension, general
terbinafine	1-Naphthalenemethanamine, N-(6,6-dimethyl-2-hepten-4-ynyl)-N-methyl-, (E)- [CAS]	78628-80-5 91161-71-6	EP 24587	Antifungal	Infection, dermatological
terbutaline	1,3-Benzenediol, 5-[2-[(1,1-dimethylethyl)amino]-1-hydroxyethyl]- [CAS]	23031-25-6		Formulation, mucosal, topical	Dysmenorrhoea
terconazole	Piperazine, 1-[4-[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-4-(1-methylethyl)-, cis- [CAS]	67915-31-5	US 4358449	Antifungal	Vaginitis
terfenadine	1-Piperidinebutanol, Alpha-[4-(1,1-dimethylethyl)phenyl]-4-(hydroxydiphenylmethyl)- [CAS]	50679-08-8	US 3878217	Antiallergic, non-asthma	
terguride	Urea, N,N-diethyl-N'-[(8Alpha)-6-methylergolin-8-yl]- [CAS]	37686-84-3	EP 159522	Antiprolactin	Hyperprolactinaemia
Terlipressin		14636-12-5			
Terodiline		15793-40-5			
Terofenamate		29098-15-5			
Terpin		80-53-5			

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
tertalolol	2-Propanol, 1-[(3,4-dihydro-2H-1-benzothioopyran-8-yl)oxy]-3-[(1,1-dimethylethyl)amino]-, hydrochloride, (+)- [CAS]	33580-30-2 83688-84-0 34784-64-0	GB 1308191	Antihypertensive, adrenergic	Hypertension, general
tert-Pentyl Alcohol		75-85-4			
tesaglitazar	(2S)-2-ethoxy-3-[4-[2-[4-[(methylsulfonyl)oxy]phenyl]ethoxy]phenyl]propanoic acid			Antidiabetic	Diabetes, Type II
tesmilifene	Ethanamine, N,N-Diethyl-2-(4-(phenylmethyl)phenoxy)- [CAS]	92981-78-7 968-93-4		Radio/chemosensitizer	Cancer, breast
Testolactone					
Testosterone	androst-4-en-3-one, 17-hydroxy-, (17β)- [CAS]	58-22-0 5949-44-0		Formulation, transdermal, systemic	Hormone replacement therapy
tetrabamate		60763-47-5	DE 2748794	Anxiolytic	Addiction, alcohol
Tetrabarbital		76-23-3			
Tetrabenazine		58-46-8			
Tetracaine		136-47-0			
Tetrachloroethylene		127-18-4			
tetracine	Benzoic acid, 4-(butylamino)-, 2-(dimethylamino)ethyl ester [CAS]	94-24-6		Formulation, transdermal, systemic	Pain, general
tetracycline	2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, [4S-(4A)pha,4aAlpha,5aAlpha,6β,12aAlpha)]- [CAS]	60-54-8		Formulation, oral, other	Infection, oral
Tetrahydrozoline		84-22-0			
Tetrandrine		518-34-3			
Tetranolol		52094-70-9			
Tetrazepam		10379-14-3			
Tetrofosmin		127502-06-1			
tetroxoprim	2,4-Pyrimidinediamine, 5-[[[3,5-dimethoxy-4-(2-methoxyethoxy)phenyl]methyl]-[CAS]	53808-87-0 74515-38-1	US 3992379	Trimethoprim and analogues	Infection, general
Tevenel®		4302-95-8			

PCT/US02/44640

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
tezacitabine	Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)- [CAS]	130306-02-4	US 5616702	Anticancer, antimetabolite	Cancer, colorectal
tezosentan	2-Pyridinesulfonamide, N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(2-(1H-tetrazol-5-yl)-4-pyridinyl)-4-pyrimidinyl)-5-(1-methylethyl)- [CAS]	180384-57-0		Cardio stimulant	Oedema, general
thalidomide	1H-Isindole-1,3(2H)-dione, 2-(2,6-dioxo-3-piperidinyl)- [CAS]	50-35-1		Dermatological	Infection, dermatological
Thenaldine		86-12-4			
Theridiamine		91-79-2			
Theobromine		83-67-0			
Theofibrate		54504-70-0			
theophylline	1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl- [CAS]	58-55-9		Formulation, modified-release, other	Asthma
Thiabendazole		5967-84-0			
Thiacetazone		148-79-8			
		104-06-3			
thiacymserine	Carbamic acid, [4-(1-methylethyl)phenyl]-, (3aS,8aS)-3,3a,8,8a-tetrahydro-3a,8-dimethyl-2H-thieno[2,3-b]indol-5-yl ester [CAS]	145209-51-4		Cognition enhancer	Alzheimer's disease
Thialbarbital		467-36-7			
Thiamine		59-43-8			
Thiamine		154-87-0			
Thiamine		67-16-3			
Thiamiprine		5581-52-2			
Thiamphenicol		15318-45-3			
Thiamylal		77-27-0			
Thiazesim		5845-26-1			
Thiazinamium		58-34-4			
Thiazolinobutazone		54749-86-9			
Thiazolsulfone		473-30-3			
Thibenzazoline		6028-35-9			
Thiethylperazine		1420-55-9			
Thimerfonate		5964-24-9			
Thimerosal		54-64-8			



API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Thiobarbital		77-32-7			
Thiobutabarbital		2095-57-0			
Thiocarbamizine		91-71-4			
Thiocarbarsone		120-02-5			
Thiocolchicine		2730-71-4			
Thiocresol		26445-03-4			
Thioctic Acid		62-46-4			
Thioglycerol		96-27-5			
Thioguanine		154-42-7			
Thioimreg	L-Thietyrosinyl-glycyl-glycine			Anticancer, immunological	Cancer, general
Thiopental		71-73-8			
Thiopropazate		84-06-0			
Thiopropazine		316-81-4			
Thioridazine		50-52-2			
Thiothixene		5591-45-7			
Thiovir	Thiophosphonoformic acid			Antiviral, anti-HIV	Infection, HIV/AIDS
Thiphenamil		82-99-5			
Thiram		137-26-8			
Thonzylamine		63-56-9			
Thozalinone		655-05-0			
Thromboplastin		9035-58-9			
Thurfyl Nicotinate		70-19-9			
thymiectacin			US 6245750	Anticancer, other	Cancer, colorectal
Thymol		89-83-8			
Thymopentin		69558-55-0			
Thymyl N-Isoamylcarbamate		578-20-1			
Thypropic Acid		51-26-3			
Thyroxine		51-48-9			
Tiadenol		6964-20-1			
tiagabine	3-Piperidinecarboxylic acid, 1-[4,4-bis(3-methyl-2-thienyl)-3-butenyl]-, (R)- [CAS]	115103-54-3	WO 8700171	Antiepileptic	Epilepsy, general
Tiamenidine		31428-61-2			

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
tianeptine	Heptanoic acid, 7-[(3-chloro-6,11-dihydro-6-methylidbenzo[c,f][1,2]thiazepin-11-yl)amino]-, S,S-dioxide [CAS]	72797-41-2 66981-73-5	GB 1269551	Antidepressant	Depression, general
tiapride	Benzamide, N-[2-(diethylamino)ethyl]-2-methoxy-5-(methylsulfonyl)- [CAS]	51012-32-9	GB 1394563	Neuroleptic	
tiaprofenic acid	2-Thiopheneacetic acid, 5-benzoyl- $\alpha$ -methyl- [CAS]	33005-95-7	GB 1331505	Antiarthritic, other	
Tiamide		32527-55-2			
tiazofurin	4-Thiazolecarboxamide, 2- $\beta$ -D-ribofuranosyl- [CAS]	60084-10-8	EP 54432	Anticancer, antimetabolite	Cancer, leukaemia, chronic myelogenous
Tibezonium		54663-47-7			
tibolone	19-Norepregn-5(10)-en-20-yn-3-one, 17-hydroxy-7-methyl-, (7 $\alpha$ ,17 $\alpha$ )- [CAS]	5630-53-5	EP 389035	Menopausal disorders	Hormone replacement therapy
Ticarcillin		34787-01-4			
ticlopidine	Thieno[3,2-c]pyridine, 5-[(2-chlorophenyl)methyl]-4,5,6,7-tetrahydro- [CAS]	53885-35-1 55142-85-3	GB 1554424	Antithrombotic	
Ticrynafen		40180-04-9			
tiemonium	4-(3-hydroxy-3-phenyl-3-thien-2-yl-propyl)-4-methylmorpholinium	6252-92-2 144-12-7		Antispasmodic	
tigecycline	2-Naphthacenecarboxamide, 4,7-bis(dimethylamino)-9-[[[(1,1-dimethylethyl)amino]acetyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)- [CAS]	220620-09-7	EP 582829	Tetracycline	Infection, general
Tigemonam		102507-71-1			
Tigloidine		495-83-0			
Tilidine		20380-58-9			
Tilisolol		85136-71-6			
tilmacoxib	Benzenesulfonamide, 4-(4-cyclohexyl-2-methyl-5-oxazolyl)-2-fluoro- [CAS]	180200-68-4	WO 9619463	Alimentary/Metabolic, other	Polyp
tiludronic acid	Phosphonic acid, [[(4-chlorophenyl)thio]methylene]bis- [CAS]	89987-06-4	EP 100718	Osteoporosis treatment	Paget's disease
Timentin		86482-18-0		Antibiotic, other	Infection, general

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
tiamepidium	Piperidinium, 3-(di-2-thienylmethylene)-5-methoxy-1,1-dimethyl-, [CAS]	35035-05-3	GB 1358446	Antispasmodic	
Timiperone		57648-21-2			
timolol	(-)-1-(t-butylamino)-3-[(4-morpholino-1,2,5-thiadiazol-3-yl)oxy]-2-propanolmaleate (1:1) salt	26839-75-8 26921-17-5	GB 1253709	Antihypertensive, adrenergic, antiglaucoma	
Timonacic		444-27-9			
Tin Ethyl Etiopurpurin		113471-15-1			
tinazoline	1H-Indole, 3-[(4,5-dihydro-1H-imidazol-2-yl)thio]- [CAS]	62882-99-9	US 3376311	Vasodilator, peripheral	
Tinidazole		19387-91-8			
Tinoridine		24237-54-5			
Tiocarlide		910-86-1			
Tioclomarol		22619-35-8			
tioconazole	1H-Imidazole, 1-[2-[(2-chloro-3-thienyl)methoxy]-2-(2,4-dichlorophenyl)ethyl]-[CAS]	61675-64-7 65899-73-2	US 4062966	Antifungal	Infection, fungal, general
tiopronin	Glycine, N-(2-mercapto-1-oxopropyl)- [CAS]	1953-02-2	US 3246025	Urological	Homocystinuria
tiotropium	3-Oxa-9-azoniatricyclo(3.3.1.0 <sup>2,4</sup> )nonane, 7-((hydroxydi-2-thienylacetyl)oxy)-9,9-dimethyl-, [CAS]	136310-93-5	EP 418716	COPD treatment	Chronic obstructive pulmonary disease
Tioxolone		4991-65-5			
Tipepidine		5169-78-8			
tipifarnib	2(1H)-Quinolone, 6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl [CAS]	192185-68-5 192185-72-1	WO 9716443	Anticancer, other	Cancer, breast
tipranavir	N-[3-{1(R)-[4-Hydroxy-2-oxo-6(R)-(2-phenylethyl)-6-propyl-5,6-dihydro-2H-pyran-3-yl]propyl}phenyl]-5-(trifluoromethyl)pyridine-2-sulfonamide	174484-41-4		Antiviral, anti-HIV	Infection, HIV/AIDS
tiqizium	2H-Quinolizinium, 3-(di-2-thienylmethylene)octahydro-5-methyl-, [CAS]	71731-58-3	US 4205074	Antispasmodic	

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
tirapazamine	1,2,4-Benzotriazin-3-amine, 1,4-dioxide- [CAS]	20028-80-2 27314-97-2 5424-06-6	DE 2204574	Radio/chemosensitizer	Cancer, lung, non-small cell
Tiratricol		51-24-1			
tirilazad	Pregna-1,4,9(11)-triene-3,20-dione, 21-[4-(2,6-di-1-pyrrolidinyl-4-pyrimidinyl)-1-piperazinyl]-16-methyl-, (16Alpha)-, [CAS]	110101-65-0 110101-67-2 110101-66-1	WO 8701706	Neuroprotective	Haemorrhage, subarachnoid
tirofiban	L-Tyrosine, N-(butylsulfonyl)-O-[4-(4-piperidinyl)butyl]-, [CAS]	142373-60-2 144494-65-5	EP 478363	Antithrombotic	Infarction, myocardial
tiopramide	Benzenepropanamide, Alpha-(benzoylamino)-4-[2-(diethylamino)ethoxy]-N,N-dipropyl-, (+)-, [CAS]	55837-29-1 13825-74-6	DE 2503992	Antispasmodic	Muscle spasm, general
Titanium Sulfate					
tixocortol	Pregn-4-ene-3,20-dione, 21-[(2,2-dimethyl-1-oxopropyl)thio]-11,17-dihydroxy-, (11S)- [CAS]	55560-96-8 61951-99-3	GB 1475795	Antiallergic, non-asthma, mucosal, topical	Rhinitis, allergic, general
tizanidine	2,1,3-Benzothiadiazol-4-amine, 5-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-[CAS]	51322-75-9	GB 1429926	Muscle relaxant	Spastic paralysis
TLK-199	Glycine, L-Gamma-glutamyl-S-(phenylmethyl)-L-cysteinyl-2-phenyl-, diethyl ester, (2R)-, [CAS]	168682-53-9	US 5679643	Immunostimulant, other	Myelodysplastic syndrome
TLK-286	Glycine, L-Gamma-glutamyl-3-[[2-[[bis(2-chloroethyl)amino]phosphinyl]oxy]ethyl]sulfonyl]-L-alanyl-2-phenyl-, (2R)-, [CAS]	158382-37-7	US 5545621	Anticancer, other	Cancer, ovarian
TNF- $\beta$ analogue			RU 2035185	Anticancer, immunological	Cancer, general
TNP-470		129298-91-5			
TO-186	Pregna-1,4-diene-3,20-dione, 9-fluoro-11 $\beta$ ,17,21-trihydroxy-16.beta.-methyl-, 17-butyrate 21-propionate [CAS]	5534-02-1		Antipruritic/inflamm, allergic	
tobramycin	O-3-amino-3-deoxy-Alpha-D-glucopyranosyl (1,6)-O-(2,6-diamino-2,3,6-trideoxy-Alpha-D-ribo-hexopyranosyl-(1-4)-2-deoxy- [CAS]	32986-56-4		Formulation, inhalable, topical	Infection, respiratory tract, general

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
tocainide	Propanamide, 2-amino-N-(2,6-dimethylphenyl)- [CAS]	41708-72-9	US 4218477	Antiarrhythmic	Fibrillation, ventricular
Tocamphyl		5634-42-4			
tocladesine	8-Chloroadenosine 3'5'-cyclic phosphate	41941-56-4		Anticancer, other	Cancer, colorectal
Tocoretinate		40516-48-1			
Todralazine		14679-73-3			
Tofenacin		15301-93-6			
tofimilast	5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine,9-cyclopentyl-7-ethyl-6,9-dihydro-3-(2-thienyl)-	185954-27-2		Antiasthma	Asthma
tofisopam	5H-2,3-Benzodiazepine, 1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-[CAS]	22345-47-7	GB 1334271	Anxiolytic	Anxiety, general
Tolazamide		1156-19-0			
Tolazoline		59-98-3			
Tolbutamide		64-77-7			
tolcapone	Methanone, (3,4-dihydroxy-5-nitrophenyl)(4-methylphenyl)- [CAS]	134308-13-7	EP 237929	Antiparkinsonian	Parkinson's disease
tolciclate	Carbamothioic acid, methyl(3-methylphenyl)-, O-(1,2,3,4-tetrahydro-1,4-methanonaphthalen-6-yl) ester [CAS]	50838-36-3	GB 1364407	Antifungal	Infection, dermatological
Tolcyclamide		664-95-9			
tolevamer	Benzenesulfonic acid, 4-ethenyl-, homopolymer,	28038-50-8		Antibacterial, other	Infection, Clostridium, general
tolferamic acid	Benzoic acid, 2-[(3-chloro-2-methylphenyl)amino]- [CAS]	13710-19-5	DE 1543295	Anti-inflammatory	Inflammation, general
Tolindate		27877-51-6			
Toliprolol		2933-94-0			
Tolmetin		26171-23-3			
Tolnafate		2398-96-1			
Tolonidine		4201-22-3			
Tolonium		92-31-9			



API Generic Name	API Chemical Name	CAS No.	Patent Reference		Example of Therapeutic Use	Example of Indication
toloxatone	2-Oxazolidinone, 5-(hydroxymethyl)-3-(3-methylphenyl)- [CAS]	29218-27-7	GB	1250538	Antidepressant	
Tolperisone		728-88-1				
Tolpropamine		5632-44-0				
Tolrestat		82964-04-3				
tolserine	Carbamic acid, (2-methylphenyl)-, (3aS,8aR)-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo[2,3-b]indol-5-yl ester [CAS]	145209-30-9			Cognition enhancer	Alzheimer's disease
tolterodine	Phenol, 2-(3-(bis(1-methylethyl)amino)-1-phenylpropyl)-4-methyl-, (R)- [CAS]	124937-51-5	EP	325571	Urological	Incontinence
tolvaptan	Benzamide, N-[4-[(7-chloro-2,3,4,5-tetrahydro-5-hydroxy-1H-1-benzazepin-1-yl)carbonyl]-3-methylphenyl]-2-methyl- [CAS]	150683-30-0	EP	450097	Cardiovascular	Heart failure
Tolycaine		3686-58-6				
Topiramate	Beta-D-Fructopyranose, 2,3:4,5-bis-O-(1-methylethylidene)-, sulfamate [CAS]	97240-79-4	EP	533483	Antiepileptic	Epilepsy, generalized, tonic-clonic
topoisomerase inhibitors			US	5733880	Anticancer, other	Cancer, general
topotecan	1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, 9-[[dimethylamino)methyl]-4-ethyl-4,10-dihydroxy-, (S)- [CAS]	123948-87-8	EP	321122	Anticancer, other	Cancer, ovarian
torasemide	3-Pyridinesulfonamide, N-[[[(1-methylethyl)amino]carbonyl]-4-[(3-methylphenyl)amino]- [CAS]	56211-40-6	US	4018929	Antihypertensive, diuretic	Hypertension, general
torcetrapib	ethyl (2R,4S)-4-[[[3,5-bis(trifluoromethyl)benzyl](methoxycarbonyl)amino]-2-ethyl-6-(trifluoromethyl)-3,4-dihydroquinoline-1(2H)-carboxylate	262352-17-0			Hypolipaeic/Antiatherosclerosis	Atherosclerosis
torcitabine	$\beta$ -L-2'Deoxyctidine				Antiviral, other	Infection, hepatitis-B virus
toremifene	Ethanamine, 2-[4-(4-chloro-1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethyl-, (Z)-[CAS]	89778-26-7 89778-27-8	EP	95875	Anticancer, hormonal	Cancer, breast
Torsemide		56211-40-6				

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Tositumomab		208921-02-2			
tosufloxacin	1,8-Naphthyridine-3-carboxylic acid, 7-(3-amino-1-pyrrolidinyl)-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-, [CAS]	100490-36-6 115964-29-9	US 4704459	Quinolone antibacterial	Infection, urinary tract
tramadol	Cyclohexanol, 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)-, cis-(+/-)-[CAS]	27203-92-5 36282-47-0 1082-57-1		Analgesic, other	Pain, general
Tramazoline					
trandolapril	1H-Indole-2-carboxylic acid, 1-[2-[(1-carboxy-3-phenylpropyl)amino]-1-oxopropyl]octahydro-, [2S-[1[R*(R*)],2Alpha,3aAlpha,7aBeta]- [CAS]	87679-71-8 87679-37-6 52-53-9	DE 3151690	Antihypertensive, renin system	Hypertension, general
tranexamic acid	Cyclohexanecarboxylic acid, 4-(aminomethyl)-, trans- [CAS]	1197-18-8	US 3950405	Antifibrinolytic	Menstrual disorder, general
tranilast	Benzoic acid, 2-[[3-(3,4-dimethoxyphenyl)-1-oxo-2-propenyl]amino]- [CAS]	53902-12-8	US 3940422	Vulnerary	Wound healing
trans-retinoic acid	Retinoic acid [CAS]	302-79-4		Anticancer, other	Cancer, general
Tranylcypromine		155-09-9			
trapidil	[1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, N,N-diethyl-5-methyl- [CAS]	15421-84-8	DD 55956	Vasodilator, coronary	
Trastuzumab		180288-69-1			
travoprost	5-Heptenoic acid, 7-(3,5-dihydroxy-2-(3-hydroxy-4-(3-(trifluoromethyl)phenoxy)-1-butenyl)cyclopentyl)-, 1-methylethylester (1R(1Alpha(Z),2S(1E,3R*),3Alpha,5Alpha)[CAS]	157283-68-6		Formulation, mucosal, topical	Glaucoma
Traxanox		58712-69-9			
traxoprodil	1-Piperidineethanol, 4-hydroxy-Alpha-(4-hydroxyphenyl)-beta-methyl-4-phenyl-, (AlphaS,betaS)- [CAS]	134234-12-1 188591-67-5		Analgesic, other	Pain, general
trazodone	1,2,4-Triazolo[4,3-a]pyridin-3(2H)-one, 2-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-[CAS]	19794-93-5 25332-39-2	US 4215104	Antidepressant	
Tremacamra		155576-45-7			

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Trenbolone		10161-33-8			
Trengestone		5192-84-7			
treosulfan	1,2,3,4-Butanetetrol, 1,4-dimethanesulfonate, [S-(R*,R*)]- [CAS]	299-75-2	WO 8401506	Anticancer, alkylating	
trepiibutone	Benzenebutanoic acid, 2,4,5-triethoxy-Gamma-oxo- [CAS]	41826-92-0	GB 1387733	Antispasmodic	
treprostinal	Prosta-5,13-dien-1-olic acid, 6,9-epoxy-11,15-dihydroxy-, [5Z,9Alpha,11Alpha,13E,15S]- [CAS]	35121-78-9 61849-14-7	US 6054486	Formulation, parenteral, other	Hypertension, pulmonary
tretinoin	Retinoic acid [CAS]	302-79-4		Formulation, dermal, topical	Acne
tretoquinol	6,7-Isoquinolinediol, 1,2,3,4-tetrahydro-1-[[3,4,5-trimethoxyphenyl)methyl]-, (S)- [CAS]	18559-59-6 30418-38-3 21650-42-0	ZA 6802416	Antiasthma	
TRH		24305-27-9			
TRI-50b	TRI 50b [CAS]	226214-49-9		Antithrombotic	Thrombosis, general
Triacetin		102-76-1			
Triamcinolone Acetonide		76-25-5			
Triamcinolone Benetonide		31002-79-6			
Triamcinolone Hexacetonide		5611-51-8			
triamcinolone	Pregna-1,4-diene-3,20-dione, 9-fluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]-, (11B,16Alpha)- [CAS]	76-25-5 124-94-7		Formulation, inhalable, topical	Asthma
Triamterene		396-01-0			
triapine	Triapine [CAS]	236392-56-6	US 6458816	Anticancer, antimetabolite	Cancer, leukaemia, general
Triaziquone		68-76-8			
triazolam	8-chloro-6-(2-chlorophenyl)-1-methyl-4H-[1,2,4]-triazolo[4,3-a][1,4]benzodiazepine	28911-01-5	US 3980790	Hypnotic/Sedative	Insomnia
Tribenoside		10310-32-4			
Trichlorfon		52-68-6			
Trichlormethiazide		133-67-5			
Trichlormethine		555-77-1			
Trichloroethylene		79-01-6			
Triclobisonium		79-90-3			
Triclocarban		101-20-2			

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Triclofenol Piperazine		5714-82-9			
Triclofos		306-52-5			
Triclosan		3380-34-5			
Tricromyl		85-90-5			
Tridihexethyl Iodide		125-99-5			
trientine	1,2-Ethanediamine, N,N2-bis(2aminoethyl)-, [CAS]	38260-01-4 112-24-3		Metabolic and enzyme disorders	Wilson's disease
Triethanolamine		102-71-6			
Triethylenemelamine		51-18-3			
Triethylenephosphoramidate		545-55-1			
Triethylenethiophosphoramidate		52-24-4			
Trifluoperazine		117-89-5			
Trifluoperidol		749-13-3			
Trifluopromazine		146-54-3			
trifluridine	Thymidine, Alpha,Alpha,Alpha-trifluoro- [CAS]	70-00-8	US 3201387	Antiviral, other	Infection, herpes virus, general
triflusal	Benzoic acid, 2-(acetyloxy)-4-(trifluoromethyl)- [CAS]	322-79-2	US 4096252	Antithrombotic	Thrombosis, general
Trihexyphenidyl		52-49-3			
trilostane	Androst-2-ene-2-carbonitrile, 4,5-epoxy-3,17-dihydroxy-, (4Alpha,5Alpha,17Beta)- [CAS]	13647-35-3	US 3296255	Anticancer, hormonal	Cancer, breast
Trimazosin		35795-16-5			
trimebutine	Benzoic acid, 3,4,5-trimethoxy-, 2-(dimethylamino)-2-phenylbutyl ester, (Z)-2-butenedioate (1:1) [CAS]	34140-59-5 39133-31-8	DE 2151716	Antispasmodic	
Trimecaine		616-68-2			
Trimeprazine		84-96-8			
Trimetazidine		5011-34-7			
Trimethadione		127-48-0			
Trimethaphan		68-91-7			
Trimethobenzamide		138-56-7			
Trimethoprim		738-70-5			
Trimetozine		635-41-6			

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
trimetrexate	2,4-Quinazolinodiamine, 5-methyl-6-[[[(3,4,5-trimethoxyphenyl)amino]methyl]-[CAS]	52128-35-5 82952-64-5	US 4391809	Antifungal	Infection, Pneumocystis jirovecii
trimipramine	5H-Dibenz[b,f]azepine-5-propanamine, 10,11-dihydro-N,N,β-trimethyl-, (Z)-2-butenedioate (1:1) [CAS]	521-78-8 739-71-9		Antidepressant	
Trimoprostil		69900-72-7			
Trioxsalen		3902-71-4			
tripamide	Benzamide, 3-(aminosulfonyl)-4-chloro-N-(octahydro-4,7-methano-2H-isoindol-2-yl)-, (3aAlpha,4Alpha,7Alpha,7aAlpha)- [CAS]	73803-48-2	JP 7305585	Antihypertensive, diuretic	Hypertension, general
Triparanol		78-41-1			
Tripelennamine		91-81-6			
Tripolidine		486-12-4			
triptorelin	Luteinizing hormone-releasing factor (p1g), 6-D-tryptophan- [CAS]	124508-66-3 57773-63-4	US 4010125	Releasing hormones	Cancer, prostate
tritiozine	Morpholine, 4-[thioxo(3,4,5-trimethoxyphenyl)methyl]- [CAS]	35619-65-9	US 3862138	Antilulcer	
Triloqualine		14504-73-5			
TRK-530	Phosphonic acid, [[4-(methylthio)phenyl]thio]methylene]bis-, disodium salt [CAS]	151425-92-2	WO 9410181	Antiarthritic, other	Arthritis, rheumatoid
TRK-820	2-Propenamide, N-[(5Alpha,6β)-17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-yl]-3-(3-furanyl)-N-methyl-, monohydrochloride, (2E)- [CAS]	152658-17-8	WO 9315081	Antipruritic/inflamm, non-allergic	Pruritus
Troclosene		2244-21-5			
trofosfamide	3-2-(chloroethyl)-2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorin 2-oxide	22089-22-1	GB 1188159	Anticancer, alkylating	
Trogilitazone		97322-87-7			
Troleandomycin		2751-9-9			
Trolnitrate		588-42-1			



API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
tramantadine	N-(1-adamantyl)-2-(2-dimethylamine ethoxy)acetamide	53783-83-8	DE 1941218	Antiviral, other	Infection, herpes simplex virus
Tromethamine		77-86-1			
Tropacine		6878-98-4			
Tropesin		65189-78-8			
Tropicamide		1508-75-4			
tropine	1H-Indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-, 2-carboxy-2-phenylethyl ester, (+/-)- [CAS]	65189-78-8		Antiarthritic, other	
tropisetron	1H-Indole-3-carboxylic acid, 8-methyl-8-azabicyclo[3.2.1]oct-3-yl ester, endo-[CAS]	89565-68-4	GB 2125398	Antiemetic	Chemotherapy-induced nausea and vomiting
Trospectomycin		88669-04-9			
trospium	3Alpha-HydroxySpiro[1AlphaH,5AlphaH-nortropane-8,1'-pyrrolidinium] benzilate	10405-02-4		Urological	Pollakiuria
trovafloxacin	1,8-Naphthyridine-3-carboxylic acid, 7-(6-amino-3-azabicyclo[3.1.0]hex-3-yl)-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-, (1Alpha,5Alpha,6Alpha)-, [CAS]	147059-72-1 147059-75-4	US 5164402	Quinolone antibacterial	Infection, respiratory tract, general
troxacitabine	2(1H)-Pyrimidinone, 4-amino-1-(2-(hydroxymethyl)-1,3-dioxolan-4-yl)-, (2S-cis)-[CAS]	145918-75-8		Anticancer, other	Cancer, leukaemia, acute myelogenous
Troxerutin		7085-55-4			
troxipide	Benzamide, 3,4,5-trimethoxy-N-3-piperidinyl-, (+/-)- [CAS]	30751-05-4 99777-81-8	US 3647805	Antilucer	Ulcer, gastric
Trypan Red		574-64-1			
Tryparsamide		554-72-3			
Tryptophan		73-22-3			
TSH		9002-71-5			
TSN-09	6,14-Ethenomorphinan-7-methanol, 17-(cyclopropylmethyl)-Alpha-(1,1-dimethylethyl)-, 5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-Alpha-methyl-, [5Alpha,7Alpha,(S)]- [CAS]	52485-79-7		Formulation, transdermal, patch	Pain, cancer

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
TU-2100	Nonanedioic acid, bis[(2-ethoxycarbonyl)phenyl] ester		US 6180669	Antiacne	Acne
Tuaminoheptane		123-82-0			
Tubercidin		69-33-0			
Tubocurarine Chloride		57-94-3			
tuobutanol	Benzenemethanol, 2-chloro-Alpha-[[[(1,1-dimethylethyl)amino]methyl]- [CAS]	41570-61-0	DE 2244737	Antiasthma	Asthma
TV-3326	N-(Propargyl-(3R)aminoindan-5-yl)-ethyl methyl carbamate			Cognition enhancer	Alzheimer's disease
TY-11223	Acetic acid, [2-[2,3,3a,6,7,7a-hexahydro-2-hydroxy-1-(3-hydroxy-4,4-dimethyl-1,6-nonadienyl)-1H-inden-5-yl]ethoxy]-, [1S-[1Alpha(R*),2B,3aAlpha,7aAlpha]]- [CAS]	140694-43-5	US 4837342	Antithrombotic	Unspecified
TY-12533	6,7,8,9-Tetrahydro-2-methyl-5H-cyclohepta[b]pyridine-3-carbonylguanidine maleate				
TYB-3215	D-Glucitol, 1,4:3,6-dianhydro-, dinitrate [CAS]	87-33-2	US 6258829	Antiarrhythmic	Unspecified
Tybamate		4268-36-4		Formulation, modified-release, other	Angina, general
tyloxapol	4-(1,1,3,3-Tetramethylbutyl)phenol polymer with formaldehyde and oxirane [CAS]	25301-02-4		Formulation, inhalable, topical	Cystic fibrosis
Tymazoline		24243-97-8			
Tyramine		51-67-2			
Tyropanoate		7246-21-1			
Uberimex		58970-76-6			
ufenamate	Benzoic acid, 2-[[3-(trifluoromethyl)phenyl]amino]-, butyl ester [CAS]	67330-25-0	BE 861852	Antipruritic/inflamm, non-allergic	
Undecylenic Acid		112-38-9			
Unoprostone		120373-36-6			

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
UR-8880	4-[4-Chloro-5-(3-fluoro-4-methoxyphenyl)imidazol-1-imidazol-1-yl]benzenesulfonamide- [CAS]			Anti-inflammatory	Inflammation, general
Uracil Mustard		66-75-1			
Uralyt-U	1,2,3-Propanetricarboxylic acid, 2-hydroxy-, potassium sodium salt (5:6:6), hydrate [CAS]	55049-48-4	US 4400535	Urological	
urapidil	2,4(1H,3H)-Pyrimidinedione, 6-[3-[4-(2-methoxyphenyl)-1-piperazinyl]propyl]amino]-1,3-dimethyl- [CAS]	34661-75-1	GB 1309324	Antihypertensive, adrenergic	Hypertension, general
urea	Urea [CAS]	57-13-6		Antipsoriasis	
Uredepa		302-49-8			
Urethan		51-79-6			
Uridine 5 $\phi$ -Triphosphate		63-39-8			
Urinastatin		80449-31-6			
ursodeoxycholic acid	3 $\alpha$ ,7 $\beta$ -dihydroxy-5 $\beta$ -cholan-24-oic acid [CAS]	128-13-2		Formulation, other, Cirrhosis, primary biliary, hepatic dysfunction, biliary calculus	Cirrhosis, primary biliary
Ursodiol		128-13-2			
Ushercell			US 6063773	Formulation, mucosal, topical	Contraceptive, female
Uzarin		20231-81-6			
valaciclovir	L-Valine, 2-[(2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy]ethyl ester [CAS]	124832-26-4	EP 308065	Antiviral, other	Infection, herpes simplex virus
Valacyclovir		124832-26-4			
valdecoxib	Benzenesulfonamide, 4-(5-methyl-3-phenyl-4-isoxazolyl)- [CAS]	181695-72-7	US 5859257	Antiarthritic, other	Arthritis, rheumatoid
Valdetamide		512-48-1			
Valethamate		90-22-2			
valganciclovir	L-Valine, 2-[(2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy]-3-hydroxypropyl ester [CAS]	175865-59-5 175865-60-8	EP 694547	Antiviral, other	Infection, cytomegalovirus
Valnoctamide		4171-13-5			
valomaciclovir	L-Valine (3R)-3-((2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methyl)-4-((1-oxooctadecyl)oxy)butyl ester [CAS]	195156-77-5		Antiviral, other	Infection, herpes simplex virus

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
valproate	Pentanoic acid, 2-propyl-, [CAS]	76584-70-8 1069-66-5	US 4988731	Antiepileptic	Epilepsy, generalized, tonic-clonic
Valproic Acid		99-66-1			
Valpromide		2430-27-5			
valroceamide	Pentanamide, N-(2-amino-2-oxoethyl)-2-propyl-, [CAS]	92262-58-3	US 5585358	Antiepileptic	Epilepsy, general
valrubicin	Pentanoic acid, 2-(1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetyl)amino)-Alpha-L-lyxo-hexopyranosyl)oxy)-2-naphthacetyl)-2-oxoethyl ester (2S-cis)-[CAS]	56124-62-0	US 4035566	Anticancer, antibiotic	Cancer, bladder
valsartan	L-Valine, N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- [CAS]	137862-53-4 121584-18-7	EP 443983	Antihypertensive, renin system	Hypertension, general
Valspodar					
varidenafil	Piperazine, 1-(3-(1,4-dihydro-5-methyl(-4-oxo-7-propylimidazo(5,1-f)(1,2,4)-triazin-2-yl)-4-ethoxyphenyl)sulfonyl)-4-ethyl- [CAS]	224785-90-4		Male sexual dysfunction	Sexual dysfunction, male, general
varespladib	Acetic acid, ((3-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl)oxy)- [CAS]	172732-68-2 172733-42-5	EP 675110	Septic shock treatment	Sepsis
Varicella Virus Vaccine					
vatanidipine	3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-[4-[4-(diphenylmethyl)-1-piperazinyl]phenyl]ethyl methyl ester, [CAS]	116308-55-5 133743-71-2	EP 257616	Neuroprotective	Hypertension, general
VEA			US 6007817	Radio/chemosensitizer	Cancer, general
vecuronium	Piperidinium, 1-[(2S,3Alpha,5Alpha,16B,17B)-3,17-bis(acetyloxy)-2-(1-piperidinyl)androstane-16-yl]-1-methyl-, [CAS]	50700-72-6 104675-29-8	US 4237126	Muscle relaxant	Anaesthesia, adjunct
Velnacrine					
venlafaxine	Cyclohexanol, 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]-, [CAS]	93413-69-5 99300-78-4	GB 2227743	Antidepressant	Depression, general

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Veralipride		66644-81-3			
verapamil	Benzeneacetone nitrile, Alpha-[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]propyl]-3,4-dimethoxy-Alpha-(1-methylethyl)- [CAS] 52-53-9			Formulation, modified-release, other	Hypertension, general
verteporfin	23H,25H-Benzo[b]porphine-9,13-dipropionic acid, 18-ethenyl-4,4a-dihydro-3,4-bis(methoxycarbonyl)-4a,8,14,19-tetramethyl-, monomethyl ester, trans- [CAS]	129497-78-5	US 5238940	Ophthalmological	Macular degeneration
vesnarinone	Piperazine, 1-(3,4-dimethoxybenzoyl)-4-(1,2,3,4-tetrahydro-2-oxo-6-quinolinyl)- [CAS]	81840-15-5	GB 2086896	Cardio stimulant	Heart failure
Vetrabutine		3735-45-3			
VF-233	Benzene carboximidamide, N,3,4,5-tetrahydro- [CAS]	95933-74-7	US 4623659	Cardiovascular	Reperfusion injury
VI-0134			US 6403597	Male sexual dysfunction	Premature ejaculation
vidarabine	9H-Purin-6-amine, 9-β-D-arabinofuranosyl- [CAS]	24356-66-9 5536-17-4	GB 1159290	Antiviral, other	Infection, herpes virus, general
vigabatrin	5-Hexenoic acid, 4-amino- [CAS]	68506-86-5 60643-86-9	GB 1472525	Antiepileptic	Epilepsy, partial (focal, local)
vilazodone	2-Benzofurancarboxamide, 5-[4-[4-(5-cyano-1H-indol-3-yl)butyl]-1-piperazinyl]- [CAS]	163521-12-8	EP 648767	Antidepressant	Depression, general
Viloxazine		46817-91-8			
Viminol		21363-18-8			
Vinbarbital		125-44-0			
Vinblastine		865-21-4			
vinburnine	Ebumamenin-14(15H)-one, (3Alpha,16Alpha)- [CAS]	474-00-0 4880-88-0	DE 1932245	Cognition enhancer	
Vincamine		1617-90-9			
Vinconate		70704-03-9			
vincristine	Vincal leukoblastine, 22-oxo-, sulfate (1:1) (salt) [CAS]	2068-78-2 57-22-7	EP 207831	Formulation, parenteral, other	Cancer, general
vindesine	Vincal leukoblastine, 3-(aminocarbonyl)-O4-deacetyl-3-de(methoxycarbonyl)- [CAS]	53643-48-4 59917-39-4	GB 1463575	Anticancer, other	Cancer, leukaemia, acute lymphocytic



API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
vinflunine	Aspidospermidine-3-carboxylic acid, 4-(acetyloxy)-6,7-didehydro-15-[(2R,4R,6S,8S)-4-(1,1-difluoroethyl)-1,3,4,5,6,7,8,9-octahydro-8-(methoxycarbonyl)-2,6-methano-2H-azecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methyl-, methyl ester, (2S,3S,4S,5Apha,12S,19Apha) - [CAS]	162652-95-1	FR 2707988	Anticancer, other	Cancer, general
vinorelbine	C'-Norvincal leukoblastine, 3',4'-didehydro-4'-deoxy- [CAS]	71486-22-1	EP 10458	Anticancer, other	Cancer, lung, non-small cell
vinpocetine	Ebumamenine-14-carboxylic acid, ethyl ester, (3Apha,16Apha)- [CAS]	42971-09-5	GB 1405127	Cognition enhancer	Cognitive disorder, general
Vinyl Ether		109-93-3			
Vinylbital		2430-49-1			
Viquidil		84-55-9			
Viridin		3306-52-3			
Visnadine		477-32-7			
Vitamin A		68-26-8			
vitamin B12	Vitamin B12 [CAS]	68-19-9		Formulation, transmucosal, nasal	Anaemia, general
vitamin C	L-Ascorbic acid [CAS]	50-81-7		Formulation, modified-release, <=24hr	Nutrition
Vitamin D2		50-14-6			
Vitamin D3		67-97-0			
Vitamin K5		83-70-5			
Vitamins, Prenatal					
VLA-4 antagonists	((R,S)-4-(4-(Amino-imino-methyl)-phenyl)-3-((4-biphenyl)-methyl)-4-methyl-2,5-dioxolimidazolidin-1-yl)-acetyl-L-N-methyl-aspartyl-L-phenylglycine		EP 842943	Antiasthma	Asthma
VNP-40101M	1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-(methylamino)carbonylhydrazine		US 6040338	Anticancer, alkylating	Cancer, general

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
voglbose	D-epi-Inositol, 3,4-dideoxy-4-[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-2-C-(hydroxymethyl)- [CAS]	83480-29-9	EP 56194	Antidiabetic	Diabetes, Type II
voriconazole	4-Pyrimidineethanol, Alpha-(2,4-difluorophenyl)-5-fluoro-β-methyl-Alpha-(1H-1,2,4-triazol-1-ylmethyl)-, (R-(R*,S*))- [CAS]	137234-62-9	EP 440372	Antifungal	Infection, fungal, general
Vorzole		129731-10-8			
VUF-K-8788	7-[3-[4-(2-Quinolinylmethyl)-1-piperazinyl]propoxy]-3,4-dihydro-2H-1,4-benzothiazine-3-one			Antialsthma	Asthma
Warfarin		81-81-2			
WF-10	Tetrachlorodecaoxide [CAS]	92047-76-2		Radio/chemoprotective	Chemotherapy-Induced Injury, bone marrow, general
WMC-79	2-(3-[4-(3-(6-oxo-6H-2,10b-diaza-aceanthrylen-5-ylamino)propyl]-piperazin-1-yl)propyl)-5-nitro-2-aza-phenalene-1,3-dione				
wound healing matrix			US 5897880	Anticancer, other	Cancer, colorectal
WP-170			US 6531121	Formulation, transdermal, patch	Ulcer, diabetic
xallproden	Pyridine, 1,2,3,6-tetrahydro-1-[2-(2-naphthalenyl)ethyl]-4-[3-(trifluoromethyl)phenyl]-, [CAS]	90494-79-4 135354-020-8	EP 101381	Cytokine	Unspecified
xamoterol	4-Morpholinecarboxamide, N-[2-[[2-hydroxy-3-(4-hydroxyphenoxy)propyl]amino]ethyl]-, (+/-)- [CAS]	73210-73-8 81801-12-9	GB 2002748	Neuroprotective	Amyotrophic lateral sclerosis
Xanomeline		131986-45-3		Cardio stimulant	Heart failure
Xanthinol Niachnate		437-74-1			
Xemlofiban		149820-74-6			
Xenbucin		959-10-4			
Xibenolol		81584-06-7			
xibornol	Phenol, 4,5-dimethyl-2-(1,7,7-trimethylbicyclo[2.2.1]hept-2-yl)-, exo- [CAS]	13741-18-9	GB 1206774	Antibacterial, other	Infection, general

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
ximelagatran	Glycine, N-((R)-cyclohexyl-2-(2S)-2-(((4-(hydroxyamino)iminomethyl)phenyl)methyl)amino)carbonyl)-1-azetidiny)2-oxoethyl ester [CAS]	192939-46-1		Antithrombotic	Thrombosis, venous
Ximoprofen		56187-89-4			
xipamide	Benzamide, 5-(aminosulfonyl)-4-chloro-N-(2,6-dimethylphenyl)-2-hydroxy- [CAS]	14293-44-8	US 3567777	Antihypertensive, diuretic	
xorphanol	Morphinan-3-ol, 17-(cyclobutylmethyl)-8-methyl-6-methylene-, (8S)- [CAS]	77287-89-9		Analgesic, other	Pain, cancer
XR-5118	2,5-Piperazinedione, 3-[[5-[[2-(dimethylamino)ethyl]thio]-2-thienyl]methylene]-6-(phenylmethylene)-, monohydrochloride, (3Z,6Z)- [CAS]	174766-49-5	WO 9532190	Anticancer, other	Cancer, general
XR-5944	N,N'-(1,2-Ethanediy)bis(imino-2,1-ethanediy)bis(9-methylphenazine-1-carboxamide)		EP 934278	Anticancer, other	Cancer, general
Xylometazoline		526-36-3			
Xylose		58-86-6			
YH-1885	2-Pyrimidinamine, 4-(3,4-dihydro-1-methyl-2(1H)-isoquinolinyl)-N-(4-fluorophenyl)-5,6-dimethyl-, monohydrochloride [CAS]	178307-42-1	WO 9605177	Antulcer	Ulcer, GI, general
YM-511	Benzonitrile, 4-[[[(4-bromophenyl)methyl]-4H-1,2,4-triazol-4-ylamino]- [CAS]	148869-05-0	WO 9305027	Anticancer, hormonal	Cancer, breast
YM-598	potassium(E)-N-[6-methoxy-5-(2-methoxyphenoxy)-2-(pyrimidin-2-yl)pyrimidin-4-yl]-2-phenylethanesulfonamide			Anticancer, other	Cancer, prostate
Yohimbine		146-48-5			
YT-146	Adenosine, 2-(1-octynyl)- [CAS]	90596-75-1	US 5270304	Anti-inflammatory	Inflammation, general
Z-321	Thiazolidine, 3-((2,3-dihydro-1H-inden-2-yl)acetyl)-4-(1-pyrrolidinylcarbonyl)-, (R)- [CAS]	130849-58-0	EP 372484	Cognition enhancer	Dementia, senile, general

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Z-335	(1H-Indene-5-acetic acid, 2[[[(4-chlorophenyl)sulfonyl]amino]methyl]-2,3-dihydro, monosodium salt) [CAS]	146731-14-8	JP 92506077	Antithrombotic	Peripheral vascular disease
zafirlukast	Carbamic acid, [3-[[[2-methoxy-4-[[[(2-methylphenyl)sulfonyl]amino]carbonyl]phenyl]methyl]-1-methyl-1H-indol-5-yl]]-, cyclopentyl ester [CAS]	107753-78-6	EP 199543	Antiasthma	Asthma
zalcitabine	Cytidine, 2',3'-dideoxy- [CAS]	7481-89-2	US 4879277	Antiviral, anti-HIV	Infection, HIV/AIDS
Zaldaride		109826-26-8			
zaleplon	Acetamide, N-[3-(3-cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-N-ethyl- [CAS]	151319-34-5	EP 776898	Hypnotic/Sedative	Insomnia
zaltoprofen	Dibenzo[b,f]thiepin-2-acetic acid, 10,11-dihydro-Alpha-methyl-10-oxo- [CAS]	74711-43-6	JP 55053282	Anti-inflammatory	
zanamivir	5-Acetamido-2,6-anhydro-3,4,5-trideoxy-4-guanidino-D-glycero-D-galacto-non-2-enonic acid [CAS]	139110-80-8	WO 9116320	Antiviral, other	Infection, Influenza virus
zanapezil	1-Propanone, 3-(1-(phenylmethyl)-4-piperidinyl)-1-(2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)- [CAS]	142852-50-4	EP 487071	Cognition enhancer	Alzheimer's disease
Zatebradine		85175-67-3			
ZD-0473	Platinum, amminedichloro(2-methylpyridine)(SP-4-3)- [CAS]	181630-15-9	EP 727430	Anticancer, alkylating	Cancer, ovarian
ZD-0947			WO 9528388	Urological	Overactive bladder
ZD-6126	N-acetylcolchicol-O-phosphate			Anticancer, other	Cancer, general
ZD-9331	1H-Tetrazole-5-butanolic acid, Alpha-((4-(((1,4-dihydro-2,7-dimethyl-4-oxo-6-quinazolinyl)methyl)-2-propynylamino)-2-fluorobenzoyl)amino) (S)- [CAS]	153537-73-6	GB 2264946	Anticancer, antimetabolite	Cancer, pancreatic
zebularine	2(1H)-Pyrimidinone, 1-β-D-ribofuranosyl- [CAS]	3690-10-6		Anticancer, other	Cancer, general
zelandopam	7,8-Isoquinolinediol, 4-(3,4-dihydroxyphenyl)-1,2,3,4-tetrahydro-, [CAS]	138086-00-7	JP 03190818	Vasodilator, renal	Hypertension, general
Zenarestat		112733-06-9			
Ziconotide		107452-89-1			
zidovudine	Thymidine, 3'-azido-3'-deoxy- [CAS]	30516-87-1	US 4724232	Antiviral, anti-HIV	Infection, HIV/AIDS

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
zileuton	Urea, N-(1-benzo[b]thien-2-ylethyl)-N-hydroxy- [CAS]	111406-87-2	EP 279263	Antiasthma	Asthma
Zimeldine		56775-88-3			
zinc acetate	hexakis(m-acetato)-lm4-oxotetrazinc	12129-82-7		Antiviral, other	Infection, herpes simplex virus prophylaxis
zinc acexamate	Hexanoic acid, 6-(acetylamino)-, zinc salt (2:1)- [CAS]	70020-71-2	EP 369088	Antilulcer	Ulcer, duodenal
zinc ibuprofenate		78416-80-5		Anti-inflammatory, topical	Inflammation, dermal
Zinc p-Phenolsulfonate		127-82-2			
Zinc Salicylate		16283-36-6			
Zinostatin		9014-2-2			
zinostatin stimalamer		123760-07-6	EP 136791	Anticancer, antibiotic	Cancer, liver
Zipeprol		34758-83-3			
ziprasidone	2H-Indol-2-one, 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro- [CAS]	122883-93-6 146939-27-7	EP 281309	Neuroleptic	Schizophrenia
zofenopril	L-Proline, 1-[3-(benzoylthio)-2-methyl-1-oxopropyl]-4-(phenylthio)-, [1(R*),2Alpha,4Alpha]- [CAS]	75176-37-3 81872-10-8 81938-43-4	GB 2028327	Antihypertensive, renin system	Hypertension, general
zofenopril + HCTZ	L-Proline, 1-[3-(benzoylthio)-2-methyl-1-oxopropyl]-4-(phenylthio)-, [1(R*),2Alpha,4Alpha]- + 6-Chloro-3,4-dihydro-2H-1,2,4-benzothiazide-7-sulfonamide 1,1-dioxide [CAS]			Formulation, fixed-dose combinations	Hypertension, general
zoledronic acid	Phosphonic acid, [1-hydroxy-2-(1H-imidazol-1-yl)ethylidene]bis- [CAS]	118072-93-8 165800-06-6	EP 531253	Osteoporosis treatment	Hypercalcaemia of malignancy
zolimidine	2-(p-methylsulfonylphenyl)imidazo[1,2-a]pyridine	1222-57-7	US 3318880	Antilulcer	Gastritis
zolmitriptan	2-Oxazolidinone, 4-((3-(2-(dimethylamino)ethyl)-1H-indol-5-yl)methyl)-, (S)- [CAS]	139264-17-8	WO 9118897	Antimigraine	Migraine
zolpidem	Imidazo[1,2-a]pyridine-3-acetamide, N,N,6-trimethyl-2-(4-methylphenyl)-(R-(R*,R*))-(2,3-dihydroxybutanedioate (2:1) [CAS]	99294-93-6 82626-48-0	EP 50563	Hypnotic/Sedative	Insomnia
Zomepirac		33369-31-2			



API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
zonampanel	1(2H)-Quinoxalineacetic acid, 3,4-dihydro-7-(1H-imidazo[1-y]-6-nitro-2,3-dioxo- [CAS]	210245-80-0		Neuroprotective	Ischaemia, cerebral
zoniporide	1H-pyrazole-4-carboxamide,N-(aminoimino methyl)-5-cyclopropyl-1-(5-quinoliny)-, [CAS]	249296-45-5		Cardiovascular	Unspecified
zonisamide	1,2-Benzisoxazole-3-methanesulfonamide [CAS]	68291-97-4 68291-98-5	GB 2025931	Antiepileptic	Epilepsy, generalized, tonic-clonic
zopiclone	1-Piperazinecarboxylic acid, 4-methyl-, 6-(5-chloro-2-pyridinyl)-6,7-dihydro-7-oxo-5H-pyrrolo[3,4-b]pyrazin-5-yl ester [CAS]	43200-80-2	GB 1358680	Hypnotic/Sedative	Insomnia
Zopolrestat		110703-94-1			
Zorubicin		54083-22-6			
zosuquidar	1-Piperazineethanol, 4-(1,1-difluoro-1,1a,6,10b-tetrahydrodibenzo[a,e]cyclopropa[c]cyclohepten-6-yl)-Alpha-[(5-quinolinyloxy)methyl]-, [6(R)-(1aAlpha,6Alpha,10bAlpha)]- [CAS]	167465-36-3		Radio/chemosensitizer	Cancer, leukaemia, acute myelogenous
zotepine	Ethanamine, 2-[(8-chlorodibenzo[b,f]thiepin-10-yl)oxy]-N,N-dimethyl- [CAS]	26615-21-4	GB 1247067	Neuroleptic	Schizophrenia
ZP-123			WO 0162775	Antiarrhythmic	Arrhythmia, general
Z-tamoxifen	Ethanamine, 2-[4-(1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethyl-, (Z)- [CAS]	10540-29-1		Anticancer, hormonal	Cancer, colorectal
zuclopenthixol	1-Piperazineethanol, 4-[3-(2-chloro-9H-thioxanthen-9-ylidene)propyl]-, (Z)-[CAS]	53772-83-1 982-24-1 85721-05-7 64053-00-5	EP 270282	Neuroleptic	Psychosis, general

**CLAIMS:**

1. A pharmaceutical composition comprising a propylene glycol solvate of an API.
2. The composition according to claim 1, wherein:
  - (a) the mole ratio of propylene glycol to API in the solvate is in the range of 0.25 to 2;
  - (b) the solvate is in a crystalline form;
  - (c) the composition further comprises a powder X-ray diffraction spectrum which differs from the corresponding powder X-ray diffraction spectrum of the unsolvated API by at least one property selected from the group consisting of: a loss of at least one peak, shifting of more than half the peaks at the 2-theta angle by at least 0.3 degrees, and formation of at least one new peak;
  - (d) the solvate is stable to temperatures of up to 50 degrees C under a stream of gas in a thermogravimetric analysis apparatus;
  - (e) the API is in the form of a metal salt;
  - (f) the metal is an alkali metal or an alkaline earth metal;
  - (g) the metal is selected from Na, K, Li, Ca and Mg;
  - (h) the API is selected from an API of Table 3;
  - (i) the API has low aqueous solubility and is selected from the group consisting of steroid drugs;
  - (j) the composition further comprises a pharmaceutically-acceptable diluent, excipient or carrier;
  - (k) the API is olanzapine and the composition is characterized by a PXRD pattern comprising peaks expressed in terms of 2-theta angles, wherein:
    - (i) said form is a propylene glycol solvate of olanzapine and said PXRD pattern comprises peaks at 8.33, 15.61, and 21.41 degrees;

- (ii) said form is a propylene glycol solvate of olanzapine and said PXRD pattern comprises peaks at 8.95, 14.47, 22.03, and 23.29 degrees;
- (iii) said form is a propylene glycol solvate of olanzapine and said PXRD pattern comprises peaks at 14.47, 17.95, 19.57, and 20.65 degrees; or
- (iv) said form is a propylene glycol solvate of olanzapine and said PXRD pattern comprises peaks at 8.33, 8.95, 14.47, 15.61, 17.95, and 23.29 degrees; or
- (v) said form is a propylene glycol solvate of olanzapine and said PXRD pattern comprises peaks at 14.47, 15.61, and 20.65 degrees;
- (vi) said form is a propylene glycol solvate of olanzapine and said PXRD pattern comprises peaks at 8.33 and 21.41 degrees;
- (vii) said form is a propylene glycol solvate of olanzapine and said PXRD pattern comprises a peak at 14.47 degrees;
- (viii) said form is a propylene glycol solvate of olanzapine and said PXRD pattern comprises peaks at 14.47 and 22.03 degrees;
- (ix) said form is a propylene glycol solvate of olanzapine and said PXRD pattern comprises peaks at 17.95 and 20.65 degrees; or
- (x) said form is a propylene glycol solvate of olanzapine and said PXRD pattern comprises a peak at 8.33 degrees;
- (l) the API is cortisone acetate and the composition is characterized by a PXRD pattern comprising peaks expressed in terms of 2-theta angles, wherein:
  - (i) said form is a propylene glycol solvate of cortisone acetate and said PXRD pattern comprises peaks at 10.71, 14.54, and 18.49 degrees;

- (ii) said form is a propylene glycol solvate of cortisone acetate and said PXRD pattern comprises peaks at 5.31, 15.66, 21.33, and 23.49 degrees;
- (iii) said form is a propylene glycol solvate of cortisone acetate and said PXRD pattern comprises peaks at 5.31, 10.71, 14.54, 15.66, 18.49, 21.33, and 23.49 degrees;
- (iv) said form is a propylene glycol solvate of cortisone acetate and said PXRD pattern comprises peaks at 14.54 and 18.49 degrees;
- (v) said form is a propylene glycol solvate of cortisone acetate and said PXRD pattern comprises peaks at 15.66 and 21.33 degrees;
- (vi) said form is a propylene glycol solvate of cortisone acetate and said PXRD pattern comprises a peak at 5.31 degrees; or
- (vii) said form is a propylene glycol solvate of cortisone acetate and said PXRD pattern comprises a peak at 18.49; or
- (m) the API is naproxen sodium salt and the composition is characterized by a PXRD pattern comprising peaks expressed in terms of 2-theta angles, wherein:
  - (i) said form is a propylene glycol solvate of naproxen sodium salt and said PXRD pattern comprises peaks at 6.67, 18.55, and 22.79 degrees;
  - (ii) said form is a propylene glycol solvate of naproxen sodium salt and said PXRD pattern comprises peaks at 9.65, 15.77, and 20.83 degrees;
  - (iii) said form is a propylene glycol solvate of naproxen sodium salt and said PXRD pattern comprises peaks at 6.67 and 18.55 degrees;
  - (iv) said form is a propylene glycol solvate of naproxen sodium salt and said PXRD pattern comprises a peak at 9.65 degrees;

- (v) said form is a propylene glycol solvate of naproxen sodium salt and said PXRD pattern comprises a peak at 6.67 degrees;
  - (vi) said form is a propylene glycol solvate of naproxen sodium salt and said PXRD pattern comprises peaks at 15.77, 18.55, and 27.17 degrees; or
  - (vii) said form is a propylene glycol solvate of naproxen sodium salt and said PXRD pattern comprises peaks at 9.65 and 22.79 degrees.
- 3. A method for preparing a propylene glycol solvate of an API, which method comprises:
  - (a) contacting propylene glycol with an API in solution;
  - (b) crystallizing a propylene glycol solvate of the API from the solution; and
  - (c) isolating the solvate.
- 4. The method according to claim 3, wherein:
  - (a) the step of crystallizing the solvate comprises changing the pH of the solution to precipitate the solvate;
  - (b) the pH is raised to render the solution alkaline;
  - (c) the step of isolating the solvate includes separating the solution phase from the solvate;
  - (d) crystalline solvate is dried to remove excess solution phase;
  - (e) the composition further comprises a powder X-ray diffraction spectrum which differs from the corresponding powder X-ray diffraction spectrum of the unsolvated API by at least one property selected from the group consisting of: a loss of at least one peak, shifting of more than half the peaks at the 2-theta angle by at least 0.3 degrees, and formation of at least one new peak;



- (f) the solvate is stable to temperatures of up to 50 degrees C under a stream of gas in a thermogravimetric analysis apparatus;
- (g) the API is in the form of a metal salt;
- (h) the metal is an alkali metal or an alkaline earth metal;
- (i) the metal is selected from Na, K, Li, Ca and Mg;
- (j) the API is selected from an API of Table 3;
- (k) the API has low aqueous solubility and is selected from the group consisting of steroid drugs;
- (l) the API is olanzapine; or
- (m) the API is cortisone acetate.

5. A method for decreasing the hygroscopicity of an API, which method comprises

- (a) contacting the API with propylene glycol in solution;
- (b) crystallizing a propylene glycol solvate of the API from the solution; and
- (c) isolating the solvate, wherein the solvate has decreased hygroscopicity as compared to the API.

6. A method for increasing the aqueous solubility of an API, which method comprises

- (a) contacting the API with propylene glycol in solution;
- (b) crystallizing a propylene glycol solvate of the API from the solution; and
- (c) isolating the solvate, wherein the solvate has increased aqueous solubility as compared to the API.

**Abstract**

The invention relates to pharmaceutical compositions comprising propylene glycol solvates of APIs.

# TGA




FIGURE 1




FIGURE 2A




FIGURE 2B




FIGURE 2C




FIGURE 2D

TGA




FIGURE 3






FIGURE 4

TGA




FIGURE 5




FIGURE 6

### TGA




FIGURE 7

5/15




FIGURE 8

# TGA




FIGURE 9

6/15

## DSC




FIGURE 10




FIGURE 11A




FIGURE 11B




FIGURE 12

# TGA




FIGURE 13

# DSC




FIGURE 14

9/15






FIGURE 15A




FIGURE 15B

10/15




FIGURE 16




FIGURE 17

# TGA




FIGURE 18




FIGURE 19

12/15

# TGA




FIGURE 20




FIGURE 21




FIGURE 22




FIGURE 23




FIGURE 24